{"/":{"title":"ü™¥ Harit's External Brain","content":"\n## ‡∏≠‡∏≤‡∏à‡∏°‡∏µ‡∏™‡∏£‡∏∏‡∏õ‡∏ú‡∏¥‡∏î‡πÑ‡∏î‡πâ‡∏ô‡∏∞‡∏Ñ‡πâ‡∏≤‡∏ö ‡∏≠‡πà‡∏≤‡∏ô‡∏Å‡∏±‡∏ô‡∏≠‡∏¢‡∏≤‡∏Å‡∏£‡∏∞‡∏°‡∏±‡∏î‡∏£‡∏∞‡∏ß‡∏±‡∏á‡∏ô‡πâ‡∏≤ ‡πÄ‡∏ß‡πá‡∏ö‡∏ô‡∏µ‡πâ‡πÄ‡∏Å‡∏¥‡∏î‡∏à‡∏≤‡∏Å‡∏Ñ‡∏ß‡∏≤‡∏°‡∏≠‡∏¢‡∏≤‡∏Å‡∏´‡∏≤‡∏ó‡∏≥‡∏Ç‡∏≠‡∏á‡∏ï‡∏±‡∏ß‡πÄ‡∏≠‡∏á‡∏à‡πâ‡∏≤‡∏≤‡∏≤ #‡∏û‡∏≠‡∏à‡∏≠ üíñ\n\n**‡πÄ‡∏ß‡πá‡∏ö‡πÑ‡∏ã‡∏ï‡πå‡∏ô‡∏µ‡πâ‡∏£‡∏±‡∏ô‡πÑ‡∏î‡πâ‡πÇ‡∏î‡∏¢**\n- [Quartz ‡∏Ç‡∏≠‡∏á Jacky Zhao](https://github.com/akumaharit/quartz)\n- [Github Page ‡∏Ç‡∏≠‡∏á Github](https://pages.github.com/)\n- [Obsidian (Markdown Editor)](https://obsidian.md/)\n- [Hugo (website framework)](https://gohugo.io/)\n\n**Changelogs**\n- 8/3/2566: published website, PTHER I data from personal obsidian vault, excluding some notes causing website deployment errors.\n\n**Todo**\n- ‡∏à‡∏±‡∏î‡πÄ‡∏£‡∏µ‡∏¢‡∏á‡∏Ç‡πâ‡∏≠‡∏°‡∏π‡∏•‡πÉ‡∏´‡∏°‡πà‡πÅ‡∏•‡πâ‡∏ß push ‡πÄ‡∏Ç‡πâ‡∏≤‡∏≠‡∏µ‡∏Å‡∏Ñ‡∏£‡∏±‡πâ‡∏á\n- ‡∏´‡∏≤‡∏ó‡∏≤‡∏á sync ‡∏ó‡∏µ‡πà‡∏î‡∏µ‡∏Å‡∏ß‡πà‡∏≤‡∏ô‡∏µ‡πâ‡∏£‡∏∞‡∏´‡∏ß‡πà‡∏≤‡∏á personal vault ‡∏Å‡∏±‡∏ö‡πÄ‡∏ß‡πá‡∏ö\n- ‡∏®‡∏∂‡∏Å‡∏©‡∏≤ hugo\n- ‡∏®‡∏∂‡∏Å‡∏©‡∏≤ github action\n- ‡∏≠‡∏≤‡∏à‡∏ô‡∏≥‡∏°‡∏≤‡∏õ‡∏£‡∏∞‡∏¢‡∏∏‡∏Å‡∏ï‡πå‡πÉ‡∏ä‡πâ‡∏Å‡∏±‡∏ö‡∏ï‡∏¥‡∏ß‡πÉ‡∏ö‡∏õ‡∏£‡∏∞‡∏Å‡∏≠‡∏ö? ‡πÄ‡∏ô‡∏∑‡πà‡∏≠‡∏á‡∏à‡∏≤‡∏Å‡∏°‡∏µ vault ‡πÉ‡∏ö‡∏õ‡∏£‡∏∞‡∏Å‡∏≠‡∏ö‡∏≠‡∏¢‡∏π‡πà‡πÅ‡∏•‡πâ‡∏ß\n- ‡∏õ‡∏¥‡∏î‡∏Ç‡πâ‡∏≠‡∏°‡∏π‡∏•‡∏™‡πà‡∏ß‡∏ô‡∏ï‡∏±‡∏ß?\n\n### Exam 1\n\n| Topic                                                                            | Percent |\n| -------------------------------------------------------------------------------- | ------- |\n| [[notes/Asthma 2022]] / [[notes/COPD 2022]] / [[notes/Drug Induced Pulmonary Disease]]             | 7.7%    | \n| [[notes/Respiratory Failure]]                                                          | 7.7%    |\n| [[notes/Acute Asthma \u0026 COPD Exacerbation]]                                             | 7.7%    |\n| [[6 - ADR Cross Reactivity]]                                                         | 0%      |\n| [[notes/Glaucoma (‡∏ï‡πâ‡∏≠‡∏´‡∏¥‡∏ô)]] / [[notes/AMD]]                                                           | 7.7%    |\n| [[notes/Drug Induced Eye Disorder]] / [[notes/Drug Induced Ear Disorder]]                                               | 7.7%    |\n\n[[notes/Exam 1 Addition Notes]]\n\n\n---\n\n### Exam 2\n\n| Topic                                    | Percent |\n| ---------------------------------------- | ------- |\n| [[notes/UGIB]]                            | ‡∏Ñ‡∏≤‡∏ö 8   |\n| [[notes/IBD]]                             | ‡∏Ñ‡∏≤‡∏ö 8   |\n| [[notes/Viral Hepatitis]]                 | ‡∏Ñ‡∏≤‡∏ö 9   |\n| [[notes/Alcoholic hepatitis]]             | ‡∏Ñ‡∏≤‡∏ö 9   |\n| [[notes/Cirrhosis]]                       | ‡∏Ñ‡∏≤‡∏ö 10  |\n| [[notes/DIGI]]                            | ‡∏Ñ‡∏≤‡∏ö 11  |\n| [[notes/DILI]]                            | ‡∏Ñ‡∏≤‡∏ö 11  |\n| [[notes/Drug dosing in liver impairment]] | ‡∏Ñ‡∏≤‡∏ö 11  |\n| [[notes/Synovial Analysis]]               | ‡∏Ñ‡∏≤‡∏ö 12  |\n| [[notes/OA]]                              | ‡∏Ñ‡∏≤‡∏ö 12  |\n| [[notes/RA]]                              | ‡∏Ñ‡∏≤‡∏ö 13  |\n| [[notes/Drug Induced bone joint \u0026 muscle disease]]                                         |  ‡∏Ñ‡∏≤‡∏ö 13       |\n| [[24 - Steroid]]                         | ‡∏Ñ‡∏≤‡∏ö 14  |\n| [[notes/SLE]]                             | ‡∏Ñ‡∏≤‡∏ö 14  |\n\n- ‡πÇ‡∏£‡∏Ñ‡∏Ç‡πâ‡∏≠‡∏ó‡∏±‡πâ‡∏á‡∏´‡∏°‡∏î ‡∏ú‡∏π‡πâ‡∏´‡∏ç‡∏¥‡∏á‡∏û‡∏ö‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤‡∏ú‡∏π‡πâ‡∏ä‡∏≤‡∏¢ ‡∏¢‡∏Å‡πÄ‡∏ß‡πâ‡∏ô gout\n- ‡πÄ‡∏î‡∏µ‡πã‡∏¢‡∏ß‡∏≠‡πà‡∏≤‡∏ô‡∏ä‡∏µ‡∏ó‡∏û‡∏µ‡πà‡∏¢‡∏® 3 ‡∏≠‡∏±‡∏ô‡∏ô‡∏±‡πâ‡∏ô DIGI DILI dose in liver impair ‡πÅ‡∏•‡∏∞ drug induced ‡∏Ç‡∏≠‡∏á‡∏û‡∏µ‡πà‡∏ô‡∏∏‡∏™ ‡∏≠‡πà‡∏≤‡∏ô‡∏à‡∏ö‡∏ó‡∏µ‡∏•‡∏∞‡∏≠‡∏±‡∏ô ‡πÅ‡∏•‡πâ‡∏ß‡∏≠‡πà‡∏≤‡∏ô‡πÇ‡∏û‡∏¢ ‡πÅ‡∏•‡πâ‡∏ß‡∏ó‡∏≥‡∏™‡∏£‡∏∏‡∏õ ‡∏ó‡∏≥‡∏ã‡πâ‡∏≥‡∏à‡∏ô‡∏Å‡∏ß‡πà‡∏≤‡∏à‡∏ö\n\n\n\n---\n\n## Backup\nHost your second brain and [digital garden](https://jzhao.xyz/posts/networked-thought) for free. Quartz features\n\n1. Extremely fast natural-language [[notes/search]]\n2. Customizable and hackable design based on [Hugo](https://gohugo.io/)\n3. Automatically generated backlinks, link previews, and local graph\n4. Built-in [[notes/CJK + Latex Support (ÊµãËØï) | CJK + Latex Support]] and [[notes/callouts | Admonition-style callouts]]\n5. Support for both Markdown Links and Wikilinks\n\nCheck out some of the [amazing gardens that community members](notes/showcase.md) have published with Quartz or read about [why I made Quartz](notes/philosophy.md) to begin with.\n\n## Get Started\n\u003e üìö Step 1: [Setup your own digital garden using Quartz](notes/setup.md)\n\nReturning user? Figure out how to [[notes/updating|update]] your existing Quartz garden.\n\nIf you prefer browsing the contents of this site through a list instead of a graph, you see a list of all [setup-related notes](/tags/setup).\n\n### Troubleshooting\n- üöß [Troubleshooting and FAQ](notes/troubleshooting.md)\n- üêõ [Submit an Issue](https://github.com/jackyzha0/quartz/issues)\n- üëÄ [Discord Community](https://discord.gg/cRFFHYye7t)","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/AMD":{"title":"AMD","content":"- AMD = Age-Related Macular Degeneration : AMD\n\t- AMD ‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πà CPU ‡πÅ‡∏ï‡πà‡∏Ñ‡∏∑‡∏≠‡πÇ‡∏£‡∏Ñ\n\t- ![[Pasted image 20230201155250.png|225]]\n- AMD = neurodegenerative disease\n\t- retinal pigment epithelial ‡∏ö‡∏£‡∏¥‡πÄ‡∏ß‡∏ì macula ‡∏ñ‡∏π‡∏Å‡∏ó‡∏≥‡∏•‡∏≤‡∏¢‡πÄ‡∏Å‡∏¥‡∏î loss of central vision\n\t- RPE ‡∏°‡∏µ photoreceptor ‡πÄ‡∏¢‡∏≠‡∏∞\n\t- Note: glaucoma ‡∏à‡∏∞‡πÄ‡∏õ‡πá‡∏ô‡∏ó‡∏µ‡πà optic nerve!\n\t\t- ![[Pasted image 20230201155550.png]]\n\n\n## Pathophysiology:\n- drusen ‡∏™‡∏≤‡∏£‡∏õ‡∏£‡∏∞‡∏Å‡∏≠‡∏ö‡πÑ‡∏Ç‡∏°‡∏±‡∏ô‡πÇ‡∏õ‡∏£‡∏ï‡∏µ‡∏ô ‡∏Ç‡∏ô‡∏≤‡∏î‡πÄ‡∏•‡πá‡∏Å‡∏û‡∏ö‡πÑ‡∏î‡πâ‡πÉ‡∏ô‡∏ú‡∏π‡πâ‡∏™‡∏π‡∏á‡∏≠‡∏≤‡∏¢‡∏∏ ‡∏ñ‡πâ‡∏≤‡∏Ç‡∏ô‡∏≤‡∏î‡πÉ‡∏´‡∏ç‡πã‡∏™‡∏±‡∏°‡∏û‡∏±‡∏ô‡∏ò‡πå‡∏Å‡∏±‡∏ö AMD\n- drusen maybe ‡πÄ‡∏Å‡∏¥‡∏î‡∏à‡∏≤‡∏Å metabolism disorder\n- drusen ‡∏™‡∏∞‡∏™‡∏°‡∏ö‡∏£‡∏¥‡πÄ‡∏ß‡∏ì RPE ‡πÅ‡∏•‡∏∞ Bruch's membrane -\u003e photoreceptor apoptosis, RPE degeneration! #recall1\n\n## Risks\n- age \u003e 55\n- ‡∏°‡πà‡∏≤‡∏ô‡∏ï‡∏≤‡∏™‡∏µ‡∏≠‡πà‡∏≠‡∏ô -\u003e use sunglasses\n- pale skin\n- genetics\n- smoke\n- high fat dietary -\u003e ‡∏•‡∏î‡∏Å‡∏≤‡∏£‡∏Å‡∏¥‡∏ô ‡∏Å‡∏¥‡∏ô‡πÑ‡∏ü‡πÄ‡∏ö‡∏≠‡∏£‡πå ‡∏Å‡∏¥‡∏ô omega3 ‡∏Å‡∏¥‡∏ô antioxidant\n- DLP -\u003e statin\n\n## Classification\n![[Pasted image 20230201155802.png]]\n- AREDs Classification\n\t- No AMD (cat1) : no or few small drusen\n\t\t- ‡∏õ‡πâ‡∏≠‡∏á ‡∏ä‡∏∞‡∏•‡∏≠‡∏Å‡∏≤‡∏£‡πÄ‡∏Å‡∏¥‡∏î\n\t- Early AMD (cat2) : multiple small drusen, **mild abnormal RPE**\n\t\t- ‡∏õ‡πâ‡∏≠‡∏á ‡∏ä‡∏∞‡∏•‡∏≠‡∏Å‡∏≤‡∏£‡πÄ‡∏Å‡∏¥‡∏î\n\t- Intermediate AMD (cat3) : one large drusen, numerous intermediate, geographic atrophy\n\t\t- ‡∏ä‡∏∞‡∏•‡∏≠‡∏Å‡∏≤‡∏£‡∏î‡∏≥‡πÄ‡∏ô‡∏¥‡∏ô‡πÇ‡∏£‡∏Ñ **antioxidant vitamins \u0026 minerals**\n\t- Advanced AMD (cat4) : GA of the RPE involving foveal ‡πÅ‡∏•‡∏∞‡∏°‡∏µ neovascular maculopathy\n\t\t- ‡∏¢‡∏±‡∏ö‡∏¢‡∏±‡πâ‡∏á‡∏Å‡∏≤‡∏£‡∏™‡∏£‡πâ‡∏≤‡∏á‡∏´‡∏•‡∏≠‡∏î‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡∏ú‡∏¥‡∏î‡∏õ‡∏Å‡∏ï‡∏¥\n\t\t\t- anti-VEGF\n\t\t\t- photodynamic therapy with IV **verteporfin** (‡∏¢‡∏≤ cytotoxic ‡πÅ‡∏ï‡πà‡∏ñ‡∏π‡∏Å‡∏Å‡∏£‡∏∞‡∏ï‡∏∏‡πâ‡∏ô‡∏î‡πâ‡∏ß‡∏¢‡πÅ‡∏™‡∏á laser)\n\t\t\t- surgery\n\t\t- ‡∏≠‡∏¢‡πà‡∏≤‡πÉ‡∏´‡πâ‡∏ï‡∏≤‡∏ö‡∏≠‡∏î\n\n- Antioxidants ‡∏ó‡∏µ‡πà‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡∏Å‡∏≤‡∏£‡∏ä‡∏∞‡∏•‡∏≠‡∏Å‡∏≤‡∏£‡∏î‡∏≥‡πÄ‡∏ô‡∏¥‡∏ô‡πÇ‡∏£‡∏Ñ\n\t-  ![[Pasted image 20230201160306.png|500]]\n\t- Memo: E C Zinc ‡∏õ‡∏¥‡∏î // Areds ‡πÄ‡∏Å‡πà‡∏≤‡πÉ‡∏ä‡πâ beta-carotene ‡πÄ‡∏õ‡∏•‡∏µ‡πà‡∏¢‡∏ô‡πÄ‡∏õ‡πá‡∏ô lutein and zeaxanthin\n- ‡∏¢‡∏≤‡∏ó‡∏µ‡πà‡πÉ‡∏ä‡πâ‡πÉ‡∏ô Advanced AMD\n\t- ![[Pasted image 20230201160311.png|475]]\n\t- ![[Pasted image 20230201160317.png|500]]\n\t\t- Memo: Rani = ‡∏•‡∏≤‡πÅ‡∏•‡πâ‡∏ß‡∏à‡∏≤‡∏Å 1 ‡πÄ‡∏î‡∏∑‡∏≠‡∏ô‡πÄ‡∏õ‡πá‡∏ô 3 ‡πÄ‡∏î‡∏∑‡∏≠‡∏ô‡∏•‡∏∞‡∏Å‡∏±‡∏ô (‡∏´‡∏•‡∏±‡∏á‡∏â‡∏µ‡∏î‡πÑ‡∏õ‡πÅ‡∏•‡πâ‡∏ß 3-4 ‡πÄ‡∏Ç‡πá‡∏°) ‡πÄ‡∏£‡∏µ‡∏¢‡∏Å‡∏ß‡πà‡∏≤ TREX (Treat and Extend) Regimen\n\t\t- Rani ‡∏¢‡∏±‡∏á‡πÄ‡∏õ‡πá‡∏ô‡πÅ‡∏Ñ‡πà antibody fragment ‡∏î‡πâ‡∏ß‡∏¢ ‡∏Å‡πá‡∏Ñ‡∏∑‡∏≠‡∏•‡∏≤‡∏à‡∏≤‡∏Å monoclonal antibody\n\n- ‡∏†‡∏≤‡∏û‡∏õ‡∏£‡∏∞‡∏Å‡∏≠‡∏ö‡∏Å‡∏≤‡∏£‡∏â‡∏µ‡∏î Intravitreal\n![[Pasted image 20230201160320.png|500]]\n","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/Acute-Asthma-COPD-Exacerbation":{"title":"Acute Asthma \u0026 COPD Exacerbation","content":"## Definitions\n- **Asthma**: progressive increase in asthma symptoms\n- **COPD**: dyspnea and/or cough and sputum that worsen over \u003c 14 days\n- ‡∏ñ‡πâ‡∏≤‡∏°‡∏µ fever ‡∏≠‡∏≤‡∏à‡πÄ‡∏õ‡πá‡∏ô complication ‡∏≠‡∏¢‡πà‡∏≤‡∏á‡∏≠‡∏∑‡πà‡∏ô ‡∏≠‡∏≤‡∏à‡∏à‡πÄ‡∏õ‡πá‡∏ô CAP associated COPD exacerbation\n\n## Criteria for acute exacerbation\n- Asthma: typical symptoms / ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡πÄ‡∏ô‡πâ‡∏ô sputum ‡πÅ‡∏ï‡πà‡∏à‡∏∞ **progressive**\n- **COPD**: Worsening symptoms of dyspnea **or** increase in sputum volume **or** increase in sputum purulence #recall1\n\n## Pathophysiology\n\n![[Pasted image 20230131215618.png|450]]\n- Asthma: ‡∏≠‡∏≤‡∏à‡∏°‡∏≤‡∏à‡∏≤‡∏Å allergens, pollution, respiratory viruses\n\t- exacerbation ‡∏°‡∏±‡∏Å‡πÄ‡∏õ‡πá‡∏ô‡πÄ‡∏£‡πá‡∏ß‡∏´‡∏≤‡∏¢‡πÄ‡∏£‡πá‡∏ß\n- AECOPD: ‡∏°‡∏±‡∏Å‡∏à‡∏∞‡∏°‡∏≤‡∏à‡∏≤‡∏Å infection (‡∏û‡∏ö‡∏ö‡πà‡∏≠‡∏¢), pollution, tobacco\n\t- ‡πÄ‡∏™‡∏°‡∏´‡∏∞‡πÄ‡∏¢‡∏≠‡∏∞‡∏Ç‡∏∂‡πâ‡∏ô ‡∏Ç‡∏∏‡πà‡∏ô -\u003e bacterial\n\t- ‡πÄ‡∏™‡∏°‡∏´‡∏∞‡πÄ‡∏¢‡∏≠‡∏∞‡πÅ‡∏•‡∏∞ **eosinophilia -\u003e viral** #recall2 \n\n## Classification\n- Asthma\n\t- ![[Pasted image 20230131220751.png]]\n\t- Severe: accessory muscle use ‡∏´‡∏£‡∏∑‡∏≠ O2 Sat \u003c90% (PaO2 ‡∏ô‡πâ‡∏≠‡∏¢‡∏Å‡∏ß‡πà‡∏≤ 60) / ‡∏û‡∏π‡∏î‡πÑ‡∏°‡πà‡πÄ‡∏õ‡πá‡∏ô‡∏Ñ‡∏≥‡πÅ‡∏•‡πâ‡∏ß \n- COPD\n\t- ![[Pasted image 20230131220054.png]]\n\t- Mild\n\t\t- Dyspnea VAS \u003c 5\n\t\t- RR \u003c 24\n\t\t- SaO2 \u003e= 92 room air\n\t- Moderate\n\t\t- Dyspnea VAVS \u003e= 5\n\t\t- RR \u003e 24\n\t\t- SaO2 \u003c 92\n\t\t- ABG ‡∏ñ‡πâ‡∏≤‡∏°‡∏µ: ‡∏≠‡∏≤‡∏à Hypoxemia PaO2 \u003c= 60 mmHg ‡πÅ‡∏•‡∏∞‡∏´‡∏£‡∏∑‡∏≠ hypercapnia (PaCO2 \u003e 45) ‡πÅ‡∏ï‡πà‡πÑ‡∏°‡πà acidosis\n\n## Asthma Management\n- Self Management:\n\t- ‡πÄ‡∏û‡∏¥‡πà‡∏°‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ reliever ‡πÅ‡∏•‡∏∞ controller\n\t- ‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å PEF or FEV \u003c 60% best ‡∏´‡∏£‡∏∑‡∏≠‡πÑ‡∏°‡πà‡∏î‡∏µ‡∏Ç‡∏∂‡πâ‡∏ô‡πÉ‡∏ô 48 ‡∏ä‡∏°‡πÉ‡∏´‡πâ add prednisolone 40-50 mg/day (‡∏Å‡πá‡∏Ñ‡∏∑‡∏≠‡∏Å‡∏¥‡∏ô 4x2 ‡∏´‡∏£‡∏∑‡∏≠ max 8 tab/day) **‡∏à‡∏±‡∏î‡πÄ‡∏õ‡πá‡∏ô emergency**\n- Primary Care:\n\t-  Mild or Moderate\n\t\t- SABA with or without SAMA 4-10 puffs by pMDI + spacer q20min for 1 hrs ‡∏´‡∏£‡∏∑‡∏≠‡∏≠‡∏≤‡∏à‡πÉ‡∏´‡πâ‡πÄ‡∏õ‡πá‡∏ô nebulizers ‡πÅ‡∏ï‡πà‡∏ï‡πâ‡∏≠‡∏á dilute aerosol min 3 ml at gas flow 6-8 L/min ‡πÅ‡∏•‡∏∞‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πâ‡∏ñ‡πâ‡∏≤‡∏ï‡∏¥‡∏î‡πÄ‡∏ä‡∏∑‡πâ‡∏≠ viral respiratory\n\t\t\t- Note: SAMA in severe case only! ‡∏Å‡∏•‡∏±‡∏ß‡πÄ‡∏™‡∏°‡∏´‡∏∞‡πÅ‡∏´‡πâ‡∏á\n\t\t\t- ‡πÅ‡∏•‡πâ‡∏ß F/U ‡∏û‡∏≠‡πÉ‡∏´‡πâ‡πÑ‡∏õ 3 doses (1 hrs)\n\t\t- Prednisolone (within 1 hrs if indicated in ER) 40-50 mg/day (od or bid) for 5-7 days #recall2 \n\t\t\t- ‡∏ñ‡πâ‡∏≤‡πÑ‡∏°‡πà‡∏î‡∏µ‡∏Ç‡∏∂‡πâ‡∏ô‡πÉ‡∏ô 2-3 ‡∏ß‡∏±‡∏ô ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡πÅ‡∏¢‡πà‡∏•‡∏á‡πÄ‡∏£‡πá‡∏ß ‡∏°‡∏µ‡∏õ‡∏£‡∏∞‡∏ß‡∏±‡∏ï‡∏¥ sudden severe exacerbation ‡∏°‡∏≤‡∏Å‡πà‡∏≠‡∏ô ‡∏Å‡πá‡πÉ‡∏ä‡πâ‡πÄ‡∏•‡∏¢ ‡πÄ‡∏û‡∏∑‡πà‡∏≠‡πÄ‡∏£‡πà‡∏á‡πÉ‡∏´‡πâ exacerbation ‡∏´‡∏≤‡∏¢‡πÄ‡∏£‡πá‡∏ß\n\t\t\t- ‡πÉ‡∏ä‡πâ dexa 16mg/day od for 2 days ‡πÅ‡∏ó‡∏ô‡πÑ‡∏î‡πâ ‡πÅ‡∏•‡πâ‡∏ß‡∏Ñ‡πà‡∏≠‡∏¢‡∏ï‡πà‡∏≠‡∏î‡πâ‡∏ß‡∏¢ prednisolone\n\t\t\t- ‡∏ñ‡πâ‡∏≤‡πÉ‡∏´‡πâ oral ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏Å‡πá inhale ‡∏Å‡πá‡πÑ‡∏î‡πâ ‡πÅ‡∏ï‡πà‡∏õ‡∏£‡∏∞‡∏™‡∏¥‡∏ó‡∏ò‡∏¥‡∏†‡∏≤‡∏û oral = iv\n\t\t\t- ‡πÑ‡∏°‡πà‡∏ï‡πâ‡∏≠‡∏á tape ‡∏ñ‡πâ‡∏≤‡πÉ‡∏´‡πâ‡∏ô‡πâ‡∏≠‡∏¢‡∏Å‡∏ß‡πà‡∏≤ 2 wks\n\t\t\t- ‡∏ô‡∏¥‡∏¢‡∏°‡πÉ‡∏´‡πâ‡∏ï‡∏≠‡∏ô‡πÄ‡∏ä‡πâ‡∏≤‡πÄ‡∏û‡∏£‡∏≤‡∏∞ cortisol ‡∏™‡∏π‡∏á\n\t\t- Oxygen therapy target 93-95%\n\t\t- Extra: Symbicort (ICS-Formoterol) ‡πÉ‡∏ô‡πÄ‡∏Ñ‡∏™ mild ‡∏≠‡∏≤‡∏à‡πÄ‡∏£‡∏µ‡∏¢‡∏Å‡∏ß‡πà‡∏≤ AIR (anti inflammatory reliever) ‡πÉ‡∏ä‡πâ‡πÑ‡∏î‡πâ‡∏°‡∏≤‡∏Å‡∏™‡∏∏‡∏î 12 ‡∏Ñ‡∏£‡∏±‡πâ‡∏á‡∏ï‡πà‡∏≠‡∏ß‡∏±‡∏ô ‡πÇ‡∏î‡∏¢‡πÉ‡∏ä‡πâ 1 inhalation as needed ‡πÉ‡∏ä‡πâ‡∏ã‡πâ‡∏≥‡πÑ‡∏î‡πâ‡πÅ‡∏ï‡πà‡πÑ‡∏°‡πà‡πÄ‡∏Å‡∏¥‡∏ô 6 ‡πÉ‡∏ô 1 occasion\n\t- Severe:\n\t\t- ‡∏™‡πà‡∏á‡∏ï‡πà‡∏≠ acute care\n- Acute Care:\n\t- Mild or Moderate\n\t\t- ‡πÉ‡∏´‡πâ Berodual (‡∏°‡∏µ ipratropium bromide) ‡πÄ‡∏°‡∏∑‡πà‡∏≠ ventolin ‡∏™‡∏∏‡∏î‡πÅ‡∏•‡πâ‡∏ß‡πÑ‡∏°‡πà‡∏î‡∏µ‡∏Ç‡∏∂‡πâ‡∏ô\n\t- Severe:\n\t\t- ‡∏™‡∏≤‡∏î‡πÅ‡∏°‡πâ‡∏á‡πÉ‡∏´‡πâ‡∏´‡∏°‡∏î‡∏ó‡∏∏‡∏Å‡∏≠‡∏¢‡πà‡∏≤‡∏á‡∏ó‡∏µ‡πà‡∏°‡∏µ ‡∏≠‡∏¥‡∏≠‡∏¥\n\t\t- Prednisolone\n\n## Asthma Pharmacology\n- Symbicort 160/4.5 mcg\n\t- ![[Pasted image 20230131221428.png]]\n\t- ‡∏Ç‡∏≠‡∏á‡πÑ‡∏ó‡∏¢‡∏Å‡∏±‡∏ö‡πÄ‡∏°‡∏Å‡∏≤‡∏ï‡πà‡∏≤‡∏á‡∏Å‡∏±‡∏ô ‡∏Ç‡∏≠‡∏á‡πÑ‡∏ó‡∏¢‡∏à‡∏∞‡πÄ‡∏õ‡πá‡∏ô delivered dose ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤‡πÄ‡∏°‡∏Å‡∏≤‡∏à‡∏∞‡πÄ‡∏õ‡πá‡∏ô metered dose\n\t\t- max formoterol 72 mcg/day (‡πÄ‡∏Ñ‡∏£‡∏∑‡πà‡∏≠‡∏á‡∏ß‡∏±‡∏î)\n\t\t- max delivered 54 mcg/day\n\t- ‡∏î‡∏±‡∏á‡∏ô‡∏±‡πâ‡∏ô‡∏™‡∏£‡∏∏‡∏õ‡πÅ‡∏•‡πâ‡∏ß ‡πÄ‡∏£‡∏≤‡πÉ‡∏ä‡πâ‡πÑ‡∏î‡πâ‡∏°‡∏≤‡∏Å‡∏™‡∏∏‡∏î 12 ‡∏Ñ‡∏£‡∏±‡πâ‡∏á‡∏ï‡πà‡∏≠‡∏ß‡∏±‡∏ô\n- Anticholinergics (Ipratropium Bromate)\n\t- No role in acute ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏Å‡∏•‡∏±‡∏ß‡∏ó‡∏≥‡πÄ‡∏™‡∏°‡∏´‡∏∞‡πÅ‡∏´‡πâ‡∏á! ‡πÅ‡∏ï‡πà‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡πÄ‡∏Ñ‡∏™ Severe ‡πÄ‡∏õ‡πá‡∏ô/ adjunct\n- Magnesium sulphate\n\t- ‡∏°‡∏µ role ‡πÅ‡∏Ñ‡πà severe ‡πÇ‡∏î‡∏¢‡πÉ‡∏´‡πâ‡πÅ‡∏Ñ‡πà‡πÉ‡∏ô‡∏Å‡∏£‡∏ì‡∏µ‡∏ó‡∏µ‡πà‡πÑ‡∏°‡πà‡∏ï‡∏≠‡∏ö‡∏™‡∏ô‡∏≠‡∏á‡∏ï‡πà‡∏≠‡∏Å‡∏≤‡∏£‡∏£‡∏±‡∏Å‡∏©‡∏≤‡∏Å‡πà‡∏≠‡∏ô‡∏´‡∏ô‡πâ‡∏≤‡πÄ‡∏•‡∏¢ ‡∏Å‡∏•‡πÑ‡∏Å‡∏Ñ‡∏∑‡∏≠‡∏Ñ‡∏•‡∏≤‡∏¢‡∏Å‡∏•‡πâ‡∏≤‡∏°‡πÄ‡∏ô‡∏∑‡πâ‡∏≠ block ach ‡πÅ‡∏•‡∏∞ histamine release\n\n## AECOPD Management\n- Mild:\n\t- short acting bronchodilators only\n- Moderate:\n\t- short acting bronchodilators\n\t- antibiotics \n\t\t- indication ‡∏Ñ‡∏∑‡∏≠ ‡∏°‡∏µ‡∏ó‡∏±‡πâ‡∏á worsening symptoms of dyspnea or increase in sputum volume or increase in sputum purulence\n\t\t- ‡∏´‡∏£‡∏∑‡∏≠ increase in sputum purulence (‡πÄ‡∏™‡∏°‡∏´‡∏∞‡πÄ‡∏õ‡∏•‡∏µ‡πà‡∏¢‡∏ô‡∏™‡∏µ) + ‡∏≠‡∏∞‡πÑ‡∏£‡∏Å‡πá‡πÑ‡∏î‡πâ‡∏™‡∏±‡∏Å‡∏≠‡∏±‡∏ô\n\t\t- **‡∏´‡∏£‡∏∑‡∏≠ mechanical ventilation** #recall2 \n\t\t- ‡πÉ‡∏ä‡πâ azithromycin 250 x2  5-7 ‡∏ß‡∏±‡∏ô\n\t- and/or oral corticosteroid\n- Severe:\n\t- require hospitalization or visit emergency room\n- Cautions!\n\t- MDI with or without spacer ‡πÉ‡∏´‡πâ‡∏ú‡∏•‡πÑ‡∏°‡πà‡∏ï‡πà‡∏≤‡∏á‡∏Å‡∏±‡∏ô\n\t- ‡πÑ‡∏°‡πà‡∏°‡∏µ‡πÅ‡∏ô‡∏∞‡∏ô‡∏≥ ICS-formoterol **as-needed** ‡∏™‡∏≥‡∏´‡∏£‡∏±‡∏ö AECOPD ‡πÅ‡∏ï‡πà‡∏à‡∏∞‡πÉ‡∏´‡πâ‡∏ï‡∏≤‡∏° indicated ‡πÉ‡∏ô [[notes/COPD 2022]])\n\t\t- AECOPD ‡∏à‡∏∞‡∏°‡∏µ‡πÉ‡∏ä‡πâ‡πÅ‡∏Ñ‡πà ventolin, berodual or inhalex\n\t- SAMA ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡πÄ‡∏û‡∏¥‡πà‡∏° FEV1\n- Addition Therapy:\n\t- Systemic corticosteroid:\n\t\t- prednisolone 40-50 mg/day 5 days\n\t\t- IV methylprednisolone 40mg/day\n\t\t- nebulized budesonide\n\t\t- ‡∏´‡∏ß‡∏±‡∏á‡∏ú‡∏• shorten recovery time, improve oxygenation, reduce LOS and risk of early relapse\n\t- Oxygen Therapy\n\t\t- Keep 88-92%\n\t- Mechanical Ventilation\n\t\t- ![[Pasted image 20230131224257.png|300]]\n\t\t- NIV: ‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡πÄ‡∏Ñ‡∏™‡πÄ‡∏™‡∏°‡∏´‡∏∞‡πÄ‡∏¢‡∏≠‡∏∞ ‡∏°‡∏µ‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ‡πÄ‡∏õ‡πá‡∏ô routine ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏•‡∏î‡∏≠‡∏±‡∏ï‡∏£‡∏≤‡∏Å‡∏≤‡∏£‡πÄ‡∏™‡∏µ‡∏¢‡∏ä‡∏µ‡∏ß‡∏¥‡∏ï, intubation rate, decreased VAP ‡πÅ‡∏ï‡πà‡πÉ‡∏ä‡πâ‡πÅ‡∏Ñ‡πà‡∏™‡∏±‡πâ‡∏ô ‡πÜ 4 hours\n\t\t- Intubation: ‡∏à‡∏∞‡πÉ‡∏ä‡πâ‡πÅ‡∏Ñ‡πà‡∏Å‡∏£‡∏ì‡∏µ‡πÉ‡∏ä‡πâ NIV ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/Alcoholic-hepatitis":{"title":"Alcoholic hepatitis","content":"## Alcoholic\n- \u003e 80% ‡∏à‡∏∞‡∏°‡∏µ fatty liver -\u003e 20-40% fibrosis -\u003e 10-20% cirrhosis ‡πÅ‡∏•‡∏∞ 1-2% of cirrhosis ‡∏à‡∏∞‡πÄ‡∏õ‡πá‡∏ô HCC\n- ‡∏´‡∏≤‡∏Å asymptomatic ‡πÅ‡∏•‡πâ‡∏ß‡∏ï‡∏£‡∏ß‡∏à‡∏û‡∏ö ‡πÉ‡∏´‡πâ‡∏£‡∏µ‡∏ö‡∏£‡∏±‡∏Å‡∏©‡∏≤‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏¢‡∏±‡∏á‡∏°‡∏µ‡πÇ‡∏≠‡∏Å‡∏≤‡∏™‡∏¢‡πâ‡∏≠‡∏ô‡∏Å‡∏•‡∏±‡∏ö‡πÑ‡∏î‡πâ ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å symptomatic ‡πÅ‡∏•‡πâ‡∏ß‡∏°‡∏±‡∏Å‡∏à‡∏∞‡πÄ‡∏õ‡πá‡∏ô‡∏ä‡πà‡∏ß‡∏á‡∏ó‡∏µ‡πà‡∏ï‡∏±‡∏ö‡∏ñ‡∏π‡∏Å‡∏ó‡∏≥‡∏•‡∏≤‡∏¢ (‡πÄ‡∏Å‡∏¥‡∏î fibrous) -\u003e cirrosis ‡∏î‡∏±‡∏á‡∏ô‡∏±‡πâ‡∏ô‡∏Å‡∏≤‡∏£‡∏£‡∏±‡∏Å‡∏©‡∏≤‡∏à‡∏∞‡πÄ‡∏õ‡πá‡∏ô‡∏Å‡∏≤‡∏£‡∏£‡∏±‡∏Å‡∏©‡∏≤‡πÅ‡∏ö‡∏ö‡∏õ‡∏£‡∏∞‡∏Ñ‡∏±‡∏ö‡∏õ‡∏£‡∏∞‡∏Ñ‡∏≠‡∏á\n- ‡∏°‡∏≤‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà alcohol ‡∏ó‡∏≥‡πÉ‡∏´‡πâ antioxidants ‡πÑ‡∏°‡πà‡πÄ‡∏û‡∏µ‡∏¢‡∏á‡∏û‡∏≠ ‡∏´‡∏£‡∏∑‡∏≠‡∏°‡∏≤‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà alcohol ‡∏ñ‡∏π‡∏Å‡πÄ‡∏õ‡∏•‡∏µ‡πà‡∏¢‡∏ô‡πÄ‡∏õ‡πá‡∏ô acetaldehyde or ROS by alcohol dehydrogenase and cytochrome p450 2E1 ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏≠‡∏±‡∏Å‡∏Å‡∏≤‡∏£‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö\n- ‡∏≠‡∏µ‡∏Å‡∏ó‡∏≤‡∏á‡∏Å‡πá‡∏Ñ‡∏∑‡∏≠ alcohol ‡∏ó‡∏≥‡πÉ‡∏´‡πâ gut permeability ‡πÄ‡∏û‡∏¥‡πà‡∏°‡∏Ç‡∏∂‡πâ‡∏ô ‡πÄ‡∏Å‡∏¥‡∏î‡∏Å‡∏≤‡∏£‡∏£‡∏±‡∏ö‡∏™‡∏≤‡∏£‡∏ï‡πà‡∏≤‡∏á ‡πÜ ‡∏°‡∏≤‡∏Å‡∏Ç‡∏∂‡πâ‡∏ô ‡∏Å‡∏£‡∏∞‡∏ï‡∏∏‡πâ‡∏ô‡πÄ‡∏ã‡∏•‡∏•‡πå‡∏ï‡∏±‡∏ö‡πÉ‡∏´‡πâ‡∏ó‡∏≥‡∏á‡∏≤‡∏ô‡∏°‡∏≤‡∏Å‡∏Ç‡∏∂‡πâ‡∏ô (activation of sinusoidal kupffer cells) ‡∏à‡∏∂‡∏á‡πÄ‡∏Å‡∏¥‡∏î‡∏Å‡∏≤‡∏£‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡∏°‡∏≤‡∏Å‡∏Ç‡∏∂‡πâ‡∏ô\n- ‡πÄ‡∏°‡∏∑‡πà‡∏≠‡πÄ‡∏Å‡∏¥‡∏î‡∏Å‡∏≤‡∏£‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö ‡∏´‡∏≤‡∏Å‡∏°‡∏µ fibrosis ‡∏Å‡πá‡∏à‡∏∞‡∏Å‡∏•‡∏≤‡∏¢‡πÄ‡∏õ‡πá‡∏ô cirrosis ‡πÑ‡∏î‡πâ‡πÉ‡∏ô‡∏ó‡∏µ‡πà‡∏™‡∏∏‡∏î\n- ‡∏ó‡∏≤‡∏á‡∏£‡∏±‡∏Å‡∏©‡∏≤‡∏Ñ‡∏∑‡∏≠‡∏Å‡∏≤‡∏£‡∏´‡∏¢‡∏∏‡∏î‡∏î‡∏∑‡πà‡∏° alcohol \n- ‡πÄ‡∏£‡∏≤‡∏à‡∏∞‡∏Å‡∏•‡∏±‡∏ß‡∏†‡∏≤‡∏ß‡∏∞ alcohol withdrawal ‡πÉ‡∏ô‡πÄ‡∏£‡∏∑‡πà‡∏≠‡∏á‡∏Ç‡∏≠‡∏á‡∏Å‡∏≤‡∏£‡∏ä‡∏±‡∏Å‡∏°‡∏≤‡∏Å‡∏ó‡∏µ‡πà‡∏™‡∏∏‡∏î\n- ‡∏≠‡∏¢‡πà‡∏≤‡∏•‡∏∑‡∏°‡∏ó‡∏µ‡πà‡∏à‡∏∞‡∏ó‡∏î‡πÅ‡∏ó‡∏ô‡∏û‡∏•‡∏±‡∏á‡∏á‡∏≤‡∏ô ‡∏´‡∏£‡∏∑‡∏≠‡∏™‡∏≤‡∏£‡∏≠‡∏≤‡∏´‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏Ç‡∏≤‡∏î‡∏´‡∏≤‡∏¢‡πÑ‡∏õ‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡πÄ‡∏õ‡πá‡∏ô‡πÇ‡∏£‡∏Ñ‡∏ï‡∏±‡∏ö‡∏à‡∏≤‡∏Å alcohol ‡πÄ‡∏ä‡πà‡∏ô vitamin A D **B1 B12** folate zinc\n- ‡∏Å‡∏≤‡∏£‡∏£‡∏±‡∏Å‡∏©‡∏≤\n![[Pasted image 20230306211454.png|575]]\n- steroid ‡∏à‡∏∞‡πÉ‡∏ä‡πâ‡πÄ‡∏õ‡πá‡∏ô‡∏£‡∏∞‡∏¢‡∏∞‡πÄ‡∏ß‡∏•‡∏≤ 4 ‡∏™‡∏±‡∏õ‡∏î‡∏≤‡∏´‡πå\n- ‡∏≠‡∏≤‡∏à‡πÉ‡∏ä‡πâ methyprednisolone 32 mg/day (IV) ‡πÅ‡∏ó‡∏ô prednisolone (oral)\n- ‡∏Ñ‡∏∞‡∏Å‡∏ô‡∏ô‡∏Å‡∏≤‡∏£‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô‡∏ó‡∏µ‡πà‡πÄ‡∏Å‡∏µ‡πà‡∏¢‡∏ß‡∏Ç‡πâ‡∏≠‡∏á\n\t- Maddrey, mDF (cutpoint 32)\n\t- MELD (cutpont 21)\n\t- Lille's score (cutpont 0.45)\n\n## Non-Alcoholic (NAFLD -\u003e non-alcoholic fatty liver disease)\n- ![[Pasted image 20230306211633.png|500]]\n\t- NAFL = non-alcoholic fatty liver\n\t- NASH = non-alcoholic steatohepatitis\n- ![[Pasted image 20230306211638.png|500]]\n\t- ‡∏î‡∏±‡∏á‡∏ô‡∏±‡πâ‡∏ô ‡∏ï‡πà‡∏≠‡πÉ‡∏´‡πâ‡∏°‡∏µ‡πÅ‡∏Ñ‡πà obesity ‡∏Å‡πâ‡∏ô‡πà‡∏≤‡∏Å‡∏•‡∏±‡∏ß (20-25% ‡∏à‡∏∞‡∏Å‡∏•‡∏≤‡∏¢‡πÄ‡∏õ‡πá‡∏ô NASH)\n- ![[Pasted image 20230306211913.png]]\n- NAFLD ‡πÄ‡∏û‡∏¥‡πà‡∏° cardiorisk ‡πÑ‡∏î‡πâ ‡πÄ‡∏ß‡∏•‡∏≤ approach ‡∏Å‡πá‡∏ï‡∏≤‡∏°‡∏ù‡∏±‡πà‡∏á cardio ‡πÑ‡∏î‡πâ‡πÄ‡∏•‡∏¢\n- metformin ‡∏ö‡∏≤‡∏á‡∏Ñ‡∏ô‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡πÄ‡∏õ‡πâ‡∏ô‡πÄ‡∏ö‡∏≤‡∏´‡∏ß‡∏≤‡∏ô ‡πÅ‡∏ï‡πà‡πÉ‡∏ä‡πâ‡πÄ‡∏ô‡∏∑‡πà‡∏≠‡∏á‡∏à‡∏≤‡∏Å high risk\n- hepatoprotectives ‡∏Ñ‡∏∑‡∏≠‡∏û‡∏ß‡∏Å‡∏ó‡∏µ‡πà‡∏ä‡πà‡∏ß‡∏¢‡πÄ‡∏™‡∏£‡∏¥‡∏° membrane ‡∏ï‡∏±‡∏ö\n- lifestyle modification (EASL 2018):\n\t- energy restriction\n\t- macronutrient composition\n\t- fructose intake\n\t- alcohol intake\n\t- coffee drinking\n\t- exercise/physical activity","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/Asthma-2022":{"title":"Asthma 2022","content":"# Subject: Pharmacotherapy I \n\n**Author:** ‡∏û‡∏≠‡∏à‡∏≠ c91 rx80\n**Note:** ‡πÇ‡∏õ‡∏£‡∏î‡∏≠‡πà‡∏≤‡∏ô‡∏ï‡∏≤‡∏°‡∏®‡∏£‡∏±‡∏ó‡∏ò‡∏≤ \n**Finished Date:** [[2023-02-01]]\n\n## Asthma and COVID-19\n\u003e [!note] ‡πÇ‡∏Ñ‡∏ß‡∏¥‡∏î‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á Asthma ‡∏´‡∏£‡∏∑‡∏≠ Asthma ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á‡πÇ‡∏Ñ‡∏ß‡∏¥‡∏î ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤‡πÄ‡∏õ‡πá‡∏ô uncontrolled Asthma ‡∏à‡∏∞‡∏°‡∏µ‡∏≠‡∏±‡∏ï‡∏£‡∏≤‡∏Å‡∏≤‡∏£‡πÄ‡∏™‡∏µ‡∏¢‡∏ä‡∏µ‡∏ß‡∏¥‡∏ï‡∏ó‡∏µ‡πà‡∏™‡∏π‡∏á‡∏Ç‡∏∂‡πâ‡∏ô‡∏ñ‡πâ‡∏≤‡∏ï‡∏¥‡∏î‡πÇ‡∏Ñ‡∏ß‡∏¥‡∏î\n- ‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á‡∏ï‡∏¥‡∏î‡πÇ‡∏Ñ‡∏ß‡∏¥‡∏î‡∏°‡∏≤‡∏Å‡∏Ç‡∏∂‡πâ‡∏ô\n- ‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏ó‡∏µ‡πà‡∏Ñ‡∏∏‡∏°‡πÇ‡∏Ñ‡∏ß‡∏¥‡∏î‡πÑ‡∏î‡πâ well-controlled ‡πÅ‡∏•‡∏∞ mild-mod asthma ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á‡∏à‡∏∞‡πÄ‡∏õ‡πá‡∏ô severe covid\n- ‡∏Ñ‡∏ô‡∏ó‡∏µ‡πà well-controlled ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏ï‡∏≤‡∏¢‡πÄ‡∏¢‡∏≠‡∏∞‡∏Ç‡∏∂‡πâ‡∏ô\n- **‡πÅ‡∏ï‡πà** ‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏ó‡∏µ‡πà‡πÉ‡∏ä‡πâ OCS ‡∏≠‡∏±‡∏ï‡∏£‡∏≤‡∏Å‡∏≤‡∏£‡∏ï‡∏≤‡∏¢‡πÄ‡∏¢‡∏≠‡∏∞‡∏Ç‡∏∂‡πâ‡∏ô (‡πÄ‡∏û‡∏£‡∏≤‡∏∞ uncontrolled) ‡πÅ‡∏•‡∏∞‡∏Ñ‡∏ô‡∏ó‡∏µ‡πà hospitalized with severe asthma ‡∏≠‡∏±‡∏ï‡∏£‡∏≤‡∏Å‡∏≤‡∏£‡∏ï‡∏≤‡∏¢‡πÄ‡∏¢‡∏≠‡∏∞‡∏Ç‡∏∂‡πâ‡∏ô\n- ‡∏ä‡πà‡∏ß‡∏á‡πÇ‡∏Ñ‡∏ß‡∏¥‡∏î asthma exacerbation ‡πÅ‡∏•‡∏∞ influenza-related illness ‡∏•‡∏î‡∏•‡∏á\n- **‡∏î‡∏±‡∏á‡∏ô‡∏±‡πâ‡∏ô ‡πÉ‡∏´‡πâ‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏Ñ‡∏∏‡∏° asthma ‡πÉ‡∏´‡πâ‡πÑ‡∏î‡πâ‡πÅ‡∏•‡∏∞‡∏•‡∏î‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ OCS**\n\n### Intranasal Corticosteroid\n- ‡∏°‡∏µ 1 ‡∏Å‡∏≤‡∏£‡∏®‡∏∂‡∏Å‡∏©‡∏≤‡∏ß‡πà‡∏≤ ICS ‡πÉ‡∏ô asthma (pt age \u003e=50) ‡∏•‡∏î‡∏Å‡∏≤‡∏£‡∏ï‡∏≤‡∏¢‡∏à‡∏≤‡∏Å‡πÇ‡∏Ñ‡∏ß‡∏¥‡∏î ‡πÑ‡∏î‡πâ‡∏î‡∏µ‡∏Å‡∏ß‡πà‡∏≤ ‡∏Ñ‡∏ô‡∏ó‡∏µ‡πà‡πÄ‡∏õ‡πá‡∏ô‡πÇ‡∏Ñ‡∏ß‡∏¥‡∏î‡πÅ‡∏•‡∏∞‡πÑ‡∏°‡πà‡∏°‡∏µ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏õ‡∏≠‡∏î‡πÉ‡∏î ‡πÜ ‡πÄ‡∏•‡∏¢ ‡πÅ‡∏ï‡πà‡∏Å‡πá‡πÄ‡∏û‡∏¥‡πà‡∏° infection ‡πÑ‡∏î‡πâ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏°‡∏±‡∏ô‡∏Å‡πá‡πÄ‡∏õ‡πá‡∏ô steroid\n- ‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏ó‡∏∏‡∏Å‡∏Ñ‡∏ô‡∏Ñ‡∏ß‡∏£‡∏°‡∏µ Asthma Action Plans\n\n### Nebulizers\n- **‡πÄ‡∏õ‡πá‡∏ô‡πÇ‡∏Ñ‡∏ß‡∏¥‡∏î‡∏≠‡∏¢‡πà‡∏≤‡πÉ‡∏ä‡πâ nebulizers** (‡∏à‡∏≥‡πÄ‡∏õ‡πá‡∏ô‡∏à‡∏£‡∏¥‡∏á‡πÉ‡∏´‡πâ‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡∏´‡πâ‡∏≠‡∏á negative pressure) ‡πÅ‡∏•‡∏∞ **‡πÄ‡∏ß‡∏•‡∏≤‡πÉ‡∏ä‡πâ pMDI / bronchodilator ‡πÉ‡∏´‡πâ‡πÉ‡∏™‡πà spacer** ‡∏¢‡∏Å‡πÄ‡∏ß‡πâ‡∏ô‡πÉ‡∏ô‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏ó‡∏µ‡πà acute severe asthma\n\n### Vaccination\n- ‡∏â‡∏µ‡∏î‡∏ß‡∏±‡∏Ñ‡∏ã‡∏µ‡∏ô‡πÇ‡∏Ñ‡∏ß‡∏¥‡∏î‡∏ó‡∏∏‡∏Å 6 ‡πÄ‡∏î‡∏∑‡∏≠‡∏ô\n- ‡πÑ‡∏°‡πà‡πÉ‡∏´‡πâ biologic ‡∏Å‡∏±‡∏ö‡∏ß‡∏±‡∏Ñ‡∏ã‡∏µ‡∏ô‡πÇ‡∏Ñ‡∏ß‡∏¥‡∏î‡πÉ‡∏ô‡∏ß‡∏±‡∏ô‡πÄ‡∏î‡∏µ‡∏¢‡∏ß‡∏Å‡∏±‡∏ô\n- ‡∏â‡∏µ‡∏î‡πÑ‡∏Ç‡πâ‡∏´‡∏ß‡∏±‡∏î‡πÉ‡∏´‡∏ç‡πà‡∏ó‡∏∏‡∏Å‡∏õ‡∏µ ‡πÅ‡∏•‡∏∞‡∏â‡∏µ‡∏î‡∏û‡∏£‡πâ‡∏≠‡∏°‡πÇ‡∏Ñ‡∏ß‡∏¥‡∏î‡πÑ‡∏î‡πâ\n\n### Assessment\n- ‡πÄ‡∏Å‡∏ì‡∏ë‡πå‡πÉ‡∏ô‡∏Å‡∏≤‡∏£‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô‡∏Å‡∏≤‡∏£‡∏Ñ‡∏ß‡∏ö‡∏Ñ‡∏∏‡∏°‡πÇ‡∏£‡∏Ñ [[Asthma \u0026 COPD#Assessment]]\n\t- ‡∏°‡∏µ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡πÉ‡∏ô‡∏ä‡πà‡∏ß‡∏á‡∏Å‡∏•‡∏≤‡∏á‡∏ß‡∏±‡∏ô \u003e2 ‡∏Ñ‡∏£‡∏±‡πâ‡∏á/wk\n\t- ‡∏°‡∏µ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡πÉ‡∏ô‡∏ä‡πà‡∏ß‡∏á‡∏Å‡∏•‡∏≤‡∏á‡∏Ñ‡∏∑‡∏ô‡∏´‡∏£‡∏∑‡∏≠‡∏ï‡∏∑‡πà‡∏ô‡∏°‡∏≤‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏Å‡∏≥‡πÄ‡∏£‡∏¥‡∏ö\n\t- ‡πÉ‡∏ä‡πâ reliever \u003e2‡∏Ñ‡∏£‡∏±‡πâ‡∏á/wk\n\t- ‡∏°‡∏µ‡∏Ç‡∏µ‡∏î‡∏à‡∏≥‡∏Å‡∏±‡∏î‡πÉ‡∏ô‡∏Å‡∏≤‡∏£‡∏ó‡∏≥‡∏Å‡∏¥‡∏à‡∏Å‡∏£‡∏£‡∏°‡πÄ‡∏ô‡∏∑‡πà‡∏≠‡∏á‡∏à‡∏≤‡∏Å asthma\n- 0 ‡∏Ç‡πâ‡∏≠ = well control\n- 1-2 ‡∏Ç‡πâ‡∏≠ = partly control\n- 3-4 ‡∏Ç‡πâ‡∏≠ = uncontrolled\n\n## Diagnosis\n- test before treating\n- ‡∏ó‡∏∏‡∏Å‡∏Ñ‡∏ô‡∏Ñ‡∏ß‡∏£‡πÑ‡∏î‡πâ‡∏ó‡∏≥ spirometry ‡πÄ‡∏õ‡πá‡∏ô baseline\n- diagnosis ‡∏î‡πâ‡∏ß‡∏¢ [[#Clinical Presentation]] ‡πÄ‡∏õ‡πá‡∏ô‡∏´‡∏•‡∏±‡∏Å**‡πÅ‡∏ï‡πà definite ‡∏î‡πâ‡∏ß‡∏¢ bronchus response** ([[#Lung Function]])\n \u003e [!warning] ‡∏£‡∏∞‡∏ß‡∏±‡∏á! ‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ ICS ‡∏à‡∏∞‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏ú‡∏•‡πÄ‡∏û‡∏µ‡πâ‡∏¢‡∏ô‡πÑ‡∏î‡πâ ‡∏Ñ‡∏ß‡∏£‡∏´‡∏¢‡∏∏‡∏î‡∏Å‡πà‡∏≠‡∏ô\n\n### Clinical Presentation\n- ‡πÄ‡∏î‡πà‡∏ô wheeze \u003e cough *‡∏ï‡πà‡∏≤‡∏á‡∏à‡∏≤‡∏Å COPD ‡∏ó‡∏µ‡πà cough \u003e wheeze*\n- isolated cough ‡πÑ‡∏°‡πà‡∏Ñ‡πà‡∏≠‡∏¢‡∏û‡∏ö\n- ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏î‡∏µ ‡πÜ ‡∏´‡∏≤‡∏¢ ‡πÜ ‡∏°‡∏±‡∏Å‡πÅ‡∏¢‡πà‡∏ï‡∏≠‡∏ô‡∏ï‡∏∑‡πà‡∏ô‡∏´‡∏£‡∏∑‡∏≠‡∏ô‡∏≠‡∏ô\n- ‡∏°‡∏µ‡∏™‡∏¥‡πà‡∏á‡∏Å‡∏£‡∏∞‡∏ï‡∏∏‡πâ‡∏ô‡πÑ‡∏î‡πâ ‡πÅ‡∏•‡∏∞‡πÅ‡∏¢‡πà‡∏•‡∏á‡∏ñ‡πâ‡∏≤‡∏ï‡∏¥‡∏î‡πÄ‡∏ä‡∏∑‡πâ‡∏≠‡πÑ‡∏ß‡∏£‡∏±‡∏™‡πÑ‡∏î‡πâ\n\n### Lung Function\n$$ Peak\\,flow\\,variaiblity = \\frac{(PEF‡∏™‡∏π‡∏á‡∏™‡∏∏‡∏î-PEF‡∏ï‡πà‡∏≥‡∏™‡∏∏‡∏î)}{(PEF‡∏™‡∏π‡∏á‡∏™‡∏∏‡∏î+PEF‡∏ï‡πà‡∏≥‡∏™‡∏∏‡∏î)/2}*100  $$\n- PEF = Peak Expiratory Flow (‡πÄ‡∏õ‡πà‡∏≤)\n- ‡∏™‡∏π‡∏á‡∏™‡∏∏‡∏î ‡∏´‡∏°‡∏≤‡∏¢‡∏ñ‡∏∂‡∏á ‡∏Ñ‡πà‡∏≤‡∏î‡∏µ‡∏∏‡∏™‡∏î\n- ‡∏ï‡πà‡∏≥‡∏™‡∏∏‡∏î ‡∏´‡∏°‡∏≤‡∏¢‡∏ñ‡∏∂‡∏á ‡∏Ñ‡πà‡∏≤‡πÅ‡∏¢‡πà‡∏™‡∏∏‡∏î\n#### ‡∏Å‡∏≤‡∏£ diagnosis ‡∏ï‡πâ‡∏≠‡∏á‡∏°‡∏µ 2 ‡∏≠‡∏¢‡πà‡∏≤‡∏á‡πÑ‡∏î‡πâ‡πÅ‡∏Å‡πà\n\u003e[!note] *The FEV1 measures how much air you can exhale in one second. The FVC measures the total amount of air you can exhale forcefully in one breath.*\n1. **Documented expiratory airflow limitation:** ‡∏≠‡∏±‡∏ô‡∏ô‡∏µ‡πâ‡∏Ñ‡πà‡∏≤ normal FEV1/FVC \u003e 0.75-0.8 (adult) ‡πÅ‡∏•‡∏∞ \u003e0.9 (children)\n2. **Documented excessive variability in lung function:** ‡∏≠‡∏¢‡πà‡∏≤‡∏á‡πÉ‡∏î‡∏≠‡∏¢‡πà‡∏≤‡∏á‡∏´‡∏ô‡∏∂‡πà‡∏á‡πÑ‡∏î‡πâ‡πÅ‡∏Å‡πà\n\t- positive bronchodilator responsiveness test ‡πÇ‡∏î‡∏¢  #recall2 \n\t\t- Adult FEV1 \u003e 12% and \u003e200mL\n\t\t- Children FEV1 \u003e 12%\n\t- PEF variability \u003e 10% (adult) or \u003e13% (children) #recall2 \n\n## Treatment\n- Track 1 : ICS + Formoterol as needed\n- Track 2 : SABA (Salbutamol) ‡πÅ‡∏¢‡∏Å‡∏Å‡∏±‡∏ö ICS ‡πÇ‡∏î‡∏¢‡∏û‡πà‡∏ô ICS ‡∏û‡∏£‡πâ‡∏≠‡∏°‡∏Å‡∏±‡∏ö SABA (‡πÅ‡∏Ñ‡πà‡πÅ‡∏¢‡∏Å device)\n\t- ‡πÉ‡∏ä‡πâ‡πÑ‡∏î‡πâ‡∏ñ‡πâ‡∏≤ no exacerbation for 12 months and good compliance\n\t- ‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ SABA ‡πÄ‡∏î‡∏µ‡πà‡∏¢‡∏ß ‡πÜ ‡πÄ‡∏û‡∏¥‡πà‡∏° exacerbation / ‡πÄ‡∏û‡∏¥‡πà‡∏°‡∏ú‡∏• hyperresponsiveness / ‡πÄ‡∏û‡∏¥‡πà‡∏°‡∏Å‡∏≤‡∏£‡∏ï‡∏≠‡∏ö‡∏™‡∏ô‡∏≠‡∏á‡∏ï‡πà‡∏≠‡∏Å‡∏£‡∏∞‡∏ö‡∏ß‡∏ô‡∏Å‡∏≤‡∏£‡πÅ‡∏û‡πâ / ‡∏î‡∏∑‡πâ‡∏≠‡∏¢‡∏≤ (‡∏•‡∏î‡∏Å‡∏≤‡∏£‡∏ï‡∏≠‡∏ö‡∏™‡∏ô‡∏≠‡∏á‡∏ï‡πà‡∏≠ bronchodilator) / ‡πÄ‡∏û‡∏¥‡πà‡∏° mortality **(Novel START)**\n![[Pasted image 20221203155154.png|625]]\n- ‡∏ñ‡πâ‡∏≤‡∏ô‡∏≤‡∏ô ‡πÜ ‡πÄ‡∏õ‡πá‡∏ô‡∏ó‡∏µ‡∏Å‡πá step 1-2\n\t- **‡∏ñ‡πâ‡∏≤‡πÉ‡∏ä‡πâ ICS ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡πÉ‡∏ô step2 ‡πÉ‡∏´‡πâ‡πÉ‡∏ä‡πâ Antileukotrienes ‡πÑ‡∏î‡πâ‡πÄ‡∏ä‡πà‡∏ô Montelukast** (‡πÄ‡∏õ‡πá‡∏ô controller ‡πÄ‡∏ó‡πà‡∏≤‡∏ô‡∏±‡πâ‡∏ô) ‡∏õ‡∏£‡∏∞‡∏™‡∏¥‡∏ó‡∏ò‡∏¥‡∏†‡∏≤‡∏û‡πÑ‡∏°‡πà‡πÄ‡∏ó‡πà‡∏≤ ICS ‡∏à‡∏∂‡∏á‡πÅ‡∏ô‡∏∞‡∏ô‡∏≥‡πÉ‡∏´‡πâ‡πÉ‡∏ä‡πâ add-on therapy ‡πÄ‡∏û‡∏∑‡πà‡∏≠‡∏ó‡∏î‡πÅ‡∏ó‡∏ô low dose ICS ‡πÉ‡∏ô‡∏Å‡∏£‡∏ì‡∏µ‡∏ó‡∏µ‡πà‡πÉ‡∏ä‡πâ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ ‡πÑ‡∏°‡πà‡∏≠‡∏¢‡∏≤‡∏Å‡πÉ‡∏ä‡πâ ‡∏´‡∏£‡∏∑‡∏≠‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡πÑ‡∏°‡πà‡∏°‡∏≤‡∏Å\n\t\t- ‡∏°‡∏µ 3 ‡∏Ç‡∏ô‡∏≤‡∏î 4,5,10 mg\n\t\t- ‡∏ä‡πà‡∏ß‡∏¢‡∏•‡∏î‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡πÇ‡∏£‡∏Ñ‡∏´‡∏∑‡∏î‡πÉ‡∏ô‡∏Ñ‡∏ô‡∏ó‡∏µ‡πà‡∏°‡∏µ‡∏†‡∏≤‡∏ß‡∏∞‡πÅ‡∏û‡πâ ‡πÜ ‡∏£‡πà‡∏ß‡∏°‡∏î‡πâ‡∏ß‡∏¢ ‡πÄ‡∏ä‡πà‡∏ô allergic rhinitis, exercise induced asthma, aspirin hypersensitivity\n\t- ‡∏ñ‡πâ‡∏≤‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡πÅ‡∏û‡πâ HDM ‡∏°‡∏µ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡πÅ‡∏•‡∏∞‡∏õ‡∏£‡∏∞‡∏ß‡∏±‡∏ï‡∏¥ AR ‡πÉ‡∏´‡πâ‡πÉ‡∏ä‡πâ HDM SLIT ‡πÑ‡∏î‡πâ ‡∏£‡∏∞‡∏ß‡∏±‡∏á 1st dose anaphylaxis ‡πÅ‡∏•‡∏∞ onset ‡∏¢‡∏≤‡∏≠‡∏¢‡∏π‡πà‡∏ó‡∏µ‡πà 1 months (‡∏´‡∏ß‡∏±‡∏á‡∏ú‡∏•‡πÄ‡∏û‡∏¥‡πà‡∏° QoL) ‡πÅ‡∏ô‡∏∞‡∏ô‡∏≥‡πÉ‡∏ô‡∏Ñ‡∏ô‡∏ó‡∏µ‡πà‡πÉ‡∏ä‡πâ ICS ‡πÅ‡∏•‡πâ‡∏ß FEV1 \u003e 70% predicted\n- ‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å‡πÄ‡∏õ‡πá‡∏ô‡∏´‡∏•‡∏≤‡∏¢‡∏ß‡∏±‡∏ô‡∏Å‡πá step 3 (‡∏°‡∏≤‡πÉ‡∏ä‡πâ ICS-LABA)\n- ‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å‡πÄ‡∏õ‡πá‡∏ô‡∏ó‡∏∏‡∏Å‡∏ß‡∏±‡∏ô‡πÄ‡∏•‡∏¢‡∏Å‡πá‡πÄ‡∏Ç‡πâ‡∏≤ step 4-5\n\t- step 5 ‡πÉ‡∏´‡πâ‡πÅ‡∏¢‡∏Å‡∏Å‡πà‡∏≠‡∏ô‡∏ß‡πà‡∏≤ Type 2 (allergic \u0026 eosinophillia) ‡∏Å‡πá‡∏Ñ‡∏∑‡∏≠ severe ‡∏Å‡∏ß‡πà‡∏≤ ‡πÅ‡∏•‡∏∞‡∏à‡∏∞‡∏ï‡∏≠‡∏ö‡∏™‡∏ô‡∏≠‡∏á‡∏ï‡πà‡∏≠ corticosteroid ‡πÄ‡∏¢‡∏≠‡∏∞‡∏´‡∏£‡∏∑‡∏≠ Non-Type 2 (less severe ‡πÅ‡∏•‡∏∞‡∏ï‡∏≠‡∏ö‡∏™‡∏ô‡∏≠‡∏á‡∏ï‡πà‡∏≠ corticosteroid ‡∏ô‡πâ‡∏≠‡∏¢)\n\t- **‡∏ñ‡πâ‡∏≤‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ step 4-5 ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ allergic ‡∏à‡∏∞ add LAMA** ‡πÄ‡∏õ‡πá‡∏ô add-on ‡∏Å‡πá‡πÑ‡∏î‡πâ\n\t- **‡∏ñ‡πâ‡∏≤ step 5 ‡πÅ‡∏•‡∏∞‡πÑ‡∏°‡πà‡∏£‡∏π‡πâ‡∏à‡∏∞‡∏ó‡∏≥‡πÄ‡∏ä‡∏µ‡πâ‡∏¢‡πÑ‡∏£‡πÅ‡∏•‡πâ‡∏ß ‡πÅ‡∏•‡∏∞‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ allergic ‡∏Å‡πá Azithromycin 500 mg** TIW for 6 months addon ‡∏ï‡∏≠‡∏ô refer specialist ‡∏≠‡∏¢‡πà‡∏≤‡∏•‡∏∑‡∏°‡πÄ‡∏ä‡πá‡∏Ñ mycobacteria / ECG for long QTc (‡∏Å‡∏¥‡∏ô‡∏´‡∏ß‡∏±‡∏á‡∏ú‡∏•‡∏•‡∏î Exacerbation)\n### ‡∏Å‡∏£‡∏ì‡∏µ step-5 ‡πÅ‡∏•‡πâ‡∏ß control ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ -\u003e refer specialist\n- ‡πÄ‡∏Ç‡πâ‡∏≤‡πÄ‡∏Å‡∏ì‡∏ë‡πå \"Difficulty to treat Asthma\"\n- ‡πÉ‡∏´‡πâ investigate ‡πÄ‡∏ä‡πá‡∏Ñ‡πÉ‡∏´‡πâ‡∏ä‡∏±‡∏ß‡∏£‡πå ‡∏õ‡∏±‡∏à‡∏à‡∏±‡∏¢‡∏≠‡∏∑‡πà‡∏ô ‡πÜ ‡πÄ‡∏ä‡πà‡∏ô GERD, Psychiatry, ‡∏≠‡πâ‡∏ß‡∏ô, ‡∏ô‡∏≠‡∏ô‡∏Å‡∏£‡∏ô \n- Assess Adjust Review\n- ‡∏ñ‡πâ‡∏≤ 3-6 months ‡∏¢‡∏±‡∏á uncontrolled -\u003e Severe Asthma \n\n### Severe Asthma\n- Investigate ‡∏ß‡πà‡∏≤ Type 2 or Non-Type 2\n- **Type 2 = Blood EO \u003e= 150 ul or FeNO \u003e= 20 ppb** #recall2 \n- ‡∏û‡∏¥‡∏à‡∏≤‡∏ì‡∏≤ Biologics ‡∏ñ‡πâ‡∏≤‡πÄ‡∏õ‡πá‡∏ô Non-Type 2 ‡πÅ‡∏•‡∏∞‡∏≠‡∏¢‡πà‡∏≤‡∏•‡∏∑‡∏°‡∏•‡∏≠‡∏á‡πÉ‡∏ä‡πâ LAMA/Azithromycin ‡∏Å‡πà‡∏≠‡∏ô\n\u003e[!note] TSLP = cytokine ‡∏ó‡∏µ‡πà‡∏ô‡πà‡∏≤‡∏à‡∏∞‡πÄ‡∏Å‡∏µ‡πà‡∏¢‡∏ß‡∏Å‡∏±‡∏ö asthma ‡∏ó‡∏µ‡πà‡∏™‡∏∏‡∏î / obalizumab ‡πÉ‡∏ä‡πâ‡∏Å‡∏±‡∏ö severe asthma\n\n### ‡∏•‡∏î‡∏¢‡∏≤?\n- ‡∏ï‡πâ‡∏≠‡∏á well controlled 3-6 months ‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô‡πÉ‡∏´‡πâ‡∏î‡∏µ‡∏ó‡∏∏‡∏Å‡∏õ‡∏±‡∏à‡∏à‡∏±‡∏¢ ‡πÅ‡∏•‡∏∞‡∏≠‡∏¢‡πà‡∏≤‡∏•‡∏î‡∏ä‡πà‡∏ß‡∏á‡∏ó‡∏µ‡πà‡∏ô‡πà‡∏≤‡∏à‡∏∞‡∏Å‡∏≥‡πÄ‡∏£‡∏¥‡∏ö‡πÄ‡∏ä‡πà‡∏ô ‡∏ù‡∏∏‡πà‡∏ô pm2.5\n- ‡∏ñ‡πâ‡∏≤‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡πÉ‡∏ä‡πâ controller ‡∏´‡∏•‡∏≤‡∏¢‡∏ï‡∏±‡∏ß\n\t- ‡πÄ‡∏ß‡∏•‡∏≤‡∏•‡∏î ‡πÉ‡∏´‡πâ‡∏•‡∏î high dose steroid ‡∏Å‡πà‡∏≠‡∏ô ‡πÅ‡∏•‡πâ‡∏ß‡∏Ñ‡πà‡∏≠‡∏¢‡∏•‡∏î add-on\n- ‡∏ñ‡πâ‡∏≤‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡πÉ‡∏ä‡πâ ICS+LABA\n\t- ‡πÉ‡∏´‡πâ‡∏•‡∏î ICS ‡πÉ‡∏´‡πâ‡∏ï‡πà‡∏≥‡∏ó‡∏µ‡πà‡∏™‡∏∏‡∏î‡∏à‡∏ô‡πÄ‡∏´‡∏•‡∏∑‡∏≠ ICS+LABA ‡∏ï‡πà‡∏≥‡∏™‡∏∏‡∏î‡∏ß‡∏±‡∏ô‡∏•‡∏∞‡∏Ñ‡∏£‡∏±‡πâ‡∏á \n- ‡∏™‡∏∏‡∏î‡∏ó‡πâ‡∏≤‡∏¢‡∏•‡∏î‡πÉ‡∏´‡πâ‡πÄ‡∏´‡∏•‡∏∑‡∏≠ ICS-formoterol\n\n### ICS Potency\n![[Pasted image 20230129174631.png|600]]\n\n### Asthma Exacerbation\n- Oxygen: nasal cannula keep 93-95% (‡∏õ‡∏Å‡∏ï‡∏¥ \u003e95% ‡∏ñ‡πâ‡∏≤ \u003e92% ‡πÄ‡∏Ç‡πâ‡∏≤‡∏£‡∏û. ‡∏ß‡∏±‡∏î‡∏ï‡∏≠‡∏ô‡∏Å‡πà‡∏≠‡∏ô‡πÉ‡∏´‡πâ O2 ‡∏´‡∏£‡∏∑‡∏≠‡∏ñ‡∏≠‡∏î mask 5 mins)\n- ‡πÉ‡∏ä‡πâ SABA ‡∏≠‡∏≤‡∏à‡∏ï‡πà‡∏≠ spacer (nebulize ‡∏£‡∏∞‡∏ß‡∏±‡∏á viral spread)\n- epinephrine ‡∏ñ‡πâ‡∏≤‡πÄ‡∏Ç‡πâ‡∏≤‡πÄ‡∏Å‡∏ì‡∏ë‡πå anaphylaxis\n- systemic corticosteroid (oral ‡∏ú‡∏•‡πÄ‡∏ó‡πà‡∏≤‡∏Å‡∏±‡∏ö IV) ‡πÉ‡∏´‡πâ 5-7 ‡∏ß‡∏±‡∏ô\n\t- Prednisolone 50 mg od morning (‡∏ô‡∏¥‡∏¢‡∏°‡πÉ‡∏ä‡πâ pred 5 mg 2x3 pc, 30-50 mg /day ‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤)\n\t- Dexa 0.6 mg /kg 1-2 d ‡πÅ‡∏•‡πâ‡∏ß‡πà‡∏Ñ‡∏≠‡∏¢‡∏™‡∏•‡∏±‡∏ö‡πÑ‡∏õ pred\n\t- Hydrocor 200 mg in divided (‡∏ô‡∏¥‡∏¢‡∏° hydro 100 mg q 6 - 8 hr)\n\n### Pre-exercise\n- ‡πÉ‡∏ä‡πâ SABA ‡∏´‡∏£‡∏∑‡∏≠ low dose ICS-formoterol ‡∏Å‡πà‡∏≠‡∏ô‡∏≠‡∏≠‡∏Å‡∏Å‡∏≥‡∏•‡∏±‡∏á‡∏Å‡∏≤‡∏¢ 5-20 ‡∏ô‡∏≤‡∏ó‡∏µ\n- ‡∏≠‡∏¢‡πà‡∏≤‡∏•‡∏∑‡∏° warm-up","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/CJK-+-Latex-Support-%E6%B5%8B%E8%AF%95":{"title":"CJK + Latex Support (ÊµãËØï)","content":"\n## Chinese, Japanese, Korean Support\nÂá†‰πéÂú®Êàë‰ª¨ÊÑèËØÜÂà∞‰πãÂâçÔºåÊàë‰ª¨Â∑≤ÁªèÁ¶ªÂºÄ‰∫ÜÂú∞Èù¢„ÄÇ\n\nÏö∞Î¶¨Í∞Ä Í∑∏Í≤ÉÏùÑ ÏïåÍ∏∞ÎèÑ Ï†ÑÏóê Ïö∞Î¶¨Îäî ÎïÖÏùÑ Îñ†ÎÇ¨ÏäµÎãàÎã§.\n\nÁßÅ„Åü„Å°„Åå„Åù„Çå„ÇíÁü•„Çã„Åª„ÅºÂâç„Å´„ÄÅÁßÅ„Åü„Å°„ÅØÂú∞Èù¢„ÇíÈõ¢„Çå„Å¶„ÅÑ„Åæ„Åó„Åü„ÄÇ\n\n## Latex\n\nBlock math works with two dollar signs `$$...$$`\n\n$$f(x) = \\int_{-\\infty}^\\infty\n    f\\hat(\\xi),e^{2 \\pi i \\xi x}\n    \\,d\\xi$$\n\t\nInline math also works with single dollar signs `$...$`. For example, Euler's identity but inline: $e^{i\\pi} = -1$\n\nAligned equations work quite well:\n\n$$\n\\begin{aligned}\na \u0026= b + c \\\\ \u0026= e + f \\\\\n\\end{aligned}\n$$\n\nAnd matrices\n\n$$\n\\begin{bmatrix}\n1 \u0026 2 \u0026 3 \\\\\na \u0026 b \u0026 c\n\\end{bmatrix}\n$$\n\n## RTL\nMore information on configuring RTL languages like Arabic in the [config](notes/config.md) page.\n","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/COPD-2022":{"title":"COPD 2022","content":"## ‡∏°‡∏µ‡∏Å‡∏≤‡∏£‡∏ó‡∏≥ Taxonomy by Etiotypes\n- COPD-G (alpha-1 antitrypsin deficiency)\n- COPD-I (copd from infections)\n- COPD-A (copd \u0026 asthma) \n\t- ‡πÉ‡∏ô GINA ‡∏à‡∏∞‡πÄ‡∏õ‡πá‡∏ô‡∏≠‡∏µ‡∏Å‡∏Ç‡∏∑‡πà‡∏≠ : asthma overlap COPD \n\n## Clinical Indicators\n- Dypsnea ‡∏ó‡∏µ‡πà progessive, worsen with exercise, persistent\n- Recurrent Wheeze\n- Chronic Cough\n\n## GOLD Grade (post bronco FEV1)\n- **‡∏ö‡πà‡∏á‡∏ö‡∏≠‡∏Å‡∏Ñ‡∏ß‡∏≤‡∏°‡∏£‡∏∏‡∏ô‡πÅ‡∏£‡∏á‡∏Ç‡∏≠‡∏á‡∏Å‡∏≤‡∏£‡∏≠‡∏∏‡∏î‡∏ï‡∏±‡πâ‡∏ô**\n- **Memo:** 80 50 30 30  ‡πÄ‡∏Å‡∏£‡∏î‡∏™‡∏π‡∏á‡∏¢‡∏¥‡πà‡∏á‡∏´‡∏ô‡∏±‡∏Å\n![[Pasted image 20230201140901.png]]\n\n## MRC Dyspnea Scale\n- **‡∏ö‡πà‡∏á‡∏ö‡∏≠‡∏Å‡∏Ñ‡∏ß‡∏≤‡∏°‡∏£‡∏∏‡∏ô‡πÅ‡∏£‡∏á‡∏Ç‡∏≠‡∏á‡∏≠‡∏≤‡∏Å‡∏≤‡∏£**\n- **Memo:** \n\t- ‡∏≠‡∏≠‡∏Å‡∏Å‡∏≥‡∏•‡∏±‡∏á‡∏Å‡∏≤‡∏¢‡∏´‡∏ô‡∏±‡∏Å‡∏ñ‡∏∂‡∏á‡πÄ‡∏õ‡πá‡∏ô\n\t- ‡πÄ‡∏î‡∏¥‡∏ô‡∏Ç‡∏∂‡πâ‡∏ô‡πÄ‡∏Ç‡∏≤‡πÄ‡∏õ‡πá‡∏ô\n\t- ‡πÄ‡∏î‡∏¥‡∏ô‡∏ä‡πâ‡∏≤‡∏Å‡∏ß‡πà‡∏≤‡πÄ‡∏û‡∏∑‡πà‡∏≠‡∏ô‡∏ï‡πâ‡∏≠‡∏á‡∏´‡∏¢‡∏∏‡∏î‡∏´‡∏≤‡∏¢‡πÉ‡∏à \n\t- ‡πÄ‡∏î‡∏¥‡∏ô‡∏ô‡∏¥‡∏î‡∏´‡∏ô‡πà‡∏≠‡∏¢‡πÄ‡∏´‡∏ô‡∏∑‡πà‡∏≠‡∏¢ ‡∏ï‡πâ‡∏≠‡∏á‡∏û‡∏±‡∏Å\n\t- ‡∏≠‡∏¢‡∏π‡πà‡∏ô‡∏¥‡πà‡∏á‡∏Å‡πá‡πÄ‡∏´‡∏ô‡∏∑‡πà‡∏≠‡∏¢\n![[Pasted image 20230201141054.png]]\n\n## CAT\n- **‡∏ö‡πà‡∏á‡∏ö‡∏≠‡∏Å‡∏Ñ‡∏ß‡∏≤‡∏°‡∏£‡∏∏‡∏ô‡πÅ‡∏£‡∏á‡∏Ç‡∏≠‡∏á‡∏≠‡∏≤‡∏Å‡∏≤‡∏£** \n![[Pasted image 20230201141131.png]]\n\n## GOLD ABE\n![[Pasted image 20230201142047.png|525]]\n\n\n## Diagnosis\n- Spirometry check FEV1/FVC \u003c 0.7 ‡πÅ‡∏•‡πâ‡∏ß‡∏Ñ‡πà‡∏≠‡∏¢‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô FEV1 ‡πÄ‡∏ó‡∏µ‡∏¢‡∏ö predicted (GOLD) ‡πÅ‡∏•‡πâ‡∏ß‡∏°‡∏≤‡∏ó‡∏≥ GOLD ABE ‡∏î‡∏π‡∏ß‡πà‡∏≤‡∏Å‡∏•‡∏∏‡πà‡∏°‡πÑ‡∏´‡∏ô\n\n\n## Management\n![[Pasted image 20230201142222.png]]\n![[Pasted image 20230201144313.png]]\n- ‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πâ ICS monotherapy\n- **‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πâ ICS ‡∏ñ‡πâ‡∏≤‡∏°‡∏µ pneumonia hx, blood eos \u003c 100, hx of TB**\n- ‡∏ñ‡πâ‡∏≤‡∏à‡∏∞‡πÉ‡∏ä‡πâ ICS ‡πÉ‡∏´‡πâ‡πÉ‡∏ä‡πâ‡πÄ‡∏õ‡πá‡∏ô ICS + LABA + LAMA\n- ‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ SABA or SAMA ‡πÄ‡∏û‡∏¥‡πà‡∏° FEV1 ‡πÅ‡∏•‡∏∞‡∏•‡∏î symptoms\n\t- ‡∏ñ‡πâ‡∏≤‡πÉ‡∏ä‡πâ‡∏ó‡∏±‡πâ‡∏á‡∏Ñ‡∏π‡πà‡πÄ‡∏•‡∏¢ ‡∏î‡∏µ‡∏Å‡∏ß‡πà‡∏≤‡πÉ‡∏ä‡πâ‡πÄ‡∏î‡∏µ‡πà‡∏¢‡∏ß‡πÅ‡∏ô‡πà‡∏ô‡∏≠‡∏ô\n- LABA LAMA ‡∏Å‡πá‡∏ä‡πà‡∏ß‡∏¢‡∏ó‡∏±‡πâ‡∏á‡∏Ñ‡∏π‡πà ‡πÅ‡∏•‡∏∞ LAMA ‡∏î‡∏µ‡∏Å‡∏ß‡πà‡∏≤ LABA\n\t- ‡πÉ‡∏ä‡πâ long acting ‡∏î‡∏µ‡∏Å‡∏ß‡πà‡∏≤ short\n- ‡∏ñ‡πâ‡∏≤‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ COPD have features of ASTHMA ‡∏Å‡πá‡∏ï‡πâ‡∏≠‡∏á‡∏°‡∏µ ICS ‡∏£‡πà‡∏ß‡∏°‡∏î‡πâ‡∏ß‡∏¢‡πÄ‡∏™‡∏°‡∏≠\n- PDE4 inhibitors (Rofluimilast) ‡∏°‡∏µ role ‡πÉ‡∏ô‡∏Ñ‡∏ô‡∏ó‡∏µ‡πà very severe airflow limitation\n\t- ‡∏´‡πâ‡∏≤‡∏°‡πÉ‡∏ä‡πâ‡∏Ñ‡∏π‡πà‡∏Å‡∏±‡∏ö theophylline\n\t- ADR: weight loss\n- OCS ‡πÑ‡∏°‡πà‡∏°‡∏µ role ‡πÉ‡∏ô COPD / role ‡πÑ‡∏°‡πà‡∏ä‡∏±‡∏î!\n- azithromycin ‡∏•‡∏î exacerbation ‡πÑ‡∏î‡πâ‡πÅ‡∏ï‡πà‡∏î‡∏∑‡πâ‡∏≠‡∏¢‡∏≤ ‡πÅ‡∏•‡∏∞‡∏°‡∏µ‡∏õ‡∏±‡∏ç‡∏´‡∏≤‡∏Å‡∏≤‡∏£‡πÑ‡∏î‡πâ‡∏¢‡∏¥‡∏ô‡∏ï‡∏≤‡∏°‡∏°‡∏≤\n- NAC Long ‡∏ï‡πà‡∏≤‡∏á ‡πÜ ‡πÉ‡∏ä‡πâ‡πÑ‡∏î‡πâ‡∏´‡∏°‡∏î\n- ‡∏ñ‡πâ‡∏≤‡∏Ç‡∏≤‡∏î alpha-1 antitrpysin ‡∏Å‡πá‡∏≠‡∏≤‡∏à‡πÉ‡∏´‡πâ\n- Anti-tussive ‡πÑ‡∏°‡πà‡∏°‡∏µ Role\n- Vasodilators ‡πÑ‡∏°‡πà‡∏°‡∏µ Role\n\n\n## Vaccination\n- ‡∏â‡∏µ‡∏î Influenza\n- ‡∏â‡∏µ‡∏î COVID-19\n- ‡∏â‡∏µ‡∏î PCV20 OR PCV15 then PPSV23\n- ‡∏â‡∏µ‡∏î Pneumococcal\n- ‡∏â‡∏µ‡∏î Tdap (dTaP or dTPa) ‡πÅ‡∏•‡∏∞ zoster\n\t- ‡∏Ñ‡∏ô‡πÅ‡∏Å‡πà‡∏Ñ‡∏ß‡∏£‡πÉ‡∏ä‡πâ acellular ‡πÅ‡∏•‡∏∞‡∏Ñ‡∏ß‡∏£ boost ‡∏î‡πâ‡∏ß‡∏¢\n\n## Other Mangement\n- Pulmonary Rehab\n\t- ‡∏•‡∏î‡∏Å‡∏≤‡∏£‡πÄ‡∏Ç‡πâ‡∏≤‡∏£‡∏û\n\t- ‡∏•‡∏î anxiety and depression\n- Education\n\t- educate ‡∏≠‡∏¢‡πà‡∏≤‡∏á‡πÄ‡∏î‡∏µ‡∏¢‡∏ß‡πÑ‡∏°‡πà‡∏û‡∏≠ ‡∏ï‡πâ‡∏≠‡∏á‡∏°‡∏µ‡πÅ‡∏û‡∏•‡∏ô‡∏î‡πâ‡∏ß‡∏¢ ‡∏Å‡∏≤‡∏£‡∏ï‡∏¥‡∏î‡∏ï‡∏≤‡∏°‡∏î‡πâ‡∏ß‡∏¢\n- Oxygen\n\t- ‡πÅ‡∏•‡πâ‡∏ß‡πÅ‡∏ï‡πà‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ ‡∏ñ‡πâ‡∏≤‡πÄ‡∏õ‡πá‡∏ô‡∏´‡∏ô‡∏±‡∏Å (severe resting arterial hypoxemia) ‡πÅ‡∏•‡πâ‡∏ß‡πÉ‡∏´‡πâ oxygen longterm ‡∏Å‡πá‡∏ä‡πà‡∏ß‡∏¢‡πÄ‡∏û‡∏¥‡πà‡∏° survival\n- Palliative, End of Life, Hospice\n\t- ‡∏£‡∏∞‡∏ß‡∏±‡∏á opiod ‡∏Å‡∏î‡∏Å‡∏≤‡∏£‡∏´‡∏≤‡∏¢‡πÉ‡∏à\n\t- copd ‡∏°‡∏±‡∏Å‡πÄ‡∏õ‡πá‡∏ô gerd ‡∏ö‡πà‡∏≠‡∏¢‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏Å‡∏¥‡∏ô‡∏ô‡πâ‡∏≠‡∏¢ ‡∏´‡∏£‡∏∑‡∏≠‡∏Å‡∏•‡πâ‡∏≤‡∏°‡πÄ‡∏ô‡∏∑‡πâ‡∏≠‡πÑ‡∏°‡πà‡∏°‡∏µ‡πÅ‡∏£‡∏á ‡∏à‡∏∂‡∏á‡∏Ñ‡∏ß‡∏£‡πÉ‡∏´‡πâ‡∏≠‡∏≤‡∏´‡∏≤‡∏£‡πÄ‡∏™‡∏£‡∏¥‡∏°\n\n## Oxygen\n-  Arterial hypoxemia defined as)\n\t- PaO2 \u003c 55 mmHg ‡∏´‡∏£‡∏∑‡∏≠ SaO2 \u003c 88% #recall2 \n\t- ‡∏´‡∏£‡∏∑‡∏≠ PaO \u003e 55 ‡πÅ‡∏ï‡πà \u003c 60 mmHg + Right Heart Failure\n- ‡πÉ‡∏´‡πâ oxygen keep SaO2 \u003e 90%\n\n\n## COPD and Comorbidity\n- GERD ‡∏°‡∏µ‡∏ú‡∏•‡πà‡∏ï‡∏≠ exacerbation\n- ‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ COPD ‡∏ñ‡πâ‡∏≤ suspect COVID-19 ‡πÅ‡∏•‡πâ‡∏ß hypoxemia ‡∏≠‡∏≤‡∏à‡πÉ‡∏´‡πâ anticoagulant ‡πÅ‡∏•‡∏∞‡πÉ‡∏ä‡πâ Remdesivir\n\t- ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏à‡∏∞‡∏≠‡∏¢‡∏π‡πà‡πÉ‡∏ô‡∏†‡∏≤‡∏ß‡∏∞ hypercoagulable state \u0026 VTE","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/Cirrhosis":{"title":"Cirrhosis","content":"## Risk Factors\n- HCV HBV\n\t- ‡∏õ‡∏•. hepatitis ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡πÅ‡∏õ‡∏•‡∏ß‡πà‡∏≤‡∏à‡∏∞‡∏ï‡πâ‡∏≠‡∏á‡∏à‡∏ö‡∏ó‡∏µ‡πà cirrhosis ‡πÄ‡∏™‡∏°‡∏≠‡πÑ‡∏õ!\n- NAFLD or Alcohol\n\n## Pathophysiology\n- ‡∏Å‡∏≤‡∏£‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡πÄ‡∏£‡∏∑‡πâ‡∏≠‡∏£‡∏±‡∏á ‡∏à‡∏ô‡πÄ‡∏Å‡∏¥‡∏î‡∏û‡∏±‡∏á‡∏ú‡∏∑‡∏î ‡∏ô‡∏≥‡πÑ‡∏õ‡∏™‡∏π‡πà‡∏†‡∏≤‡∏ß‡∏∞‡∏ï‡∏±‡∏ö‡πÅ‡∏Ç‡πá‡∏á\n- ‡∏†‡∏≤‡∏ß‡∏∞‡∏ï‡∏±‡∏ö‡πÅ‡∏Ç‡πá‡∏á ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡πÄ‡∏Å‡∏¥‡∏î‡∏†‡∏≤‡∏ß‡∏∞ *(‡∏ó‡∏µ‡πà‡∏ó‡∏≥‡∏ï‡∏±‡∏ß‡∏´‡∏ô‡∏≤ (bold) ‡∏´‡∏°‡∏≤‡∏¢‡∏ñ‡∏∂‡∏á‡πÄ‡∏õ‡πá‡∏ô‡∏™‡∏≤‡πÄ‡∏´‡∏ï‡∏∏‡∏´‡∏•‡∏±‡∏Å‡πÉ‡∏ô‡∏Å‡∏≤‡∏£‡πÄ‡∏™‡∏µ‡∏¢‡∏ä‡∏µ‡∏ß‡∏¥‡∏ï*\n\t- ‡∏Ñ‡∏ß‡∏≤‡∏°‡∏î‡∏±‡∏ô‡πÉ‡∏ô‡∏ï‡∏±‡∏ö‡∏™‡∏π‡∏á\n\t\t- ascites\n\t\t- varices\n\t\t**- SBP**\n\t- ‡∏Å‡∏≤‡∏£‡∏ó‡∏≥‡∏á‡∏≤‡∏ô‡∏Ç‡∏≠‡∏á‡∏ï‡∏±‡∏ö‡∏•‡∏î‡∏•‡∏á\n\t\t- coagulopathy\n\t\t**- variceal bleeding**\n\t\t- hepatic encephalopathy\n- ‡∏†‡∏≤‡∏ß‡∏∞ cirrhosis ‡∏à‡∏∞‡∏°‡∏µ‡∏û‡∏ß‡∏Å fibrous septum ‡∏°‡∏≤‡πÅ‡∏ó‡∏£‡∏Å ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏Å‡∏≤‡∏£ metabolism ‡∏™‡∏≤‡∏£‡∏ï‡πà‡∏≤‡∏á ‡πÜ ‡πÄ‡∏õ‡πá‡∏ô‡πÑ‡∏õ‡πÑ‡∏î‡πâ‡∏¢‡∏≤‡∏Å‡∏Ç‡∏∂‡πâ‡∏ô ‡πÅ‡∏•‡∏∞‡∏¢‡∏±‡∏á‡∏°‡∏µ fatty cysts ‡∏°‡∏≤‡πÅ‡∏ó‡∏£‡∏Å‡∏≠‡∏µ‡∏î‡πâ‡∏ß‡∏¢\n\n## Symptoms ‡∏ï‡∏≤‡∏°‡∏£‡∏∞‡∏ö‡∏ö‡∏≠‡∏ß‡∏±‡∏¢‡∏ß‡∏∞‡∏ï‡πà‡∏≤‡∏á ‡πÜ\n- Neurologic\n\t- Hepatic encephalopathy\n\t- Peripheral neuropathy (‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏Å‡∏≤‡∏£ abs vit B ‡∏•‡∏î‡∏•‡∏á)\n- Gastrointestinal\n\t- varices\n- Reproductive\n\t- ‡∏Å‡∏î GnRH ‡πÑ‡∏î‡πâ ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡πÄ‡∏Å‡∏¥‡∏î‡∏õ‡∏±‡∏ç‡∏´‡∏≤‡∏ó‡∏≤‡∏á‡∏î‡πâ‡∏≤‡∏ô sex ‡∏ï‡πà‡∏≤‡∏á ‡πÜ ‡∏ï‡∏≤‡∏°‡∏°‡∏≤ ‡πÅ‡∏•‡∏∞‡∏¢‡∏±‡∏á‡∏°‡∏µ gynecomastia (male) ‡πÄ‡∏Å‡∏¥‡∏î‡∏Ç‡∏∂‡πâ‡∏ô‡πÑ‡∏î‡πâ‡∏≠‡∏µ‡∏Å\n- Integumentary\n\t- jaundice\n\t- ‡πÅ‡∏•‡∏∞‡∏Å‡πá‡∏û‡∏ß‡∏Å‡∏ú‡∏∑‡πà‡∏ô ‡πÜ ‡∏ï‡πà‡∏≤‡∏á ‡πÜ ‡πÄ‡∏ä‡πà‡∏ô spider angioma, petechiae, purpura\n- Hematologic\n\t- Anemia of chronic disease\n\t- thrombocytopenia\n\t- leukopenia\n\n## Portal Hypertension\n\n![[Pasted image 20230307134046.png|425]]\n\n### Pathophysiology\n- ‡πÄ‡∏Å‡∏¥‡∏î‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà portal pressure ‡πÄ‡∏û‡∏¥‡πà‡∏°‡∏Ç‡∏∂‡πâ‡∏ô‡∏™‡∏π‡∏á‡∏Å‡∏ß‡πà‡∏≤‡∏õ‡∏Å‡∏ï‡∏¥ Hepatic-venous pressure gradient (HPVG) \u003e 5 mgHg\n- ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏Ñ‡∏ß‡∏≤‡∏°‡∏î‡∏±‡∏ô‡πÉ‡∏ô‡∏´‡∏•‡∏≠‡∏î‡πÄ‡∏•‡∏∑‡∏≠‡∏î Esophageal, gastric, anorectal ‡∏™‡∏π‡∏á‡∏Ç‡∏∂‡πâ‡∏ô‡∏ï‡∏≤‡∏° ‡πÄ‡∏Å‡∏¥‡∏î‡∏Å‡∏•‡∏≤‡πÄ‡∏¢‡∏õ‡πá‡∏ô varices ‡πÑ‡∏î‡πâ\n- ‡πÄ‡∏°‡∏∑‡πà‡∏≠ HPVG \u003e 10-12 mmHg ‡∏à‡∏∞‡πÄ‡∏´‡πá‡∏ô‡∏Å‡∏≤‡∏£‡πÇ‡∏õ‡πà‡∏á‡∏û‡∏≠‡∏á‡∏Ç‡∏≠‡∏á‡∏´‡∏•‡∏≠‡∏î‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡∏ä‡∏±‡∏î‡πÄ‡∏à‡∏ô\n\n### Clinical Features\n- Palmar erythema (‡∏´‡∏•‡∏≠‡∏î‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡∏ó‡∏µ‡πà‡∏°‡∏∑‡∏≠‡πÄ‡∏Å‡∏¥‡∏î‡∏•‡∏±‡∏Å‡∏©‡∏ì‡∏∞‡∏Ç‡∏≠‡∏á erythema)\n- Spider navi (angioma) ; ‡πÄ‡∏ß‡∏•‡∏≤‡πÉ‡∏ä‡πâ‡∏≠‡∏∞‡πÑ‡∏£‡∏Å‡∏î‡∏à‡∏∞‡∏Å‡∏•‡∏±‡∏ö‡∏°‡∏≤‡πÄ‡∏õ‡πâ‡∏ô‡∏õ‡∏Å‡∏ï‡∏¥ ‡πÅ‡∏ï‡πà‡∏û‡∏≠‡πÄ‡∏î‡πâ‡∏á‡∏Å‡∏•‡∏±‡∏ö‡∏Å‡πá‡∏à‡∏∞‡∏Å‡∏•‡∏±‡∏ö‡∏°‡∏≤‡∏°‡∏µ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡πÄ‡∏´‡∏°‡∏≠‡∏∑‡∏ô‡πÄ‡∏î‡∏¥‡∏°\n- Jaundice\n- Caput medusae\n- Red wale mark ‡πÄ‡∏õ‡πá‡∏ô‡∏à‡∏∏‡∏î‡∏Ñ‡∏•‡πâ‡∏≤‡∏¢‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡∏≠‡∏≠‡∏Å ‡∏û‡∏ö‡πÉ‡∏ô‡∏ó‡∏≤‡∏á‡πÄ‡∏î‡∏¥‡∏ô‡∏≠‡∏≤‡∏´‡∏≤‡∏£ ‡πÄ‡∏õ‡πá‡∏ô predictor ‡πÑ‡∏î‡πâ‡∏ß‡πà‡∏≤‡πÄ‡∏™‡πâ‡∏ô‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡πÅ‡∏î‡∏á‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á‡πÅ‡∏ï‡∏Å‡∏™‡∏π‡∏á\n\n### Treatment\n- screen varicies ‡πÉ‡∏ô‡∏ú‡∏π‡πâ‡∏õ‡πà‡∏ß‡∏¢ cirrhosis ‡∏ó‡∏∏‡∏Å‡∏£‡∏≤‡∏¢ ‡πÇ‡∏î‡∏¢‡∏Å‡∏≤‡∏£‡∏™‡πà‡∏≠‡∏á‡∏Å‡∏•‡πâ‡∏≠‡∏á\n- ‡∏ó‡∏≥‡∏Å‡∏≤‡∏£ primary prophylaxis ‡∏õ‡πâ‡∏≠‡∏á‡∏Å‡∏±‡∏ô [[#Variceal Bleeding]] (mortality 7-15%) ‡πÉ‡∏ô‡∏£‡∏≤‡∏¢‡∏ó‡∏µ‡πà‡∏û‡∏ö varicies ‡πÅ‡∏•‡∏∞‡∏°‡∏µ‡∏Ñ‡∏ß‡∏≤‡∏°‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á‡∏™‡∏π‡∏á ‡πÄ‡∏ä‡πà‡∏ô Varicies ‡∏Ç‡∏ô‡∏≤‡∏î‡∏õ‡∏≤‡∏ô‡∏Å‡∏•‡∏≤‡∏á‡∏´‡∏£‡∏∑‡∏≠‡πÉ‡∏´‡∏ç‡πà, ‡∏û‡∏ö red-wale make, child-pugh score ‡∏£‡∏∞‡∏î‡∏±‡∏ö C\n- ‡∏ó‡∏≥‡∏Å‡∏≤‡∏£ secondary prophylaxis ‡πÄ‡∏û‡∏∑‡πà‡∏≠‡∏õ‡πâ‡∏≠‡∏á‡∏Å‡∏±‡∏ô rebleeding (mortality 33%) ‡∏ó‡∏≥‡πÉ‡∏ô‡∏ú‡∏π‡πâ‡∏õ‡πà‡∏ß‡∏¢‡∏ó‡∏∏‡∏Å‡∏£‡∏≤‡∏¢‡∏ó‡∏µ‡πà‡πÄ‡∏Ñ‡∏¢‡πÄ‡∏Å‡∏¥‡∏î [[#Variceal Bleeding]]\n\n### Prophylaxis\n- BBs + EVL/EBL\n\t- non-selective beta-blockers (propanolol. nadolol. carvedilol)\n\t\t- ‡πÄ‡∏£‡∏¥‡πà‡∏°‡∏Ç‡∏ô‡∏≤‡∏î‡∏ï‡πà‡∏≥ titrate ‡∏Ç‡∏∂‡πâ‡∏ô\n\t\t- b1 block ‡∏•‡∏î HR / b2 block ‡∏•‡∏î splanchnic cirrulation\n\t\t- goal: HR at rest ‡∏•‡∏î‡∏•‡∏á 20-25% (‡∏õ‡∏£‡∏∞‡∏°‡∏≤‡∏ì 1/4) ‡∏´‡∏£‡∏∑‡∏≠ HR 55-60 bpm ‡∏´‡∏£‡∏∑‡∏≠‡πÉ‡∏ä‡πâ‡∏Ç‡∏ô‡∏≤‡∏î‡∏¢‡∏≤‡∏™‡∏π‡∏á‡∏™‡∏∏‡∏î‡∏ó‡∏µ‡πà‡∏ú‡∏π‡πâ‡∏õ‡πà‡∏ß‡∏¢‡∏ó‡∏ô‡πÑ‡∏î‡πâ\n\t- ‡∏≠‡∏≤‡∏à‡∏ó‡∏≥ variceal ligation, band ligation (EVL, EBL) ‡πÉ‡∏ô‡∏ú‡∏π‡πâ‡∏õ‡πà‡∏ß‡∏¢‡∏ó‡∏µ‡πà‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á‡∏™‡∏π‡∏á\n\n## Complication\n\n### Variceal Bleeding\n- ‡∏Å‡∏≤‡∏£‡∏£‡∏±‡∏Å‡∏©‡∏≤\n\t- Resuscitation / ABC / Sedation\n\t\t- ‡∏ï‡πâ‡∏≠‡∏á hematemesis ‡πÅ‡∏•‡∏∞ malena ‡πÅ‡∏ï‡πà‡∏°‡∏±‡∏Å‡πÑ‡∏°‡πà hematochezia\n\t\t- ‡∏£‡∏±‡∏Å‡∏©‡∏≤ hemodynamic stability ‡πÇ‡∏î‡∏¢‡∏Å‡∏≤‡∏£‡πÉ‡∏´‡πâ‡∏û‡∏ß‡∏Å colloidal fluid (‡πÄ‡∏ä‡πà‡∏ô albumin +- blood products ‡∏ï‡πà‡∏≤‡∏á ‡πÜ ‡πÄ‡∏ä‡πà‡∏ô PRC, FFP, platelet ‡∏ï‡∏≤‡∏°‡∏ú‡∏•‡∏ï‡∏£‡∏ß‡∏à‡∏ó‡∏µ‡πà‡∏ú‡∏¥‡∏î‡∏õ‡∏Å‡∏ï‡∏¥)\n\t\t- ‡∏£‡∏∞‡∏ß‡∏±‡∏á‡∏Å‡∏≤‡∏£ aspiration\n\t\t- sedate ‡πÄ‡∏ï‡∏£‡∏µ‡∏¢‡∏° endoscopy\n\t- ‡∏•‡∏î‡∏Å‡∏≤‡∏£‡πÄ‡∏™‡∏µ‡∏¢‡πÄ‡∏•‡∏∑‡∏≠‡∏î / prophylactic ABs\n\t\t- ‡∏•‡∏î‡∏Å‡∏≤‡∏£‡πÄ‡∏™‡∏µ‡∏¢‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡∏î‡πâ‡∏ß‡∏¢ vasoactive agent\n\t\t\t- splanchnic vasoconstrictor ‡∏¢‡∏±‡∏ö‡∏¢‡∏±‡πâ‡∏á‡∏Å‡∏≤‡∏£‡∏´‡∏•‡∏±‡πà‡∏á vasodilatory peptide ‡πÄ‡∏ä‡πà‡∏ô glucagon ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏´‡∏•‡∏≠‡∏î‡πÄ‡∏•‡∏∑‡∏≠‡∏î splanchnic ‡∏´‡∏î‡∏ï‡∏±‡∏ß\n\t\t\t- ‡πÄ‡∏ä‡πà‡∏ô octreotide (‡∏≠‡∏ô‡∏∏‡∏û‡∏±‡∏ô‡∏ò‡∏π‡πå‡∏Ç‡∏≠‡∏á somatostatin) ‡∏≠‡∏≠‡∏Å‡∏§‡∏ó‡∏ò‡∏¥‡πå‡∏¢‡∏≤‡∏ß‡∏Ç‡∏∂‡πâ‡∏ô ‡∏´‡∏£‡∏∑‡∏≠ terlipressin ‡∏´‡∏£‡∏∑‡∏≠ somatostatin\n\t\t- ‡∏õ‡πâ‡∏≠‡∏á‡∏Å‡∏±‡∏ô‡∏Å‡∏≤‡∏£‡πÄ‡∏Å‡∏¥‡∏î SBP\n\t- Endoscopy diagnostic and Treatment\n\t\t- ‡∏™‡πà‡∏≠‡∏á‡∏Å‡∏•‡πâ‡∏≠‡∏á‡πÄ‡∏û‡∏∑‡πà‡∏≠‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô‡∏Å‡∏≤‡∏£‡∏£‡∏±‡∏Å‡∏©‡∏≤‡∏†‡∏≤‡∏¢‡πÉ‡∏ô 12 ‡∏ä‡∏°\n\t\t- IV erythromycin ‡∏Å‡πà‡∏≠‡∏ô‡∏™‡πà‡∏≠‡∏á‡∏Å‡∏•‡πâ‡∏≠‡∏á\n\t- Treatment\n\t\t- ‡πÅ‡∏•‡πâ‡∏ß‡πÅ‡∏ï‡πà‡∏´‡∏°‡∏≠‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô ‡∏≠‡∏≤‡∏à‡∏°‡∏µ‡∏Å‡∏≤‡∏£‡∏ó‡∏≥ TIPS (Transjugular intrahepatic portosystemic shunt) ‡∏´‡∏£‡∏∑‡∏≠ EVL, EIS + ‡πÉ‡∏ä‡πâ‡∏¢‡∏≤\n\t\t- role ‡πÄ‡∏£‡∏≤: ‡∏≠‡∏¢‡πà‡∏≤‡∏•‡∏∑‡∏° prophylaxis ‡∏´‡∏•‡∏±‡∏á‡∏´‡∏¢‡∏∏‡∏î vasoactive agent\n\n### Ascites\n- ‡∏†‡∏≤‡∏ß‡∏∞ [[#Portal Hypertension]] ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏™‡∏£‡πâ‡∏≤‡∏á NO ‡πÄ‡∏¢‡∏≠‡∏∞‡∏Ç‡∏∂‡πâ‡∏ô ‡∏´‡∏•‡∏≠‡∏î‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡∏Ç‡∏¢‡∏≤‡∏¢‡∏ï‡∏±‡∏ß blood pressure ‡∏•‡∏î ‡∏ó‡∏≥‡πÉ‡∏´‡πâ RAAS ‡∏ó‡∏≥‡∏á‡∏≤‡∏ô‡∏°‡∏≤‡∏Å‡∏Ç‡∏∂‡πâ‡∏ô ‡∏Å‡∏£‡∏∞‡∏ï‡∏∏‡πâ‡∏ô‡∏Å‡∏≤‡∏£‡∏Å‡∏±‡∏Å‡πÄ‡∏Å‡πá‡∏ö‡∏ô‡πâ‡∏≥ hydrostatic pressure ‡∏™‡∏π‡∏á‡∏Ç‡∏∂‡πâ‡∏ô‡∏à‡∏ô‡∏ä‡∏ô‡∏∞ osmotic pressure (‡πÄ‡∏£‡∏µ‡∏¢‡∏Å‡∏Å‡∏•‡∏∏‡πà‡∏°‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏ï‡∏£‡∏á‡∏ô‡∏µ‡πâ‡∏ß‡πà‡∏≤ hepatorenal syndrome)\n- ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏ï‡∏±‡∏ö‡∏û‡∏±‡∏á‡∏ó‡∏≥‡πÉ‡∏´‡πâ albumin ‡∏ô‡πâ‡∏≠‡∏¢‡∏•‡∏á ‡πÄ‡∏™‡∏£‡∏¥‡∏°‡πÉ‡∏´‡πâ‡πÄ‡∏Å‡∏¥‡∏î ascites\n- ascites ‡πÄ‡∏Å‡∏¥‡∏î‡∏Ç‡∏∂‡πâ‡∏ô 50% ‡πÉ‡∏ô‡∏ú‡∏π‡πâ‡∏õ‡πà‡∏ß‡∏¢ cirrhosis ‡∏´‡∏•‡∏±‡∏á‡∏ú‡πà‡∏≤‡∏ô‡πÑ‡∏õ 10 ‡∏õ‡∏µ\n- diagnosis\n\t- low serum albumin\n\t- serum-ascites albumin gradient (SAAG) \u003e/= 1.1 g/dl\n\t- shifting dullness, fluid thrill\n\t\t- ‡∏ñ‡πâ‡∏≤‡πÄ‡∏õ‡πá‡∏ô‡∏´‡∏ô‡∏±‡∏Å shifting dullness ‡∏≠‡∏≤‡∏à‡πÄ‡∏õ‡πá‡∏ô negative ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡πÄ‡∏≠‡∏µ‡∏¢‡∏á‡πÑ‡∏õ‡∏Å‡πá‡πÑ‡∏°‡πà‡∏°‡∏µ‡∏à‡∏∏‡∏î‡πÑ‡∏´‡∏ô‡πÄ‡∏Ñ‡∏≤‡∏∞‡πÑ‡∏î‡πâ‡∏¢‡∏¥‡∏ô‡πÄ‡∏™‡∏µ‡∏¢‡∏á‡πÅ‡∏•‡πâ‡∏ß ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏°‡∏µ‡πÅ‡∏ï‡πà‡∏ô‡πâ‡∏≥\n\t\t- ‡∏ñ‡πâ‡∏≤‡πÄ‡∏õ‡πá‡∏ô‡∏´‡∏ô‡∏±‡∏Å‡∏à‡∏ô‡πÑ‡∏°‡πà‡πÄ‡∏´‡∏•‡∏∑‡∏≠‡∏≠‡∏≤‡∏Å‡∏≤‡∏®‡πÄ‡∏•‡∏¢ fluid thrill ‡∏Å‡πá‡∏≠‡∏≤‡∏à negative ‡πÑ‡∏î‡πâ\n- treatment\n\t- ‡∏•‡∏î‡∏õ‡∏£‡∏¥‡∏°‡∏≤‡∏ì‡∏ô‡πâ‡∏≥ intracellular ‡πÄ‡∏û‡∏∑‡πà‡∏≠‡πÉ‡∏´‡πâ extracellular ‡∏•‡∏î ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤‡∏•‡∏î‡πÄ‡∏£‡πá‡∏ß‡πÄ‡∏Å‡∏¥‡∏ô‡πÑ‡∏õ‡∏à‡∏∞‡∏¢‡∏¥‡πà‡∏á‡πÄ‡∏Å‡∏¥‡∏î hepatorenal syndrome ‡πÑ‡∏î‡πâ\n\t- ‡∏•‡∏î‡∏ô‡πâ‡∏≥‡∏´‡∏≥‡∏ô‡∏±‡∏Å‡∏•‡∏á‡∏õ‡∏£‡∏∞‡∏°‡∏≤‡∏ì‡∏© 0.5 kg ‡∏ï‡πà‡∏≠‡∏ß‡∏±‡∏ô\n\t- ‡∏´‡∏¢‡∏∏‡∏î‡∏¢‡∏≤‡∏ó‡∏µ‡πà‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏ö‡∏ß‡∏°‡∏ô‡πâ‡∏≥ ‡∏´‡∏£‡∏∑‡∏≠‡∏û‡∏¥‡∏©‡∏ï‡πà‡∏≠‡∏ï‡∏±‡∏ö\n\t- ‡∏à‡∏≥‡∏Å‡∏±‡∏î‡πÄ‡∏Å‡∏•‡∏∑‡∏≠ ‡∏´‡∏≤‡∏Å‡πÄ‡∏Å‡∏•‡∏∑‡∏≠‡πÄ‡∏¢‡∏≠‡∏∞ (2 g of sodum per day) ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤‡πÄ‡∏Å‡∏•‡∏∑‡∏≠‡∏ô‡πâ‡∏≠‡∏¢ (serum sodium \u003c 120 mg/dl) ‡πÉ‡∏´‡πâ‡∏à‡∏≥‡∏Å‡∏±‡∏î‡∏ô‡πâ‡∏≥‡πÅ‡∏ó‡∏ô\n\t- ‡πÉ‡∏ä‡πâ aldosterone antagonist (spironolactone) +- furosemide (100/40 ratio) max ‡∏ó‡∏µ‡πà 400/160 mg\n\t\t- aldosterone ‡πÄ‡∏Å‡∏µ‡πà‡∏¢‡∏ß‡∏Ç‡πâ‡∏≠‡∏á‡∏Å‡∏±‡∏ö‡∏Å‡∏≤‡∏£‡πÄ‡∏Å‡∏¥‡∏î ascites ‡∏à‡∏∂‡∏á‡∏°‡∏µ‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ spironolactone\n\t\t- spironolactone ‡πÄ‡∏õ‡πá‡∏ô k-sparing ‡∏à‡∏∂‡∏á‡∏ä‡πà‡∏ß‡∏¢‡∏Ñ‡πâ‡∏≤‡∏ô‡∏Å‡∏±‡∏ö furosemide ‡∏ó‡∏µ‡πà‡∏Ç‡∏±‡∏ö K\n\t\t- ‡∏´‡∏≤‡∏Å‡∏à‡∏≥‡πÄ‡∏õ‡πá‡∏ô (‡∏£‡∏∏‡∏ô‡πÅ‡∏£‡∏á,‡πÑ‡∏°‡πà‡∏ï‡∏≠‡∏ö‡∏™‡∏ô‡∏≠‡∏á‡∏ï‡πà‡∏≠‡∏¢‡∏≤‡∏Ç‡∏±‡∏ö‡∏õ‡∏±‡∏™‡∏™‡∏≤‡∏ß‡∏∞) ‡∏≠‡∏≤‡∏à‡∏ó‡∏≥ paracentesis **‡πÇ‡∏î‡∏¢‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å‡∏≠‡∏≠‡∏Å‡∏°‡∏≤ \u003e 5 L ‡πÉ‡∏´‡πâ IV albumin ‡∏ä‡∏î‡πÄ‡∏ä‡∏¢ 6-8 g albumin ‡∏ï‡πà‡∏≠ 1 L ‡∏Ç‡∏≠‡∏á ascetic fluid ‡∏î‡πâ‡∏ß‡∏¢**\n\t\t\t- 5 L ‡πÄ‡∏û‡∏£‡∏≤‡∏∞ study / cost ‡πÄ‡∏ô‡∏∑‡πà‡∏≠‡∏á‡∏à‡∏≤‡∏Å‡∏¢‡∏≤‡πÅ‡∏û‡∏á\n\n### SBP - spontaneous bacterial peritonitis\n- Pathophysiology\n\t- ‡πÄ‡∏Å‡∏¥‡∏î‡∏à‡∏≤‡∏Å integrity ‡∏Ç‡∏≠‡∏á‡∏•‡∏≥‡πÑ‡∏™‡πâ‡∏•‡∏î‡∏•‡∏á ‡∏Å‡∏≤‡∏£‡πÄ‡∏Ñ‡∏•‡∏∑‡πà‡∏≠‡∏ô‡πÑ‡∏´‡∏ß‡∏•‡∏≥‡πÑ‡∏™‡πâ‡∏•‡∏î‡∏•‡∏á ‡∏†‡∏π‡∏°‡∏¥‡∏Ñ‡∏∏‡πâ‡∏°‡∏Å‡∏±‡∏ô‡∏•‡∏î‡∏•‡∏á ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡πÄ‡∏ä‡∏∑‡πâ‡∏≠‡πÅ‡∏ö‡∏Ñ‡∏ó‡∏µ‡πÄ‡∏£‡∏µ‡∏¢‡πÄ‡∏û‡∏¥‡πà‡∏°‡∏à‡∏≥‡∏ô‡∏ß‡∏ô‡πÑ‡∏î‡πâ‡∏á‡πà‡∏≤‡∏¢‡∏Ç‡∏∂‡πâ‡∏ô\n\t- ‡∏û‡∏ö E.coli , K. pneumoniae, S. pneumonia ‡πÑ‡∏î‡πâ‡∏ö‡πà‡∏≠‡∏¢ ‡πÅ‡∏•‡∏∞‡∏°‡∏±‡∏Å‡πÄ‡∏õ‡πá‡∏ô‡∏Å‡∏≤‡∏£‡∏ï‡∏¥‡∏î‡πÄ‡∏ä‡∏∑‡πâ‡∏≠‡∏ä‡∏ô‡∏¥‡∏î‡πÄ‡∏î‡∏µ‡∏¢‡∏ß\n- Indication for treatment\n\t- ascetic fluid ‡∏û‡∏ö‡πÄ‡∏ä‡∏∑‡πâ‡∏≠‡∏Å‡πà‡∏≠‡πÇ‡∏£‡∏Ñ + ascetic fluid PMN leukocyte \u003e/= 250 cells/mm3 ‡πÇ‡∏î‡∏¢‡πÑ‡∏°‡πà‡∏°‡∏µ‡∏™‡∏≤‡πÄ‡∏´‡∏ï‡∏∏‡∏≠‡∏∑‡πà‡∏ô‡∏Ç‡∏≠‡∏á‡∏Å‡∏≤‡∏£‡∏ï‡∏¥‡∏î‡πÄ‡∏ä‡∏∑‡πâ‡∏≠\n\t- ‡∏´‡∏£‡∏∑‡∏≠ ‡∏û‡∏ö‡πÄ‡∏ä‡∏∑‡πâ‡∏≠‡∏Å‡πà‡∏≠‡πÇ‡∏£‡∏Ñ‡πÅ‡∏ï‡πà PMN leukocyte \u003c 250 cells/mm3 **(bacteriascite stage)**\n- ‡∏ú‡∏π‡πâ‡∏õ‡πà‡∏ß‡∏¢‡∏ó‡∏µ‡πà‡∏°‡∏µ Scr \u003e 1 mg/dl ‡∏´‡∏£‡∏∑‡∏≠ BUN \u003e 30 mg/dl ‡∏´‡∏£‡∏∑‡∏≠ total bilirubin \u003e 4 mg/dl ‡∏Ñ‡∏ß‡∏£‡πÑ‡∏î‡πâ‡∏£‡∏±‡∏ö albumin ‡πÄ‡∏™‡∏£‡∏¥‡∏° 1.5 g / kg ‡∏†‡∏≤‡∏¢‡πÉ‡∏ô 6 ‡∏ä‡∏°‡∏´‡∏•‡∏±‡∏á‡πÄ‡∏£‡∏¥‡πà‡∏°‡∏°‡∏µ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£ ‡∏ï‡∏≤‡∏°‡∏î‡πâ‡∏ß‡∏¢ 1 g / kg ‡πÉ‡∏ô‡∏ß‡∏±‡∏ô‡∏ó‡∏µ‡πà 3\n- Treatment\n\t- cefotaxime 2 g q 8 h ‡∏´‡∏£‡∏∑‡∏≠ 3rd gen ‡∏≠‡∏∑‡πà‡∏ô ‡πÜ BL-BI / amox-clav ‡∏£‡∏±‡∏Å‡∏©‡∏≤ 5 ‡∏ß‡∏±‡∏ô ‡∏´‡∏£‡∏∑‡∏≠ 7 ‡∏ß‡∏±‡∏ô‡∏ñ‡πâ‡∏≤‡∏°‡∏µ variceal bleeding ‡∏´‡∏£‡∏∑‡∏≠\n\t- **ciprofloxacin** IV 400 mg q 12 h 8 ‡∏ß‡∏±‡∏ô\n- Prophylaxis ‡πÉ‡∏ô‡∏ú‡∏π‡πâ‡∏õ‡πà‡∏ß‡∏¢‡∏ó‡∏µ‡πà‡∏°‡∏µ variceal bleeding\n\t- ceftriaxone 1 g q 24 h 7 ‡∏ß‡∏±‡∏ô ‡∏´‡∏£‡∏∑‡∏≠\n\t- **norfloxacin** po 400 mg q 12 h 7 ‡∏ß‡∏±‡∏ô ‡∏´‡∏£‡∏∑‡∏≠\n\t- **ciprofloxacin** IV 400 mg q 12 h 7 ‡∏ß‡∏±‡∏ô ‡∏´‡∏£‡∏∑‡∏≠\n\t- **ciprofloxacin** po 500 mg q 12 7 ‡∏ß‡∏±‡∏ô h\n- Secondary Prophylaxis ‡πÉ‡∏ô‡∏ú‡∏π‡πâ‡∏ó‡∏µ‡πà‡πÄ‡∏Ñ‡∏¢‡∏°‡∏µ SBP ‡∏´‡∏£‡∏∑‡∏≠‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á‡∏™‡∏π‡∏á\n\t- **norfloxacin** po 400 mg od ‡∏ï‡∏•‡∏≠‡∏î‡∏£‡∏∞‡∏¢‡∏∞‡πÄ‡∏ß‡∏•‡∏≤‡∏ó‡∏µ‡πà‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á / ‡∏ï‡∏•‡∏≠‡∏î‡∏ä‡∏µ‡∏ß‡∏¥‡∏ï ‡∏´‡∏£‡∏∑‡∏≠\n\t- DS cotrimoxazole OD ‡∏ï‡∏•‡∏≠‡∏î‡∏£‡∏∞‡∏¢‡∏∞‡πÄ‡∏ß‡∏•‡∏≤‡∏ó‡∏µ‡πà‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á / ‡∏ï‡∏•‡∏≠‡∏î‡∏ä‡∏µ‡∏ß‡∏¥‡∏ï ‡∏´‡∏£‡∏∑‡∏≠\n\t- **ciprofloxacin** 500 mg od ‡∏ï‡∏•‡∏≠‡∏î‡∏£‡∏∞‡∏¢‡∏∞‡πÄ‡∏ß‡∏•‡∏≤‡∏ó‡∏µ‡πà‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á / ‡∏ï‡∏•‡∏≠‡∏î‡∏ä‡∏µ‡∏ß‡∏¥‡∏ï ‡∏´‡∏£‡∏∑‡∏≠\n\t- ciprofloxacin 750 once weekly ‡∏ï‡∏•‡∏≠‡∏î‡∏£‡∏∞‡∏¢‡∏∞‡πÄ‡∏ß‡∏•‡∏≤‡∏ó‡∏µ‡πà‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á / ‡∏ï‡∏•‡∏≠‡∏î‡∏ä‡∏µ‡∏ß‡∏¥‡∏ï\n\n### Hepatitis encephalopathy\n- Pathophysiology\n\t- ‡πÄ‡∏Å‡∏¥‡∏î‡∏Å‡∏≤‡∏£‡∏™‡∏∞‡∏™‡∏°‡∏Ç‡∏≠‡∏á gut-derived nitrogenous substances ‡πÄ‡∏ä‡πà‡∏ô ammonia, glutamine ‡πÄ‡∏™‡∏µ‡∏¢‡∏™‡∏°‡∏î‡∏∏‡∏• BCAA/AAA ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏Å‡∏≤‡∏£‡∏ó‡∏≥‡∏á‡∏≤‡∏ô‡∏Ç‡∏≠‡∏á‡∏™‡∏°‡∏≠‡∏á‡∏´‡∏£‡∏∑‡∏≠‡∏Å‡∏≤‡∏£‡∏™‡∏£‡πâ‡∏≤‡∏á‡∏™‡∏≤‡∏£‡∏™‡∏∑‡πà‡∏≠‡∏õ‡∏£‡∏∞‡∏™‡∏≤‡∏ó‡∏ú‡∏¥‡∏î‡∏õ‡∏Å‡∏ï‡∏¥\n- Classification\n\t- A - acute liver failure\n\t- B - portosystemic bypass without intrinsic liver disease\n\t- C - cirrohosis\n\t- ‡∏°‡∏µ‡∏Å‡∏≤‡∏£‡πÅ‡∏ö‡πà‡∏á‡∏Ñ‡∏ß‡∏≤‡∏°‡∏£‡∏∏‡∏ô‡πÅ‡∏£‡∏á‡∏ï‡∏≤‡∏° grade ‡∏î‡πâ‡∏ß‡∏¢‡∏à‡∏≤‡∏Å 0-4 ‡πÇ‡∏î‡∏¢\n\t\t- 0 ‡∏Ñ‡∏∑‡∏≠‡πÑ‡∏°‡πà‡πÄ‡∏õ‡πá‡∏ô\n\t\t- minimal ‡∏Ñ‡∏∑‡∏≠‡πÄ‡∏ä‡∏∑‡πà‡∏≠‡∏°‡∏ã‡∏∂‡∏°‡∏°‡∏µ‡πÅ‡∏ï‡πà‡∏≠‡∏≤‡∏Å‡∏≤‡∏£ psycho \n\t\t- 2 ‡πÄ‡∏£‡∏¥‡πà‡∏° retard \n\t\t- 3 4 ‡∏Å‡πá‡∏´‡∏ô‡∏±‡∏Å‡πÄ‡∏•‡∏¢‡∏à‡πâ‡∏≤\n- Treatment ‡πÇ‡∏î‡∏¢‡∏Å‡∏≤‡∏£‡∏•‡∏î ammonia ‡πÉ‡∏ô‡πÄ‡∏•‡∏∑‡∏≠‡∏î\n\t- **‡∏•‡∏î‡∏Å‡∏≤‡∏£‡∏£‡∏±‡∏ö‡∏õ‡∏£‡∏∞‡∏ó‡∏≤‡∏ô AAA** **‡πÄ‡∏û‡∏¥‡πà‡∏° BCAA**\n\t\t- aromatic amino acid\n\t\t- bcaa = branched-chain amino acid\n\t- ‡∏à‡∏≥‡∏Å‡∏±‡∏î‡πÇ‡∏õ‡∏£‡∏ï‡∏µ‡∏ô ‡πÑ‡∏°‡πà‡πÄ‡∏Å‡∏¥‡∏ô 10-20 g ‡∏ï‡∏≠‡∏ô‡∏Å‡∏≥‡πÄ‡∏£‡∏¥‡∏ö ‡πÅ‡∏•‡πâ‡∏ß‡∏Ñ‡πà‡∏≠‡∏¢‡∏õ‡∏£‡∏±‡∏ö‡∏Ç‡∏∂‡πâ‡∏ô‡πÄ‡∏õ‡πá‡∏ô 1.2-1.5 g /kg (‡∏Ñ‡∏ô‡∏õ‡∏Å‡∏ï‡∏¥ 1g/kg, ‡πÑ‡∏ï 0.8g/kg)\n\t- Lactulose ‡∏à‡∏ô‡∏ñ‡πà‡∏≤‡∏¢ 2-3 ‡∏Ñ‡∏£‡∏±‡πâ‡∏á‡∏ï‡πà‡∏≠‡∏ß‡∏±‡∏ô\n\t\t- **Lactulose promotes the growth of¬†lactic acid bacteria** ‡∏ã‡∏∂‡πà‡∏á‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏°‡∏µ lactic acid ‡πÑ‡∏õ‡πÄ‡∏õ‡∏•‡∏µ‡∏¢‡πà‡∏ô‡πÉ‡∏´‡πâ ammonia ‡πÅ‡∏ï‡∏Å‡∏ï‡∏±‡∏ß‡πÅ‡∏•‡πâ‡∏ß‡∏Ç‡∏±‡∏ö‡∏≠‡∏≠‡∏Å‡∏á‡πà‡∏≤‡∏¢‡∏Ç‡∏∂‡πâ‡∏ô\n\t- oral antibiotics ‡πÉ‡∏ô‡∏Å‡∏£‡∏ì‡∏µ‡∏ó‡∏µ‡πà lactulose fail / ‡∏´‡∏£‡∏∑‡∏≠‡∏Å‡∏¥‡∏ô‡πÄ‡∏û‡∏∑‡πà‡∏≠‡∏•‡∏î urease producing bacteria\n\t\t- metronidazole\n\t\t- neomycin\n\t\t- rifaximin\n### Coagulopathy\n- ‡πÄ‡∏Å‡∏¥‡∏î‡πÑ‡∏î‡πâ‡∏ó‡∏±‡πâ‡∏á bleed / clot\n- ‡∏≠‡∏≤‡∏à‡∏°‡∏≤‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡πÄ‡∏Å‡∏¥‡∏î thrombocytopenia ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏Å‡∏≤‡∏£‡∏ó‡∏≥‡∏á‡∏≤‡∏ô‡∏Ç‡∏≠‡∏á‡πÄ‡∏Å‡∏•‡πá‡∏î‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡∏•‡∏î‡∏•‡∏á‡πÑ‡∏î‡πâ","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/DIGI":{"title":"DIGI","content":"### Gingival Enlargement\n- Phenytoin\n- DHP-CCBs (‡∏û‡∏ß‡∏Å amlodipine)\n- Cyclosporin\n### Oropharyngeal Candidiasis\n- ‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡∏Å‡∏î‡∏†‡∏π‡∏°‡∏¥‡∏Ñ‡∏∏‡πâ‡∏°‡∏Å‡∏±‡∏ô ‡∏ó‡∏±‡πâ‡∏á systemic ‡πÅ‡∏•‡∏∞ locally\n- ‡πÉ‡∏ä‡πâ genteal violet, fluconazole oral or clotrimazole oral ‡∏£‡∏±‡∏Å‡∏©‡∏≤\n### Oral lichen planus\n- ‡∏õ‡∏è‡∏¥‡∏Å‡∏¥‡∏£‡∏¥‡∏¢‡∏≤‡∏†‡∏π‡∏°‡∏¥‡∏Ñ‡∏∏‡πâ‡∏°‡∏Å‡∏±‡∏ô\n- metoprolol\n- imatinib\n- ticlopidine\n### Pill esophagitis\n- ‡∏Å‡∏≤‡∏£‡∏£‡∏∞‡∏Ñ‡∏≤‡∏¢‡πÄ‡∏Ñ‡∏∑‡∏≠‡∏á‡∏à‡∏≤‡∏Å‡∏¢‡∏≤‡∏ó‡∏µ‡πà‡πÄ‡∏õ‡πá‡∏ô‡∏Ç‡∏≠‡∏á**‡πÅ‡∏Ç‡πá‡∏á**\n- ‡∏Ñ‡∏∏‡∏ì‡∏™‡∏°‡∏ö‡∏±‡∏ï‡∏¥‡∏ó‡∏≤‡∏á‡πÄ‡∏Ñ‡∏°‡∏µ‡∏Ç‡∏≠‡∏á‡∏¢‡∏≤ ‡∏≠‡∏≤‡∏à‡πÄ‡∏™‡∏£‡∏¥‡∏° ‡πÄ‡∏ä‡πà‡∏ô Bisphosphonate, quinidine, tetracycline, potassium chloride, iron suppl, NSAIDs\n- ‡πÅ‡∏Å‡πâ‡∏î‡πâ‡∏ß‡∏¢‡∏Å‡∏≤‡∏£‡∏î‡∏∑‡πà‡∏°‡∏ô‡πâ‡∏≥‡πÄ‡∏¢‡∏≠‡∏∞ ‡πÜ ‡πÇ‡∏î‡∏¢‡∏î‡∏∑‡πà‡∏°‡∏Å‡πà‡∏≠‡∏ô‡∏Å‡∏¥‡∏ô‡∏ô‡∏¥‡∏î‡∏ô‡∏∂‡∏á (hydrate ‡∏´‡∏•‡∏≠‡∏î‡∏≠‡∏≤‡∏´‡∏≤‡∏£) ‡πÅ‡∏•‡πâ‡∏ß‡∏î‡∏∑‡πà‡∏°‡πÄ‡∏¢‡∏≠‡∏∞ ‡πÜ ‡∏ï‡∏≤‡∏°‡∏ó‡∏µ‡∏´‡∏•‡∏±‡∏á ‡∏´‡∏•‡∏±‡∏á‡∏Å‡∏¥‡∏ô\n### GERD\n- Lower ESP\n\t- CCB ‡∏ó‡∏±‡πâ‡∏á‡∏™‡∏≠‡∏á‡∏Å‡∏•‡∏∏‡πà‡∏°\n\t- opiate\n\t- TCA\n\t- BZ\n\t- ‡∏û‡∏ß‡∏Å b-block b a-agonist a-block\n- Irritate mucosa\n\t- nsaids,\n\t- tetracycline,\n\t- bisphosphonate\n### NSAIDs Gastropathy\n![[Pasted image 20230308173816.png|525]]\n- ‡∏ó‡∏±‡πâ‡∏á‡∏ú‡∏•‡∏¢‡∏±‡∏ö‡∏¢‡∏±‡πâ‡∏á COX-1 (‡∏¢‡∏±‡∏ö‡∏¢‡∏±‡πâ‡∏á PGE2) ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏¢‡∏±‡∏ö‡∏¢‡∏±‡πâ‡∏á‡∏Å‡∏≤‡∏£‡∏™‡∏£‡πâ‡∏≤‡∏á mucous ‡πÅ‡∏•‡∏∞‡∏ú‡∏•‡∏à‡∏≤‡∏Å local irritation (pH ‡∏¢‡∏≤‡πÄ‡∏õ‡πá‡∏ô‡∏Å‡∏£‡∏î)\n- enteric nsaids ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏ä‡πà‡∏ß‡∏¢\n- ‡∏Å‡∏¥‡∏ô‡∏´‡∏•‡∏±‡∏á‡∏≠‡∏≤‡∏´‡∏≤‡∏£‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏ä‡πà‡∏ß‡∏¢ ‡πÅ‡∏ï‡πà‡∏ó‡∏≥‡πÉ‡∏´‡πâ onset ‡∏ä‡πâ‡∏≤‡∏Ç‡∏∂‡πâ‡∏ô‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤\n- ‡∏Å‡∏≤‡∏£‡πÄ‡∏õ‡∏•‡∏µ‡πà‡∏¢‡∏ô‡πÑ‡∏õ‡πÉ‡∏ä‡πâ cox-2 ‡πÅ‡∏•‡∏∞/‡∏´‡∏£‡∏∑‡∏≠ ppi ‡∏ä‡πà‡∏ß‡∏¢‡πÄ‡∏û‡∏¥‡πà‡∏°/‡πÄ‡∏™‡∏£‡∏¥‡∏° ‡πÑ‡∏°‡πà‡πÉ‡∏´‡πâ‡πÄ‡∏Å‡∏¥‡∏î side effect ‡∏ó‡∏≤‡∏á GI\n### NSAID Enteropathy\n- ‡πÑ‡∏î‡πâ‡∏£‡∏±‡∏ö‡∏Ñ‡∏ß‡∏≤‡∏°‡∏™‡∏ô‡πÉ‡∏à‡∏ô‡πâ‡∏≠‡∏¢\n- ‡πÄ‡∏Å‡∏¥‡∏î‡∏à‡∏≤‡∏Å enterohepatic circulation ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏•‡∏≥‡πÑ‡∏™‡πâ‡∏™‡∏±‡∏°‡∏ú‡∏±‡∏™‡∏Å‡∏±‡∏ö NSAIDs ‡πÄ‡∏¢‡∏≠‡∏∞ ‡πÄ‡∏Å‡∏¥‡∏î‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏ô‡πâ‡∏≥‡∏î‡∏µ‡∏°‡∏±‡∏ô‡∏à‡∏±‡∏ö‡∏Å‡∏±‡∏ö nsaids ‡πÅ‡∏•‡πâ‡∏ß‡∏ñ‡∏π‡∏Å reuptake ‡∏Ç‡∏∂‡πâ‡∏ô‡πÑ‡∏õ\n- ‡∏Å‡∏≤‡∏£‡∏™‡∏±‡∏°‡∏ú‡∏±‡∏™‡∏ô‡∏≤‡∏ô ‡πÜ ‡∏ó‡∏≥‡πÉ‡∏´‡πâ oxidative phosphorylation ‡∏Ç‡∏≠‡∏á enterocytes ‡∏ñ‡∏π‡∏Å‡∏¢‡∏±‡∏ö‡∏¢‡∏±‡πâ‡∏á ‡πÄ‡∏Å‡∏¥‡∏î apoptosis\n- ‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ NSAIDs (cox2) ‡πÅ‡∏•‡∏∞/‡∏´‡∏£‡∏∑‡∏≠ PPI ‡∏Å‡∏ß‡∏ô‡∏™‡∏°‡∏î‡∏∏‡∏•‡∏Ç‡∏≠‡∏á microbiome ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏°‡∏µ gram-neg bac ‡πÄ‡∏¢‡∏≠‡∏∞‡∏Ç‡∏∂‡πâ‡∏ô ‡∏™‡πà‡∏á‡πÄ‡∏™‡∏£‡∏¥‡∏°‡∏Å‡∏£‡∏∞‡∏ö‡∏ß‡∏ô‡∏Å‡∏≤‡∏£ enterohepatic circulation ‡πÑ‡∏î‡πâ\n### Nausea\n- local irritation\n\t- nsaids\n\t- electrolytes (KCl, Fe2+)\n\t- antibiotics (tetracycline, clav)\n\t- metformin\n- systemic via CTZ\n\t- chemo\n\t- opiods\n\t- digoxin\n\t- antibiotics ‡∏û‡∏ß‡∏Å macrolide, FQ\n\t- estrogen\n\t- antiparkinson ‡πÄ‡∏ä‡πà‡∏ô levodopa\n### Constipation\n- Opioids\n- anticholinergic\n- clonidine\n- calcium channel blocker\n- iron\n### Diarrhea\n- laxative\n- stimulant\n- erythromycin\n- alpha-glucosidase inhibitor (‡∏ô‡πâ‡∏≥‡∏ï‡∏≤‡πÇ‡∏°‡∏•‡πÉ‡∏´‡∏ç‡πà ‡∏•‡∏≥‡πÑ‡∏™‡πâ‡∏ä‡πà‡∏ß‡∏¢‡πÉ‡∏´‡∏ç‡πà ‡∏Å‡∏•‡∏≤‡∏¢‡πÄ‡∏õ‡πá‡∏ô organic acid ‡∏ã‡∏∂‡πà‡∏á‡∏î‡∏∂‡∏á‡∏ô‡πâ‡∏≥‡∏î‡∏µ)\n- lipase inhibitor ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏•‡∏≥‡πÑ‡∏™‡πâ‡∏°‡∏±‡∏ô\n### Pseudomembranous Colitis\n- ‡∏£‡∏±‡∏Å‡∏©‡∏≤‡∏î‡πâ‡∏ß‡∏¢ metronidazole, vancomycin, bacitracin\n- ‡πÄ‡∏•‡∏µ‡πà‡∏¢‡∏á‡∏¢‡∏≤ antiperistalsis ‡πÄ‡∏ä‡πà‡∏ô loperamide\n### Melanosis Coli\n- ‡πÄ‡∏Å‡∏¥‡∏î‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ‡∏¢‡∏≤ anthraquinoens (senna, rhubarb) ‡∏£‡∏∞‡∏¢‡∏∞‡∏¢‡∏≤‡∏ß ‡πÄ‡∏Å‡∏¥‡∏î‡∏Å‡∏≤‡∏£‡∏ï‡∏≤‡∏¢‡∏Ç‡∏≠‡∏á‡πÄ‡∏ã‡∏•‡∏•‡πå‡∏™‡∏∞‡∏™‡∏°‡πÄ‡∏õ‡πá‡∏ô‡∏£‡∏≠‡∏¢‡∏™‡∏µ‡πÄ‡∏Ç‡πâ‡∏°‡∏ó‡∏µ‡πà lamina propria ‡∏Ç‡∏≠‡∏á‡∏•‡∏≥‡πÑ‡∏™‡πâ\n- ‡∏°‡∏∞‡πÄ‡∏£‡πá‡∏á‡πÉ‡∏ô‡∏™‡∏±‡∏ï‡∏ß‡πå‡∏ó‡∏î‡∏•‡∏≠‡∏á ‡πÅ‡∏ï‡πà‡πÑ‡∏°‡πà‡∏™‡∏±‡∏°‡∏û‡∏±‡∏ô‡∏ò‡πå‡∏Å‡∏±‡∏ö‡∏Å‡∏≤‡∏£‡πÄ‡∏Å‡∏¥‡∏î‡∏°‡∏∞‡πÄ‡∏£‡πá‡∏á‡πÉ‡∏ô‡∏°‡∏ô‡∏∏‡∏©‡∏¢‡πå","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/DILI":{"title":"DILI","content":"### Toxicity\n- 10-20% of acute liver failure are associated with DILI\n- ‡∏°‡∏µ‡∏´‡∏•‡∏≤‡∏¢‡∏Å‡∏•‡πÑ‡∏Å‡∏°‡∏≤‡∏Å ‡πÜ ‡πÄ‡∏ä‡πà‡∏ô oxidative stress, mitochondrial impairment\n- mostly type A ADR ‡πÅ‡∏•‡∏∞‡∏õ‡πâ‡∏≠‡∏á‡∏Å‡∏±‡∏ô‡πÑ‡∏î‡πâ ‡πÅ‡∏ï‡πà‡∏Ñ‡∏≤‡∏î‡πÄ‡∏î‡∏≤‡∏¢‡∏≤‡∏Å‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏õ‡∏±‡∏à‡∏à‡∏±‡∏¢‡∏ó‡∏≤‡∏á genetic ‡∏ó‡∏µ‡πà‡∏°‡∏µ‡∏Ñ‡∏ß‡∏≤‡∏° polymorph ‡∏™‡∏π‡∏á\n\n### WHO Definition of Hepatotoxicity\n| Grade              | ALT Criteria |\n| ------------------ | -------- |\n| Grade 1 (mild)     |\u003c 2.5 times ULN|\n| Grade 2 (mild)     |    2.5-5 times ULN      |\n| Grade 3 (moderate) |5-10 times ULN|\n| Grade 4 (severe)                   |\u003e 10 times ULN|\n\n### Risk Factor\n- young age -\u003e valproic acid toxicity\n- chronic alcohol abuse -\u003e malnutrition or fasting -\u003e depletes glutathione\n- HIV -\u003e glutathione ‡∏à‡∏∞‡∏ô‡πâ‡∏≠‡∏¢‡∏≠‡∏¢‡∏π‡πà‡πÅ‡∏•‡πâ‡∏ß‡πÉ‡∏ô‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏Å‡∏•‡∏∏‡πà‡∏°‡∏ô‡∏µ‡πâ\n- hep B ‡πÅ‡∏•‡∏∞ hep C (‡∏û‡∏ß‡∏Å hep ‡∏ó‡∏µ‡πà chronic) \n\n### Drug Reported\n- Hepatocellular necrosis -\u003e Acetaminophen, Isoniazid, Lovastatin\n- Cholestasis -\u003e Estrogen, Erythromycin, amox/clav\n- Veno-occlusive disease -\u003e ‡∏û‡∏ß‡∏Å‡∏¢‡∏≤‡∏°‡∏∞‡πÄ‡∏£‡πá‡∏á\n\n### Assessment\n\n#### Naranjo\n- overestimate risk, assess ‡πÑ‡∏î‡πâ‡∏¢‡∏≤‡∏Å ‡∏à‡∏∂‡∏á‡∏°‡∏µ‡∏Å‡∏≤‡∏£‡∏Ñ‡∏¥‡∏î‡∏Ñ‡πâ‡∏ô **RUCAM** ‡πÇ‡∏î‡∏¢‡∏°‡∏µ‡∏Ñ‡∏∞‡πÅ‡∏ô‡∏ô‡∏£‡∏∞‡∏´‡∏ß‡πà‡∏≤‡∏á -10 ‡∏ñ‡∏∂‡∏á 14 ‡πÉ‡∏ä‡πâ‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô **DILI**\n\n### Laboratory\n- ALT ‡∏°‡∏≤‡∏à‡∏≤‡∏Å‡πÄ‡∏ã‡∏•‡∏•‡πå‡∏ï‡∏±‡∏ö‡πÇ‡∏î‡∏¢‡∏ï‡∏£‡∏á\n- ALP ‡πÅ‡∏•‡∏∞ GGT ‡∏≠‡∏¢‡∏π‡πà‡πÉ‡∏ô bile duct\n- Bilirubin ‡πÑ‡∏ß‡πâ‡πÉ‡∏ä‡πâ‡∏î‡∏π prognosis ‡πÑ‡∏î‡πâ ‡∏à‡∏∞‡∏™‡∏π‡∏á‡∏ñ‡πâ‡∏≤‡∏£‡∏∏‡∏ô‡πÅ‡∏£‡∏á\n\n#### R-Ratio\n- ![[Pasted image 20230308221530.png|550]]\n\n\n### DILI Classification\n\n#### Acute Hepatocellular DILI\n- moa: direct liver injury\n- s/s ‡πÅ‡∏ö‡∏ö‡πÇ‡∏£‡∏Ñ‡∏ï‡∏±‡∏ö\n- ALT ‡∏à‡∏∞ \u003e 2x ULN ‡∏°‡∏±‡∏Å 10x-100x\n\n#### Acute cholestatic DILI\n- s/s ‡πÅ‡∏ö‡∏ö‡∏õ‡∏ß‡∏î‡πÄ‡∏Å‡∏£‡πá‡∏á ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏Ç‡∏±‡∏ö‡∏ô‡πâ‡∏≥‡∏î‡∏µ‡∏≠‡∏≠‡∏Å‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ\n- ALP ‡πÅ‡∏•‡∏∞ GGT ‡∏°‡∏±‡∏Å‡∏à‡∏∞ \u003e 2x ULN\n- ALT ‡∏≠‡∏≤‡∏à‡∏™‡∏π‡∏á‡πÄ‡∏•‡πá‡∏Å‡∏ô‡πâ‡∏≠‡∏¢\n- Cong ‡∏™‡∏π‡∏á‡∏Å‡∏ß‡πà‡∏≤‡∏õ‡∏Å‡∏ï‡∏¥ ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏Ç‡∏±‡∏ö‡∏≠‡∏≠‡∏Å‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡πÄ‡∏•‡∏¢‡∏Å‡∏£‡∏∞‡∏à‡∏≤‡∏¢‡∏Å‡∏•‡∏±‡∏ö‡πÑ‡∏õ‡∏ó‡∏µ‡πà‡πÄ‡∏•‡∏∑‡∏≠‡∏î\n\n#### Acute mixed-pattern DILI\n- ‡∏à‡∏∞‡πÄ‡∏Å‡∏¥‡∏î‡∏≠‡∏±‡∏ô‡πÉ‡∏î‡∏≠‡∏±‡∏ô‡∏´‡∏ô‡∏∂‡πà‡∏á‡∏Å‡πà‡∏≠‡∏ô‡∏Å‡πá‡πÑ‡∏î‡πâ ‡πÅ‡∏•‡πâ‡∏ß‡∏°‡∏±‡∏Å‡∏ï‡∏≤‡∏°‡∏°‡∏≤‡∏î‡πâ‡∏ß‡∏¢‡∏≠‡∏µ‡∏Å‡∏≠‡∏±‡∏ô ‡πÄ‡∏ä‡πà‡∏ô hepatocellular ‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡∏ï‡πà‡∏≠ ‡πÜ ‡∏à‡∏ô‡∏ñ‡∏∏‡∏á‡∏ô‡πâ‡∏≥‡∏î‡∏µ‡πÇ‡∏î‡∏ô‡∏î‡πâ‡∏ß‡∏¢ ‡∏´‡∏£‡∏∑‡∏≠ cholestatic ‡πÅ‡∏•‡πâ‡∏ß‡∏°‡∏±‡∏ô‡πÇ‡∏õ‡πà‡∏á‡πÑ‡∏õ‡πÄ‡∏ö‡∏µ‡∏¢‡∏î‡∏ï‡∏±‡∏ö ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏ï‡∏±‡∏ö‡πÄ‡∏õ‡πá‡∏ô‡∏î‡πâ‡∏ß‡∏¢\n- ‡∏°‡∏±‡∏Å‡∏à‡∏∞‡∏™‡∏π‡∏á‡∏´‡∏°‡∏î‡πÄ‡∏•‡∏¢‡∏ó‡∏±‡πâ‡∏á ALT ALP GGT bilirubin\n\n#### Chronic Hepatitis\n- moa: ‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡πÑ‡∏°‡πà‡∏£‡∏∏‡∏ô‡πÅ‡∏£‡∏á ‡∏°‡∏±‡∏Å‡πÄ‡∏õ‡πá‡∏ô chronic ‡πÅ‡∏•‡∏∞‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏°‡∏≤‡∏ï‡∏≠‡∏ô‡∏£‡∏∏‡∏ô‡πÅ‡∏£‡∏á‡πÅ‡∏•‡πâ‡∏ß\n- S/S ‡πÅ‡∏ö‡∏ö‡πÇ‡∏£‡∏Ñ‡∏ï‡∏±‡∏ö ‡∏ï‡∏±‡∏ö‡∏°‡πâ‡∏≤‡∏°‡πÇ‡∏ï ‡∏≠‡∏≤‡∏à‡∏ï‡∏±‡∏ö‡πÅ‡∏Ç‡πá‡∏á\n- ALT \u003e2xULN ‡∏™‡∏π‡∏á‡∏ô‡∏¥‡∏î‡∏´‡∏ô‡πà‡∏≠‡∏¢‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏ï‡∏≤‡∏¢‡πÅ‡∏ö‡∏ö‡∏ä‡πâ‡∏≤ ‡πÜ\n- ALP GGT ‡∏Ñ‡πà‡∏≠‡∏ô‡∏Ç‡πâ‡∏≤‡∏á‡∏õ‡∏Å‡∏ï‡∏¥\n- Bilirubin ‡πÅ‡∏•‡∏∞ INR ‡∏Ñ‡πà‡∏≠‡∏ô‡∏Ç‡πâ‡∏≤‡∏á‡∏™‡∏π‡∏á‡∏Å‡∏ß‡πà‡∏≤‡∏õ‡∏Å‡∏ï‡∏¥‡πÄ‡∏û‡∏£‡∏≤‡∏∞ cirrhosis\n\n#### Veno-occlusive DILI\n- MOA: ‡∏≠‡∏∏‡∏î‡∏ï‡∏±‡∏ô‡∏´‡∏•‡∏≠‡∏î‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡πÉ‡∏ô‡πÄ‡∏ô‡∏∑‡πâ‡∏≠‡πÄ‡∏¢‡∏∑‡πà‡∏≠‡∏ï‡∏±‡∏ö\n- s/s portal hypertension ‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏°‡∏±‡∏ô‡∏≠‡∏∏‡∏î‡∏ï‡∏±‡∏ô ‡∏Ñ‡∏ß‡∏≤‡∏°‡∏£‡∏∏‡∏ô‡πÅ‡∏£‡∏á‡∏´‡∏•‡∏≤‡∏Å‡∏´‡∏•‡∏≤‡∏¢\n- **‡∏û‡∏ö‡πÄ‡∏à‡∏≠‡πÑ‡∏î‡πâ‡πÄ‡∏¢‡∏≠‡∏∞‡πÉ‡∏ô‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏ó‡∏µ‡πà‡πÉ‡∏ä‡πâ‡∏¢‡∏≤‡πÄ‡∏Ñ‡∏°‡∏µ‡∏ö‡∏≥‡∏ö‡∏±‡∏î**\n- ALT \u003e2xULN\n- ALP GGT ‡∏Ñ‡πà‡∏≠‡∏ô‡∏Ç‡πâ‡∏≤‡∏á‡∏õ‡∏Å‡∏ï‡∏¥\n- Bilirubin ‡∏™‡∏π‡∏á‡∏Å‡∏ß‡πà‡∏≤‡∏õ‡∏Å‡∏ï‡∏¥ \n\n#### Antituberculosis DILI\n- ‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô‡∏à‡∏≤‡∏Å ALT ‡πÄ‡∏õ‡πá‡∏ô‡∏´‡∏•‡∏±‡∏Å\n- Types\n\t- ![[Pasted image 20230308222035.png|525]]\n- Isoniazid and NAT2\n\t- NAT2 ‡πÉ‡∏ä‡πâ acetylation ‡∏ï‡∏±‡∏ß isoniazid ‡πÉ‡∏´‡πâ‡πÑ‡∏î‡πâ acetylhydrazine ‡πÅ‡∏•‡∏∞ hydrazine ‡∏ã‡∏∂‡πà‡∏á‡∏ô‡πà‡∏≤‡∏à‡∏∞‡πÄ‡∏õ‡πá‡∏ô metabolite ‡∏ó‡∏µ‡πà‡πÄ‡∏õ‡πá‡∏ô‡∏™‡∏≤‡πÄ‡∏´‡∏ï‡∏∏‡∏Ç‡∏≠‡∏á‡∏Å‡∏≤‡∏£‡πÄ‡∏Å‡∏¥‡∏î DILI\n\t- slow acetylator ‡∏à‡∏∞‡πÄ‡∏Å‡∏¥‡∏î DILI ‡πÑ‡∏î‡πâ‡πÄ‡∏¢‡∏≠‡∏∞‡∏Å‡∏ß‡πà‡∏≤ ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏ï‡∏±‡∏ö expose ‡∏Å‡∏±‡∏ö metabolite ‡∏ô‡∏µ‡πâ‡πÑ‡∏î‡πâ‡∏ô‡∏≤‡∏ô‡∏Å‡∏ß‡πà‡∏≤\n- ‡∏Å‡πà‡∏≠‡∏ô‡πÄ‡∏£‡∏¥‡πà‡∏°‡∏¢‡∏≤ TB ‡∏≠‡∏¢‡πà‡∏≤‡∏•‡∏∑‡∏°‡πÄ‡∏à‡∏≤‡∏∞‡∏î‡∏π baseline ‡πÇ‡∏î‡∏¢‡πÄ‡∏â‡∏û‡∏≤‡∏∞‡πÉ‡∏ô‡∏Ñ‡∏ô‡∏ó‡∏µ‡πà‡∏°‡∏µ risk ‡∏ï‡∏≤‡∏°‡∏ó‡∏µ‡πà‡∏Å‡∏•‡πà‡∏≤‡∏ß‡πÑ‡∏õ‡πÅ‡∏•‡πâ‡∏ß‡πÉ‡∏ô‡∏™‡πà‡∏ß‡∏ô‡∏Ç‡∏≠‡∏á [[#Risk Factor]]\n- ‡∏≠‡∏≤‡∏à‡∏à‡∏∞‡∏ï‡πâ‡∏≠‡∏á‡∏ï‡∏£‡∏ß‡∏à‡∏ñ‡∏µ‡πà ‡πÜ ‡∏´‡∏•‡∏±‡∏á‡πÄ‡∏£‡∏¥‡πà‡∏°‡∏¢‡∏≤‡∏ä‡πà‡∏ß‡∏á 1 mo ‡πÅ‡∏£‡∏Å\n- **‡∏´‡∏≤‡∏Å N/V** ‡∏£‡∏∞‡∏´‡∏ß‡πà‡∏≤‡∏á‡πÉ‡∏ä‡πâ‡∏¢‡∏≤‡∏ß‡∏±‡∏ì‡πÇ‡∏£‡∏Ñ ‡πÉ‡∏´‡πâ‡πÄ‡∏à‡∏≤‡∏∞‡∏î‡∏π lab\n\t- AST/ALT \u003e 3x ULN ‡∏´‡∏¢‡∏∏‡∏î H R Z\n\t- AST/ALT \u003c= 3x ULN ‡∏£‡∏±‡∏ö‡∏õ‡∏£‡∏∞‡∏ó‡∏≤‡∏ô‡∏¢‡∏≤‡∏ï‡πà‡∏≠‡∏õ‡∏Å‡∏ï‡∏¥ ‡∏ï‡∏¥‡∏î‡∏ï‡∏≤‡∏°‡∏≠‡∏µ‡∏Å‡∏Ñ‡∏£‡∏±‡πâ‡∏á 3 days\n- ‡∏´‡∏≤‡∏Å‡∏ú‡∏•‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡∏ú‡∏¥‡∏î‡∏õ‡∏Å‡∏ï‡∏¥‡∏£‡∏∞‡∏´‡∏ß‡πà‡∏≤‡∏á‡πÉ‡∏ä‡πâ‡∏¢‡∏≤‡∏ß‡∏±‡∏ì‡πÇ‡∏£‡∏Ñ **‡πÅ‡∏ï‡πà‡πÑ‡∏°‡πà‡∏°‡∏µ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£**\n\t- Total bilirubin \u003e 3 mg/dl ‡πÅ‡∏ï‡πà AST/ALT ‡∏õ‡∏Å‡∏ï‡∏¥ ‡∏´‡∏£‡∏∑‡∏≠‡πÄ‡∏û‡∏¥‡πà‡∏°‡πÅ‡∏ï‡πà‡πÑ‡∏°‡πà‡πÄ‡∏Å‡∏¥‡∏ô 3x ULN ‡πÉ‡∏´‡πâ‡∏´‡∏¢‡∏∏‡∏î‡πÅ‡∏Ñ‡πà R ‡πÄ‡∏û‡∏£‡∏≤‡∏∞ cholestatic ‡πÅ‡∏ô‡πà‡∏ô‡∏≠‡∏ô‡∏ô‡∏ô‡∏ô‡∏ô\n\t- AST/ALT \u003e 5 ‡πÄ‡∏ó‡πà‡∏≤ ‡∏´‡∏¢‡∏∏‡∏î H R Z\n\t- AST/ALT \u003c= 5 ‡πÄ‡∏ó‡πà‡∏≤ ‡∏£‡∏±‡∏ö‡∏õ‡∏£‡∏∞‡∏ó‡∏≤‡∏ô‡∏¢‡∏≤‡∏ï‡πà‡∏≠ ‡∏ï‡∏¥‡∏î‡∏ï‡∏≤‡∏°‡∏≠‡∏µ‡∏Å‡∏Ñ‡∏£‡∏±‡πâ‡∏á 1 week\n- Re-challenge\n\t- ‡∏Å‡∏•‡∏±‡∏ö‡∏°‡∏≤‡πÉ‡∏ä‡πâ‡∏ï‡πà‡∏≠‡πÄ‡∏°‡∏∑‡πà‡∏≠ AST/ALT \u003c 2x ULN ‡πÅ‡∏•‡∏∞ total bilirubin \u003c 1.5 mg/dl\n\t- ‡πÉ‡∏´‡πâ H R Z ‡πÄ‡∏£‡∏µ‡∏¢‡∏á‡∏ï‡∏≤‡∏°‡∏•‡∏≥‡∏î‡∏±‡∏ö ‡∏´‡πà‡∏≤‡∏á‡∏Å‡∏±‡∏ô 1 week ‡πÄ‡∏à‡∏≤‡∏∞‡∏î‡∏π‡∏Ñ‡πà‡∏≤‡πÅ‡∏•‡∏õ‡∏†‡∏≤‡∏¢‡πÉ‡∏ô 1 week ‡∏´‡∏•‡∏±‡∏á‡πÉ‡∏ä‡πâ‡∏¢‡∏≤‡πÅ‡∏ï‡πà‡∏•‡∏∞‡∏ï‡∏±‡∏ß ‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å‡πÑ‡∏°‡πà‡∏û‡∏ö‡∏Ñ‡∏ß‡∏≤‡∏°‡∏ú‡∏¥‡∏î‡∏õ‡∏Å‡∏ï‡∏¥‡∏Å‡πá‡∏ó‡∏≥‡∏ï‡πà‡∏≠‡πÄ‡∏£‡∏∑‡πà‡∏≠‡∏¢ ‡πÜ ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å‡∏™‡∏π‡∏á‡∏Ç‡∏∂‡πâ‡∏ô‡∏°‡∏≤‡∏ï‡∏≤‡∏°‡πÄ‡∏Å‡∏ì‡∏ë‡πå‡πÄ‡∏î‡∏¥‡∏° ‡πÉ‡∏´‡πâ‡∏´‡∏¢‡∏∏‡∏î‡∏¢‡∏≤‡∏ï‡∏±‡∏ß‡∏ô‡∏±‡πâ‡∏ô**‡πÅ‡∏•‡∏∞‡∏´‡πâ‡∏≤‡∏°‡πÉ‡∏ä‡πâ‡∏≠‡∏µ‡∏Å**\n","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/Drug-Induced-Ear-Disorder":{"title":"Drug Induced Ear Disorder","content":"\n  - Middle Ear\n\t  - ‡∏ä‡∏±‡πâ‡∏ô‡∏Ç‡πâ‡∏≤‡∏á‡πÉ‡∏ô Ear-drum ‡πÄ‡∏õ‡πá‡∏ô‡∏ï‡πâ‡∏ô‡∏°‡∏≤\n\t  - ‡∏°‡∏µ‡∏Å‡∏£‡∏∞‡∏î‡∏π‡∏Å M I S\n  - Inner Ear\n\t  - ‡∏°‡∏µ‡∏Ç‡∏≠‡∏á‡πÄ‡∏´‡∏•‡∏ß Lymphatic Fluid \n\t  - Semicircular canals: Gait \u0026 Balance  \n\t\t  - ‡∏à‡∏∞‡∏°‡∏µ Hair Cell ‡∏ä‡∏∑‡πà‡∏≠\n\t\t\t  - Maculae : static balance (Memo: maculae macuta (ta = static)) #recall1\n\t\t\t\t  - ![[Pasted image 20230202180049.png]]\n\t\t\t  - Cristae : kinetic balance (Memo: cri / ki) #recall1\n\t\t\t\t  - ![[Pasted image 20230202180103.png]]\n\t  - Cochlea: Hearing\n\t\t  - ‡∏°‡∏µ Vestibular Membrane ‡∏î‡πâ‡∏≤‡∏ô‡∏Ç‡πâ‡∏≤‡∏á ‡∏´‡∏•‡∏±‡πà‡∏á Endolymph ‡∏£‡∏∞‡∏´‡∏ß‡πà‡∏≤‡∏á‡∏ï‡∏£‡∏á‡∏Å‡∏•‡∏≤‡∏á‡∏°‡∏µ Organ of corti ‡∏°‡∏µ hair-cell ‡∏Å‡∏£‡∏∞‡∏à‡∏∏‡∏Å‡∏≠‡∏¢‡∏π‡πà\n\t\t  - ![[Pasted image 20230202175722.png|325]]\n\t\t  - ![[Pasted image 20230202175916.png|450]]\n  - Vestibulocochlear nerve (VIII Carnial nerve)\n  - Oscillopsia ‡∏Ñ‡∏∑‡∏≠‡∏Å‡∏≤‡∏£‡πÄ‡∏´‡πá‡∏ô‡∏†‡∏≤‡∏û‡πÅ‡∏Å‡∏ß‡πà‡∏á ‡∏à‡∏£‡∏¥‡∏á ‡πÜ ‡∏°‡∏±‡∏ô‡πÄ‡∏Å‡∏µ‡πà‡∏¢‡∏ß‡∏Ç‡πâ‡∏≠‡∏á‡∏Å‡∏±‡∏ö‡∏Å‡∏≤‡∏£‡∏ó‡∏≥‡∏á‡∏≤‡∏ô‡∏Ç‡∏≠‡∏á‡∏´‡∏π ‡πÉ‡∏ô‡∏™‡πà‡∏ß‡∏ô‡∏Ç‡∏≠‡∏á‡∏Å‡∏≤‡∏£‡∏ó‡∏£‡∏á‡∏ï‡∏±‡∏ß (Vestibular)\n  - Aminoglycoside\n\t  - reactive oxygen species ‡πÉ‡∏ô inner ear\n\t  - ![[Pasted image 20230202180342.png]]\n  - Loop Diuretics\n\t  - ‡∏£‡∏ö‡∏Å‡∏ß‡∏ô‡∏™‡∏°‡∏î‡∏∏‡∏• endocochlear fluid ‡πÇ‡∏î‡∏¢‡∏Ç‡∏±‡∏î‡∏Ç‡∏ß‡∏≤‡∏á adenylate cyclase ‡πÅ‡∏•‡∏∞ G-protein ‡∏Ç‡∏≠‡∏á stria vascularis\n\t  - ‡∏£‡∏ö‡∏Å‡∏ß‡∏ô‡∏£‡∏∞‡∏î‡∏±‡∏ö K+ ‡πÉ‡∏ô endolymph\n\t  - Tinnitus ‡πÅ‡∏•‡∏∞ reversible sensorineural hearing loss ‡πÄ‡∏Å‡∏¥‡∏î‡πÄ‡∏°‡∏∑‡πà‡∏≠‡πÑ‡∏î‡πâ‡∏£‡∏±‡∏ö‡∏¢‡∏≤‡∏ï‡πà‡∏≠‡πÄ‡∏ô‡∏∑‡πà‡∏≠‡∏á‡πÄ‡∏õ‡πá‡∏ô‡πÄ‡∏ß‡∏•‡∏≤‡∏ô‡∏≤‡∏ô\n\t  - Cochleotoxicity ‡∏Å‡πà‡∏≠‡∏ô‡πÅ‡∏•‡πâ‡∏ß‡∏à‡∏∂‡∏á Vestibulotoxicity ‡∏ï‡∏≤‡∏°‡∏°‡∏≤‡∏´‡∏≤‡∏Å‡πÉ‡∏ä‡πâ‡∏¢‡∏≤‡πÄ‡∏õ‡πá‡∏ô‡∏£‡∏∞‡∏¢‡∏∞‡πÄ‡∏ß‡∏•‡∏≤‡∏ô‡∏≤‡∏ô\n  - Quinine #recall2\n\t  - **‡∏•‡∏î‡∏Å‡∏≤‡∏£‡πÑ‡∏´‡∏•‡πÄ‡∏ß‡∏µ‡∏¢‡∏ô‡πÄ‡∏•‡∏∑‡∏≠‡∏î**‡πÉ‡∏ô cochlear ‡∏ó‡∏≥‡∏•‡∏≤‡∏¢ hair-cell\n\t  - Cinchonism -\u003e Tinnitus ‡πÅ‡∏•‡∏∞ reversible sensorineural hearing loss \n\t\t  - cinchona alkaloid\n\t\t  - ![[Pasted image 20230202195400.png|250]]\n\t  - Cochleotoxicity ‡∏Å‡πà‡∏≠‡∏ô‡πÅ‡∏•‡πâ‡∏ß‡∏à‡∏∂‡∏á Vestibulotoxicity ‡∏ï‡∏≤‡∏°‡∏°‡∏≤‡∏´‡∏≤‡∏Å‡πÉ‡∏ä‡πâ‡∏¢‡∏≤‡πÄ‡∏õ‡πá‡∏ô‡∏£‡∏∞‡∏¢‡∏∞‡πÄ‡∏ß‡∏•‡∏≤‡∏ô‡∏≤‡∏ô\n  - Chloroquine \n\t  - ‡∏à‡∏±‡∏ö‡∏Å‡∏±‡∏ö melanin ‡πÉ‡∏ô **stria vascularis** ‡πÄ‡∏Å‡∏¥‡∏î‡∏û‡∏¥‡∏©‡∏ï‡πà‡∏≠‡∏´‡∏π‡πÇ‡∏î‡∏¢‡∏ï‡∏£‡∏á ‡∏£‡∏ö‡∏Å‡∏ß‡∏ô‡∏£‡∏∞‡∏î‡∏±‡∏ö K+ ‡∏Ç‡∏≠‡∏á endolymph #recall2 \n\t  - Tinnitus ‡πÅ‡∏•‡∏∞ reversible sensorineural hearing loss ‡πÄ‡∏Å‡∏¥‡∏î‡πÄ‡∏°‡∏∑‡πà‡∏≠‡πÑ‡∏î‡πâ‡∏£‡∏±‡∏ö ‡∏¢‡∏≤‡∏ï‡πà‡∏≠‡πÄ‡∏ô‡∏∑‡πà‡∏≠‡∏á‡πÄ‡∏õ‡πá‡∏ô‡πÄ‡∏ß‡∏•‡∏≤‡∏ô‡∏≤‡∏ô\n\t  - ‡∏≠‡∏≤‡∏à‡∏û‡∏ö vestibular symptoms ‡∏´‡∏≤‡∏Å‡∏¢‡∏±‡∏á‡∏Ñ‡∏á‡πÑ‡∏î‡πâ‡∏£‡∏±‡∏ö‡∏¢‡∏≤‡∏ï‡πà‡∏≠‡πÄ‡∏ô‡∏∑‡πà‡∏≠‡∏á\n\t  - **‡πÉ‡∏ä‡πâ‡πÄ‡∏ß‡∏•‡∏≤‡∏ô‡∏≤‡∏ô‡πÉ‡∏ô‡∏Å‡∏≤‡∏£‡∏Å‡∏•‡∏±‡∏ö‡∏™‡∏π‡πà‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏õ‡∏Å‡∏ï‡∏¥** #recall2 \n  - Salicylates (+- NSAIDs)\n\t  - ‡πÄ‡∏Å‡∏¥‡∏î‡πÄ‡∏°‡∏∑‡πà‡∏≠‡∏Å‡∏¥‡∏ô ASA \u003e 2.7 g/day #recall1\n\t  - ‡∏•‡∏î‡∏Å‡∏≤‡∏£‡πÑ‡∏´‡∏•‡πÄ‡∏ß‡∏µ‡∏¢‡∏ô‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡πÉ‡∏ô cochlear ‡∏£‡∏ö‡∏Å‡∏ß‡∏ô‡πÄ‡∏™‡πâ‡∏ô‡∏õ‡∏£‡∏∞‡∏™‡∏≤‡∏ó‡∏Ñ‡∏π‡πà‡∏ó‡∏µ‡πà 8 #recall2\n\t  - Salicylism -\u003e Tinnitus ‡πÅ‡∏•‡∏∞ reversible sensorineural hearing loss \n\t  - ‡∏ö‡∏≤‡∏á‡∏Ñ‡∏ô‡∏à‡∏∞‡πÄ‡∏õ‡πá‡∏ô‡∏õ‡∏±‡∏ç‡∏´‡∏≤‡πÄ‡∏£‡∏∑‡πâ‡∏≠‡∏£‡∏±‡∏á\n\t  - ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏î‡∏µ‡∏Ç‡∏∂‡πâ‡∏ô‡πÄ‡∏°‡∏∑‡πà‡∏≠‡∏´‡∏¢‡∏∏‡∏î‡∏¢‡∏≤‡πÑ‡∏õ 24-72 ‡∏ä‡∏°\n  - Chemotherapeutics\n\t  - Platinum compounds\n\t\t  - hair cell ‡πÉ‡∏ô inner ear ‡∏•‡∏î‡∏•‡∏á ‡∏£‡∏ö‡∏Å‡∏ß‡∏ô‡∏Å‡∏≤‡∏£‡∏ó‡∏≥‡∏á‡∏≤‡∏ô‡∏Ç‡∏≠‡∏á mitochondria\n\t\t  - ‡πÄ‡∏õ‡πá‡∏ô‡∏û‡∏¥‡∏©‡∏ï‡πà‡∏≠ **organ of corti and stria vascularis** ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏Å‡∏≤‡∏£‡∏ó‡∏≥‡∏á‡∏≤‡∏ô‡∏Ç‡∏≠‡∏á endocochlear ‡∏ú‡∏¥‡∏î‡∏õ‡∏Å‡∏ï‡∏¥ #recall2 \n\t  - Vinca alkaloids\n\t\t  - ‡∏ï‡∏±‡∏ß‡∏°‡∏±‡∏ô‡∏°‡∏µ‡∏Ñ‡∏ß‡∏≤‡∏° neurotoxicity\n\t\t  - ‡∏û‡∏¥‡∏©‡∏ï‡πà‡∏≠‡∏£‡∏∞‡∏ö‡∏ö‡∏õ‡∏£‡∏∞‡∏™‡∏≤‡∏ó‡∏Å‡∏≤‡∏£‡πÑ‡∏î‡πâ‡∏¢‡∏¥‡∏ô\n  - Topical otic medications\n\t  - ‡∏™‡πà‡∏ß‡∏ô‡πÉ‡∏´‡∏ç‡πà‡πÄ‡∏Å‡∏¥‡∏î‡∏ó‡∏µ‡πà outer ear\n\t  - middle and inner ear ‡∏à‡∏∞‡πÄ‡∏Å‡∏¥‡∏î‡∏ñ‡πâ‡∏≤ eardrum ‡πÅ‡∏ï‡∏Å\n\t  - cosolvent ‡πÄ‡∏ä‡πà‡∏ô PG ‡∏´‡∏£‡∏∑‡∏≠ antiseptics ‡πÄ‡∏ä‡πà‡∏ô alcohol, chlorhexidine, BAK ‡∏°‡∏µ‡∏ú‡∏•‡∏ï‡πà‡∏≠‡∏Å‡∏≤‡∏£‡πÑ‡∏î‡πâ‡∏¢‡∏¥‡∏ô\n\t  - hair cell sensitive ‡∏ï‡πà‡∏≠ temperature ‡∏Å‡∏≤‡∏£‡πÑ‡∏î‡πâ‡∏¢‡∏¥‡∏ô‡∏à‡∏∞‡πÑ‡∏î‡πâ‡∏£‡∏±‡∏ö‡∏ú‡∏•‡∏Å‡∏£‡∏∞‡∏ó‡∏ö‡∏ñ‡πâ‡∏≤‡∏°‡∏µ temp ‡πÅ‡∏õ‡∏Å ‡πÜ\n  - ‡∏†‡∏≤‡∏ß‡∏∞‡∏Ç‡∏≤‡∏î‡∏ô‡πâ‡∏≥ ‡∏´‡∏£‡∏∑‡∏≠ E'lyte imbalance ‡∏´‡∏£‡∏∑‡∏≠ CKD ‡∏≠‡∏≤‡∏à‡∏™‡πà‡∏á‡∏ú‡∏•‡∏ï‡πà‡∏≠‡∏Å‡∏≤‡∏£‡πÑ‡∏î‡πâ‡∏¢‡∏¥‡∏ô‡∏´‡∏£‡∏∑‡∏≠‡πÄ‡∏õ‡πá‡∏ô risk factor ‡∏≠‡∏¢‡∏π‡πà‡πÅ‡∏•‡πâ‡∏ß","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/Drug-Induced-Eye-Disorder":{"title":"Drug Induced Eye Disorder","content":"### Management\n- dose, duration, t1/2\n- physicochemical properties\n- individual blood-retina barrier/ blood-aqueous barrier/ physio/ ‡∏¢‡∏≤‡∏≠‡∏∑‡πà‡∏ô ‡πÜ\n- monitoring : monitor what drug? what to monitor? is TDM viable?\n\n### Drug Induced Eye Disorder\n- Contact Dermatitis\n\t- ‡∏´‡∏ô‡∏±‡∏á‡∏ï‡∏≤‡∏ö‡∏≤‡∏á ‡∏à‡∏∂‡∏á‡πÄ‡∏Å‡∏¥‡∏î‡πÑ‡∏î‡πâ‡∏á‡πà‡∏≤‡∏¢\n\t- ‡∏´‡∏ô‡∏±‡∏á‡∏ï‡∏≤‡∏°‡∏µ‡∏ï‡πà‡∏≠‡∏°‡πÑ‡∏Ç‡∏°‡∏±‡∏ô ‡∏ä‡πà‡∏ß‡∏¢‡∏™‡∏£‡πâ‡∏≤‡∏á film ‡πÉ‡∏´‡πâ‡∏ô‡πâ‡∏≥‡∏ï‡∏≤ ‡∏î‡∏±‡∏á‡∏ô‡∏±‡πâ‡∏ô‡πÄ‡∏Å‡∏µ‡πà‡∏¢‡∏ß‡∏Å‡∏±‡∏ö‡∏ï‡∏≤‡πÅ‡∏´‡πâ‡∏á‡∏î‡πâ‡∏ß‡∏¢\n- Angioedema\n\t- ‡πÄ‡∏Å‡∏¥‡∏î‡∏ó‡∏µ‡πà‡∏ï‡∏≤‡πÑ‡∏î‡πâ ‡πÄ‡∏õ‡∏•‡∏∑‡∏≠‡∏Å‡∏ï‡∏≤ ‡∏õ‡∏≤‡∏Å genital\n\t- ‡πÑ‡∏°‡πà‡∏à‡∏≥‡πÄ‡∏õ‡πá‡∏ô‡∏ï‡πâ‡∏≠‡∏á‡πÄ‡∏Å‡∏¥‡∏î‡πÅ‡∏Ñ‡πà‡∏ï‡∏≤‡∏Ç‡πâ‡∏≤‡∏á‡πÄ‡∏î‡∏µ‡∏¢‡∏ß ‡∏™‡∏≠‡∏á‡∏Ç‡πâ‡∏≤‡∏á‡∏Å‡πá‡πÑ‡∏î‡πâ\n\t- True-allergy vs Pseudo-allergy (NSAIDs)\n- Ptosis \n\t- ‡∏´‡∏ô‡∏±‡∏á‡∏ï‡∏≤‡∏ï‡∏Å ‡πÄ‡∏õ‡∏•‡∏∑‡∏≠‡∏Å‡∏ï‡∏≤‡∏≠‡πà‡∏≠‡∏ô‡πÅ‡∏£‡∏á\n\t- ‡∏™‡πà‡∏ß‡∏ô‡πÉ‡∏´‡∏ç‡πà‡πÄ‡∏Å‡∏¥‡∏î‡∏à‡∏≤‡∏Å‡∏¢‡∏≤‡πÑ‡∏õ interfere neuromuscular junction\n\t- ‡∏¢‡∏≤**‡∏™‡πà‡∏ß‡∏ô‡πÉ‡∏´‡∏ç‡πà‡πÄ‡∏Å‡∏¥‡∏î‡πÅ‡∏ö‡∏ö Reversible**\n\t\t- Botox\n\t\t- Pregabalin\n\t\t- Cortocosteroid\n\t\t- Chloroquine\n\t\t- High dose opids\n\t\t- neuromuscular blockers\n\t- ‡∏¢‡∏≤**‡∏ö‡∏≤‡∏á‡∏ï‡∏±‡∏ß‡πÄ‡∏Å‡∏¥‡∏î‡πÅ‡∏ö‡∏ö Irreversible**\n\t\t- Vinca alkaloids #recall1\n\t\t\t- Vincristine \u003e Vinblastine\n- Eyelid pigmentation \n\t- prostaglandin analogs ‡πÄ‡∏ä‡πà‡∏ô bimatoprost\n\t- ‡πÄ‡∏õ‡∏•‡∏∑‡∏≠‡∏Å‡∏ï‡∏≤‡∏î‡∏π‡πÄ‡∏Ç‡πâ‡∏°‡∏Ç‡∏∂‡πâ‡∏ô\n- Poliosis  #recall1\n\t- ‡∏´‡∏á‡∏≠‡∏Å‡∏õ‡∏≠‡∏¢‡πÄ‡∏â‡∏û‡∏≤‡∏∞‡∏ó‡∏µ‡πà / ‡∏ú‡∏¥‡∏ß‡∏™‡∏µ‡∏Ç‡∏≤‡∏ß‡πÑ‡∏î‡πâ‡∏î‡πâ‡∏ß‡∏¢‡πÉ‡∏ô‡∏ö‡∏£‡∏¥‡πÄ‡∏ß‡∏ì‡∏ó‡∏µ‡πà‡πÄ‡∏õ‡πá‡∏ô\n\t- chloroquine, hydroxychloroquine ‡∏°‡∏±‡∏Å‡πÄ‡∏à‡∏≠‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ‡πÄ‡∏õ‡πá‡∏ô DMARDs \u003e malaria ‡πÄ‡∏û‡∏£‡∏≤‡∏∞ chronic use\n\t- ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡πÄ‡∏°‡πá‡∏î‡∏™‡∏µ **melanin** ‡∏ú‡∏¥‡∏î‡∏õ‡∏Å‡∏ï‡∏¥\n\t- ‡∏¢‡∏≤‡∏≠‡∏∑‡πà‡∏ô ‡πÜ ‡∏ó‡∏µ‡πà‡∏û‡∏ö‡πÄ‡∏à‡∏≠‡πÑ‡∏î‡πâ‡∏≠‡∏µ‡∏Å #recall2 \n\t\t- chlorpromazine\n\t\t- silver salts\n\t\t- phenolic solutions\n- Antimalarial-induced eye disorders \n\t- Chloroquine, hydroxychloroquine\n\t- Corneal deposits ‡∏°‡∏±‡∏ô‡πÑ‡∏õ‡∏à‡∏±‡∏ö‡∏Å‡∏±‡∏ö melanin pignent ‡∏ó‡∏µ‡πà RPE ‡πÄ‡∏Å‡∏¥‡∏î‡∏Å‡∏≤‡∏ô‡∏™‡∏∞‡∏™‡∏° ‡∏Ñ‡∏ß‡∏≤‡∏°‡πÄ‡∏Ç‡πâ‡∏°‡∏Ç‡πâ‡∏ô‡πÄ‡∏¢‡∏≠‡∏∞ ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡πÄ‡∏Å‡∏¥‡∏î bull's-eye maculopathy/retinopathy ‡πÄ‡∏Å‡∏¥‡∏î nyctalopia ‡πÑ‡∏î‡πâ #recall1\n- Hypertrichosis\n\t- prostaglandin analogs ‡πÄ‡∏ä‡πà‡∏ô bimatoprost\n\t- ‡∏Ç‡∏ô‡∏ï‡∏≤‡∏¢‡∏≤‡∏ß‡∏Ç‡∏∂‡πâ‡∏ô eye-lid ‡πÄ‡∏Ç‡πâ‡∏°\n- Iris pigmentation\n\t- prostaglandin analogs ‡πÄ‡∏ä‡πà‡∏ô latanoprost\n\t- iris ‡πÄ‡∏Ç‡πâ‡∏°‡∏Ç‡∏∂‡πâ‡∏ô ‡∏≠‡∏≤‡∏à‡πÑ‡∏°‡πà‡∏ä‡∏±‡∏î‡πÉ‡∏ô‡∏Ñ‡∏ô‡πÑ‡∏ó‡∏¢‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡πÄ‡∏£‡∏≤‡πÄ‡∏Ç‡πâ‡∏°‡∏≠‡∏¢‡∏π‡πà‡πÅ‡∏•‡πâ‡∏ß\n- Drug-induced conjunctivitis (keratoconjunctivitis sicca)\n\t- Tear production\n\t\t- diuretics\n\t\t- anticholinergics\n\t- Tear film quality\n\t\t- vitamin A\n\t\t- isotretinoin\n\t- unknown mech\n\t\t- cyclophosphamide\n\t\t- methotrexate\n\t- SJS/TEN\n- Favipiravir-induced blue eyes\n\t- metabolites ‡πÑ‡∏õ deposit ‡∏ó‡∏µ‡πà cornea\n\t- ‡∏´‡∏¢‡∏∏‡∏î‡∏¢‡∏≤‡∏Å‡πá‡∏´‡∏≤‡∏¢ ‡πÑ‡∏°‡πà‡πÄ‡∏õ‡πá‡∏ô‡∏≠‡∏±‡∏ô‡∏ï‡∏£‡∏≤‡∏¢\n- Cataract #recall1\n\t- ‡πÄ‡∏Å‡∏¥‡∏î‡∏à‡∏≤‡∏Å oxidative stress ‡∏ó‡∏µ‡πà lens\n\t- lens ‡∏Ç‡∏∏‡πà‡∏ô ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏Å‡∏≤‡∏£‡∏´‡∏±‡∏Å‡πÄ‡∏´‡πÅ‡∏™‡∏á‡πÄ‡∏õ‡∏•‡∏µ‡πà‡∏¢‡∏ô ‡πÑ‡∏°‡πà‡∏à‡∏≥‡πÄ‡∏õ‡πá‡∏ô‡∏ï‡πâ‡∏≠‡∏á‡πÄ‡∏õ‡πá‡∏ô‡∏™‡∏≠‡∏á‡∏Ç‡πâ‡∏≤‡∏á\n\t- **Corticosteroids ‡∏ó‡∏±‡πâ‡∏á‡∏Å‡∏¥‡∏ô‡πÅ‡∏•‡∏∞ drop**\n\t- Allopurinol\n\t- Busulfan\n\t- Phenothiazines\n- Anticholinergics-related eye disorders\n\t- ‡∏ó‡∏ß‡∏ô parasympathetic \n\t\t- ![[Pasted image 20230130184158.png|325]] \n\t- Blurred vision\n\t\t- Mydriasis\n\t\t\t- Note: cholinergic ‡∏´‡∏î pupils miosis ‡∏î‡∏±‡∏á‡∏ô‡∏±‡πâ‡∏ô anti ‡∏à‡∏∂‡∏á‡∏Ç‡∏¢‡∏≤‡∏¢ (mydriasis) #recall2 \n\t\t- Cycloplegia\n\t- Elevated IOP -\u003e Glaucoma\n\t\t- ‡∏≠‡∏≤‡∏à‡πÄ‡∏Å‡∏¥‡∏î‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏°‡∏±‡∏ô mydriasis / cycloplegia\n\t- Dry eye\n\t- ‡∏¢‡∏≤‡∏ó‡∏µ‡πà‡πÄ‡∏Å‡∏µ‡πà‡∏¢‡∏ß‡∏Ç‡πâ‡∏≠‡∏á‡πÅ‡∏•‡∏∞‡∏°‡∏±‡∏Å‡∏•‡∏∑‡∏°‡∏Å‡∏±‡∏ô ‡πÄ‡∏ä‡πà‡∏ô Orphenadrine, Paroxetine, Benztropine, Trihexyphenidyl, Atropine\n- **Amiodarone**-induced eye disorders\n\t- t1/2 ‡∏¢‡∏≤‡∏ô‡∏≤‡∏ô\n\t- ‡∏¢‡∏≤ arrythymia ‡∏ó‡∏µ‡πà‡∏≠‡∏≠‡∏Å‡∏§‡∏ó‡∏ò‡πå‡∏´‡∏•‡∏≤‡∏¢ class ‡∏à‡∏∂‡∏á‡πÄ‡∏à‡∏≠‡∏ö‡πà‡∏≠‡∏¢ ‡∏´‡∏°‡∏≠‡∏ä‡∏≠‡∏ö‡πÉ‡∏ä‡πâ\n\t- Bilateral corneal deposits\n\t- Anterior subcapsular lens opacities\n\t- Halo vision\n\t- Optic neuropathy\n- Antiepileptic-induced eye disorders\n\t- CBZ, Phenytoin, lamotrigine\n\t\t- blurred vision\n\t\t- dose dependent: #recall1\n\t\t\t- **diplopia** ‡πÄ‡∏´‡πá‡∏ô‡∏†‡∏≤‡∏û‡∏ã‡πâ‡∏≠‡∏ô static \n\t\t\t- **nystagmus** ‡πÄ‡∏´‡πá‡∏ô‡∏†‡∏≤‡∏û‡∏ã‡πâ‡∏≠‡∏ô‡πÅ‡∏ï‡πà‡∏°‡∏±‡∏ô‡πÅ‡∏Å‡∏ß‡πà‡∏á‡πÑ‡∏õ‡∏°‡∏≤‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏ï‡∏≤ fix ‡πÉ‡∏´‡πâ‡∏ô‡∏¥‡πà‡∏á‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ\n\t- Topiramate #recall2 \n\t\t- ‡∏°‡∏µ **report angle-closure glaucoma** ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏°‡∏±‡∏ô‡∏°‡∏µ‡∏ú‡∏•‡∏ï‡πà‡∏≠ nerve ‡∏ó‡∏µ‡πà‡∏Ñ‡∏∏‡∏° iris\n- Color perception disturbance\n\t- Sildenafil, tadalafil, vardenafil (unknown MOA)\n\t\t- color blindness\n\t\t- blurred vision\n\t\t- photophobia\n\t- Digoxin\n\t\t- ‡πÅ‡∏™‡∏á‡πÄ‡∏´‡∏•‡∏∑‡∏≠‡∏á‡πÄ‡∏Ç‡∏µ‡∏¢‡∏ß\n\t- Interferon alpha\n\t\t- ‡∏™‡∏°‡∏±‡∏¢‡∏Å‡πà‡∏≠‡∏ô‡πÄ‡∏à‡∏≠‡∏ö‡πà‡∏≠‡∏¢‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡πÉ‡∏ä‡πâ‡∏Å‡∏±‡∏ö‡πÑ‡∏ß‡∏£‡∏±‡∏™‡∏ï‡∏±‡∏ö‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö\n\t- Ethambutol\n\t\t- ‡πÄ‡∏à‡∏≠‡∏ö‡πà‡∏≠‡∏¢‡πÉ‡∏ô TB\n\t- Metronidazole\n\t\t- ‡πÄ‡∏à‡∏≠‡∏ô‡πâ‡∏≠‡∏¢‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏Ñ‡∏ô‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡πÉ‡∏ä‡πâ‡∏ô‡∏≤‡∏ô ‡∏™‡πà‡∏ß‡∏ô‡πÉ‡∏´‡∏ç‡πà‡πÉ‡∏ä‡πâ short terms #recall2 \n\t- Antimalarials\n\t\t- ‡∏û‡∏ß‡∏Å HCQ, CQ, ‡∏ô‡πà‡∏≤‡∏à‡∏∞ MOA: deposit ‡∏ó‡∏µ‡πà retina","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/Drug-Induced-Pulmonary-Disease":{"title":"Drug Induced Pulmonary Disease","content":"\nps. incidence unknown ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏á‡∏≤‡∏ô‡∏ß‡∏¥‡∏à‡∏±‡∏¢‡∏°‡∏µ‡∏ô‡πâ‡∏≠‡∏¢ ‡∏Å‡∏≤‡∏£‡πÄ‡∏Å‡πá‡∏ö‡∏Ç‡πâ‡∏≠‡∏°‡∏π‡∏•‡∏°‡∏µ‡∏ô‡πâ‡∏≠‡∏¢\n\n## Drug Induced Apnea\n- Definitions: ‡∏≠‡∏∏‡∏î‡∏Å‡∏±‡πâ‡∏ô‡∏ó‡∏≤‡∏á‡πÄ‡∏î‡∏¥‡∏ô‡∏´‡∏≤‡∏¢‡πÉ‡∏à‡∏™‡∏°‡∏ö‡∏π‡∏£‡∏ì‡πå ‡∏´‡∏£‡∏∑‡∏≠ ‡∏≠‡∏∏‡∏î‡∏Å‡∏±‡πâ‡∏ô‡∏ö‡∏≤‡∏á‡∏™‡πà‡∏ß‡∏ô‡πÅ‡∏ï‡πà‡∏°‡∏µ‡∏õ‡∏±‡∏à‡∏à‡∏±‡∏¢‡πÄ‡∏™‡∏£‡∏¥‡∏°\n- ‡∏Å‡∏•‡πÑ‡∏Å: CNS Depression, Respiratory muscle dysfunction, Myopathy\n- Drug Causes:\n\t- BZDs + Phenobarbital to stop status epilepticus (‡πÑ‡∏°‡πà‡∏™‡∏±‡∏°‡∏û‡∏±‡∏ô‡∏ò‡πå‡∏Å‡∏±‡∏ö rate ‡∏¢‡∏≤) ‡∏≠‡∏≤‡∏à‡πÉ‡∏™‡πà mechanical ventilation ‡∏Å‡πà‡∏≠‡∏ô‡πÉ‡∏´‡πâ‡∏¢‡∏≤\n\t- BZDs ‡πÄ‡∏Å‡∏¥‡∏î‡∏ö‡πà‡∏≠‡∏¢‡∏°‡∏≤‡∏Å ‡πÄ‡∏Å‡∏µ‡πà‡∏¢‡∏ß‡∏Å‡∏±‡∏ö t1/2 ‡∏Ç‡∏≠‡∏á‡∏¢‡∏≤ ‡πÄ‡∏ä‡πà‡∏ô long-acting ‡∏¢‡∏±‡∏á‡∏§‡∏ó‡∏ò‡∏¥‡πå‡πÑ‡∏°‡πà‡∏´‡∏°‡∏î‡πÅ‡∏•‡πâ‡∏ß‡∏°‡∏≤‡πÉ‡∏ä‡πâ short-acting\n\t\t- ‡∏¢‡∏≤‡∏ó‡∏∏‡∏Å‡∏Å‡∏•‡∏∏‡πà‡∏°‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á‡πÄ‡∏ó‡πà‡∏≤‡∏Å‡∏±‡∏ô\n\t\t- ‡πÑ‡∏°‡πà‡∏Ñ‡∏ß‡∏£‡πÉ‡∏ä‡πâ‡∏£‡πà‡∏ß‡∏° opioid ‡∏´‡∏£‡∏∑‡∏≠ CYP3A4 inhibitors\n\t\t- ‡πÑ‡∏°‡πà‡∏Ñ‡∏ß‡∏£‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡∏ú‡∏π‡πâ‡∏™‡∏π‡∏á‡∏≠‡∏≤‡∏¢‡∏∏\n\t- Neuromuscular blocking agents\n\t\t- ‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ‡∏£‡∏∞‡∏¢‡∏∞‡πÄ‡∏ß‡∏•‡∏≤‡∏ô‡∏≤‡∏ô\n\t\t- ‡∏£‡∏∞‡∏ß‡∏±‡∏á‡πÉ‡∏ô‡∏Ñ‡∏ô‡∏°‡∏µ‡∏õ‡∏±‡∏ç‡∏´‡∏≤‡∏ï‡∏±‡∏ö‡πÑ‡∏ï\n\t\t- ‡∏û‡∏ö‡πÄ‡∏à‡∏≠‡πÉ‡∏ô‡∏Ñ‡∏ô‡πÉ‡∏ä‡πâ pancuronium ‡πÅ‡∏•‡∏∞ vecuronium\n\t- Steroids\n\t\t- **‡∏Ç‡∏∂‡πâ‡∏ô‡∏Å‡∏±‡∏ö‡πÇ‡∏î‡∏™** #recall1\n\t\t- fluorinated steroid ‡πÄ‡∏ä‡πà‡∏ô triam, dexa ‡∏°‡∏µ‡πÇ‡∏≠‡∏Å‡∏≤‡∏™‡∏Å‡∏¥‡∏î myopathy ‡∏™‡∏π‡∏á‡∏Å‡∏ß‡πà‡∏≤‡πÄ‡∏û‡∏£‡∏≤‡∏∞ lipophilicity ‡∏™‡∏π‡∏á #recall1 \n\t\t- ‡πÉ‡∏ô‡∏Å‡∏≤‡∏£‡∏®‡∏∂‡∏Å‡∏©‡∏≤‡∏™‡∏±‡∏ï‡∏ß‡πå‡∏û‡∏ö‡∏ß‡πà‡∏≤ ‡∏Ç‡∏ô‡∏≤‡∏î‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤‡∏´‡∏£‡∏∑‡∏≠‡πÄ‡∏ó‡πà‡∏≤‡∏Å‡∏±‡∏ö 2mg/kg prednisolone ‡∏ó‡∏≥‡πÉ‡∏´‡πâ atrohpy\n\n## Drug Induced Asthma/Bronchospasm\n- ‡∏´‡∏•‡∏≤‡∏¢‡∏Å‡∏•‡πÑ‡∏Å\n- ‡∏≠‡∏≤‡∏à‡∏°‡∏µ‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡πÅ‡∏û‡πâ‡∏´‡∏£‡∏∑‡∏≠‡πÑ‡∏°‡πà‡πÅ‡∏û‡πâ‡∏Å‡πá‡πÑ‡∏î‡πâ (anaphylaxis or anaphylactoid)\n- ‡∏û‡∏ö‡∏ö‡πà‡∏≠‡∏¢‡πÉ‡∏ô‡∏Ñ‡∏ô‡∏ó‡∏µ‡πà‡∏°‡∏µ‡∏õ‡∏±‡∏à‡∏à‡∏±‡∏¢‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á ‡πÅ‡∏û‡πâ‡∏¢‡∏≤ ‡∏´‡∏£‡∏∑‡∏≠ asthma ‡πÄ‡∏î‡∏¥‡∏°‡∏≠‡∏¢‡∏π‡πà‡πÅ‡∏•‡πâ‡∏ß\n- ‡∏¢‡∏≤‡∏ó‡∏µ‡πà‡∏û‡∏ö‡∏ö‡πà‡∏≠‡∏¢\n\t- NSAIDs (Cox1) / Aspirin\n\t\t- ![[Pasted image 20230201173204.png]]\n\t\t- aspirin is a irreversible inhibitor = ‡∏´‡∏¢‡∏∏‡∏î‡∏¢‡∏≤‡πÅ‡∏•‡πâ‡∏ß‡∏à‡∏∞‡πÉ‡∏ä‡πâ‡πÄ‡∏ß‡∏•‡∏≤‡∏ô‡∏≤‡∏ô‡∏°‡∏≤‡∏Å ‡∏Å‡∏ß‡πà‡∏≤‡∏à‡∏∞‡∏´‡∏≤‡∏¢\n\t- Paracetamol\n\t- beta-blockers\n\t\t- ‡πÄ‡∏ú‡∏•‡∏≠‡∏ö‡∏•‡πâ‡∏≠‡∏Ñ beta2\n\t- radiocontrast dyes\n\t- sulfite\n\t\t- IL-G ‡πÄ‡∏û‡∏¥‡πà‡∏° -\u003e bronchospasm\n\t- ACEI\n\t\t- bradykinin and substance P ‡∏Ñ‡∏±‡πà‡∏á -\u003e bronchospasm\n- ‡∏õ‡∏Å‡∏ï‡∏¥‡∏à‡∏∞‡πÄ‡∏Å‡∏¥‡∏î‡πÄ‡∏£‡πá‡∏ß ‡∏´‡∏≤‡∏¢‡πÄ‡∏£‡πá‡∏ß ‡πÑ‡∏°‡πà‡∏ï‡πâ‡∏≠‡∏á‡∏°‡∏≤‡∏ï‡∏¥‡∏î‡∏ï‡∏≤‡∏°‡∏£‡∏∞‡∏¢‡∏∞‡∏¢‡∏≤‡∏ß ‡∏ô‡∏≠‡∏Å‡∏à‡∏≤‡∏Å‡∏ß‡πà‡∏≤‡∏à‡∏∞‡∏°‡∏µ complication ‡∏ï‡πà‡∏≠‡∏°‡∏≤‡∏≠‡∏µ‡∏Å‡πÄ‡∏ä‡πà‡∏ô [[#Drug Induced Lung Disease/Pulmonary Fibrosis]]\n\n## Drug Induced Interstitial Lung Disease/Pulmonary Fibrosis\n- https://www.pneumotox.com/drug/index/\n- ‡∏¢‡∏≤‡∏ó‡∏µ‡πà‡πÄ‡∏Å‡∏µ‡πà‡∏¢‡∏ß‡∏Ç‡πâ‡∏≠‡∏á\n\t- Methotrexate (‡πÄ‡∏à‡∏≠‡∏ö‡πà‡∏≠‡∏¢)\n\t- Amiodarone\n\t- Lenalidomide\n- Risk Factors\n\t- Amiodarone \u003e 400 mg **daily**\n\t- Carmustine \u003e 1400 mg/m2 cumulative\n\t\t- pervention: ICS fluticasone q12hr\n\t- Bleomycin \u003e 360 unit cumulative\n\t- Oxygen therapy high conc (60% or more FiO2)\n- ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£ \n\t- ‡πÅ‡∏£‡∏Å‡πÄ‡∏£‡∏¥‡πà‡∏°‡∏Å‡πá ILD ‡∏≠‡∏≤‡∏à‡∏´‡∏≤‡∏¢‡πÉ‡∏à‡πÑ‡∏°‡πà‡∏≠‡∏≠‡∏Å **‡∏°‡∏µ eosinophil ‡∏Ç‡∏∂‡πâ‡∏ô** ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤‡πÄ‡∏õ‡πá‡∏ô ILD ‡∏ô‡∏≤‡∏ô ‡πÜ ‡∏Å‡πá‡∏à‡∏∞‡πÄ‡∏£‡∏¥‡πà‡∏°‡∏´‡∏≤‡∏¢‡πÉ‡∏à‡πÑ‡∏°‡πà‡∏≠‡∏≠‡∏Å‡∏°‡∏≤‡∏Å‡∏Ç‡∏∂‡πâ‡∏ô ‡∏≠‡∏≠‡∏Å‡∏Å‡∏≥‡∏•‡∏±‡∏á‡∏Å‡∏≤‡∏¢‡πÑ‡∏°‡πà‡∏Ñ‡πà‡∏≠‡∏¢‡πÑ‡∏î‡πâ ‡∏à‡∏ô fibrosis ‡∏Å‡πá‡∏à‡∏∞‡∏°‡∏µ sign of cyanosis #recall1 \n- Management:\n\t- ‡∏´‡∏≤‡∏ï‡πâ‡∏ô‡πÄ‡∏´‡∏ï‡∏∏‡πÉ‡∏´‡πâ‡πÄ‡∏à‡∏≠\n\t- **‡∏´‡∏¢‡∏∏‡∏î‡∏¢‡∏≤‡∏ï‡πâ‡∏ô‡πÄ‡∏´‡∏ï‡∏∏ ‡∏ñ‡πâ‡∏≤‡πÄ‡∏õ‡πá‡∏ô‡πÅ‡∏ö‡∏ö acute ‡∏°‡∏±‡∏Å‡∏à‡∏∞‡∏´‡∏≤‡∏¢‡∏†‡∏≤‡∏¢‡πÉ‡∏ô 48 ‡∏ä‡∏° ‡∏´‡∏£‡∏∑‡∏≠ 7-10 ‡∏ß‡∏±‡∏ô‡∏´‡∏•‡∏±‡∏á‡∏´‡∏¢‡∏∏‡∏î‡∏¢‡∏≤ / ‡∏´‡∏•‡∏±‡∏á‡πÄ‡∏£‡∏¥‡πà‡∏° steroid**\n\t- ‡∏ö‡∏≤‡∏á‡πÄ‡∏Ñ‡∏™‡∏≠‡∏≤‡∏à‡∏ï‡πâ‡∏≠‡∏á steroid\n\t- ‡∏ï‡∏¥‡∏î‡∏ï‡∏≤‡∏°‡∏ß‡πà‡∏≤‡∏à‡∏∞‡πÄ‡∏Å‡∏¥‡∏î fibrosis ‡πÑ‡∏´‡∏°\n\t- ‡∏´‡∏≤‡∏Å‡πÄ‡∏õ‡πá‡∏ô fibrosis ‡πÅ‡∏•‡πâ‡∏ß ‡∏à‡∏∞‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πâ corticosteroid! #recall1 #recall2 \n\t- ‡∏¢‡∏≤‡∏™‡∏≥‡∏´‡∏£‡∏±‡∏ö Fibrosis:\n\t\t- Nintedanib, Pirfenidone  #recall2","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/Drug-Induced-bone-joint-muscle-disease":{"title":"Drug Induced bone joint \u0026 muscle disease","content":"## Osteoporosis, Osteomalacia\n- Cause: Primary (aging, deceased gonadal function in early menopause), **Secondary (exposure, medical disorders)**\n- ‡πÇ‡∏£‡∏Ñ‡∏Å‡∏£‡∏∞‡∏î‡∏π‡∏Å‡∏ô‡πà‡∏ß‡∏°: ‡∏Å‡∏£‡∏∞‡∏î‡∏π‡∏Å‡πÅ‡∏Ç‡πá‡∏á‡∏≠‡πà‡∏≠‡∏ô ‡πÇ‡∏Ñ‡πâ‡∏á‡∏á‡∏≠‡πÑ‡∏î‡πâ ‡πÄ‡∏Å‡∏¥‡πÄ‡∏î‡∏à‡∏≤‡∏Å‡∏Ñ‡∏ß‡∏≤‡∏°‡∏ú‡∏¥‡∏î‡∏õ‡∏Å‡∏ï‡∏¥‡πÉ‡∏ô‡∏Å‡∏≤‡∏£‡πÄ‡∏Å‡∏¥‡∏î mineralization ‡∏Ç‡∏≠‡∏á osteoid ‡∏°‡∏≤‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡∏Ç‡∏≤‡∏î vitamin D ‡∏´‡∏£‡∏∑‡∏≠‡πÉ‡∏ô‡πÄ‡∏î‡πá‡∏Å growth plate ‡πÄ‡∏Å‡∏¥‡∏î mineralization ‡∏ú‡∏¥‡∏î‡∏õ‡∏Å‡∏ï‡∏¥ ‡πÄ‡∏£‡∏µ‡∏¢‡∏Å rickets (juvenile osteomalacia)\n- steroid **‡∏ä‡∏±‡∏î‡∏™‡∏∏‡∏î**\n\t- ‡πÄ‡∏û‡∏¥‡πà‡∏°‡∏Å‡∏≤‡∏£‡∏Ñ‡∏•‡∏≤‡∏¢‡∏Å‡∏£‡∏∞‡∏î‡∏π‡∏Å\n\t- ‡∏•‡∏î‡∏Å‡∏≤‡∏£‡∏™‡∏£‡πâ‡∏≤‡∏á‡∏Å‡∏£‡∏∞‡∏î‡∏π‡∏Å\n\t- ‡∏•‡∏î‡∏Å‡∏≤‡∏£‡∏î‡∏π‡∏î‡∏ã‡∏∂‡∏°‡πÅ‡∏Ñ‡∏•‡πÄ‡∏ã‡∏µ‡∏¢‡∏°\n\t- ‡πÄ‡∏û‡∏¥‡πà‡∏°‡∏Å‡∏≤‡∏£ express ‡∏Ç‡∏≠‡∏á RANKL\n\t- dose and duration dependent, higher cumulative exposure\n- antiepileptics\n\t- phenytoin, CBZ, phenobarbital ‡πÄ‡∏õ‡πá‡∏ô cyp inducer ‡∏ó‡∏≥‡πÉ‡∏´‡πâ vit d metabolism ‡∏™‡∏π‡∏á‡∏Ç‡∏∂‡πâ‡∏ô ‡∏°‡∏µ‡∏õ‡∏£‡∏¥‡∏°‡∏≤‡∏ì‡πÉ‡∏ô‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡∏•‡∏î‡∏•‡∏á ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏Å‡∏≤‡∏£‡∏î‡∏π‡∏î‡∏ã‡∏∂‡∏°‡πÅ‡∏Ñ‡∏•‡πÄ‡∏ã‡∏µ‡∏¢‡∏°‡∏•‡∏î‡∏•‡∏á -\u003e vit D def and osteomalacia\n\t- valproic acid **‡πÄ‡∏û‡∏¥‡πà‡∏°‡∏Å‡∏≤‡∏£‡∏Ç‡∏±‡∏ö‡πÅ‡∏Ñ‡∏•‡πÄ‡∏ã‡∏µ‡∏¢‡∏°**‡πÅ‡∏•‡∏∞‡∏ü‡∏≠‡∏™‡∏ü‡∏≠‡∏£‡∏±‡∏™ -\u003e osteomalacia\n\t- levetiracetam -\u003e no report but ‡∏Ç‡πâ‡∏≠‡∏°‡∏π‡∏•‡∏î‡∏π‡∏î‡∏µ‡∏ß‡πà‡∏≤‡∏ó‡∏≥‡πÉ‡∏´‡πâ BMD ‡∏î‡∏µ‡∏Ç‡∏∂‡πâ‡∏ô\n- antiretroviral therapy\n\t- NRTIs \u003e PIs\n\t- TDF \u003e other NRTI\n\t- RTV \u003e other PIs\n\t- ‡πÄ‡∏û‡∏¥‡πà‡∏°‡∏Å‡∏≤‡∏£‡∏™‡∏•‡∏≤‡∏¢‡∏Å‡∏£‡∏∞‡∏î‡∏π‡∏Å‡πÅ‡∏•‡∏∞‡∏•‡∏î‡∏Å‡∏≤‡∏£‡∏™‡∏£‡πâ‡∏≤‡∏á\n- Antineoplastic agents\n\t- ‡∏Ñ‡∏•‡πâ‡∏≤‡∏¢ primary osteoporosis ‡∏Å‡∏î‡∏Å‡∏≤‡∏£‡∏ó‡∏≥‡∏á‡∏≤‡∏ô‡∏Ç‡∏≠‡∏á gonadal function\n\t- renal phosphate wasting leading to osteomalacia and bone loss\n- aromatase inhibitors\n\t- ‡∏¢‡∏±‡∏ö‡∏¢‡∏±‡πâ‡∏á‡∏Å‡∏≤‡∏£‡πÄ‡∏õ‡∏•‡∏µ‡πà‡∏¢‡∏ô peripheral androgen to estrogen\n- depot medroxyprogesterone\n\t- suppress HPA axis ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏•‡∏î estrogen\n- gonadotropin releasing hormone agonist\n\t- ‡∏•‡∏î‡∏Å‡∏≤‡∏£‡∏ú‡∏•‡∏¥‡∏ï sex hormone\n- SGLT2 inhibitor\n\t- canagliflozin ‡πÄ‡∏û‡∏¥‡πà‡∏° risk ‡πÅ‡∏ï‡πà‡∏ï‡∏±‡∏ß‡∏≠‡∏∑‡πà‡∏ô‡∏¢‡∏±‡∏á‡πÑ‡∏°‡πà‡∏°‡∏µ‡∏Ç‡πâ‡∏≠‡∏°‡∏π‡∏•‡∏ä‡∏±‡∏î‡πÄ‡∏à‡∏ô\n\t- ‡πÄ‡∏Å‡∏¥‡∏î‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡πÄ‡∏û‡∏¥‡πà‡∏° PTH ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡πÄ‡∏Å‡∏¥‡∏î bone resorption\n- TZD\n\t- decrease osteoblastogenesis\n- Furosemide\n\t- ‡πÄ‡∏û‡∏¥‡πà‡∏°‡∏Å‡∏≤‡∏£‡∏Ç‡∏±‡∏ö calcium\n- PPI\n\t- ‡πÑ‡∏°‡πà‡∏ó‡∏£‡∏≤‡∏ö mech ‡πÅ‡∏ï‡πà‡πÄ‡∏û‡∏¥‡πà‡∏° fracture ‡πÅ‡∏ô‡πà ‡πÜ ‡∏™‡πà‡∏ß‡∏ô BMD ‡πÑ‡∏°‡πà‡πÅ‡∏ô‡πà‡πÉ‡∏à\n- high-dose long-term heparin fracture ‡πÑ‡∏î‡πâ‡∏™‡∏π‡∏á‡∏Å‡∏ß‡πà‡∏≤ low-molecular weight heparins\n- thyroid hormone\n\t- ‡∏Å‡∏î TSH ‡πÄ‡∏¢‡∏≠‡∏∞‡πÄ‡∏Å‡∏¥‡∏ô‡πÑ‡∏õ (\u003c0.1)\n- Vit A\n\t- high dose ‡πÄ‡∏Å‡∏¥‡∏ô‡πÑ‡∏õ (x2 Upper normal)\n\n### Osteoporosis Diagnosis\n- BMD ‡πÉ‡∏ä‡πâ DXA ‡∏ß‡∏±‡∏î\n\t- post menopausal women ‡∏´‡∏£‡∏∑‡∏≠ male 50yrs + ‡πÉ‡∏ä‡πâ T-score\n\t\t- ‡∏ô‡πâ‡∏≠‡∏¢‡∏Å‡∏ß‡πà‡∏≤‡∏´‡∏£‡∏∑‡∏≠‡πÄ‡∏ó‡πà‡∏≤‡∏Å‡∏±‡∏ö -2.5 ‡∏Å‡∏£‡∏∞‡∏î‡∏π‡∏Å‡∏û‡∏£‡∏∏‡∏ô\n\t\t- ‡∏ñ‡πâ‡∏≤ -2.5 ‡∏ñ‡∏∂‡∏á -1 osteopenia\n\t\t- ‡∏ñ‡πâ‡∏≤‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤ -1 ‡∏õ‡∏Å‡∏ï‡∏¥\n\t- pre menopausal ‡∏ä‡∏≤‡∏¢‡∏≠‡∏≤‡∏¢‡∏∏‡∏ô‡πâ‡∏≠‡∏¢‡∏Å‡∏ß‡πà‡∏≤ 50 ‡∏´‡∏£‡∏∑‡∏≠‡πÄ‡∏î‡πá‡∏Å\n\t\t- Z-score ‡∏ô‡πâ‡∏≠‡∏¢‡∏Å‡∏ß‡πà‡∏≤‡πÄ‡∏ó‡πà‡∏≤‡∏Å‡∏±‡∏ö -2 osteoporosis\n- ‡πÅ‡∏•‡∏∞/‡∏´‡∏£‡∏∑‡∏≠ ‡∏°‡∏µ‡∏†‡∏≤‡∏ß‡∏∞ fragile \n\n### Assessment\n- FRAX\n\n### Bone Healthy\n- Alcohol \u003c= 1 /day (women) and \u003c= 2 /day (men)\n- caffeine intake \u003c= 2\n- smoking cessation\n\n### ‡∏Å‡∏≤‡∏£‡∏õ‡πâ‡∏≠‡∏á‡∏Å‡∏±‡∏ô\n- 2000-4000 unit/day of vit D3 ‡∏´‡∏£‡∏∑‡∏≠ 50,000 units vit D2 every 1-2 weeks ‡πÉ‡∏ô‡∏ú‡∏õ‡∏ó‡∏µ‡πà‡πÑ‡∏î‡πâ‡∏£‡∏±‡∏ö antiepileptics drug\n- ‡πÉ‡∏ä‡πâ low-molecular weight heparin ‡πÅ‡∏ó‡∏ô\n- ‡∏≠‡∏≤‡∏à‡πÉ‡∏ä‡πâ h2 ‡πÅ‡∏ó‡∏ô ppi\n- ‡∏•‡∏î‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ steroid\n\n### treatment\n- aldendronate\n- denosumab\n- raloxifene\n- calcitonin nasal\n- teriparatide\n\n## Gout, Hyperuricemia\n- diuretics (esp. HCTZ)\n\t- ‡πÄ‡∏û‡∏¥‡πà‡∏°‡∏Å‡∏≤‡∏£‡∏î‡∏π‡∏î‡∏Å‡∏•‡∏±‡∏ö‡∏Ç‡∏≠‡∏á uric acid\n- ethambutol \n\t- ‡∏•‡∏î‡∏Å‡∏≤‡∏£‡∏Ç‡∏±‡∏ö uric acid\n- pyrazinamide\n- allopurinol, febuxostat, uricosuric agents\n\t- mech unknown\n- low dose aspirin (\u003c 2 g)\n\t- ‡∏•‡∏î‡∏Å‡∏≤‡∏£‡∏Ç‡∏±‡∏ö uric acid\n- cyclosporine\n\t- ‡πÄ‡∏û‡∏¥‡πà‡∏°‡∏Å‡∏≤‡∏£‡∏î‡∏π‡∏î‡∏ã‡∏∂‡∏° uric acid\n- cytotoxic agent\n\t- ‡πÄ‡∏ã‡∏•‡∏•‡πå‡∏õ‡∏•‡πà‡∏≠‡∏¢ uric acid ‡∏≠‡∏≠‡∏Å‡∏°‡∏≤‡πÉ‡∏ô‡∏õ‡∏£‡∏¥‡∏°‡∏©‡∏£‡∏°‡∏≤‡∏Å ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏°‡∏±‡∏ô‡∏ó‡∏≥‡∏•‡∏≤‡∏¢‡πÄ‡∏ã‡∏•‡∏•‡πå ‡∏≠‡∏≤‡∏à‡πÅ‡∏Å‡πâ‡∏î‡πâ‡∏ß‡∏¢‡∏Å‡∏≤‡∏£ urine alkalinization\n- ethanol\n\t- ‡∏•‡∏î‡∏Å‡∏≤‡∏£‡∏Ç‡∏±‡∏ö uric acid ‡πÇ‡∏î‡∏¢‡∏Å‡∏≤‡∏£‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏°‡∏±‡∏ô‡∏ï‡πâ‡∏≠‡∏á‡πÅ‡∏Ç‡πà‡∏á‡∏Å‡∏±‡∏ö lactic acid\n\n### management\n- ‡∏ñ‡πâ‡∏≤‡∏´‡∏¢‡∏∏‡∏î‡∏¢‡∏≤‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ ‡∏Å‡πá‡∏£‡∏±‡∏Å‡∏©‡∏≤‡πÄ‡∏´‡∏°‡∏∑‡∏≠‡∏ô acute gout attack ‡∏à‡πâ‡∏≤‡∏≤‡∏≤‡∏≤\n\n## Myopathy\n- myalgia -\u003e muscular pain or weakness ‡πÅ‡∏ï‡πà CK ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏Ç‡∏∂‡πâ‡∏ô\n- myositis -\u003e elevated CK, often \u003e 2 times ULN\n- rhabdomyolysis -\u003e elevated CK, often \u003e 10 times ULN, **and evidence of acute renal disease  ‡πÄ‡∏ä‡πà‡∏ô ‡∏õ‡∏±‡∏™‡∏™‡∏≤‡∏ß‡∏∞‡πÑ‡∏°‡πà‡∏≠‡∏≠‡∏Å ‡∏™‡∏µ‡πÇ‡∏Ñ‡πâ‡∏Å**\n- mechanism\n\t- painful neuropathies\n\t\t- ‡∏¢‡∏≤‡πÑ‡∏Ç‡∏°‡∏±‡∏ô‡∏ï‡πà‡∏≤‡∏á ‡πÜ\n\t\t\t- ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏Å‡∏≤‡∏£‡∏™‡∏£‡πâ‡∏≤‡∏á‡πÇ‡∏õ‡∏£‡∏ï‡∏µ‡∏ô‡πÉ‡∏ô‡πÄ‡∏ã‡∏•‡∏•‡πå‡∏ú‡∏¥‡∏î‡∏õ‡∏Å‡∏ï‡∏¥ ‡∏ó‡∏≥‡πÉ‡∏´‡πâ myocyte ‡∏ï‡∏≤‡∏¢ ‡∏´‡∏£‡∏∑‡∏≠ ‡∏°‡∏µ‡∏ú‡∏•‡∏ï‡πà‡∏≠ glycoprotein ‡∏Ç‡∏≠‡∏á‡πÄ‡∏¢‡∏∑‡πà‡∏≠‡∏´‡∏∏‡πâ‡∏°‡πÄ‡∏ã‡∏•‡∏•‡πå ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡πÅ‡∏Ñ‡∏•‡πÄ‡∏ã‡∏µ‡∏¢‡∏°‡πÄ‡∏Ç‡πâ‡∏≤‡πÄ‡∏ã‡∏•‡∏•‡πå‡πÄ‡∏¢‡∏≠‡∏∞ ‡∏à‡∏ô‡∏°‡∏µ‡∏Ñ‡∏∏‡∏ì‡∏™‡∏°‡∏ö‡∏±‡∏ï‡∏¥‡πÄ‡∏õ‡∏•‡∏µ‡πà‡∏¢‡∏ô‡πÑ‡∏õ\n\t\t- zidovudine \n\t\t\t- direct toxic ‡∏ï‡πà‡∏≠ muscle mitochondria\n\t\t- proton-pump-inhibitors\n\t\t\t- polymyositis/dermatomyositis\n\t- painless myopathies\n\t\t- corticosteroid\n\t\t\t- enhanced intracellular protein breakdown and altered calcium homeostasis \n\t\t\t- **‡πÄ‡∏à‡∏≠‡∏ô‡πâ‡∏≠‡∏¢**\n\t\t- chloroquine, diuretics, laxative\n\t\t\t- neuromyopathy\n\t\t- colchicine\n\t\t\t- alter microtubular function\n- ‡∏Å‡∏≤‡∏£‡∏õ‡πâ‡∏≠‡∏á‡∏Å‡∏±‡∏ô\n\t- ‡∏Å‡πá‡∏≠‡∏¢‡πà‡∏≤‡πÉ‡∏ä‡πâ‡∏¢‡∏≤‡∏™‡∏¥ ‡∏≠‡∏¥‡∏≠‡∏¥\n\t- ‡∏≠‡∏¢‡πà‡∏≤‡∏•‡∏∑‡∏°‡∏õ‡∏£‡∏±‡∏ö‡∏¢‡∏≤‡∏ï‡∏≤‡∏°‡∏ï‡∏±‡∏ö ‡∏ï‡∏≤‡∏°‡πÑ‡∏ï‡∏Å‡πá‡∏û‡∏≠\n\t- ‡πÉ‡∏ô‡∏ú‡∏π‡πâ‡∏õ‡πà‡∏ß‡∏¢ cirrhosis \u0026 hypoalbuminemia ‡∏à‡∏∞‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á myopathy ‡∏≠‡∏¢‡∏π‡πà‡πÅ‡∏•‡πâ‡∏ß ‡πÄ‡∏•‡∏µ‡πà‡∏¢‡∏á‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ higher-risk drugs\n- ‡∏Å‡∏≤‡∏£‡∏õ‡πâ‡∏≠‡∏á‡∏Å‡∏±‡∏ô drug induced\n\t- -statin ‡πÉ‡∏ô‡∏ú‡∏õ 60+ ‡∏≠‡∏¢‡πà‡∏≤‡πÉ‡∏ä‡πâ‡∏¢‡∏≤‡∏™‡∏π‡∏á‡πÑ‡∏õ ‡∏Ñ‡πà‡∏≠‡∏¢ ‡πÜ ‡πÄ‡∏û‡∏¥‡πà‡∏°\n\t- steroid ‡πÉ‡∏ä‡πâ‡∏™‡∏±‡πâ‡∏ô‡∏ó‡∏µ‡πà‡∏™‡∏∏‡∏î ‡πÇ‡∏î‡∏™‡∏ï‡πà‡∏≥‡∏ó‡∏µ‡πà‡∏™‡∏∏‡∏î‡∏ó‡∏µ‡πà‡πÉ‡∏ä‡πâ‡πÑ‡∏î‡πâ\n- management\n\t- monitor ‡πÉ‡∏´‡πâ‡∏î‡∏µ ‡πÅ‡∏•‡πâ‡∏ß‡∏£‡∏µ‡∏ö intervention ‡∏Å‡πà‡∏≠‡∏ô‡∏à‡∏∞ rhabdomyolysis\n\t- ‡∏≠‡∏≤‡∏à‡πÉ‡∏ä‡πâ prednisolone 50-100 mg daily for up to 7 days ‡∏à‡∏ô‡∏Å‡∏ß‡πà‡∏≤‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏´‡∏≤‡∏¢ ‡πÅ‡∏•‡∏∞ tape \u003e 1 months\n\t- ‡πÄ‡∏•‡∏µ‡πà‡∏¢‡∏á‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ‡∏¢‡∏≤‡∏ï‡πâ‡∏ô‡πÄ‡∏´‡∏ï‡∏∏‡∏≠‡∏µ‡∏Å\n- management for zidovudine\n\t- ‡∏´‡∏¢‡∏∏‡∏î‡πÅ‡∏•‡∏∞‡πÄ‡∏õ‡∏•‡∏µ‡πà‡∏¢‡∏ô‡∏¢‡∏≤\n\t- ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏î‡∏µ‡∏Ç‡∏∂‡πâ‡∏ô‡πÉ‡∏ô 4-8 wks\n\t- ‡∏ñ‡πâ‡∏≤‡πÑ‡∏°‡πà‡∏î‡∏µ‡∏Ç‡∏∂‡πâ‡∏ô ‡πÉ‡∏´‡πâ biopsy\n\t\t- ‡∏ñ‡πâ‡∏≤ inflam ‡πÉ‡∏´‡πâ steroid\n\t\t- ‡∏ñ‡πâ‡∏≤‡πÑ‡∏°‡πà‡∏°‡∏µ ‡∏î‡∏π OI ‡∏î‡πâ‡∏ß‡∏¢\n- management for statin\n\t- CK \u003c 5 ULN ‡πÉ‡∏ä‡πâ‡∏ï‡πà‡∏≠‡πÅ‡∏•‡∏∞ F/U 1 mo\n\t- 5-10 UN ‡∏û‡∏¥‡∏à‡∏≤‡∏£‡∏ì‡∏≤ CVS\n\t\t- low cvs: ‡∏´‡∏¢‡∏∏‡∏î‡∏¢‡∏≤\n\t\t- high cvs: ‡πÉ‡∏ä‡πâ‡∏ï‡πà‡∏≠ ‡πÅ‡∏•‡πâ‡∏ß‡∏ï‡∏¥‡∏î‡∏ï‡∏≤‡∏° CK weekly-monthly\n\t- more than 10 ULN ‡∏´‡∏¢‡∏∏‡∏î statin\n\t\t- ‡∏ñ‡πâ‡∏≤ CK \u003c 10 ‡∏≠‡∏≤‡∏à‡πÉ‡∏ä‡πâ statin ‡∏≠‡∏µ‡∏Å‡∏Ñ‡∏£‡∏±‡πâ‡∏á ‡πÅ‡∏•‡πâ‡∏ß‡πÉ‡∏ä‡πâ‡∏û‡∏ß‡∏Å‡∏¢‡∏≤ hydrophilic ‡πÄ‡∏ä‡πà‡∏ô rosuvastatin, pravastatin, fluvastatin ‡πÄ‡∏£‡∏¥‡πà‡∏°‡∏à‡∏≤‡∏Å‡∏¢‡∏≤‡∏Ç‡∏ô‡∏≤‡∏î‡∏ô‡πâ‡∏≠‡∏¢\n\t\t- ‡∏ñ‡πâ‡∏≤‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á rhabdomyolysis (‡πÄ‡∏ä‡πà‡∏ô ‡πÑ‡∏ï‡∏û‡∏±‡∏á, CKD) ‡∏´‡πâ‡∏≤‡∏°‡πÉ‡∏´‡πâ‡∏¢‡∏≤ statin ‡∏≠‡∏µ‡∏Å‡πÄ‡∏•‡∏¢","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/Drug-dosing-in-liver-impairment":{"title":"Drug dosing in liver impairment","content":"### Child-Pugh\n- ‡πÉ‡∏ä‡πâ‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô prognosis ‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤ ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏ö‡πà‡∏á‡∏ö‡∏≠‡∏Å‡∏Ñ‡∏ß‡∏≤‡∏°‡∏™‡∏≤‡∏°‡∏≤‡∏£‡∏ñ‡∏î‡πâ‡∏≤‡∏ô synthesis ‡πÅ‡∏•‡∏∞ conjugation\n- A (5-6) -\u003e life expectancy 10-20 yr, mortality ‡∏ô‡πâ‡∏≠‡∏¢\n- B (7-9) -\u003e candidate for transplant, 30% mortality perioperative\n  C (10-15) -\u003e 1-3 yrs-\u003e 82% mortality perioperative !\n\n### MELD (Model for End-Stage Liver Disease)\n- ‡πÄ‡∏õ‡πá‡∏ô‡πÄ‡∏Ñ‡∏£‡∏∑‡πà‡∏≠‡∏á‡∏°‡∏∑‡∏≠‡πÉ‡∏ô‡∏Å‡∏≤‡∏£‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô prognosis ‡∏Ç‡∏≠‡∏á‡∏ú‡∏π‡πâ‡∏õ‡πà‡∏ß‡∏¢‡∏ï‡∏±‡∏ö‡πÅ‡∏Ç‡πá‡∏á‡∏ó‡∏µ‡πà‡πÑ‡∏î‡πâ‡∏£‡∏±‡∏ö‡∏Å‡∏≤‡∏£‡∏£‡∏±‡∏Å‡∏©‡∏≤‡∏î‡πâ‡∏ß‡∏¢ TIPS ‡∏´‡∏£‡∏∑‡∏≠‡∏£‡∏≠‡∏£‡∏±‡∏Å‡∏©‡∏≤‡∏î‡πâ‡∏ß‡∏¢‡∏Å‡∏≤‡∏£‡∏ú‡πà‡∏≤‡∏ï‡∏î‡∏±‡∏î‡∏õ‡∏•‡∏π‡∏Å‡∏ñ‡πà‡∏≤‡∏¢‡∏ï‡∏±‡∏ö (Modified MELD)\n- ‡∏°‡∏µ‡∏´‡∏•‡∏≤‡∏¢‡∏™‡∏°‡∏Å‡∏≤‡∏£‡∏ä‡∏¥‡∏ö‡∏´‡∏≤‡∏¢ ‡∏î‡∏±‡∏á‡∏ô‡∏±‡πâ‡∏ô‡∏≠‡∏¢‡πà‡∏≤‡∏•‡∏∑‡∏°‡∏ö‡∏≠‡∏Å‡∏î‡πâ‡∏ß‡∏¢‡∏ß‡πà‡∏≤‡πÉ‡∏ä‡πâ MELD ‡∏≠‡∏∞‡πÑ‡∏£\n\n### Pharmacokinetics\n- Hepatocellular injuries ‡∏õ‡∏£‡∏∞‡∏™‡∏¥‡∏ó‡∏ò‡∏¥‡∏†‡∏≤‡∏û‡πÉ‡∏ô‡∏Å‡∏≤‡∏£‡∏Ç‡∏à‡∏±‡∏î‡∏¢‡∏≤‡∏Ç‡∏≠‡∏á‡∏ï‡∏±‡∏ö‡∏•‡∏î‡∏•‡∏á‡∏≠‡∏¢‡πà‡∏≤‡∏á‡∏°‡∏≤‡∏Å\n- Cholestasis ‡∏≠‡∏±‡∏ï‡∏£‡∏≤‡∏Å‡∏≤‡∏£‡∏Ç‡∏à‡∏±‡∏î‡∏¢‡∏≤‡πÄ‡∏õ‡∏•‡∏µ‡πà‡∏¢‡∏ô‡πÅ‡∏õ‡∏•‡∏á‡πÑ‡∏°‡πà‡∏°‡∏≤‡∏Å\n- Ascites -\u003e Vd ‡∏Ç‡∏≠‡∏á‡∏¢‡∏≤‡∏ó‡∏µ‡πà‡∏•‡∏∞‡∏•‡∏≤‡∏¢‡∏ô‡πâ‡∏≥‡πÑ‡∏î‡πâ‡∏î‡∏µ‡πÄ‡∏û‡∏¥‡πà‡∏°‡∏Ç‡∏∂‡πâ‡∏ô\n- ‡πÇ‡∏õ‡∏£‡∏ï‡∏µ‡∏ô‡πÉ‡∏ô‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡∏•‡∏î‡∏•‡∏á (albumin) ‡∏¢‡∏≤‡πÉ‡∏ô‡∏£‡∏π‡∏õ‡∏≠‡∏¥‡∏™‡∏£‡∏∞‡∏°‡∏µ‡πÄ‡∏û‡∏¥‡πà‡∏°‡∏°‡∏≤‡∏Å‡∏Ç‡∏∂‡πâ‡∏ô ‡∏¢‡∏≤‡∏ó‡∏µ‡πà‡∏à‡∏±‡∏ö‡∏Å‡∏±‡∏ö‡πÇ‡∏õ‡∏£‡∏ï‡∏µ‡∏ô‡∏à‡∏∞‡∏°‡∏µ‡πÇ‡∏≠‡∏Å‡∏≤‡∏™‡πÄ‡∏Å‡∏¥‡∏î‡∏û‡∏¥‡∏©‡∏°‡∏≤‡∏Å‡∏Ç‡∏∂‡πâ‡∏ô\n- Metabolism ‡∏•‡∏î‡∏•‡∏á‡πÇ‡∏î‡∏¢‡πÄ‡∏â‡∏û‡∏≤‡∏∞ phase I (CYP2C19) ‡πÅ‡∏ï‡πà phase 2 (conjugation) ‡πÑ‡∏°‡πà‡πÅ‡∏ï‡∏Å‡∏ï‡πà‡∏≤‡∏á\n\n### ‡∏Ñ‡∏∏‡∏ì‡∏™‡∏°‡∏ö‡∏±‡∏ï‡∏¥‡∏Ç‡∏≠‡∏á‡∏¢‡∏≤\n- Hepatic Extraction Ratio : HER\n\t- ‡∏™‡∏π‡∏á (\u003e60) -\u003e F ‡∏ï‡πà‡∏≥\n\t- ‡∏õ‡∏≤‡∏ô‡∏Å‡∏•‡∏≤‡∏á (30-60) -\u003e F ‡∏õ‡∏≤‡∏ô‡∏Å‡∏•‡∏≤‡∏á\n\t- ‡∏ï‡πà‡∏≥ (\u003c30) -\u003e F ‡∏™‡∏π‡∏á\n- Protein Binding\n\t- ‡∏™‡∏π‡∏á -\u003e ‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤ 90-95% bound form\n\t- ‡∏ï‡πà‡∏≥ -\u003e ‡∏ô‡πâ‡∏≠‡∏¢‡∏Å‡∏ß‡πà‡∏≤ 90% bound form\n![[Pasted image 20230308190933.png|575]]\n\n![[Pasted image 20230308191136.png]]","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/Exam-1-Addition-Notes":{"title":"Exam 1 Addition Notes","content":"- [[Inhaler Products]]\n- Asthma\n\t- Normal\n\t\t- Diagnosis ‡∏î‡∏π‡∏à‡∏≤‡∏Å\n\t\t\t- FEV1/FVC \u003c0.75-0.8 (adult) ‡πÅ‡∏•‡∏∞\n\t\t\t- post broncho FEV1 \u003e 12% ‡∏´‡∏£‡∏∑‡∏≠\n\t\t\t- PEF \u003e 10%\n\t\t- ‡∏Å‡∏≤‡∏£‡∏£‡∏±‡∏Å‡∏©‡∏≤\n\t\t\t- step1-2\n\t\t\t\t- ICS ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏Å‡πá‡πÉ‡∏ä‡πâ montelukast\n\t\t\t\t- add HDM ‡∏ñ‡πâ‡∏≤‡πÅ‡∏û‡πâ ‡∏£‡∏∞‡∏ß‡∏±‡∏á anaphylaxis\n\t\t\t- step3 -\u003e ‡∏Å‡∏£‡∏ì‡∏µ‡∏ó‡∏µ‡πà \u003e5 days ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£\n\t\t\t\t- ‡πÉ‡∏ä‡πâ symbicort ‡πÅ‡∏ö‡∏ö od ‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πà as-needed!\n\t\t\t- step4-5 ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏ó‡∏∏‡∏Å‡∏ß‡∏±‡∏ô\n\t\t\t\t- ‡∏ñ‡πâ‡∏≤ type 2 -\u003e EOS \u003e 150 ‡πÅ‡∏•‡∏∞‡∏´‡∏£‡∏∑‡∏≠ FeNO \u003e20\n\t\t\t\t\t- ‡∏Ñ‡∏ß‡∏£‡∏ï‡∏≠‡∏ö‡∏™‡∏ô‡∏≠‡∏á‡∏ï‡πà‡∏≠ ICS ‡∏õ‡∏£‡∏±‡∏ö‡πÉ‡∏´‡πâ‡∏™‡∏∏‡∏î‡∏Å‡πà‡∏≠‡∏ô ‡πÅ‡∏•‡∏∞‡∏•‡∏≠‡∏á‡πÉ‡∏ä‡πâ Azithro / LAMA\n\t\t\t\t- ‡∏ñ‡πâ‡∏≤ not type 2\n\t\t\t\t\t- ‡∏•‡∏≠‡∏á‡πÉ‡∏ä‡πâ Azithro / LAMA ‡∏ñ‡πâ‡∏≤‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏Ñ‡πà‡∏≠‡∏¢ Biologics\n\t- Exacerbation\n\t\t- ‡πÄ‡∏û‡∏¥‡πà‡∏°‡∏≠‡∏±‡∏ï‡∏£‡∏≤‡∏Å‡∏≤‡∏£‡∏û‡πà‡∏ô ‡∏ñ‡πâ‡∏≤ PEF FEV \u003c 60% ‡πÉ‡∏´‡πâ prednisolone\n\t\t- mild-mod\n\t\t- severe\n\t\t\t- RR \u003e 30\n\t\t\t- accesory muscle\n\t\t\t- PaO2 \u003c 60 mmHg (O2Sat \u003c90%)\n\t\t- ‡∏£‡∏±‡∏Å‡∏©‡∏≤\n\t\t\t- keep O2 92-95%\n\t\t\t- predni  40-50 mg/d 5 day\n\t\t\t- ‡πÄ‡∏û‡∏¥‡πà‡∏°‡∏Å‡∏≤‡∏£‡∏û‡πà‡∏ô + ICS ‡∏î‡πâ‡∏ß‡∏¢\n- COPD\n\t- Normal\n\t\t- GOLD ‡∏ï‡πâ‡∏≠‡∏á FEV/FVC \u003c 0.7 ‡∏Å‡πà‡∏≠‡∏ô!\n\t\t\t- 80 50 30 A B C D\n\t\t- mRNC\n\t\t\t- 0 1 2 3 4\n\t\t- CAT\n\t\t\t- ‡∏´‡∏•‡∏≤‡∏¢‡∏Ç‡πâ‡∏≠‡πÄ‡∏•‡∏¢‡∏à‡∏£‡πâ‡∏≤\n\t\t- Group A B E\n\t\t\t- ‡∏ï‡∏±‡∏î‡∏ó‡∏µ‡πà Cat 10    mRNC ‡∏ó‡∏µ‡πà 0-1  \u003e=2\n\t- Exacerbation\n\t\t- ‡∏û‡πà‡∏ô‡∏ñ‡∏µ‡πà‡∏Ç‡∏∂‡πâ‡∏ô\n\t\t- ‡∏ñ‡πâ‡∏≤‡∏¢‡∏±‡∏á‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡πÉ‡∏ä‡πâ combine ‡πÉ‡∏´‡πâ‡∏°‡∏≤ combine LABA LAMA ‡∏ñ‡πâ‡∏≤ eos \u003c 300\n\t\t- ‡∏ñ‡πâ‡∏≤ eos \u003e 300 ‡πÉ‡∏´‡πâ‡πÉ‡∏ä‡πâ ICS ‡∏£‡πà‡∏ß‡∏°‡∏î‡πâ‡∏ß‡∏¢‡πÄ‡∏•‡∏¢\n\t\t- ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤ \u003c 300 ‡∏•‡∏≠‡∏á‡πÅ‡∏•‡πâ‡∏ß‡πÑ‡∏°‡πà‡∏´‡∏≤‡∏¢ ‡πÅ‡∏Ñ‡πà \u003e100 ‡∏Å‡πá‡πÉ‡∏´‡πâ‡πÑ‡∏î‡πâ ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤ \u003c 100 ‡πÉ‡∏´‡πâ‡πÉ‡∏ä‡πâ‡∏ß‡∏¥‡∏ò‡∏µ‡∏≠‡∏∑‡πà‡∏ô\n\t\t\t- ‡∏•‡∏≠‡∏á add Azithromycin ‡∏´‡∏£‡∏∑‡∏≠ Roflumilast\n\t\t- OCS Optional ‡πÅ‡∏ï‡πà‡∏°‡∏µ Role\n\t\t- O2 keep ‡πÅ‡∏Ñ‡πà 88-92% ‡∏û‡∏≠\n\t\t- ‡πÉ‡∏™‡πà INV ‡πÅ‡∏Ñ‡πà‡πÉ‡∏ô‡πÄ‡∏Ñ‡∏™‡∏ó‡∏µ‡πà‡πÑ‡∏°‡πà‡∏°‡∏µ‡πÄ‡∏™‡∏°‡∏´‡∏∞‡πÅ‡∏•‡∏∞ indicated ‡πÄ‡∏ó‡πà‡∏≤‡∏ô‡∏±‡πâ‡∏ô","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/Glaucoma-%E0%B8%95%E0%B9%89%E0%B8%AD%E0%B8%AB%E0%B8%B4%E0%B8%99":{"title":"Glaucoma (‡∏ï‡πâ‡∏≠‡∏´‡∏¥‡∏ô)","content":"\n![[Pasted image 20230202192433.png|475]]\n- IOP ‡∏ó‡∏µ‡πà‡∏™‡∏π‡∏á‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡πÄ‡∏Å‡∏¥‡∏î optic neuropathy (‡∏ó‡∏≥‡∏•‡∏≤‡∏¢‡∏£‡∏∞‡∏ö‡∏ö‡∏õ‡∏£‡∏∞‡∏™‡∏≤‡∏ó‡∏ï‡∏≤) ‡∏ó‡∏≥‡πÉ‡∏´‡πâ\n\t- Cup to Disk Ratio \u003e 0.5 (‡∏õ‡∏Å‡∏ï‡∏¥ 0.33-0.5)\n\t- Splinter hemorrhage\n\t\t- ‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡∏ó‡∏µ‡πà‡∏≠‡∏≠‡∏Å‡∏°‡∏µ oxidative stress ‡πÄ‡∏õ‡πâ‡∏ô cell toxicity\n\t- Nerve fiber defects\n\t- Blind spot enlargement\n- Aqueous humor ‡∏™‡∏£‡πâ‡∏≤‡∏á‡∏à‡∏≤‡∏Å ciliary body ‡∏ó‡∏≥‡∏´‡∏ô‡πâ‡∏≤‡∏ó‡∏µ‡πà‡∏£‡∏±‡∏Å‡∏©‡∏≤ IOP ‡πÉ‡∏´‡πâ‡∏≠‡∏¢‡∏π‡πà‡∏ä‡πà‡∏ß‡∏á‡∏õ‡∏Å‡∏ï‡∏¥\n- Aqueous humor ‡∏£‡∏∞‡∏ö‡∏≤‡∏¢‡∏≠‡∏≠‡∏Å‡∏ó‡∏≤‡∏á Trabecular meshwork (85-95%) ‡πÅ‡∏•‡∏∞ Uveoscleral route (5-15%) #recall1 \n- Tonometry ‡∏Ñ‡∏∑‡∏≠‡∏Å‡∏≤‡∏£‡∏ß‡∏±‡∏î‡πÅ‡∏£‡∏á‡∏î‡∏±‡∏ô‡πÉ‡∏ô‡∏ï‡∏≤ ‡πÅ‡∏ï‡πà‡∏õ‡∏±‡∏à‡∏à‡∏∏‡∏ö‡∏±‡∏ô‡∏ô‡∏¥‡∏¢‡∏° Fundoscopy ‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤\n- IOP ‡πÄ‡∏õ‡πá‡∏ô‡πÅ‡∏Ñ‡πà risk ‡∏´‡∏ô‡∏∂‡πà‡∏á‡πÉ‡∏ô‡∏Å‡∏≤‡∏£‡πÄ‡∏Å‡∏¥‡∏î Glaucoma ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏ö‡πà‡∏á‡∏ö‡∏≠‡∏Å‡∏ß‡πà‡∏≤‡∏à‡∏∞‡πÄ‡∏Å‡∏¥‡∏î‡πÄ‡∏™‡∏°‡∏≠‡πÑ‡∏õ ‡∏Ñ‡∏ô‡∏ö‡∏≤‡∏á‡∏Ñ‡∏ô IOP ‡∏ô‡πâ‡∏≠‡∏¢ (ex. \u003c 21 mmHg ) ‡∏Å‡πá‡πÄ‡∏õ‡πá‡∏ô‡πÑ‡∏î‡πâ\n- IOP ‡∏õ‡∏Å‡∏ï‡∏¥‡∏≠‡∏¢‡∏π‡πà‡∏ó‡∏µ‡πà 15.5 +- 10 mmHg ‡∏´‡∏•‡∏≤‡∏Å‡∏´‡∏•‡∏≤‡∏¢‡πÅ‡∏•‡πâ‡∏ß‡πÅ‡∏ï‡πà‡∏Ñ‡∏ô ‡πÅ‡∏•‡πâ‡∏ß‡πÅ‡∏ï‡πà‡πÄ‡∏ß‡∏•‡∏≤\n\t- 21-30 ‡∏°‡∏µ incidence ‡πÄ‡∏Å‡∏¥‡∏î 0.5-1/yrs ‡∏ï‡∏¥‡∏î‡∏ï‡∏≤‡∏° 5-15 yrs\n\t- \u003e 30 ‡∏°‡∏µ incidence 28%\n\n## Risks\n- Physiology ‡∏Ç‡∏≠‡∏á‡πÅ‡∏ï‡πà‡∏•‡∏∞‡∏Ñ‡∏ô ‡πÄ‡∏ä‡πà‡∏ô ‡∏°‡∏∏‡∏° sclera ‡πÅ‡∏Ñ‡∏ö\n- ‡∏¢‡∏≤ anticholinergics, decongestant, beta-2 agonist, steroid\n- ‡πÇ‡∏£‡∏Ñ immune disease\n\n## Classification\n- ‡∏ï‡πâ‡∏≠‡∏´‡∏¥‡∏ô IOP\u003e21 mmHg\n\t- ‡∏°‡∏∏‡∏°‡πÄ‡∏õ‡∏¥‡∏î\n\t- ‡∏°‡∏∏‡∏°‡∏õ‡∏¥‡∏î\n- ‡∏ï‡πâ‡∏≠‡∏´‡∏¥‡∏ô‡∏ó‡∏µ‡πà IOP ‡∏õ‡∏Å‡∏ï‡∏¥\n- ‡∏ï‡πâ‡∏≠‡∏´‡∏¥‡∏ô‡∏ó‡∏∏‡∏ï‡∏¥‡∏¢‡∏†‡∏π‡∏°‡∏¥\n- Ocular Hypertension high IOP ‡πÅ‡∏ï‡πà‡πÑ‡∏°‡πà‡∏°‡∏µ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡πÅ‡∏™‡∏î‡∏á‡∏Ç‡∏≠‡∏á‡∏ï‡πâ‡∏≠‡∏´‡∏¥‡∏ô\n\n## ‡∏ï‡πâ‡∏≠‡∏´‡∏¥‡∏ô‡∏°‡∏∏‡∏°‡πÄ‡∏õ‡∏¥‡∏î ‡∏°‡∏∏‡∏°‡∏õ‡∏¥‡∏î\n![[Pasted image 20230201154330.png|450]]\n- ‡∏õ‡∏Å‡∏ï‡∏¥‡∏û‡∏ö‡∏°‡∏∏‡∏°‡πÄ‡∏õ‡∏¥‡∏î‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤ (80-90%) ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏à‡∏∞‡πÄ‡∏Å‡∏¥‡∏î‡∏≠‡∏¢‡πà‡∏≤‡∏á‡∏ä‡πâ‡∏≤ ‡πÜ\n- ‡∏°‡∏∏‡∏°‡∏õ‡∏¥‡∏î‡∏û‡∏ö‡∏ô‡πâ‡∏≠‡∏¢ (5-10%) ‡∏û‡∏ö‡πÉ‡∏ô‡πÄ‡∏≠‡πÄ‡∏ä‡∏µ‡∏¢‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤‡∏¢‡∏∏‡πÇ‡∏£‡∏õ ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏à‡∏∞‡πÄ‡∏â‡∏µ‡∏¢‡∏ö‡∏û‡∏•‡∏±‡∏ô ‡∏Ñ‡∏ß‡∏≤‡∏°‡∏î‡∏±‡∏ô‡∏™‡∏π‡∏á‡πÄ‡∏â‡∏µ‡∏¢‡∏ö‡∏û‡∏•‡∏±‡∏ô ‡πÄ‡∏™‡πâ‡∏ô‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡πÅ‡∏î‡∏á ‡∏ï‡∏≤‡∏≠‡∏≤‡∏à‡∏Ç‡∏∏‡πà‡∏ô ‡∏Ñ‡∏•‡∏∑‡πà‡∏ô‡πÑ‡∏™‡πâ ‡∏≠‡∏≤‡πÄ‡∏à‡∏µ‡∏¢‡∏ô ‡∏õ‡∏ß‡∏î‡∏´‡∏±‡∏ß ‡∏ï‡∏≤‡πÄ‡∏ö‡∏•‡∏≠ ‡∏°‡∏≠‡∏á‡πÑ‡∏°‡πà‡∏Ñ‡πà‡∏≠‡∏¢‡πÄ‡∏´‡πá‡∏ô\n- ‡∏ï‡πâ‡∏≠‡∏´‡∏¥‡∏ô‡∏°‡∏±‡∏Å‡πÄ‡∏õ‡πá‡∏ô‡∏™‡∏≠‡∏á‡∏Ç‡πâ‡∏≤‡∏á ‡πÅ‡∏ï‡πà‡∏Å‡∏≤‡∏£‡∏£‡∏±‡∏Å‡∏©‡∏≤ ‡πÅ‡∏•‡∏∞‡∏Å‡∏≤‡∏£‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô‡∏à‡∏∞‡∏ï‡πâ‡∏≠‡∏á‡∏ó‡∏≥‡πÅ‡∏¢‡∏Å‡∏Å‡∏±‡∏ô ‡∏Å‡∏≤‡∏£‡∏ï‡∏≠‡∏ö‡∏™‡∏ô‡∏≠‡∏á‡∏ï‡πà‡∏≠‡∏¢‡∏≤‡∏≠‡∏≤‡∏à‡πÑ‡∏°‡πà‡πÄ‡∏´‡∏°‡∏∑‡∏≠‡∏ô‡∏Å‡∏±‡∏ô\n\n## Goal\n- ‡∏•‡∏î‡πÉ‡∏´‡πâ‡∏≠‡∏¢‡∏π‡πà‡∏£‡∏∞‡∏î‡∏±‡∏ö‡∏õ‡∏Å‡∏ï‡∏¥‡∏õ‡∏£‡∏∞‡∏°‡∏≤‡∏ì 15.5 mmHg ‡∏ñ‡πâ‡∏≤‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏£‡∏∏‡∏ô‡πÅ‡∏£‡∏á‡∏Å‡πá 10-12 mmHg ‡∏´‡∏£‡∏∑‡∏≠‡∏•‡∏î 20-30% ‡∏à‡∏≤‡∏Å‡∏£‡∏∞‡∏î‡∏±‡∏ö‡πÄ‡∏£‡∏¥‡πà‡∏°‡∏ï‡πâ‡∏ô\n- ‡∏Ñ‡∏∏‡∏° **circadian variation of IOP (Prostaglandin analog and CAIs ‡∏ä‡πà‡∏ß‡∏¢‡πÑ‡∏î‡πâ**) #recall1 \n\n\n![[Pasted image 20230201155043.png|525]]\n![[Pasted image 20230201155049.png]]\n![[Pasted image 20230201155053.png]]\n![[Pasted image 20230201155100.png]]\n\n- ‡∏≠‡∏¢‡πà‡∏≤‡∏•‡∏∑‡∏° Nasolacrimal Occulsion (NLO)\n- ‡∏ú‡∏•‡∏à‡∏≤‡∏Å Paper: ‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ combination ‡∏î‡∏µ‡∏Å‡∏ß‡πà‡∏≤ mono (‡∏•‡∏î IOP ‡πÑ‡∏î‡πâ‡∏î‡∏µ‡∏Å‡∏ß‡πà‡∏≤ ‡πÅ‡∏•‡∏∞‡πÄ‡∏û‡∏¥‡πà‡∏° compliance\n- **Pilocarpine use when \u003c 40 mmHg Only**\n- ‡∏ï‡∏≠‡∏ô acute glaucoma (‡∏°‡∏±‡∏Å‡πÄ‡∏õ‡πá‡∏ô closed) ‡πÄ‡∏£‡∏≤‡πÉ‡∏ä‡πâ steroid ‡πÄ‡∏û‡∏∑‡πà‡∏≠‡∏•‡∏î inflammation!","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/IBD":{"title":"IBD","content":"\n\u003e [!warning] IBD ‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πà IBS\n\u003e IBS ‡πÄ‡∏õ‡πá‡∏ô functional ‡∏ï‡πà‡∏≤‡∏á‡∏ó‡∏µ‡πà IBD ‡∏ó‡∏µ‡πà‡∏û‡∏¢‡∏≤‡∏ò‡∏¥‡∏™‡∏†‡∏≤‡∏û‡∏ä‡∏±‡∏î‡πÄ‡∏à‡∏ô\n- **Crohn's Disease vs Ulcerative Colitis**\n\t- UC ‡∏à‡∏≥‡∏ß‡πà‡∏≤ \"‡πÄ‡∏≠‡∏≤‡∏™‡∏¥\" = S\u0026S ‡πÄ‡∏î‡πà‡∏ô‡∏ï‡∏£‡∏á rectum ‡πÄ‡∏Ç‡πâ‡∏≤‡πÑ‡∏õ‡πÄ‡∏£‡∏∑‡πà‡∏≠‡∏¢ ‡πÜ ‡πÅ‡∏ï‡πà‡πÑ‡∏°‡πà‡∏•‡∏∂‡∏Å‡∏°‡∏≤‡∏Å ‡∏ï‡πà‡∏≤‡∏á‡∏à‡∏≤‡∏Å CD ‡∏ó‡∏µ‡πà‡∏Å‡∏£‡∏∞‡∏à‡∏±‡∏î‡∏Å‡∏£‡∏∞‡∏à‡∏≤‡∏¢\n\t- ‡πÄ‡∏û‡∏£‡∏≤‡∏∞ CD ‡∏Å‡∏£‡∏∞‡∏à‡∏≤‡∏¢‡∏Å‡∏£‡∏∞‡∏à‡∏≤‡∏¢ ‡∏î‡∏±‡∏á‡∏ô‡∏±‡πâ‡∏ô systemic symptoms ‡∏à‡∏∂‡∏á‡πÄ‡∏î‡πà‡∏ô‡∏Å‡∏ß‡πà‡∏≤‡∏°‡∏≤‡∏Å ‡πÜ ‡πÅ‡∏•‡∏∞‡∏¢‡∏±‡∏á‡∏°‡∏µ‡πÄ‡∏£‡∏∑‡πà‡∏≠‡∏á abdominal ‡∏ó‡∏µ‡πà‡πÄ‡∏î‡πà‡∏ô‡∏Å‡∏ß‡πà‡∏≤‡∏≠‡∏µ‡∏Å ‡πÄ‡∏ä‡πà‡∏ô tenderness, pain ‡∏Ø‡∏•‡∏Ø ‡∏£‡∏ß‡∏°‡∏ñ‡∏∂‡∏á‡πÑ‡∏Ç‡πâ‡∏≠‡∏µ‡∏Å‡∏î‡πâ‡∏ß‡∏¢ ‡πÅ‡∏•‡∏∞‡∏¢‡∏±‡∏á‡∏°‡∏µ aphthous or linear ulcers ‡∏≠‡∏µ‡∏Å\n\t- UC ‡∏à‡∏∞‡∏Ñ‡πà‡∏≠‡∏ô‡∏Ç‡πâ‡∏≤‡∏á‡∏ä‡∏±‡∏î‡πÄ‡∏à‡∏ô (and common) ‡∏ß‡πà‡∏≤‡πÄ‡∏õ‡πá‡∏ô‡∏ó‡∏µ‡πà rectum ‡πÅ‡∏•‡∏∞‡∏Å‡∏≤‡∏£‡∏Å‡∏£‡∏∞‡∏à‡∏≤‡∏¢‡∏à‡∏∞‡πÄ‡∏õ‡πá‡∏ô‡πÅ‡∏ö‡∏ö continuous\n- Epidemiology\n\t- ‡∏û‡∏ö‡πÄ‡∏¢‡∏≠‡πÉ‡∏ô‡∏ï‡∏∞‡∏ß‡∏±‡∏ô‡∏ï‡∏Å\n\t- UC ‡∏û‡∏ö‡πÑ‡∏î‡πâ‡∏ö‡πà‡∏≠‡∏¢‡∏Å‡∏ß‡πà‡∏≤ CD ‡πÅ‡∏ï‡πà‡∏ï‡πà‡∏≤‡∏á‡∏Å‡∏±‡∏ô‡∏ô‡∏¥‡∏î‡πÄ‡∏î‡∏µ‡∏¢‡∏ß\n- Pathophysiology (‡∏´‡∏•‡∏≤‡∏Å‡∏´‡∏•‡∏≤‡∏¢, in short;)\n\t- microbiome ‡πÄ‡∏™‡∏µ‡∏¢‡∏™‡∏°‡∏î‡∏∏‡∏•\n\t- ‡∏Å‡∏≤‡∏£‡∏£‡∏±‡∏ö‡∏õ‡∏£‡∏∞‡∏ó‡∏≤‡∏ô‡∏≠‡∏≤‡∏´‡∏≤‡∏£ FODMAPs\n\t- Psychological Stress\n\t- TNF-a ‡∏ó‡∏µ‡πà‡∏™‡∏π‡∏á ‡∏ó‡∏≥‡πÉ‡∏´‡πâ th1 th2 dysfunction\n- Severity\n\t- Mild \n\t\t- ‡∏ñ‡πà‡∏≤‡∏¢‡∏ô‡πâ‡∏≠‡∏¢‡∏Å‡∏ß‡πà‡∏≤‡∏ß‡∏±‡∏ô‡∏•‡∏∞ 4 ‡∏Ñ‡∏£‡∏±‡πâ‡∏á\n\t\t- ESR ‡∏õ‡∏Å‡∏ï‡∏¥ (\u003c 30 mm/h)\n\t- Moderate\n\t\t- ‡∏ñ‡πà‡∏≤‡∏¢‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤‡∏ß‡∏±‡∏ô‡∏•‡∏∞ 4 ‡∏Ñ‡∏£‡∏±‡πâ‡∏á\n\t\t- systemic ‡πÄ‡∏•‡πá‡∏Å‡∏ô‡πâ‡∏≠‡∏¢\n\t- Severe\n\t\t- ‡∏ñ‡πà‡∏≤‡∏¢‡πÄ‡∏õ‡πá‡∏ô‡πÄ‡∏•‡∏∑‡∏≠‡∏î ‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤ 6 ‡∏Ñ‡∏£‡∏±‡πâ‡∏á\n\t\t- ‡∏°‡∏µ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡πÄ‡∏ä‡∏¥‡∏á‡∏£‡∏∞‡∏ö‡∏ö\n\t- Fulminant\n\t\t- ‡∏ñ‡πà‡∏≤‡∏¢‡πÄ‡∏õ‡πá‡∏ô‡πÄ‡∏•‡∏∑‡∏≠‡∏î ‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤ 10 ‡∏Ñ‡∏£‡∏±‡πâ‡∏á\n\t\t- ‡∏Å‡∏î‡πÄ‡∏à‡πá‡∏ö\n\t\t- S\u0026S of toxic megacolon\n- Extraintestinal manifestations ‡πÄ‡∏î‡πà‡∏ô‡πÉ‡∏ô CD ‡πÄ‡∏ä‡πà‡∏ô Uveitis, Scleritis, Episcleritis ‡∏õ‡∏ß‡∏î‡∏Ç‡πâ‡∏≠ ‡∏õ‡∏ß‡∏î‡πÄ‡∏Ç‡πà‡∏≤‡∏Å‡πá‡∏û‡∏ö‡πÑ‡∏î‡πâ‡πÄ‡∏ä‡πà‡∏ô‡∏Å‡∏±‡∏ô\n- Goal of Therapy:\n\t- ‡∏•‡∏î‡∏Ñ‡∏ß‡∏≤‡∏°‡∏£‡∏∏‡∏ô‡πÅ‡∏£‡∏á\n\t- ‡∏õ‡πâ‡∏≠‡∏á‡∏Å‡∏±‡∏ô‡∏Å‡∏≤‡∏£‡πÄ‡∏Å‡∏¥‡∏î‡∏†‡∏≤‡∏ß‡∏∞‡∏∞‡πÅ‡∏ó‡∏£‡∏Å‡∏ã‡πâ‡∏≠‡∏ô\n\t- ‡∏•‡∏î‡∏Ñ‡∏ß‡∏≤‡∏°‡∏ñ‡∏µ‡πà‡πÉ‡∏ô‡∏Å‡∏≤‡∏£‡∏Å‡∏≥‡πÄ‡∏£‡∏¥‡∏ö\n- ‡∏Å‡∏≤‡∏£‡∏£‡∏±‡∏Å‡∏©‡∏≤‡πÇ‡∏î‡∏¢‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ‡∏¢‡∏≤\n\t- **Salicylate derivatives** ‡πÉ‡∏ä‡πâ‡πÑ‡∏î‡πâ‡∏ó‡∏±‡πâ‡∏á induction and maintenance\n\t\t- ‡∏ï‡∏±‡∏ß active ‡∏Ñ‡∏∑‡∏≠ 5-aminosalicylic acid (mesalamine) ‡∏°‡∏µ‡∏ú‡∏•‡∏Ç‡πâ‡∏≤‡∏á‡πÄ‡∏Ñ‡∏µ‡∏¢‡∏á‡∏™‡∏≥‡∏Ñ‡∏±‡∏ç‡πÑ‡∏î‡πâ‡πÅ‡∏Å‡πà ‡∏Ñ‡∏•‡∏∑‡πà‡∏ô‡πÑ‡∏™‡πâ ‡∏≠‡∏≤‡πÄ‡∏à‡∏µ‡∏¢‡∏ô ‡∏õ‡∏ß‡∏î‡∏®‡∏£‡∏µ‡∏©‡∏∞ ‡πÄ‡∏ö‡∏∑‡πà‡∏≠‡∏≠‡∏≤‡∏´‡∏≤‡∏£\n\t\t- Sulfasalazine (sulfapyridine + 5-ASA)\n\t\t\t- ‡∏£‡∏∞‡∏ß‡∏±‡∏á‡∏ú‡∏°‡∏£‡πà‡∏ß‡∏á ‡∏ú‡∏∑‡πà‡∏ô‡πÅ‡∏û‡πâ ‡∏£‡∏ß‡∏°‡∏ñ‡∏∂‡∏á ‡∏™‡∏≤‡∏£‡∏Ñ‡∏±‡∏î‡∏´‡∏•‡∏±‡πà‡∏á‡πÄ‡∏õ‡∏•‡∏µ‡πà‡∏¢‡∏ô‡∏™‡∏µ‡∏™‡πâ‡∏° (‡∏ô‡πâ‡∏≥‡∏ï‡∏≤ ‡πÄ‡∏´‡∏á‡∏∑‡πà‡∏≠ ‡∏õ‡∏±‡∏™‡∏™‡∏≤‡∏ß‡∏∞)\n\t\t\t- ‡∏£‡∏∞‡∏ß‡∏±‡∏á anemia thrombocytopenia\n\t\t\t- ‡∏£‡∏∞‡∏ß‡∏±‡∏á‡πÉ‡∏ô‡∏Ñ‡∏ô‡πÅ‡∏û‡πâ sulfa\n\t\t\t- sulfapyridine ‡πÄ‡∏õ‡πá‡∏ô antibiotics ‡πÅ‡∏ï‡πà‡πÄ‡∏£‡∏≤‡∏ô‡∏≥‡∏°‡∏≤‡∏ú‡∏™‡∏°‡πÄ‡∏û‡∏∑‡πà‡∏≠‡πÉ‡∏ä‡πâ‡πÄ‡∏õ‡πá‡∏ô carriers ‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤ ‡πÄ‡∏ô‡∏∑‡πà‡∏≠‡∏á‡∏à‡∏≤‡∏Å‡∏ï‡∏±‡∏ß 5-ASA ‡∏î‡∏π‡∏î‡∏ã‡∏∂‡∏°‡πÑ‡∏î‡πâ‡∏Ñ‡πà‡∏≠‡∏ô‡∏Ç‡πâ‡∏≤‡∏á‡∏ô‡πâ‡∏≠‡∏¢\n\t\t- ‡∏õ‡∏±‡∏à‡∏à‡∏∏‡∏ö‡∏±‡∏ô‡πÄ‡∏£‡∏≤‡∏°‡∏µ mesalamine ‡πÄ‡∏î‡∏µ‡πà‡∏¢‡∏ß ‡∏ó‡∏±‡πâ‡∏á‡πÉ‡∏ô‡∏£‡∏π‡∏õ‡∏Ç‡∏≠‡∏á suppository, enema, oral\n\t- Corticosteroids ‡∏°‡∏±‡∏Å‡∏à‡∏∞‡πÉ‡∏ä‡πâ‡∏£‡πà‡∏ß‡∏°‡∏Å‡∏±‡∏ö‡∏¢‡∏≤‡∏ï‡∏±‡∏ß‡∏≠‡∏∑‡πà‡∏ô‡∏î‡πâ‡∏ß‡∏¢‡πÄ‡∏™‡∏°‡∏≠\n\t\t- Prednisolone ‡πÉ‡∏ä‡πâ‡πÑ‡∏î‡πâ‡πÅ‡∏Ñ‡πà‡πÉ‡∏ô severe ‡∏õ‡∏Å‡∏ï‡∏¥‡∏à‡∏∞‡πÉ‡∏ä‡πâ‡∏õ‡∏£‡∏∞‡∏°‡∏≤‡∏ì 40-60 mg/d ‡∏õ‡∏£‡∏∞‡∏°‡∏≤‡∏ì 2-3 ‡∏ß‡∏µ‡∏Ñ\n\t\t- Budesonide ‡πÉ‡∏ä‡πâ‡πÑ‡∏î‡πâ‡∏ó‡∏±‡πâ‡∏á mild-mod-severe\n\t- Thiopurine (Azathioprine; pro-drug)\n\t\t- ‡∏ï‡πâ‡∏≠‡∏á‡∏ó‡∏î‡∏™‡∏≠‡∏ö TPMT\n\t- Anti-TNF\n\t\t- ‡∏´‡πâ‡∏≤‡∏°‡πÉ‡∏ä‡πâ‡πÉ‡∏ô toxic megacolon ‡πÅ‡∏•‡∏∞‡∏ï‡πâ‡∏≠‡∏á‡πÄ‡∏ä‡πá‡∏Ñ lab TPS, hepatitis\n\t- Anti-integrin, IL-12, IL-23 inhibitor, JAK inhibitor, Calcineurin inhibitor ‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡πÄ‡∏Ñ‡∏™‡∏ó‡∏µ‡πà‡πÑ‡∏°‡πà‡∏ï‡∏≠‡∏ö‡∏™‡∏ô‡∏≠‡∏á‡∏ï‡πà‡∏≠ steroid ‡πÅ‡∏•‡∏∞‡∏à‡∏∞‡πÉ‡∏ä‡πâ‡πÅ‡∏Ñ‡πà induction ‡πÄ‡∏û‡∏£‡∏≤‡∏∞ S/E ‡∏Ñ‡πà‡∏≠‡∏ô‡∏Ç‡πâ‡∏≤‡∏á‡πÄ‡∏¢‡∏≠‡∏∞‡∏°‡∏≤‡∏Å ‡πÜ\n- ‡πÅ‡∏ô‡∏ß‡∏ó‡∏≤‡∏á‡∏Å‡∏≤‡∏£‡∏£‡∏±‡∏Å‡∏©‡∏≤\n\t- ‡∏à‡∏∏‡∏î‡∏™‡∏±‡∏á‡πÄ‡∏Å‡∏ï: ‡πÉ‡∏ô fulminant ‡∏à‡∏∞‡πÑ‡∏õ‡πÉ‡∏ä‡πâ‡∏û‡∏ß‡∏Å methyprednisolone / hydrocortisone ‡∏Å‡πà‡∏≠‡∏ô ‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏¢‡∏Ñ‡πà‡∏≠‡∏¢‡∏•‡∏î‡πÄ‡∏õ‡πá‡∏ô prednisolone\n\t- ‡πÉ‡∏ô Cohn Disease ‡∏ñ‡πâ‡∏≤ Severe or Mod ‡∏≠‡∏≤‡∏à‡πÉ‡∏ä‡πâ Prednisolone ‡∏£‡πà‡∏ß‡∏°‡∏Å‡∏±‡∏ö TNF-a inhibitor ‡∏´‡∏£‡∏∑‡∏≠ immunosupressive ‡πÑ‡∏õ‡πÄ‡∏•‡∏¢\n\t- ![[Pasted image 20230305193915.png]]\n\t- ![[Pasted image 20230305193929.png]]\n- ‡∏õ‡∏±‡∏ç‡∏´‡∏≤‡πÇ‡∏†‡∏ä‡∏ô‡∏≤‡∏Å‡∏≤‡∏£‡πÉ‡∏ô‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ IBD\n\t- ‡πÄ‡∏ô‡∏∑‡πà‡∏≠‡∏á‡∏à‡∏≤‡∏Å‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏°‡∏µ IL-6 ‡πÅ‡∏•‡∏∞ TNF-a ‡∏ó‡∏µ‡πà‡∏™‡∏π‡∏á‡∏´‡∏£‡∏∑‡∏≠‡πÄ‡∏¢‡∏≠‡∏∞‡∏ú‡∏¥‡∏î‡∏õ‡∏Å‡∏ï‡∏¥ ‡∏à‡∏∂‡∏á‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡πÄ‡∏Å‡∏¥‡∏î‡∏Å‡∏≤‡∏£‡∏™‡∏π‡∏ç‡πÄ‡∏™‡∏µ‡∏¢‡πÇ‡∏õ‡∏£‡∏ï‡∏µ‡∏ô ‡πÅ‡∏•‡∏∞ muscle wasting ‡πÑ‡∏î‡πâ\n\t- ‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏Å‡∏¥‡∏ô‡πÑ‡∏£‡πÑ‡∏°‡πà‡∏Ñ‡πà‡∏≠‡∏¢‡πÑ‡∏î‡πâ ‡∏à‡∏∂‡∏á‡∏õ‡∏ß‡∏î‡∏ó‡πâ‡∏≠‡∏á ‡∏≠‡∏µ‡∏Å‡∏ó‡∏±‡πâ‡∏á‡∏î‡∏π‡∏î‡∏ã‡∏∂‡∏°‡∏™‡∏≤‡∏£‡∏≠‡∏≤‡∏´‡∏≤‡∏£‡πÑ‡∏î‡πâ‡∏ô‡πâ‡∏≠‡∏¢‡∏≠‡∏µ‡∏Å‡∏î‡πâ‡∏ß‡∏¢ ‡∏°‡∏µ‡πÄ‡∏ö‡∏∑‡πà‡∏≠‡∏≠‡∏≤‡∏´‡∏≤‡∏£‡∏£‡πà‡∏ß‡∏°‡∏î‡πâ‡∏ß‡∏¢\n- ‡∏Å‡∏≤‡∏£‡∏£‡∏±‡∏Å‡∏©‡∏≤‡πÇ‡∏î‡∏¢‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πâ‡∏¢‡∏≤\n\t- ‡∏Å‡∏≤‡∏£‡∏ú‡πà‡∏≤‡∏ï‡∏±‡∏î ‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡∏Ñ‡∏ô‡∏ó‡∏µ‡πà‡πÑ‡∏°‡πà‡∏ï‡∏≠‡∏ö‡∏™‡∏ô‡∏≠‡∏á\n\t- ‡∏Å‡∏≤‡∏£‡∏î‡∏π‡πÅ‡∏•‡∏î‡πâ‡∏≤‡∏ô‡πÇ‡∏†‡∏ä‡∏ô‡∏≤‡∏Å‡∏≤‡∏£, FODMAP / probiotics ‡∏ï‡πà‡∏≤‡∏á ‡πÜ \n\t\t- FODMAPs = Fermentable oligo,di and monosacharides and polyols \n\t- ‡∏™‡∏£‡πâ‡∏≤‡∏á‡πÄ‡∏™‡∏£‡∏¥‡∏°‡∏™‡∏°‡∏î‡∏∏‡∏• gut microbiota ‡πÅ‡∏•‡∏∞‡πÄ‡∏û‡∏¥‡πà‡∏° short chain fatty acid ‡πÇ‡∏î‡∏¢ probiotics ‡πÅ‡∏•‡∏∞ soluble fiber\n\t- ‡πÅ‡∏û‡∏ó‡∏¢‡πå‡∏ó‡∏≤‡∏á‡πÄ‡∏•‡∏∑‡∏≠‡∏Å ‡πÅ‡∏•‡∏∞‡∏Å‡∏≤‡∏£‡πÉ‡∏´‡πâ‡∏Ñ‡∏ß‡∏≤‡∏°‡∏£‡∏π‡πâ\n\t- ‡πÄ‡∏•‡∏µ‡πà‡∏¢‡∏á‡∏≠‡∏≤‡∏´‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏£‡∏∞‡∏ö‡∏∏‡πÑ‡∏î‡πâ‡∏ä‡∏±‡∏î‡πÄ‡∏à‡∏ô‡πÅ‡∏•‡πâ‡∏ß‡∏ß‡πà‡∏≤‡∏Å‡∏£‡∏∞‡∏ï‡∏∏‡πâ‡∏ô‡∏ï‡∏±‡∏ß‡πÇ‡∏£‡∏Ñ ‡πÅ‡∏ï‡πà‡∏Å‡πá‡∏£‡∏∞‡∏ß‡∏±‡∏á malnutrition ‡∏î‡∏±‡∏á‡∏ô‡∏±‡πâ‡∏ô‡πÄ‡∏•‡∏µ‡πà‡∏¢‡∏á‡πÅ‡∏Ñ‡πà‡∏ó‡∏µ‡πà‡∏°‡∏±‡πà‡∏ô‡πÉ‡∏à‡πÄ‡∏ó‡πà‡∏≤‡∏ô‡∏±‡πâ‡∏ô\n\t\t- ‡πÄ‡∏ä‡πà‡∏ô FODMAPs, sulfur/sulfate, ‡πÄ‡∏Ñ‡∏£‡∏∑‡πà‡∏≠‡∏á‡∏î‡∏∑‡πà‡∏° alcohol, ‡∏ô‡∏° (lactose), ‡πÄ‡∏ô‡∏∑‡πâ‡∏≠‡πÅ‡∏î‡∏á","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/OA":{"title":"OA","content":"### Definitions\n- ‡πÄ‡∏õ‡πá‡∏ô‡πÇ‡∏£‡∏Ñ progressive ‡∏ó‡∏µ‡πà‡∏Ç‡πâ‡∏≠‡πÄ‡∏™‡∏∑‡πà‡∏≠‡∏°‡∏•‡∏á‡∏≠‡∏¢‡πà‡∏≤‡∏á‡∏ï‡πà‡∏≠‡πÄ‡∏ô‡∏∑‡πà‡∏≠‡∏á\n- ‡∏û‡∏ö‡πÄ‡∏à‡∏≠‡πÑ‡∏î‡πâ‡∏ó‡∏µ‡πà‡πÄ‡∏Ç‡πà‡∏≤ ‡πÅ‡∏ï‡πà‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏à‡∏≥‡πÄ‡∏õ‡πá‡∏ô‡∏ï‡πâ‡∏≠‡∏á‡πÄ‡∏õ‡πá‡∏ô‡∏ó‡∏µ‡πà‡πÄ‡∏Ç‡πà‡∏≤\n- ‡∏°‡∏µ‡∏Å‡∏≤‡∏£‡∏ó‡∏≥‡∏•‡∏≤‡∏¢‡∏Å‡∏£‡∏∞‡∏î‡∏π‡∏Å‡∏≠‡πà‡∏≠‡∏ô‡∏ú‡∏¥‡∏ß‡∏Ç‡πâ‡∏≠ ‡∏°‡∏µ‡∏Ç‡∏≠‡∏ö‡∏Å‡∏£‡∏∞‡∏î‡∏π‡∏Å‡πÉ‡∏ô‡∏Ç‡πâ‡∏≠‡∏´‡∏ô‡∏≤‡∏ï‡∏±‡∏ß‡∏Ç‡∏∂‡πâ‡∏ô ‡∏ô‡πâ‡∏≥‡πÉ‡∏ô‡∏Ç‡πâ‡∏≠‡πÄ‡∏õ‡∏•‡∏µ‡πà‡∏¢‡∏ô‡∏ô‡∏¥‡∏î‡∏´‡∏ô‡πà‡∏≠‡∏¢‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏´‡∏•‡πà‡∏≠‡∏•‡∏∑‡πà‡∏ô‡πÑ‡∏î‡πâ‡∏ô‡πâ‡∏≠‡∏¢‡∏•‡∏á\n\n### Epidemiology\n- top 10 ‡∏Ç‡∏≠‡∏á‡πÇ‡∏£‡∏Ñ‡∏ó‡∏µ‡πà‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡πÄ‡∏Å‡∏¥‡∏î‡∏Å‡∏≤‡∏£‡∏û‡∏¥‡∏Å‡∏≤‡∏£‡πÉ‡∏ô‡πÑ‡∏ó‡∏¢\n- 55 ‡∏õ‡∏µ‡πÄ‡∏£‡∏¥‡πà‡∏°‡∏°‡∏µ‡∏Ñ‡∏ß‡∏≤‡∏°‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á‡πÅ‡∏•‡πâ‡∏ß ‡πÅ‡∏ï‡πà‡∏≠‡∏à.‡πÉ‡∏ä‡πâ‡∏ï‡∏±‡∏ß‡πÄ‡∏•‡∏Ç **45**\n\n\n### Pathophysiology\n- cartilage ‡∏õ‡∏£‡∏∞‡∏Å‡∏≠‡∏ö‡πÑ‡∏õ‡∏î‡πâ‡∏ß‡∏¢ hyaluronic acid (2-4 mg/ml), collagen, proteoglycan, chondroitin ‡πÅ‡∏•‡∏∞‡∏°‡∏µ synovial fluid ‡∏ä‡πà‡∏ß‡∏¢‡∏´‡∏•‡πà‡∏≠‡∏•‡∏∑‡πà‡∏ô ‡∏´‡∏≤‡∏Å‡∏™‡∏¥‡πà‡∏á‡πÉ‡∏î‡∏™‡∏¥‡πà‡∏á‡∏´‡∏ô‡∏∂‡πà‡∏á‡πÄ‡∏™‡∏∑‡πà‡∏≠‡∏°‡∏™‡∏†‡∏≤‡∏û‡∏Å‡πá‡∏à‡∏∞‡πÄ‡∏Å‡∏¥‡∏î‡∏õ‡∏±‡∏ç‡∏´‡∏≤‡∏ï‡∏≤‡∏°‡∏°‡∏≤‡πÑ‡∏î‡πâ\n![[Pasted image 20230307174334.png|600]] ^d2442e\n\n### Risk factors\n- ‡∏≠‡∏≤‡∏¢‡∏∏ -\u003e ‡∏≠‡∏≤‡∏¢‡∏∏‡∏°‡∏≤‡∏Å‡∏Ç‡∏∂‡πâ‡∏ô‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏à‡∏≥‡∏ô‡∏ß‡∏ô chondrocyte ‡∏•‡∏î‡∏•‡∏á ‡∏Ñ‡∏ß‡∏≤‡∏°‡∏™‡∏≤‡∏°‡∏≤‡∏£‡∏ñ‡πÉ‡∏ô‡∏Å‡∏≤‡∏£‡∏ã‡πà‡∏≠‡∏°‡πÅ‡∏ã‡∏°‡∏Ç‡∏≠‡∏á‡∏£‡πà‡∏≤‡∏á‡∏Å‡∏≤‡∏¢‡∏à‡∏∂‡∏á‡∏•‡∏î‡∏•‡∏á\n- ‡∏Ñ‡∏ß‡∏≤‡∏°‡∏≠‡πâ‡∏ß‡∏ô -\u003e ‡πÄ‡∏û‡∏¥‡πà‡∏°‡∏Ñ‡∏ß‡∏≤‡∏°‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á‡∏ï‡πà‡∏≠‡∏Å‡∏≤‡∏£‡πÄ‡∏Å‡∏¥‡∏î ‡πÇ‡∏î‡∏¢‡πÄ‡∏â‡∏û‡∏≤‡∏∞‡∏Ç‡πâ‡∏≠‡∏ó‡∏µ‡πà‡∏£‡∏±‡∏ö‡∏ô‡πâ‡∏≥‡∏´‡∏ô‡∏±‡∏Å\n- ‡∏≠‡∏≤‡∏´‡∏≤‡∏£ -\u003e ‡∏û‡∏ö‡∏Å‡∏≤‡∏£‡∏Ç‡∏≤‡∏î‡∏ß‡∏¥‡∏ï‡∏≤‡∏°‡∏¥‡∏ô‡∏î‡∏µ ‡πÉ‡∏ô‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ OA\n- ‡∏Å‡∏≤‡∏£‡πÑ‡∏î‡πâ‡∏£‡∏±‡∏ö‡∏ö‡∏≤‡∏î‡πÄ‡∏à‡πá‡∏ö -\u003e ‡∏´‡∏≤‡∏Å‡πÄ‡∏Ñ‡∏¢‡∏õ‡∏£‡∏∞‡∏™‡∏ö‡∏≠‡∏∏‡∏ö‡∏±‡∏ï‡∏¥‡πÄ‡∏´‡∏ï‡∏∏ ‡∏à‡∏∞‡∏°‡∏µ‡πÇ‡∏≠‡∏Å‡∏≤‡∏™‡πÄ‡∏Å‡∏¥‡∏î OA ‡∏™‡∏π‡∏á\n- ‡∏≠‡∏≤‡∏ä‡∏µ‡∏û\n- ‡∏Ñ‡∏ß‡∏≤‡∏°‡∏ú‡∏¥‡∏î‡∏õ‡∏Å‡∏ï‡∏¥‡∏ó‡∏≤‡∏á‡∏Å‡∏≤‡∏¢‡∏ß‡∏¥‡∏†‡∏≤‡∏Ñ -\u003e ‡∏£‡∏ß‡∏°‡∏ñ‡∏∂‡∏á‡∏û‡∏±‡∏ô‡∏ò‡∏∏‡∏Å‡∏£‡∏£‡∏°\n- ‡πÇ‡∏£‡∏Ñ‡∏£‡πà‡∏ß‡∏°‡∏≠‡∏∑‡πà‡∏ô ‡πÜ -\u003e ‡∏†‡∏≤‡∏ß‡∏∞‡πÄ‡∏Å‡∏¥‡∏î‡∏Å‡∏≤‡∏£‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö ‡πÄ‡∏ä‡πà‡∏ô RA\n\n### Staging\n- early oa ‡∏õ‡∏ß‡∏î‡∏ô‡πà‡∏≤‡∏£‡∏≥‡∏Ñ‡∏≤‡∏ç ‡πÅ‡∏•‡∏∞‡∏°‡∏±‡∏Å‡∏à‡∏∞‡∏õ‡∏ß‡∏î‡∏´‡∏•‡∏±‡∏á‡πÉ‡∏ä‡πâ‡∏Ç‡πâ‡∏≠‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤‡∏õ‡∏Å‡∏ï‡∏¥ ‡∏õ‡∏ß‡∏î‡πÅ‡∏ö‡∏ö sharp pain ‡πÅ‡∏•‡∏∞‡∏î‡∏µ‡∏Ç‡∏∂‡πâ‡∏ô‡πÄ‡∏°‡∏∑‡πà‡∏≠‡πÑ‡∏î‡πâ‡∏û‡∏±‡∏Å\n- mild oa ‡∏õ‡∏ß‡∏î‡∏ï‡πà‡∏≠‡πÄ‡∏ô‡∏∑‡πà‡∏≠‡∏á‡∏ï‡∏•‡∏≠‡∏î‡πÄ‡∏ß‡∏•‡∏≤ ‡∏Å‡∏£‡∏∞‡∏ó‡∏ö‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ‡∏ä‡∏µ‡∏ß‡∏¥‡∏ï‡∏õ‡∏£‡∏∞‡∏à‡∏≥‡∏ß‡∏±‡∏ô ‡∏≠‡∏≤‡∏à‡πÄ‡∏™‡∏µ‡∏¢‡∏ß‡πÉ‡∏ô‡∏Ç‡πâ‡∏≠‡∏´‡∏£‡∏∑‡∏≠‡πÄ‡∏°‡∏∑‡πà‡∏≠‡∏£‡∏≠‡∏ö‡∏Ç‡πâ‡∏≠‡∏°‡∏∑‡∏≠ ‡πÄ‡∏£‡∏¥‡πà‡∏°‡πÄ‡∏Å‡∏¥‡∏î morning stiffness ‡πÅ‡∏ï‡πà‡πÑ‡∏°‡πà‡πÄ‡∏Å‡∏¥‡∏ô 30 ‡∏ô‡∏≤‡∏ó‡∏µ ‡πÅ‡∏•‡∏∞‡∏Ç‡∏¢‡∏±‡∏ö‡∏Ç‡πâ‡∏≠ 2-3 ‡∏ó‡∏µ‡∏Å‡πá‡∏à‡∏∞‡∏´‡∏≤‡∏¢\n- advanced oa ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏õ‡∏ß‡∏î‡∏ï‡∏∑‡πâ‡∏≠ ‡πÜ ‡∏ï‡∏•‡∏≠‡∏î‡πÄ‡∏ß‡∏•‡∏≤ ‡∏Å‡∏≥‡πÄ‡∏£‡∏¥‡∏ö‡∏ñ‡∏µ‡πà ‡∏Ø‡∏•‡∏Ø\n\n### Clinical Features\n- ‡∏û‡∏ö‡∏ö‡πà‡∏≠‡∏¢‡∏ó‡∏µ‡πà ‡∏Ç‡πâ‡∏≠‡πÄ‡∏Ç‡πà‡∏≤ \u003e ‡∏Ç‡πâ‡∏≠‡∏™‡∏∞‡πÇ‡∏û‡∏Å = ‡∏Ç‡πâ‡∏≠‡∏°‡∏∑‡∏≠\n\t- ‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å‡∏Ç‡πâ‡∏≠‡∏°‡∏¥‡∏≠ ‡∏°‡∏±‡∏ô‡∏à‡∏∞‡πÄ‡∏õ‡πá‡∏ô‡∏ö‡∏£‡∏¥‡πÄ‡∏ß‡∏ì‡∏Ç‡πâ‡∏≠‡∏õ‡∏•‡∏≤‡∏¢ ‡πÜ\n- deformity\n- disability\n- limited range of motion\n- psychological factors\n- muscle weakness -\u003e  ‡∏≠‡∏≤‡∏à‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏°‡∏≤‡∏à‡∏≤‡∏Å‡∏î‡πâ‡∏≤‡∏ô psychi ‡πÅ‡∏ï‡πà**‡πÄ‡∏Å‡∏¥‡∏î‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏Ç‡πâ‡∏≠‡∏°‡∏µ‡∏õ‡∏±‡∏ç‡∏´‡∏≤ ‡∏Å‡∏•‡πâ‡∏≤‡∏°‡πÄ‡∏ô‡∏∑‡πâ‡∏≠‡∏à‡∏∂‡∏á‡∏ó‡∏≥‡∏á‡∏≤‡∏ô‡∏´‡∏ô‡∏±‡∏Å‡∏Ç‡∏∂‡πâ‡∏ô**\n\n\n### Diagnostic Testing\n- **‡∏î‡∏π‡∏≠‡∏≤‡∏Å‡∏≤‡∏£ ‡πÅ‡∏•‡∏∞‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡πÅ‡∏™‡∏î‡∏á** ‡∏£‡∏ß‡∏°‡∏Å‡∏±‡∏ö‡∏õ‡∏±‡∏à‡∏à‡∏±‡∏¢‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á\n- SF analysis ‡∏´‡∏£‡∏∑‡∏≠ serology ‡∏à‡∏∞‡∏ó‡∏≥‡πÄ‡∏û‡∏∑‡πà‡∏≠ R/O ‡πÇ‡∏£‡∏Ñ‡∏≠‡∏∑‡πà‡∏ô ‡πÜ\n\t- ESR, CBC, RF, ANA, Serium Calcium, ALP, Phosphorus ‡∏à‡∏∞‡∏õ‡∏Å‡∏ï‡∏¥‡∏ó‡∏±‡πâ‡∏á‡∏´‡∏°‡∏î ‡πÅ‡∏•‡∏∞‡πÑ‡∏°‡πà‡∏à‡∏≥‡πÄ‡∏õ‡πá‡∏ô‡∏ï‡πâ‡∏≠‡∏á‡πÄ‡∏à‡∏≤‡∏∞ ‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡∏Å‡∏≤‡∏£ differential\n- X-Ray ‡πÑ‡∏°‡πà‡∏à‡∏≥‡πÄ‡∏õ‡πá‡∏ô‡∏ï‡πâ‡∏≠‡∏á‡∏ó‡∏≥ **‡πÉ‡∏ä‡πâ‡πÅ‡∏Ñ‡πà‡πÉ‡∏ô‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô‡∏Å‡∏≤‡∏£‡∏î‡∏≥‡πÄ‡∏ô‡∏¥‡∏ô‡πÑ‡∏õ‡∏Ç‡∏≠‡∏á‡πÇ‡∏£‡∏Ñ ‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô‡∏Ñ‡∏ß‡∏≤‡∏°‡∏£‡∏∏‡∏ô‡πÅ‡∏£‡∏á‡∏Ç‡∏≠‡∏á‡πÇ‡∏£‡∏Ñ ‡πÅ‡∏•‡∏∞‡∏™‡∏ô‡∏±‡∏ö‡∏™‡∏ô‡∏∏‡∏ô‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏ó‡∏≤‡∏á‡∏Ñ‡∏•‡∏¥‡∏ô‡∏¥‡∏Å** / CT or MRI ‡πÑ‡∏°‡πà‡∏à‡∏≥‡πÄ‡∏õ‡πá‡∏ô ‡∏¢‡∏Å‡πÄ‡∏ß‡πâ‡∏ô‡∏à‡∏∞‡∏ï‡πâ‡∏≠‡∏á‡∏ú‡πà‡∏≤‡∏ï‡∏±‡∏î‡∏≠‡∏¢‡∏π‡πà‡πÅ‡∏•‡πâ‡∏ß\n\t- ![[Pasted image 20230307174940.png]]\n- ‡πÄ‡∏£‡∏≤‡∏™‡∏≤‡∏°‡∏≤‡∏£‡∏ñ‡∏î‡∏π‡∏•‡∏±‡∏Å‡∏©‡∏ì‡∏∞‡∏ó‡πà‡∏≤‡πÄ‡∏î‡∏¥‡∏ô ‡∏ó‡πà‡∏≤‡∏Ç‡∏¢‡∏±‡∏ö‡∏Ç‡πâ‡∏≠‡∏ï‡πà‡∏≤‡∏á ‡πÜ ‡∏Ç‡∏≠‡∏á‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡πÑ‡∏î‡πâ ‡πÄ‡∏û‡∏∑‡πà‡∏≠‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô‡∏ß‡πà‡∏≤‡∏°‡∏±‡∏ô‡πÄ‡∏õ‡πá‡∏ô‡∏Ç‡πâ‡∏≠‡πÑ‡∏´‡∏ô\n- ‡∏≠‡∏¢‡πà‡∏≤‡∏•‡∏∑‡∏°‡∏ï‡∏£‡∏ß‡∏à‡∏Ñ‡πà‡∏≤‡πÅ‡∏•‡∏õ‡∏ï‡πà‡∏≤‡∏á ‡πÜ ‡πÄ‡∏õ‡πá‡∏ô baseline ‡∏Å‡πà‡∏≠‡∏ô‡πÄ‡∏£‡∏¥‡πà‡∏°‡∏Å‡∏≤‡∏£‡∏£‡∏±‡∏Å‡∏©‡∏≤‡∏î‡πâ‡∏ß‡∏¢‡∏¢‡∏≤\n- ‡∏à‡∏∞‡∏°‡∏µ‡πÄ‡∏Å‡∏ì‡∏ë‡πå‡πÉ‡∏ô‡∏Å‡∏≤‡∏£‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô ‡∏ß‡∏¥‡∏ô‡∏¥‡∏à‡∏â‡∏±‡∏¢‡∏≠‡∏¢‡∏π‡πà ‡πÅ‡∏¢‡∏Å‡∏ï‡∏≤‡∏°‡∏≠‡∏ß‡∏±‡∏¢‡∏ß‡∏∞‡∏ó‡∏µ‡πà‡πÄ‡∏õ‡πá‡∏ô ‡πÄ‡∏ä‡πà‡∏ô Hand, Knee, Hip\n\n### Treatment\n- Holistic care, ‡∏î‡∏π‡πÉ‡∏´‡πâ‡∏Ñ‡∏£‡∏≠‡∏ö‡∏Ñ‡∏•‡∏∏‡∏° ‡∏ó‡∏±‡πâ‡∏á‡∏≠‡∏≤‡∏Å‡∏≤‡∏£ ‡∏Ñ‡∏ß‡∏≤‡∏°‡∏£‡∏∏‡∏ô‡πÅ‡∏£‡∏á ‡∏Ç‡πâ‡∏≠‡∏ó‡∏µ‡πà‡πÄ‡∏õ‡πá‡∏ô ‡∏Ñ‡∏ß‡∏≤‡∏°‡∏ú‡∏¥‡∏î‡∏õ‡∏Å‡∏ï‡∏¥‡∏Ç‡∏≠‡∏á‡∏Ç‡πâ‡∏≠ ‡∏™‡∏≤‡πÄ‡∏´‡∏ï‡∏∏ ‡∏õ‡∏±‡∏à‡∏à‡∏±‡∏¢‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á ‡πÇ‡∏£‡∏Ñ‡∏£‡πà‡∏ß‡∏° ‡∏™‡∏†‡∏≤‡∏û‡∏à‡∏¥‡∏ï‡πÉ‡∏à‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ ‡∏Ø‡∏•‡∏Ø\n\n### Pharmacological Treatment\n- Acetaminophen\n- Tramadol\n\t- ‡∏õ‡∏£‡∏±‡∏ö‡∏ï‡∏≤‡∏°‡πÑ‡∏ï\n- NSAIDs\n\t- cox1 cox2 ‡∏î‡∏π‡∏ï‡∏≤‡∏° hx ‡∏Ç‡∏≠‡∏á‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ\n\t- ‡πÇ‡∏î‡∏™‡∏à‡∏∞‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏™‡∏π‡∏á‡∏°‡∏≤‡∏Å ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏´‡∏ß‡∏±‡∏á‡∏ú‡∏• anti inflammation\n\t- ‡πÉ‡∏ä‡πâ‡∏Ç‡∏ô‡∏≤‡∏î‡∏ï‡πà‡∏≥‡∏™‡∏∏‡∏î‡∏ó‡∏µ‡πà‡πÉ‡∏ä‡πâ‡πÑ‡∏î‡πâ ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏õ‡∏ß‡∏î‡∏Ç‡∏≠‡∏á‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏°‡∏±‡∏Å‡πÄ‡∏õ‡πá‡∏ô ‡πÜ ‡∏´‡∏≤‡∏¢ ‡πÜ\n- Capsaicin\n\t- ‡∏£‡∏∞‡∏ß‡∏±‡∏á irritation, burning ‡πÅ‡∏•‡πâ‡∏ß‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏à‡∏∞‡πÑ‡∏°‡πà‡∏≠‡∏¢‡∏≤‡∏Å‡πÉ‡∏ä‡πâ‡∏¢‡∏≤ ‡∏≠‡∏¢‡πà‡∏≤‡∏•‡∏∑‡∏°‡πÄ‡∏ï‡∏∑‡∏≠‡∏ô‡πÉ‡∏´‡πâ‡∏•‡πâ‡∏≤‡∏á‡∏°‡∏∑‡∏≠\n\t- ‡πÉ‡∏ä‡πâ‡πÑ‡∏î‡πâ‡∏î‡∏µ‡πÉ‡∏ô‡∏Ç‡πâ‡∏≠ superficial joints ‡πÄ‡∏ä‡πà‡∏ô hand OA\n\t- onset 2 wks ‡∏î‡∏±‡∏á‡∏ô‡∏±‡πâ‡∏ô‡πÑ‡∏°‡πà‡πÄ‡∏´‡∏°‡∏≤‡∏∞‡∏Å‡∏±‡∏ö acute pain\n\t- ‡∏≠‡∏≠‡∏Å‡∏§‡∏ó‡∏ò‡∏¥‡πå‡πÇ‡∏î‡∏¢‡∏Å‡∏≤‡∏£ deplete substance P from sensory neurons\n\t- ‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏°‡∏±‡∏Å‡∏ó‡∏ô s/e ‡πÑ‡∏î‡πâ‡∏´‡∏•‡∏±‡∏á‡∏ú‡πà‡∏≤‡∏ô‡πÑ‡∏õ 1 week\n- Intra-articular corticosteroids\n\t- fast efficacy, peak efficacy within 1 weeks and lasting for 4 weeks in RCT or 3 months in practice\n\t- ‡∏£‡∏∞‡∏ß‡∏±‡∏á‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏ï‡∏¥‡∏î\n\t- ‡∏£‡∏∞‡∏ß‡∏±‡∏á steroid ‡∏ï‡∏Å‡∏ï‡∏∞‡∏Å‡∏≠‡∏ô -\u003e pseudogout\n\t- ‡∏£‡∏∞‡∏ß‡∏±‡∏á septic arthritis\n- SYSADOA (systemic slow acting drugs for osteoarthritis)\n\t- Intra-articular hyaluronates ([[#^d2442e|Hyaluronic acid]])\n\t\t- ‡πÄ‡∏õ‡πá‡∏ô viscosupplementation ‡πÄ‡∏û‡∏∑‡πà‡∏≠‡∏Ñ‡∏á‡∏Ñ‡∏∏‡∏ì‡∏™‡∏°‡∏±‡∏ö‡∏¥‡∏ï‡∏Ç‡∏≠‡∏á‡∏ô‡πâ‡∏≥‡πÑ‡∏Ç‡∏Ç‡πâ‡∏≠ (‡∏Ñ‡∏ß‡∏≤‡∏°‡∏´‡∏ô‡∏∑‡∏î ‡πÅ‡∏•‡∏∞‡∏Ñ‡∏ß‡∏≤‡∏°‡∏¢‡∏∑‡∏î‡∏´‡∏¢‡∏∏‡πà‡∏ô)\n\t\t- ‡∏•‡∏î‡∏Ñ‡∏ß‡∏≤‡∏°‡∏î‡∏±‡∏ô‡∏†‡∏≤‡∏¢‡πÉ‡∏ô‡∏Ç‡πâ‡∏≠ ‡πÅ‡∏•‡∏∞ inflammatory mediators\n\t\t- onset 5-13 weeks\n\t\t- ‡∏£‡∏∞‡∏ß‡∏±‡∏á pseudogout ‡∏´‡∏•‡∏±‡∏á‡∏â‡∏µ‡∏î\n\t- Glucosamine\n\t\t- amino monosaccharide ‡∏à‡∏≤‡∏Å chitin\n\t\t- ‡∏ô‡∏≥‡πÑ‡∏õ‡∏™‡∏£‡πâ‡∏≤‡∏á [[#^d2442e|proteoglycan]] ‡∏ó‡∏µ‡πà‡∏°‡∏µ‡∏ú‡∏•‡∏ï‡πà‡∏≠‡∏Å‡∏≤‡∏£‡∏™‡∏£‡πâ‡∏≤‡∏á‡∏Å‡∏£‡∏∞‡∏î‡∏π‡∏Å\n\t\t- onset 6-8 weeks\n\t\t- ‡∏¢‡∏±‡∏ö‡∏¢‡∏±‡πâ‡∏á enzyme collagenase ‡∏ã‡∏∂‡πà‡∏á‡∏™‡∏•‡∏≤‡∏¢ [[#^d2442e|collagen]]\n\t- [[#^d2442e|Chondroitin]] (‡πÄ‡∏õ‡πá‡∏ô‡∏≠‡∏±‡∏ô‡πÄ‡∏î‡∏µ‡∏¢‡∏ß‡∏µ‡∏ó‡πà‡πÄ‡∏õ‡πâ‡∏ô‡∏≠‡∏≤‡∏´‡∏≤‡∏£‡πÄ‡∏™‡∏£‡∏¥‡∏°)\n\t\t- ‡πÄ‡∏û‡∏¥‡πà‡∏°‡∏Å‡∏≤‡∏£‡∏™‡∏£‡πâ‡∏≤‡∏á hyaluronic acid\n\t\t- ‡∏•‡∏î‡∏Å‡∏≤‡∏£‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö\n\t- Diacerein\n\t\t- anti-IL-1 (‡∏Å‡∏•‡πÑ‡∏Å‡∏´‡∏•‡∏±‡∏Å)\n\t\t- ‡∏¢‡∏≤‡∏•‡∏∞‡∏•‡∏≤‡∏¢‡πÑ‡∏Ç‡∏°‡∏±‡∏ô ‡∏î‡∏π‡∏î‡∏ã‡∏∂‡∏°‡∏î‡∏µ‡πÄ‡∏ß‡∏•‡∏≤‡∏Å‡∏¥‡∏ô‡∏Å‡∏±‡∏ö‡∏≠‡∏≤‡∏´‡∏≤‡∏£\n\t\t- onset 2-4 weeks\n\t\t- ‡∏ï‡∏¥‡∏î‡∏ï‡∏≤‡∏°‡∏Ñ‡πà‡∏≤‡πÅ‡∏•‡∏õ Scr, LFTs, CBC, UA ‡∏ä‡πà‡∏ß‡∏á 3 ‡πÄ‡∏î‡∏∑‡∏≠‡∏ô‡πÅ‡∏£‡∏Å‡πÅ‡∏•‡∏∞‡∏ó‡∏∏‡∏Å 6 ‡πÄ‡∏î‡∏∑‡∏≠‡∏ô\n\t\t- ‡∏£‡∏±‡∏ö‡∏õ‡∏£‡∏∞‡∏ó‡∏≤‡∏ô 1 cap od ‡πÉ‡∏ô‡∏ä‡πà‡∏ß‡∏á 2-4 weeks ‡πÅ‡∏£‡∏Å‡πÅ‡∏•‡πâ‡∏ß‡∏Ñ‡πà‡∏≠‡∏¢‡∏õ‡∏£‡∏±‡∏ö‡πÄ‡∏û‡∏¥‡πà‡∏°‡πÄ‡∏õ‡πâ‡∏ô bid ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å**‡∏ó‡πâ‡∏≠‡∏á‡πÄ‡∏™‡∏µ‡∏¢**‡∏Å‡πâ‡∏•‡∏î‡∏¢‡∏≤\n\t\t- ‡∏´‡πâ‡∏≤‡∏°‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡∏ú‡∏π‡πâ‡∏õ‡πà‡∏ß‡∏¢‡∏ó‡∏µ‡πà‡πÅ‡∏û‡πâ anthraquinone, ‡∏™‡∏£‡∏µ‡∏°‡∏µ‡∏Ñ‡∏£‡∏£‡∏†‡πå‡πÉ‡∏´‡πâ‡∏ô‡∏°‡∏ö‡∏∏‡∏ï‡∏£, ‡∏ú‡∏π‡πâ‡∏™‡∏π‡∏á‡∏≠‡∏≤‡∏¢‡∏∏‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤ 65 ‡∏õ‡∏µ ‡∏´‡∏£‡∏∑‡∏≠‡πÄ‡∏î‡πá‡∏Å‡∏≠‡∏≤‡∏¢‡∏∏‡∏ô‡πâ‡∏≠‡∏¢‡∏Å‡∏ß‡πà‡∏≤ 15 ‡∏õ‡∏µ\n\t- Duloxetine\n\t\t- ‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏ó‡∏µ‡πà‡πÑ‡∏°‡πà response, ‡∏£‡∏∞‡∏ß‡∏±‡∏á‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ‡∏£‡πà‡∏ß‡∏°‡∏Å‡∏±‡∏ö tramadol ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏à‡∏∞‡πÄ‡∏û‡∏¥‡πà‡∏° serotonin syndrome ‡πÑ‡∏î‡πâ\n- Other topical preparation such as salicylate-containing rubefacients -\u003e **no data**\n\n### Guidelines\n\n#### ACR 2019\n![[Pasted image 20230307192954.png|600]]\n- ‡πÑ‡∏°‡πà‡πÅ‡∏ô‡∏∞‡∏ô‡∏≥ glucosamine, IL-1 antagonist\n- ‡πÉ‡∏ä‡πâ chondroitin ‡πÅ‡∏Ñ‡πà‡∏Å‡∏±‡∏ö‡∏°‡∏∑‡∏≠\n- **topical capsaicin ‡πÉ‡∏ä‡πâ‡∏Å‡∏±‡∏ö‡πÄ‡∏Ç‡πà‡∏≤ ‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πâ‡∏Å‡∏±‡∏ö‡∏°‡∏∑‡∏≠**\n- **intraarticular corticosteroid ‡πÉ‡∏ä‡πâ‡πÑ‡∏î‡πâ‡∏´‡∏°‡∏î‡πÄ‡∏•‡∏¢ ‡πÄ‡∏î‡πà‡∏ô‡πÉ‡∏ô knee,hips**\n- **intra-articular hyaluronic acid ‡∏Å‡∏±‡∏ö‡∏°‡∏∑‡∏≠**\n- topical d ‡∏≠‡∏≤‡∏à‡πÉ‡∏ä‡πâ‡πÑ‡∏î‡πâ\n- ‡∏ó‡∏∏‡∏Å‡∏£‡∏≤‡∏¢‡∏ï‡πâ‡∏≠‡∏á‡∏≠‡∏≠‡∏Å‡∏Å‡∏≥‡∏•‡∏±‡∏á‡∏Å‡∏≤‡∏¢ ‡πÅ‡∏•‡∏∞ non-pharmaco\n- ‡πÉ‡∏ä‡πâ oral nsaids ‡πÄ‡∏õ‡πá‡∏ô‡∏´‡∏•‡∏±‡∏Å‡∏ñ‡πâ‡∏≤ topical ‡∏°‡∏µ‡∏Ç‡πâ‡∏≠‡∏°‡∏π‡∏•‡πÅ‡∏ô‡πà‡∏ô ‡πÜ ‡πÅ‡∏Ñ‡πà knee ‡∏£‡∏≠‡∏á‡∏•‡∏á‡∏°‡∏≤‡∏Å‡πá‡∏°‡∏∑‡∏≠\n\n#### OARSI 2019\n- Knee\n\t- ‡πÅ‡∏ô‡∏∞‡∏ô‡∏≥ topical **nsaids** ‡πÄ‡∏õ‡πá‡∏ô‡∏´‡∏•‡∏±‡∏Å\n\t- **‡πÉ‡∏ä‡πâ intraarticular corticosteroid, intraarticular hyaluronic ‡πÑ‡∏î‡πâ (‡∏Å‡∏±‡∏ö‡πÄ‡∏Ç‡πà‡∏≤‡πÄ‡∏ó‡πà‡∏≤‡∏ô‡∏±‡πâ‡∏ô)**\n- Hip\n\t- non-selective **nsaids**, gait aids, ppi, weight mangement\n- Polyarticular (‡πÄ‡∏ä‡πà‡∏ô ‡∏°‡∏∑‡∏≠)\n\t- non-selective **nsaids**, topical nsaids gait aids, non-pharmaco ‡∏ï‡πà‡∏≤‡∏á ‡πÜ\n\n#### ‡∏¢‡∏≤‡∏â‡∏µ‡∏î‡∏¢‡∏≤‡πÉ‡∏à\n| ACR                                                    | OARSI              |\n| ------------------------------------------------------ | ------------------ |\n| IACS ‡πÉ‡∏ä‡πâ‡πÑ‡∏î‡πâ‡∏´‡∏°‡∏î‡πÄ‡∏•‡∏¢ ‡πÄ‡∏î‡πà‡∏ô knee,hips                       | IACS ‡πÉ‡∏ä‡πâ‡πÑ‡∏î‡πâ‡πÅ‡∏Ñ‡πà‡πÄ‡∏Ç‡πà‡∏≤ |\n| IAHA ‡∏≠‡∏≤‡∏à‡∏û‡∏≠‡πÉ‡∏ä‡πâ‡πÑ‡∏î‡πâ‡∏Å‡∏±‡∏ö‡∏°‡∏∑‡∏≠‡πÄ‡∏ó‡πà‡∏≤‡∏ô‡∏±‡πâ‡∏ô (‡πÅ‡∏ó‡∏ö‡πÑ‡∏°‡πà‡πÅ‡∏ô‡∏∞‡∏ô‡∏≥‡πÄ‡∏•‡∏¢‡∏î‡πâ‡∏ß‡∏¢‡∏ã‡πâ‡∏≥) |  IAHA ‡πÉ‡∏ä‡πâ‡πÑ‡∏î‡πâ‡∏Å‡∏±‡∏ö‡πÄ‡∏Ç‡πà‡∏≤                   |","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/RA":{"title":"RA","content":"### Introduction\n- ‡πÇ‡∏£‡∏Ñ‡∏Ç‡πâ‡∏≠‡∏ó‡∏µ‡πà chronic, progressive, autoimmune\n- ‡πÄ‡∏õ‡πá‡∏ô‡πÇ‡∏£‡∏Ñ‡∏ó‡∏µ‡πà symmetry ‡πÅ‡∏•‡∏∞‡∏°‡∏µ‡∏ú‡∏•‡∏ï‡πà‡∏≠ synovium ‡∏Ç‡∏≠‡∏á‡∏Ç‡πâ‡∏≠\n- ‡∏°‡∏µ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£ extra-articular involvement ‡∏´‡∏•‡∏≤‡∏Å‡∏´‡∏•‡∏≤‡∏¢ ^14dfb0\n\t- ‡∏ï‡∏≤: vasculitis\n\t- skin: rheumatoid nodule\n- 40-50% ‡∏û‡∏¥‡∏Å‡∏≤‡∏£‡πÉ‡∏ô 5 ‡∏õ‡∏µ‡∏ñ‡πâ‡∏≤‡πÑ‡∏°‡πà‡∏£‡∏±‡∏Å‡∏©‡∏≤\n\n### Risk Factors\n- 60% genetics\n\t- epigenetic modification\n\t- susceptibility genes\n- 40% non-genetic\n\n### Pathophysiology\n- ‡∏£‡∏∞‡∏¢‡∏∞‡πÅ‡∏£‡∏Å ‡πÜ (preclinical RA) ‡∏≠‡∏≤‡∏à‡πÄ‡∏Å‡∏¥‡∏î citrullination\n- ‡∏´‡∏•‡∏±‡∏á‡∏à‡∏≤‡∏Å‡∏ô‡∏±‡πâ‡∏ô‡∏°‡∏µ‡∏Å‡∏≤‡∏£‡∏™‡∏£‡πâ‡∏≤‡∏á autoantibody ‡πÅ‡∏•‡πâ‡∏ß infiltrate ‡πÄ‡∏Ç‡πâ‡∏≤‡πÑ‡∏õ‡πÉ‡∏ô‡∏ö‡∏£‡∏¥‡πÄ‡∏ß‡∏ì‡∏Ç‡πâ‡∏≠ (early RA)\n\t- autoantibodies ‡πÄ‡∏ä‡πà‡∏ô APCAs ‡πÅ‡∏•‡∏∞ RF\n- ‡∏à‡∏ô‡∏™‡∏∏‡∏î‡∏ó‡πâ‡∏≤‡∏¢ shape ‡πÄ‡∏õ‡∏•‡∏µ‡πà‡∏¢‡∏ô (established RA)\n\n### Staging\n1. Synovitis synovial membrane ‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡πÄ‡∏â‡∏¢ ‡πÜ\n2. Pannus ‡πÄ‡∏Å‡∏¥‡∏î pannus ‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏°‡∏±‡∏ô‡πÇ‡∏î‡∏ô attack / ‡∏ï‡∏±‡∏ß cartilage ‡∏™‡∏π‡∏ç‡πÄ‡∏™‡∏µ‡∏¢‡πÑ‡∏õ‡πÄ‡∏¢‡∏≠‡∏∞ **‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏°‡∏±‡∏Å CC ‡∏°‡∏≤‡πÉ‡∏ô stage ‡∏ô‡∏µ‡πâ**\n3. Fibrous ankylosis ‡∏ï‡∏±‡∏ß fibrous connective tissue invade ‡∏ï‡∏±‡∏ß‡∏ß synovial\n4. Bony ankylosis ‡∏Å‡∏£‡∏∞‡∏î‡∏π‡∏Å‡πÄ‡∏ä‡∏∑‡πà‡∏≠‡∏°‡∏Å‡∏±‡∏ô\n\n### Clinical Features\n- prolonged morning stiffness more than 30 mins\n- **‡∏≠‡∏≤‡∏à‡∏à‡∏∞‡∏õ‡∏ß‡∏î ‡∏´‡∏£‡∏∑‡∏≠‡πÑ‡∏°‡πà‡∏õ‡∏ß‡∏î‡∏Å‡πá‡πÑ‡∏î‡πâ ! ‡∏ï‡πà‡∏≤‡∏á‡∏à‡∏≤‡∏Å [[notes/OA]]**\n- symptoms **present for 6 weeks or more**\n- ‡∏°‡∏±‡∏Å‡∏û‡∏ö‡∏ó‡∏µ‡πà‡∏ö‡∏£‡∏¥‡πÄ‡∏ß‡∏ì‡∏Ç‡πâ‡∏≠‡πÄ‡∏•‡πá‡∏Å ‡πÜ ‡πÑ‡∏°‡πà‡πÄ‡∏´‡∏°‡∏∑‡∏≠‡∏ô OA ‡∏ó‡∏µ‡πà‡∏û‡∏ö‡πÄ‡∏à‡∏≠‡∏ó‡∏µ‡πà‡∏Ç‡πâ‡∏≠‡πÉ‡∏´‡∏ç‡πà\n- ‡∏°‡∏±‡∏Å‡πÄ‡∏à‡∏≠‡∏ó‡∏µ‡πà‡∏ö‡∏£‡∏¥‡πÄ‡∏ß‡∏ì‡∏Ç‡πâ‡∏≠‡πÄ‡∏•‡πá‡∏Å ‡πÜ ‡πÅ‡∏•‡∏∞‡∏Ç‡πâ‡∏≠‡∏™‡πà‡∏ß‡∏ô‡∏õ‡∏•‡∏≤‡∏¢‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤ **‡∏¢‡∏Å‡πÄ‡∏ß‡πâ‡∏ô‡∏°‡∏∑‡∏≠** ‡∏à‡∏∞‡πÄ‡∏à‡∏≠‡πÅ‡∏Ñ‡πà‡∏Ç‡πâ‡∏≠‡∏ï‡πâ‡∏ô ‡πÜ (MCP ‡πÅ‡∏•‡∏∞ PIP) ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤ OA ‡∏à‡∏∞‡πÄ‡∏õ‡πá‡∏ô PIP DIP\n\t- ![[Pasted image 20230307224543.png|375]]\n- ‡∏´‡∏≤‡∏Å‡∏Ç‡πâ‡∏≠ MCP PIP ‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡πÄ‡∏Å‡∏¥‡∏ô 3 ‡∏õ‡∏µ ‡∏≠‡∏≤‡∏à‡∏à‡∏∞‡∏ñ‡∏π‡∏Å‡∏ó‡∏≥‡∏•‡∏≤‡∏¢‡πÅ‡∏•‡∏∞‡πÄ‡∏ä‡∏∑‡πà‡∏≠‡∏°‡∏Å‡∏±‡∏ô‡πÅ‡∏ö‡∏ö‡∏ñ‡∏≤‡∏ß‡∏£ ‡πÄ‡∏Å‡∏¥‡∏î‡πÄ‡∏õ‡πá‡∏ô Z-deformity, swan neck deformity, boutonni√®re deformity\n- ‡∏≠‡∏≤‡∏à‡∏°‡∏µ [[#^14dfb0|‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏ô‡∏≠‡∏Å‡∏Ç‡πâ‡∏≠]]\n\t- generalized fatigue\n\t- rheumatoid nodule (‡∏ï‡∏£‡∏ß‡∏à)\n\n### Diagnosis\n#### Lab\n- CRP -\u003e inflammatory marker (acute)\n- ESR -\u003e inflammatory marker (chronic) \n\u003e ‡∏û‡∏ß‡∏Å CRP/ESR ‡∏ö‡πà‡∏á‡∏ö‡∏≠‡∏Å‡∏ñ‡∏∂‡∏á‡∏Å‡∏≤‡∏£‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö ‡πÅ‡∏ï‡πà‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ specific ‡∏ß‡πà‡∏≤‡πÄ‡∏Å‡∏¥‡∏î‡∏Ç‡∏∂‡πâ‡∏ô‡∏ó‡∏µ‡πà‡∏Ç‡πâ‡∏≠\n- RF -\u003e diagnostic marker ‡∏û‡∏ö‡πÉ‡∏ô‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ 70-80%\n- APCA -\u003e ‡∏Ñ‡∏•‡πâ‡∏≤‡∏¢ RF ‡πÅ‡∏ï‡πà‡∏à‡∏∞ specific ‡∏Å‡∏ß‡πà‡∏≤‡∏°‡∏≤‡∏Å ‡πÜ\n- SF analysis ‡∏°‡∏±‡∏Å‡∏à‡∏∞‡∏°‡∏µ high white blood cell count ‡πÅ‡∏•‡∏∞‡πÑ‡∏°‡πà‡∏°‡∏µ crystal or infection -\u003e [[notes/Synovial Analysis#^09e8b5|Class 2]]\n#### X-Ray\n- ‡πÉ‡∏ä‡πâ x-ray ‡∏ò‡∏£‡∏£‡∏°‡∏î‡∏≤‡∏Å‡πá‡∏û‡∏≠‡πÅ‡∏•‡πâ‡∏ß\n- ‡∏£‡∏∞‡∏¢‡∏∞‡πÅ‡∏£‡∏Å ‡πÜ ‡∏≠‡∏≤‡∏à‡∏à‡∏∞‡πÄ‡∏õ‡πá‡∏ô soft tissue swelling and joint space narrowing ‡πÅ‡∏ï‡πà‡∏£‡∏∞‡∏¢‡∏∞‡∏ó‡πâ‡∏≤‡∏¢ ‡πÜ ‡∏≠‡∏≤‡∏à‡πÄ‡∏£‡∏¥‡πà‡∏°‡πÄ‡∏´‡πâ‡∏ô joint subluxations, deviations, and secondary arthritis\n\n### Differential Diagnosis\n\u003e ‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏≠‡∏≤‡∏à‡πÄ‡∏õ‡πá‡∏ô overlap syndrome ‡πÑ‡∏î‡πâ (‡πÄ‡∏õ‡πá‡∏ô‡∏´‡∏•‡∏≤‡∏¢‡πÇ‡∏£‡∏Ñ‡∏£‡πà‡∏ß‡∏°‡∏Å‡∏±‡∏ô)\n- OA\n- crystal-induced arthritis ‡πÄ‡∏Ç‡πà‡∏ô gout, pseudogout\n- systemic lupus erythematosus\n\t-  ‡∏≠‡∏≤‡∏à Rf ‡∏ö‡∏ß‡∏Å ‡πÅ‡∏ï‡πà involve organ ‡∏≠‡∏∑‡πà‡∏ô‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤\n- vasculitis\n- spondylarthritis ‡πÄ‡∏ä‡πà‡∏ô psoriatic arthritis\n\t- Rf ‡∏•‡∏ö‡πÅ‡∏ï‡πà‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏à‡∏∞‡∏Ñ‡∏•‡πâ‡∏≤‡∏¢ RA ‡∏°‡∏≤‡∏Å ‡πÜ\n\t- ‡∏ú‡∏•‡∏ü‡∏¥‡∏•‡πå‡∏°‡∏à‡∏∞‡πÄ‡∏´‡πá‡∏ô‡∏Ñ‡∏ß‡∏≤‡∏°‡∏ú‡∏¥‡∏î‡∏õ‡∏Å‡∏ï‡∏¥‡∏≠‡∏¢‡∏π‡πà‡∏ô‡∏∞ ‡∏ï‡πà‡∏≤‡∏á‡∏à‡∏≤‡∏Å [[notes/SLE]]\n\n### Diagnosis Criteria\n- ‡πÉ‡∏´‡πâ‡∏´‡∏°‡∏≠‡∏ó‡∏≥‡πÄ‡∏ñ‡∏≠‡∏∞ ‡∏°‡∏µ‡πÄ‡∏Å‡∏ì‡∏ë‡πå‡∏Å‡∏≤‡∏£‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô‡∏ï‡∏≤‡∏° guideline\n\n### Management\n\u003e ‡∏•‡∏î inflammation! ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏™‡∏ô‡πÄ‡∏£‡∏∑‡πà‡∏≠‡∏á‡∏õ‡∏ß‡∏î‡πÑ‡∏°‡πà‡∏õ‡∏ß‡∏î\n\u003e joint damage ‡∏ó‡∏µ‡πà‡πÄ‡∏Å‡∏¥‡∏î‡∏Ç‡∏∂‡πâ‡∏ô‡πÅ‡∏•‡πâ‡∏ß‡∏à‡∏∞‡πÑ‡∏°‡πà reverse ‡∏Å‡∏•‡∏±‡∏ö‡∏Ñ‡∏∑‡∏ô‡∏°‡∏≤‡∏õ‡∏Å‡∏ï‡∏¥\n\n### Monitoring\n\u003e ‡∏ñ‡πâ‡∏≤‡πÄ‡∏Å‡∏¥‡∏î‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡πÉ‡∏ä‡πâ‡∏Ñ‡∏∞‡πÅ‡∏ô‡∏ô‡∏≠‡∏∞‡πÑ‡∏£‡∏û‡∏ß‡∏Å‡∏ô‡∏µ‡πâ‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô‡∏°‡∏≤‡πÅ‡∏ï‡πà‡πÅ‡∏£‡∏Å ‡∏Å‡πá‡πÑ‡∏°‡πà‡∏à‡∏≥‡πÄ‡∏õ‡πá‡∏ô‡∏ï‡πâ‡∏≠‡∏á‡πÉ‡∏ä‡πâ ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤‡πÉ‡∏ä‡πâ‡πÅ‡∏•‡πâ‡∏ß‡∏Å‡πá‡πÉ‡∏ä‡πâ‡πÑ‡∏õ‡∏ï‡∏•‡∏≠‡∏î ‡∏õ‡∏Å‡∏ï‡∏¥‡πÅ‡∏•‡πâ‡∏ß DAS28 ‡∏Å‡∏±‡∏ö SDAI ‡∏à‡∏∞‡∏ô‡∏¥‡∏¢‡∏°‡πÉ‡∏ä‡πâ‡∏ï‡∏¥‡∏î‡∏ï‡∏≤‡∏° / monitor ‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤ ‡∏´‡∏£‡∏∑‡∏≠‡πÑ‡∏°‡πà‡∏Å‡πá‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡∏á‡∏≤‡∏ô‡∏ß‡∏¥‡∏à‡∏±‡∏¢\n- [[Rheumatoid arthritis#^449a0a|Disease Activity]]\n\t- ‡∏à‡∏∞‡∏°‡∏µ‡∏Å‡∏≤‡∏£‡πÅ‡∏ö‡πà‡∏á‡πÄ‡∏õ‡πá‡∏ô ‡πÇ‡∏£‡∏Ñ‡∏™‡∏á‡∏ö ‡∏†‡∏≤‡∏ß‡∏∞‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡∏ô‡πâ‡∏≠‡∏¢ ‡∏†‡∏≤‡∏ß‡∏∞‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡∏õ‡∏≤‡∏ô‡∏Å‡∏•‡∏≤‡∏á ‡∏†‡∏≤‡∏ß‡∏∞‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡∏°‡∏≤‡∏Å\n\t- ‡πÄ‡∏õ‡πâ‡∏≤‡∏´‡∏°‡∏≤‡∏¢ ‚Üí ‡πÉ‡∏´‡πâ‡πÇ‡∏£‡∏Ñ‡πÄ‡∏Ç‡πâ‡∏≤‡∏™‡∏π‡πà‡∏£‡∏∞‡∏¢‡∏∞‡∏™‡∏á‡∏ö\n\t- ACR/EULAR ‡πÇ‡∏£‡∏Ñ‡∏™‡∏á‡∏ö‡∏´‡∏°‡∏≤‡∏¢‡∏ñ‡∏∂‡∏á‡∏à‡∏≥‡∏ô‡∏ß‡∏ô‡∏Ç‡πâ‡∏≠‡∏ö‡∏ß‡∏° ‚â§ 1 ‡∏Ç‡πâ‡∏≠ ‡∏´‡∏£‡∏∑‡∏≠ SDAI \u003c 3.3\n\t- DAS28\n\t    - ‡∏ô‡πâ‡∏≠‡∏¢‡∏Å‡∏ß‡πà‡∏≤ 2.6 ‡∏™‡∏á‡∏ö\n\t    - 2.6-3.2 ‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡∏ô‡πâ‡∏≠‡∏¢\n\t    - 3.2-5.1 ‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡∏õ‡∏≤‡∏ô‡∏Å‡∏•‡∏≤‡∏á\n\t    - ‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤ 5.1 ‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡∏°‡∏≤‡∏Å\n- poor prognostic factors\n\t- ‡∏Å‡∏≤‡∏£‡∏°‡∏µ RF and/or APCA high levels\n\t- high disease activity\n\t- early joint damage\n\t- failure of \u003e= 2 csDMARDs\n- ‡∏≠‡∏≤‡∏à‡∏°‡∏µ‡πÉ‡∏ä‡πâ‡∏û‡∏ß‡∏Å ACR20 ACR50 ACR70 ‡πÑ‡∏ß‡πâ‡∏î‡∏π improvement ‡∏ß‡πà‡∏≤‡∏î‡∏µ‡∏Ç‡∏∂‡πâ‡∏ô‡πÅ‡∏Ñ‡πà‡πÑ‡∏´‡∏ô\n\n### Non-pharmacological therapy\n- patient education\n- rest\n- holistic health\n- surgery last resort ‡πÅ‡∏ï‡πà‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏Å‡∏•‡∏±‡∏ö‡∏°‡∏≤ 100% ‡∏ô‡∏∞!\n- physical therapy, occupation therapy\n- weight reduction ‡∏ä‡πà‡∏ß‡∏¢‡∏•‡∏î‡∏†‡∏≤‡∏£‡∏∞‡∏Ç‡πâ‡∏≠‡πÑ‡∏î‡πâ\n\n### Pharmacological Therapy\n- NSAIDs\n\t- efficacy ‡πÑ‡∏°‡πà‡∏ï‡πà‡∏≤‡∏á‡∏Å‡∏±‡∏ô ‡πÑ‡∏°‡πà‡∏ß‡πà‡∏≤‡∏à‡∏∞ non-selective or selective ‡πÅ‡∏ï‡πà **safety** ‡∏°‡∏µ‡∏Ñ‡∏ß‡∏≤‡∏°‡πÅ‡∏ï‡∏Å‡∏ï‡πà‡∏≤‡∏á‡∏Å‡∏±‡∏ô\n\t- ‡πÉ‡∏ä‡πâ‡πÇ‡∏î‡∏™‡πÉ‡∏´‡πâ‡∏ñ‡∏∂‡∏á ‡πÄ‡∏û‡∏∑‡πà‡∏≠‡∏•‡∏î inflammation **‡∏à‡∏∞‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πà‡πÇ‡∏î‡∏™‡∏•‡∏î‡∏õ‡∏ß‡∏î‡∏ò‡∏£‡∏£‡∏°‡∏î‡∏≤**\n- Corticosteroids\n\t- ‡πÉ‡∏ä‡πâ‡∏Ç‡∏ô‡∏≤‡∏î‡∏ï‡πà‡∏≥ ‡πÄ‡∏ä‡πà‡∏ô 0.5 mkday (‡∏Ç‡∏ô‡∏≤‡∏î‡πÄ‡∏£‡∏¥‡πà‡∏°‡∏ï‡πâ‡∏ô‡∏Ñ‡∏∑‡∏≠ 7.5 mg/day) ‡∏£‡πà‡∏ß‡∏°‡∏Å‡∏±‡∏ö DMARDs ‡∏´‡∏£‡∏∑‡∏≠ NSAIDs ‡∏Å‡πá‡πÑ‡∏î‡πâ ‡πÅ‡∏•‡πâ‡∏ß‡πÅ‡∏ï‡πà‡∏ß‡πà‡∏≤‡πÄ‡∏õ‡πá‡∏ô‡∏´‡∏ô‡∏±‡∏Å‡πÄ‡∏ö‡∏≤‡πÅ‡∏Ñ‡πà‡πÑ‡∏´‡∏ô ‡πÑ‡∏°‡πà‡∏°‡∏µ‡∏Ç‡πâ‡∏≠‡∏°‡∏π‡∏•‡∏ß‡πà‡∏≤‡∏≠‡∏±‡∏ô‡πÑ‡∏´‡∏ô‡∏î‡∏µ‡∏Å‡∏ß‡πà‡∏≤‡∏Å‡∏±‡∏ô\n\t- steroid ‡∏à‡∏∞‡πÉ‡∏ä‡πâ‡πÄ‡∏°‡∏∑‡πà‡∏≠ ‡∏°‡∏µ‡∏Ç‡πâ‡∏≠‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡∏£‡∏∏‡∏ô‡πÅ‡∏£‡∏á‡∏à‡∏ô‡∏Å‡∏£‡∏∞‡∏ó‡∏ö‡∏ä‡∏µ‡∏ß‡∏¥‡∏ï‡∏õ‡∏£‡∏∞‡∏à‡∏≥‡∏ß‡∏±‡∏ô ‡∏´‡∏£‡∏∑‡∏≠‡πÑ‡∏°‡πà‡∏ï‡∏≠‡∏ö‡∏™‡∏ô‡∏≠‡∏á‡∏ï‡πà‡∏≠ NSAIDs ‡∏´‡∏£‡∏∑‡∏≠‡πÉ‡∏ä‡πâ NSAIDs ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ\n\t- **‡∏´‡∏¢‡∏∏‡∏î‡∏¢‡∏≤‡∏†‡∏≤‡∏¢‡πÉ‡∏ô 3-6 ‡πÄ‡∏î‡∏∑‡∏≠‡∏ô (ideally)**\n- Tramadol\n\t- ‡∏Å‡∏£‡∏ì‡∏µ‡∏ó‡∏µ‡πà‡∏õ‡∏ß‡∏î‡∏´‡∏ô‡∏±‡∏Å‡∏°‡∏≤‡∏Å ‡πÜ ‡∏à‡∏£‡∏¥‡∏á ‡πÜ\n- DMARDs\n\t- Synthetic\n\t\t- Conventional\n\t\t\t- HCQ/CQ **(non-immunosupressive)**\n\t\t\t\t- 200-400 mg/day\n\t\t\t\t- ‡∏ï‡∏£‡∏ß‡∏à‡∏ï‡∏≤‡∏Å‡πà‡∏≠‡∏ô ‡∏ï‡∏£‡∏ß‡∏à fundus\n\t\t\t\t- ‡∏õ‡∏ß‡∏î‡∏´‡∏±‡∏ß N/V\n\t\t\t\t- irreversible retinal damage\n\t\t\t\t- skin pigmentation\n\t\t\t\t- ‡πÉ‡∏ä‡πâ‡∏Å‡∏±‡∏ö constitutional symptoms ‡πÑ‡∏î‡πâ ‡πÅ‡∏ï‡πà‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏ä‡πà‡∏ß‡∏¢‡∏•‡∏î joint damage progression\n\t\t\t- Sulfasalazine **(non-immunosupressive)**\n\t\t\t\t- enteric coated\n\t\t\t\t- ‡∏ï‡∏±‡∏ß‡∏°‡∏±‡∏ô‡πÄ‡∏õ‡πá‡∏ô NSAIDs ‡πÅ‡∏•‡∏∞‡πÄ‡∏õ‡πá‡∏ô‡∏¢‡∏≤‡∏Å‡∏•‡∏∏‡πà‡∏° sulfa\n\t\t\t\t- ‡∏ï‡∏±‡∏ß CBC ‡∏î‡πâ‡∏ß‡∏¢ ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏Å‡∏î‡∏Å‡∏≤‡∏£‡∏ó‡∏≥‡∏á‡∏≤‡∏ô‡∏Ç‡∏≠‡∏á‡πÑ‡∏Ç‡∏Å‡∏£‡∏∞‡∏î‡∏π‡∏Å‡πÑ‡∏î‡πâ‡πÄ‡∏´‡∏°‡∏∑‡∏≠‡∏ô MTX (myelosuppression) ‡∏ï‡∏≤‡∏°‡∏à‡∏£‡∏¥‡∏á‡∏≠‡∏≤‡∏à‡∏ï‡πâ‡∏≠‡∏á‡πÉ‡∏™‡πà folic ‡πÅ‡∏ï‡πà‡∏°‡∏±‡∏ô‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡πÄ‡∏î‡πà‡∏ô‡πÄ‡∏ó‡πà‡∏≤ MTX\n\t\t\t- Methotrexate\n\t\t\t\t- hep tox\n\t\t\t\t- interstitial pneumonitis\n\t\t\t\t- ‡∏ï‡∏£‡∏ß‡∏à‡∏Å‡∏≤‡∏£‡∏ó‡∏≥‡∏á‡∏≤‡∏ô‡∏Ç‡∏≠‡∏á‡∏õ‡∏≠‡∏î‡∏Å‡πà‡∏≠‡∏ô‡πÉ‡∏ä‡πâ ‡∏ú‡∏¥‡∏î‡∏õ‡∏Å‡∏ï‡∏¥‡∏Å‡πá‡∏´‡πâ‡∏≤‡∏°‡πÉ‡∏ä‡πâ\n\t\t\t\t- ‡∏ï‡∏£‡∏ß‡∏à viral hepatitis ‡∏Å‡πà‡∏≠‡∏ô‡πÄ‡∏£‡∏¥‡πà‡∏°‡∏¢‡∏≤\n\t\t\t\t- ‡∏≠‡∏¢‡πà‡∏≤‡∏•‡∏∑‡∏° folic acid\n\t\t\t\t- ‡∏´‡∏¢‡∏∏‡∏î‡∏¢‡∏≤‡∏Å‡πà‡∏≠‡∏ô‡∏ó‡πâ‡∏≠‡∏á 3 ‡πÄ‡∏î‡∏∑‡∏≠‡∏ô\n\t\t\t\t\t- ‡∏ñ‡πâ‡∏≤‡πÉ‡∏ä‡πâ‡πÇ‡∏î‡∏™‡∏™‡∏π‡∏á (‡πÄ‡∏ä‡πà‡∏ô 15, 20, 25mg) ‡πÉ‡∏´‡πâ‡∏™‡∏•‡∏±‡∏ö‡πÑ‡∏õ SC ‡πÄ‡∏û‡∏£‡∏≤‡∏∞ F oral ‡πÑ‡∏°‡πà‡∏î‡∏µ ‡πÅ‡∏•‡∏∞‡πÇ‡∏î‡∏™‡πÄ‡∏î‡∏¥‡∏°‡∏Ç‡∏≠‡∏á oral ‡∏ñ‡πâ‡∏≤‡πÉ‡∏ä‡πâ‡∏Å‡∏±‡∏ö SC ‡∏°‡∏±‡∏Å‡∏à‡∏∞‡πÉ‡∏´‡πâ‡∏ú‡∏•‡∏Å‡∏≤‡∏£‡∏£‡∏±‡∏Å‡∏©‡∏≤‡∏ó‡∏µ‡πà‡∏î‡∏µ‡∏Å‡∏ß‡πà‡∏≤\n\t\t\t- Leflunomide\n\t\t\t\t- diarrhea ‡πÄ‡∏î‡πà‡∏ô\n\t\t\t\t- ‡∏ï‡∏£‡∏ß‡∏à viral hepatitis ‡∏Å‡πà‡∏≠‡∏ô‡πÄ‡∏£‡∏¥‡πà‡∏°‡∏¢‡∏≤\n\t\t\t- Azathioprine\n\t\t\t- Minocycline **(non-immunosupressive)**\n\t\t\t- Cyclosporin A (CsA)\n\t\t\t\t- ‡πÄ‡∏õ‡πá‡∏ô calcineurin inhibitor\n\t\t\t\t- ‡∏ï‡∏£‡∏ß‡∏à‡∏ï‡∏±‡∏ö ‡πÑ‡∏ï ‡πÄ‡∏•‡∏∑‡∏≠‡∏î\n\t\t\t\t- ‡∏°‡∏±‡∏ô‡∏à‡∏∞‡πÄ‡∏û‡∏¥‡πà‡∏° photosensitivity ‡∏£‡∏∞‡∏ß‡∏±‡∏á‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å‡∏°‡∏µ‡∏Å‡∏≤‡∏£‡∏â‡∏≤‡∏¢‡∏£‡∏±‡∏á‡∏™‡∏µ‡∏≠‡∏¢‡∏π‡πà‡πÅ‡∏•‡πâ‡∏ß\n\t\t\t\t- high BP ‡πÅ‡∏•‡∏∞ gingival hyperplasia ‡πÑ‡∏î‡πâ\n\t\t- Targeted **(‡πÉ‡∏´‡∏°‡πà‡∏™‡∏∏‡∏î)**\n\t\t\t- Janus kinase (JAK inhibitor) ‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πà‡∏¢‡∏≤ biologics !\n\t\t\t\t- ‡πÉ‡∏´‡πâ‡∏ï‡∏£‡∏ß‡∏à lipid profile, ‡πÅ‡∏•‡∏∞‡∏´‡πâ‡∏≤‡∏°‡πÄ‡∏£‡∏¥‡πà‡∏°‡πÉ‡∏ä‡πâ‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å ANc \u003c 1000 ‡∏´‡∏£‡∏∑‡∏≠ Hb \u003c 9 gbdl\n\t\t\t\t- ‡∏ï‡∏£‡∏ß‡∏à lipid profile ‡∏´‡∏•‡∏±‡∏á‡πÄ‡∏£‡∏¥‡πà‡∏°‡∏¢‡∏≤ 3 ‡πÄ‡∏î‡∏∑‡∏≠‡∏ô\n\t\t\t\t- ‡πÄ‡∏û‡∏¥‡πà‡∏° risk infection, blood clot ‡πÅ‡∏•‡∏∞ lipids (dose dependent)\n\t\t\t\t- **Tofacitinib**\n\t\t\t\t\t- CYP3A4 ‡πÅ‡∏•‡∏∞ CYP2C19 !!!\n\t\t\t\t- Baricitinib\n\t- Biological\n\t\t- **‡∏à‡∏∞‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏ó‡∏µ‡πà‡∏°‡∏µ infection ‡πÅ‡∏•‡∏∞‡∏à‡∏∞‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πâ live vaccine ‡∏£‡∏∞‡∏´‡∏ß‡πà‡∏≤‡∏á‡πÉ‡∏´‡πâ biological !!!**\n\t\t- Conventional\n\t\t\t- TNF-alpha inhibitor ‡πÄ‡∏õ‡πâ‡∏ô‡∏¢‡∏≤ biological ‡∏ï‡∏±‡∏ß‡πÅ‡∏£‡∏Å ‡πÅ‡∏ï‡πà‡∏´‡πâ‡∏≤‡∏°‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡∏Ñ‡∏ô‡∏ó‡∏µ‡πà‡πÄ‡∏õ‡πá‡∏ô SLE, lupus overlap syndrome, CHF\n\t\t\t- CD80 and CD86 inhibitor\n\t\t\t\t- Abatacept\n\t\t\t- anti PD20\n\t\t\t\t- Rituximab -\u003e ‡∏£‡∏∞‡∏ß‡∏±‡∏á‡πÅ‡∏û‡πâ ‡∏î‡∏±‡∏á‡∏ô‡∏±‡πâ‡∏ô‡πÉ‡∏´‡πâ methyprednisolone ‡∏Å‡πà‡∏≠‡∏ô‡πÉ‡∏ä‡πâ‡∏¢‡∏≤ ‡∏´‡∏£‡∏∑‡∏≠ paracetamol+hypersens\n\t\t\t- IL-6R inhibitor\n\t\t\t\t- Tocilizumab -\u003e ‡πÄ‡∏û‡∏¥‡πà‡∏° liver transminases\n\t\t\t- IL-1 inhibitor ‡∏°‡∏µ‡∏°‡∏≤‡∏ô‡∏≤‡∏ô‡πÅ‡∏ï‡πà‡πÑ‡∏°‡πà effective\n\t\t- Biosimilar\n\n\n### Guideline\n- start DMARDs ASAP ‡∏´‡∏•‡∏±‡∏á‡∏ß‡∏¥‡∏ô‡∏¥‡∏à‡∏â‡∏±‡∏¢\n- goal: low disease activity or sustained remission\n- monitor ‡∏ñ‡∏µ‡πà‡πÉ‡∏ô‡∏ä‡πà‡∏ß‡∏á‡πÅ‡∏£‡∏Å q 1-3 mo. ‡∏´‡∏≤‡∏Å‡πÑ‡∏°‡πà‡∏î‡∏µ‡∏Ç‡∏∂‡πâ‡∏ô‡πÉ‡∏ô 3-6 mo. ‡πÉ‡∏´‡πâ adjust therapy\n\t- ‡∏´‡∏≤‡∏Å‡πÉ‡∏ä‡πâ csDMARD ‡∏Ñ‡∏£‡∏ö 2 ‡∏ï‡∏±‡∏ß‡πÑ‡∏°‡πà‡∏î‡∏µ‡∏Ç‡∏∂‡πâ‡∏ô ‡∏´‡∏£‡∏∑‡∏≠ poor prognostic factor ‡πÉ‡∏´‡πâ‡πÉ‡∏ä‡πâ‡∏ï‡∏±‡∏ß bDMARD ‡πÅ‡∏ï‡πà‡∏≠‡∏≤‡∏à‡πÉ‡∏ä‡πâ JAK-inhibitor ‡πÑ‡∏î‡πâ ‡πÅ‡∏ï‡πà‡∏ï‡πâ‡∏≠‡∏á‡∏î‡∏π risk factor ‡∏î‡πâ‡∏ß‡∏¢‡∏ß‡πà‡∏≤‡∏°‡∏µ‡∏õ‡∏±‡∏ç‡∏´‡∏≤‡∏î‡∏±‡∏á‡∏ï‡πà‡∏≠‡πÑ‡∏õ‡∏ô‡∏µ‡πâ‡∏°‡∏±‡πâ‡∏¢: ‡∏≠‡∏≤‡∏¢‡∏∏‡πÄ‡∏Å‡∏¥‡∏ô 65 ‡∏õ‡∏µ, past smoking, CV risk factors, risk of malignancy, risk of thromboembolic events\n\t- ‡∏à‡∏∞‡∏™‡∏•‡∏±‡∏ö ‡∏´‡∏£‡∏∑‡∏≠ add bDMARD/tsDMARD ‡∏Å‡πá‡πÑ‡∏î‡πâ ‡πÅ‡∏ï‡πà‡πÅ‡∏ô‡∏∞‡∏ô‡∏≥‡πÉ‡∏´‡πâ add ‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤‡∏™‡∏•‡∏±‡∏ö\n\t- IL-6 inhibitor (Tocilizumab) ‡πÄ‡∏õ‡πá‡∏ô bDMARDs ‡∏ó‡∏µ‡πà‡∏≠‡∏≤‡∏à‡∏°‡∏µ efficacy ‡πÄ‡∏¢‡∏≠‡∏∞‡∏Å‡∏ß‡πà‡∏≤‡∏ñ‡πâ‡∏≤‡∏ô‡∏≥‡πÑ‡∏õ‡πÉ‡∏ä‡πâ‡∏£‡πà‡∏ß‡∏°‡∏Å‡∏±‡∏ö tsDMARDs\n\t-  **‡∏´‡∏°‡∏≤‡∏¢‡πÄ‡∏´‡∏ï‡∏∏: ‡∏Ç‡∏≠‡∏á‡πÑ‡∏ó‡∏¢‡∏ö‡∏≠‡∏Å‡∏ß‡πà‡∏≤‡πÉ‡∏´‡πâ‡∏•‡∏≠‡∏á‡∏à‡∏ô‡∏Ñ‡∏£‡∏ö 3 ‡∏ï‡∏±‡∏ß ‡πÇ‡∏î‡∏¢‡∏ï‡∏±‡∏ß‡∏•‡∏∞ 2 ‡πÄ‡∏î‡∏∑‡∏≠‡∏ô ‡∏à‡∏∂‡∏á‡∏Ñ‡πà‡∏≠‡∏¢‡∏™‡∏•‡∏±‡∏ö‡πÄ‡∏õ‡πâ‡∏ô bDMARDs**\n- ‡∏ñ‡πâ‡∏≤‡∏à‡∏∞‡πÄ‡∏£‡∏¥‡πà‡∏° bDMARDs ‡πÉ‡∏´‡πâ‡∏´‡∏¢‡∏∏‡∏î GCs ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏Ñ‡∏π‡πà‡∏¢‡∏≤‡∏ô‡∏µ‡πâ‡πÑ‡∏°‡πà‡∏à‡∏≥‡πÄ‡∏õ‡πá‡∏ô ‡πÅ‡∏•‡∏∞‡∏¢‡∏±‡∏á‡πÄ‡∏û‡∏¥‡πà‡∏° AE ‡∏≠‡∏µ‡∏Å\n- ‡∏ñ‡πâ‡∏≤‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏Ñ‡∏∏‡∏°‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡πÑ‡∏î‡πâ‡πÅ‡∏ï‡πà‡∏¢‡∏±‡∏á‡πÉ‡∏ä‡πâ GCs ‡∏≠‡∏¢‡∏π‡πà ‡πÅ‡∏™‡∏î‡∏á‡∏ß‡πà‡∏≤‡∏≠‡∏≤‡∏à‡πÑ‡∏°‡πà‡πÄ‡∏û‡∏µ‡∏¢‡∏á‡∏û‡∏≠ ‡πÉ‡∏´‡πâ‡∏õ‡∏£‡∏±‡∏ö‡∏Å‡∏≤‡∏£‡∏£‡∏±‡∏Å‡∏©‡∏≤‡∏´‡∏•‡∏±‡∏Å‡∏´‡∏£‡∏∑‡∏≠‡∏û‡∏¢‡∏≤‡∏¢‡∏≤‡∏°‡∏´‡∏•‡∏∏‡∏î steroid\n- short-term GCs = 3 months, long-term = 3-6 months, chronic = more than 6 motnhs\n- MTX = first line ‡∏¢‡∏Å‡πÄ‡∏ß‡πâ‡∏ô‡∏°‡∏µ con\n- ‡∏´‡∏≤‡∏Å‡πÄ‡∏Å‡∏¥‡∏î Flare ‡∏°‡∏±‡∏Å‡∏´‡∏°‡∏≤‡∏¢‡∏ñ‡∏∂‡∏á‡∏¢‡∏≤‡∏ó‡∏µ‡πà‡πÉ‡∏ä‡πâ‡∏Ñ‡∏∏‡∏°‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡πÑ‡∏°‡πà‡πÄ‡∏û‡∏µ‡∏¢‡∏á‡∏û‡∏≠\n- GCs ‡πÑ‡∏ß‡πâ‡πÉ‡∏ä‡πâ‡∏Å‡∏±‡∏ö ‡πÑ‡∏î‡πâ\n- JAK inhibitor and bDMARDs ‡πÑ‡∏°‡πà‡∏ï‡πà‡∏≤‡∏á‡∏Å‡∏±‡∏ô‡πÉ‡∏ô‡πÅ‡∏á‡πà safety/efficacy\n- contraindication ‡πÉ‡∏´‡πâ‡πÉ‡∏ä‡πâ leflunomide or sulfasalazine\n- ‡∏´‡∏•‡∏±‡∏á‡∏´‡∏¢‡∏∏‡∏î steroid ‡πÅ‡∏•‡πâ‡∏ß‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏Ñ‡∏∏‡∏°‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡πÑ‡∏î‡πâ‡∏î‡∏µ ‡∏≠‡∏≤‡∏à‡∏•‡∏î bDMARDs/tsDMARDs ‡πÅ‡∏•‡∏∞‡∏´‡∏£‡∏∑‡∏≠ csDMARDs\n- ![[Pasted image 20230308124045.png]]","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/Respiratory-Failure":{"title":"Respiratory Failure","content":"\n## Basics to Respiratory Failure\n- Respiratory Disease\n\t1. Obstructive lung disease (small airway obstruction), asthma, chronic bronchitis\n\t2. Restrictive lung disease (reduced lung volume), pulmonary fibrosis, disease of the chest wall or pleura\n\t3. Abnormalities of the vasculature, pulmonary embolism and pulmonary hypertension\n\t- Others: malignancy and pneumonia\n- Respiratory Distress\n\t- patient's subjective sensation of dyspnea + signs indicated difficulty breathing\n- Dyspnea\n\t- feeling of difficult, labored, uncomfortable breathing ‡∏´‡∏£‡∏∑‡∏≠‡∏°‡∏µ PE ‡πÄ‡∏ä‡πà‡∏ô tachypnea and tachycardia, use of accessory respiratory muscle \n- Respiratory Failure\n\t- is defined as inadequate gas exchange\n\t- Classification\n\t\t- Type 1 : hypoxia (PaO2 \u003c 60 mmHg) + PaCO2 Normal\n\t\t- Type 2 : hypoxia (PaO2 \u003c 60 mmHg) + hypercapnia (PaCO2 \u003e 45 mmHg)\n- Typical approach to respiratory disease:\n\t- PMH (optional) ‡∏ñ‡πâ‡∏≤‡∏°‡∏µ‡∏Å‡πá‡∏à‡∏∞‡∏ä‡πà‡∏ß‡∏¢ R/O ‡πÑ‡∏î‡πâ‡∏ß‡πà‡∏≤‡∏°‡∏≤‡∏à‡∏≤‡∏Å‡∏≠‡∏∞‡πÑ‡∏£ ‡πÄ‡∏ä‡πà‡∏ô HF, ‡∏°‡∏∞‡πÄ‡∏£‡πá‡∏á‡∏õ‡∏≠‡∏î\n\t- **PE**\n\t- LAB (optional)\n- Physical Examination\n\t- Summary\n\t\t- ![[Pasted image 20230130194617.png]]\n\t- Oxygenation\n\t\t- SpO2 - finger, toe\n\t\t\t- ‡∏£‡∏∞‡∏ß‡∏±‡∏á‡πÄ‡∏•‡πá‡∏ö‡∏ó‡∏≤‡∏™‡∏µ‡∏´‡∏ô‡∏≤ ‡∏´‡∏£‡∏∑‡∏≠‡∏™‡∏µ‡πÅ‡∏ü‡∏ô‡∏ã‡∏µ‡πÄ‡∏Å‡∏¥‡∏ô‡πÑ‡∏õ\n\t\t- PaO2 - arterial blood gas\n\t\t- Dyspnea ‡∏°‡∏±‡∏Å \u003c90% (PaO2 ‡∏õ‡∏£‡∏∞‡∏°‡∏≤‡∏ì 60) ‡∏´‡∏≤‡∏Å‡∏Ñ‡πà‡∏≤‡∏ô‡∏µ‡πâ = ER ‡πÄ‡∏û‡∏£‡∏≤‡∏∞ severe hypoxia\n\t- Adventitious lung (abnormal) sound\n\t\t- Stridor\n\t\t\t- ‡πÄ‡∏™‡∏µ‡∏¢‡∏á‡πÄ‡∏´‡∏°‡∏∑‡∏≠‡∏ô‡∏Ñ‡∏ô‡∏Å‡∏≥‡∏•‡∏±‡∏á panic ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏î‡∏π‡πÄ‡∏´‡∏°‡∏∑‡∏≠‡∏ô‡πÄ‡∏ö‡∏µ‡∏¢‡∏î ‡πÜ ‡∏´‡∏≤‡∏¢‡πÉ‡∏à‡πÑ‡∏°‡πà‡∏≠‡∏≠‡∏Å‡∏à‡∏∞‡∏Ç‡∏≤‡∏î‡πÉ‡∏à‡∏ï‡∏≤‡∏¢ ‡πÑ‡∏°‡πà‡πÄ‡∏ä‡∏¥‡∏á wheeze ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏°‡∏±‡∏ô‡∏î‡∏π‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πà‡∏ô‡∏Å‡∏´‡∏ß‡∏µ‡∏î\n\t\t\t- airway edema, upper airway disease, obstruction\n\t\t- Wheeze\n\t\t\t- ‡πÄ‡∏™‡∏µ‡∏¢‡∏á‡πÄ‡∏´‡∏°‡∏∑‡∏≠‡∏ô‡∏ô‡∏Å‡∏´‡∏ß‡∏µ‡∏î ‡πÄ‡∏™‡∏µ‡∏¢‡∏á‡πÅ‡∏´‡∏•‡πà‡∏°\n\t\t\t- asthma, ‡∏≠‡∏≤‡∏à‡∏°‡∏µ‡∏ö‡πâ‡∏≤‡∏á‡πÉ‡∏ô copd, asthma exacerbation ‡πÑ‡∏£‡∏á‡∏µ‡πâ or covid w/ inflammation\n\t\t- Rhonchi\n\t\t\t- ‡πÄ‡∏™‡∏µ‡∏¢‡∏á‡∏ó‡∏∏‡πà‡∏° ‡∏°‡∏±‡∏Å‡∏°‡∏≤‡∏à‡∏≤‡∏Å bronchus / large airway ‡∏ó‡∏µ‡πà‡∏°‡∏µ large secretion ‡πÄ‡∏™‡∏µ‡∏¢‡∏á‡πÄ‡∏Å‡∏¥‡∏î‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏≠‡∏≤‡∏Å‡∏≤‡∏®‡∏°‡∏±‡∏ô‡∏ú‡πà‡∏≤‡∏ô‡∏™‡∏≤‡∏£‡∏Ñ‡∏±‡∏î‡∏´‡∏•‡∏±‡πà‡∏á ‡πÄ‡∏™‡∏µ‡∏¢‡∏á‡∏≠‡∏≤‡∏à‡∏´‡∏≤‡∏¢‡∏´‡∏•‡∏±‡∏á‡∏à‡∏≤‡∏Å‡πÑ‡∏≠\n\t\t- Crepitation (crackles or rales)\n\t\t\t- ‡∏°‡∏±‡∏Å‡∏à‡∏∞‡∏´‡∏°‡∏≤‡∏¢‡∏ñ‡∏∂‡∏á‡∏ó‡∏µ‡πà‡∏ñ‡∏∏‡∏á‡∏•‡∏°\n\t\t\t- coarse crackles\n\t\t\t\t- ‡πÄ‡∏™‡∏µ‡∏¢‡∏á‡∏à‡∏∞‡∏ó‡∏∏‡πà‡∏° ‡∏Ñ‡∏•‡πâ‡∏≤‡∏¢ rhonchi ‡∏°‡∏±‡∏Å‡∏à‡∏∞‡πÑ‡∏î‡πâ‡∏¢‡∏¥‡∏ô‡∏ó‡∏±‡πà‡∏ß‡∏ó‡∏±‡πâ‡∏á‡∏õ‡∏≠‡∏î\n\t\t\t- fine crackles\n\t\t\t\t- ‡πÄ‡∏™‡∏µ‡∏¢‡∏á‡∏à‡∏∞‡∏™‡∏±‡πâ‡∏ô‡∏Å‡∏ß‡πà‡∏≤ coarse ‡πÅ‡∏•‡∏∞‡πÑ‡∏°‡πà‡∏ó‡∏∏‡πà‡∏° ‡∏≠‡∏≤‡∏à‡πÑ‡∏î‡πâ‡∏¢‡∏¥‡∏ô‡πÅ‡∏Ñ‡πà‡∏™‡πà‡∏ß‡∏ô‡∏•‡πà‡∏≤‡∏á ‡πÜ ‡∏Ç‡∏≠‡∏á‡∏õ‡∏≠‡∏î ‡πÄ‡∏Å‡∏µ‡πà‡∏¢‡∏ß‡∏Ç‡πâ‡∏≠‡∏á‡∏Å‡∏±‡∏ö pneumonia ‡πÅ‡∏•‡∏∞ **CHF**\n\t- Imaging\n\t\t- CXR\n\t\t\t- ‡∏°‡∏µ‡∏£‡∏ñ portable ‡πÅ‡∏ï‡πà‡∏Å‡πá‡∏≠‡∏≤‡∏à‡∏à‡∏∞‡∏ä‡πâ‡∏≤\n\t\t\t- pulmonary infiltrate ‡πÄ‡∏õ‡πá‡∏ô‡∏Ñ‡∏≥‡∏ó‡∏±‡πà‡∏ß‡πÑ‡∏õ\n\t\t\t- ‡∏ó‡∏µ‡πà‡πÄ‡∏´‡∏•‡∏∑‡∏≠‡∏à‡∏∞‡πÄ‡∏â‡∏û‡∏≤‡∏∞‡πÄ‡∏à‡∏≤‡∏∞‡∏à‡∏á consolidation, air bronchogram, lung atelectasis, cephalization ‡∏≠‡∏≤‡∏à‡∏°‡∏µ‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ‡∏Ñ‡∏≥‡∏ß‡πà‡∏≤ interstitial, nodules or masses ‡∏î‡πâ‡∏ß‡∏¢\n\t\t- CT-Scan\n\t\t\t- ‡∏ï‡πâ‡∏≠‡∏á‡πÉ‡∏ä‡πâ RA ‡∏Ñ‡πà‡∏≠‡∏ô‡∏Ç‡πâ‡∏≤‡∏á invasive\n\t\t- Lung U/S\n\t\t\t- ‡∏ñ‡πâ‡∏≤‡∏ü‡∏±‡∏á‡∏°‡∏≤‡πÄ‡∏õ‡πá‡∏ô A-line = ‡∏õ‡∏Å‡∏ï‡∏¥ ‡∏ñ‡πâ‡∏≤ B-line ‡πÅ‡∏™‡∏î‡∏á‡∏ß‡πà‡∏≤‡∏°‡∏µ‡∏Ñ‡∏•‡∏∑‡πà‡∏ô‡∏ô‡πâ‡∏≥‡∏™‡∏∞‡∏ó‡πâ‡∏≠‡∏ô‡∏≠‡∏≠‡∏Å‡∏°‡∏≤ (extravasated fluid into interstitium and alveoli)\n\t\t- CTPA\n\t\t\t- advanced case only\n\t\t\t- ‡πÄ‡∏Å‡∏µ‡πà‡∏¢‡∏ß‡∏Å‡∏±‡∏ö pulmonary thromboembolism\n\n## Respiratory Mechanics\n- Two-component of respiratory system\n\t- Resistive = airways\n\t- Elastic = lung parenchyma and chest wall\n- Flow \u0026 Resistance\n\t- Work of breathing (WOB) ‡∏Ñ‡∏∑‡∏≠‡∏á‡∏≤‡∏ô‡∏ó‡∏µ‡πà‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡∏Å‡∏≤‡∏£‡πÄ‡∏≠‡∏≤‡∏ä‡∏ô‡∏∞ flow resistance ‡πÅ‡∏•‡∏∞ elastic forces\n\t- ‡∏ö‡∏≤‡∏á‡∏Ñ‡∏£‡∏±‡πâ‡∏á‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ WOB ‡πÄ‡∏¢‡∏≠‡∏∞‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏´‡∏≤‡∏¢‡πÉ‡∏à‡πÑ‡∏°‡πà‡∏™‡∏≠‡∏î‡∏Ñ‡∏•‡πâ‡∏≠‡∏á‡∏Å‡∏±‡∏ö ventilator ‡∏Å‡πá‡∏≠‡∏≤‡∏à‡πÉ‡∏´‡πâ fentanyl ‡πÄ‡∏û‡∏∑‡πà‡∏≠‡∏•‡∏î WOB\n\t- ‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡πÉ‡∏ä‡πâ‡∏õ‡∏≠‡∏î‡πÑ‡∏õ‡∏ô‡∏≤‡∏ô ‡πÜ ‡∏°‡∏±‡∏ô‡∏≠‡∏≤‡∏à‡∏ó‡∏≥‡πÉ‡∏´‡πâ respiratory muscle fatigue and lead to respiratory failure\n- Positive end expiratory pressure (PEEP)\n\t- ‡∏Ñ‡∏∑‡∏≠ pressure ‡∏ó‡∏µ‡πà‡πÄ‡∏´‡∏•‡∏∑‡∏≠‡πÉ‡∏ô‡∏õ‡∏≠‡∏î‡∏´‡∏•‡∏±‡∏´‡∏≤‡∏¢‡πÉ‡∏à‡∏≠‡∏≠‡∏Å **‡∏õ‡∏Å‡∏ï‡∏¥ normal or physiological ‡∏à‡∏∞ 5-7 cm of H2O** \n\t- PEEP ‡∏õ‡πâ‡∏≠‡∏á‡∏Å‡∏±‡∏ô‡πÑ‡∏°‡πà‡πÉ‡∏´‡πâ alveoli collapse shut ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏´‡∏≤‡∏¢‡πÉ‡∏à‡πÑ‡∏î‡πâ ‡∏î‡∏±‡∏á‡∏ô‡∏±‡πâ‡∏ô‡∏¢‡∏¥‡πà‡∏á‡πÄ‡∏¢‡∏≠‡∏∞‡∏Å‡πá‡∏à‡∏∞‡∏¢‡∏¥‡πà‡∏á‡πÄ‡∏û‡∏¥‡πà‡∏° SpO2\n\t- ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤ PEEP ‡πÄ‡∏¢‡∏≠‡∏∞‡πÑ‡∏õ‡∏à‡∏∞‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏Ñ‡∏ß‡∏≤‡∏°‡∏î‡∏±‡∏ô‡πÉ‡∏ô‡∏õ‡∏≠‡∏î‡πÄ‡∏¢‡∏≠‡∏∞ ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡∏°‡∏≤‡πÄ‡∏•‡∏µ‡πâ‡∏¢‡∏á‡∏´‡∏±‡∏ß‡πÉ‡∏à‡∏ô‡πâ‡∏≠‡∏¢ ‡∏Ñ‡∏ß‡∏≤‡∏°‡∏î‡∏±‡∏ô‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡∏ï‡∏Å\n- Acute Respiratory Distress Syndrome (ARDS)\n\t- ![[Pasted image 20230130221736.png|325]]\n\t- Memo: TOIO ‡πÇ‡∏î‡∏¢ O = PaO2/FiO2 \u003c 300 mHg #recall1  #recall2  (Note: ‡∏£‡∏∞‡∏ß‡∏±‡∏á‡∏à‡∏≥‡∏ú‡∏¥‡∏î ‡∏≠‡∏±‡∏ô‡∏ô‡∏µ‡πâ‡∏Ñ‡πà‡∏≤‡∏ô‡πâ‡∏≠‡∏¢‡∏¢‡∏¥‡πà‡∏á‡πÅ‡∏¢‡πà ‡∏Ñ‡πà‡∏≤‡πÄ‡∏¢‡∏≠‡∏∞‡∏¢‡∏¥‡πà‡∏á‡∏î‡∏µ!)\n\t- FiO2 ‡∏´‡∏°‡∏≤‡∏¢‡∏ñ‡∏∂‡∏á fraction of oxygen ‡∏ó‡∏µ‡πà‡πÉ‡∏´‡πâ‡πÑ‡∏õ\n\t- PaO2 ‡∏õ‡∏Å‡∏ï‡∏¥‡∏à‡∏∞‡∏≠‡∏¢‡∏π‡πà‡∏ó‡∏µ‡πà 60-100\n\n## Respiratory Support\n- Oxygen Supplementation\n\t- Nasal cannula \u003c simple face mask \u003c non-rebreathing face mask \u003c high flow nasal cannula (HFNC)\n\t\t- nasal cannula \u0026 simple face mask ‡πÉ‡∏´‡πâ FiO2 ‡∏°‡∏≤‡∏Å‡∏™‡∏∏‡∏î 0.40\n\t\t- non-rebreathing face mask ‡πÉ‡∏´‡πâ‡πÑ‡∏î‡πâ‡∏°‡∏≤‡∏Å‡∏™‡∏∏‡∏î 0.7 (theory ‡∏Å‡πá‡∏ï‡πâ‡∏≠‡∏á 1.0)\n\t\t- HFNC ‡πÉ‡∏´‡πâ‡πÑ‡∏î‡πâ‡∏ï‡∏±‡πâ‡∏á‡πÅ‡∏ï‡πà 0.21-1.0 ‡∏•‡∏î WOB ‡πÑ‡∏î‡πâ‡∏î‡∏µ\n\t- Ambu Bag ‡πÉ‡∏´‡πâ FiO2 ‡πÑ‡∏î‡πâ 1\n\t- ‡∏ó‡∏∏‡∏Å L/min ‡∏Ç‡∏≠‡∏á oxygen ‡∏à‡∏∞‡πÄ‡∏û‡∏¥‡πà‡∏° FiO2 ‡∏õ‡∏£‡∏∞‡∏°‡∏≤‡∏ì 3% (0.03)\n\n## Inhalation Therapy\n- ‡∏Å‡∏≤‡∏£‡πÉ‡∏´‡πâ pMDI ‡∏™‡∏≥‡∏´‡∏£‡∏±‡∏ö‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏ó‡∏µ‡πà‡πÉ‡∏™‡πà ventilation ‡πÉ‡∏´‡πâ‡πÄ‡∏ö‡∏¥‡πâ‡∏•‡πÇ‡∏î‡∏™ x2 (‡∏õ‡∏£‡∏∞‡∏°‡∏≤‡∏ì 4-8 puff) ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏°‡∏µ‡πÄ‡∏™‡∏µ‡∏¢‡πÑ‡∏õ‡πÉ‡∏ô circuits\n- Nebulizers ‡πÄ‡∏Ñ‡∏£‡∏∑‡πà‡∏≠‡∏á‡∏ï‡∏µ‡πÉ‡∏´‡πâ‡πÄ‡∏õ‡πá‡∏ô‡∏•‡∏∞‡∏≠‡∏≠‡∏á‡∏ù‡∏≠‡∏¢\n\t- delivery ‡∏¢‡∏≤‡πÑ‡∏î‡πâ‡∏Å‡∏≤‡∏Å -\u003e ‡∏î‡∏µ ‡πÑ‡∏î‡πâ‡πÅ‡∏Å‡πà\n\t\t- jet nebulizer -\u003e ultrasonic nebulizer -\u003e vibrating mesh nebulizer #recall2 \n\t\t- ![[Pasted image 20230130222446.png|450]]\n\t- **‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πâ‡∏Å‡∏±‡∏ö‡πÇ‡∏£‡∏Ñ‡∏ï‡∏¥‡∏î‡∏ï‡πà‡∏≠!!! ‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å‡∏°‡∏µ infectious disease ‡∏ó‡∏µ‡πà‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡πÄ‡∏õ‡πá‡∏ô‡∏≠‡∏¢‡∏π‡πà ‡∏à‡∏∞‡πÄ‡∏õ‡∏•‡∏µ‡πà‡∏¢‡∏ô‡πÑ‡∏õ‡πÉ‡∏ä‡πâ MDI ‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤**\n\n## Ventilations\n- Noninvasive Ventilation (NIV) ‡πÄ‡∏õ‡πá‡∏ô‡πÄ‡∏´‡∏°‡∏∑‡∏≠‡∏ô bridge ‡πÑ‡∏ß‡πâ treat acute respiratory failure ‡πÅ‡∏•‡∏∞‡πÉ‡∏ä‡πâ‡πÅ‡∏Ñ‡πà‡∏Å‡∏±‡∏ö‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏ó‡∏µ‡πà‡∏ô‡πà‡∏≤‡∏à‡∏∞‡∏î‡∏µ‡∏Ç‡∏∂‡πâ‡∏ô‡πÉ‡∏ô 48-72 ‡∏ä‡∏° ‡πÑ‡∏°‡πà‡∏á‡∏±‡πâ‡∏ô‡∏Å‡πá‡πÑ‡∏õ‡πÉ‡∏ä‡πâ invasive ‡πÄ‡∏•‡∏¢\n\t- Indications ‡∏´‡∏•‡∏±‡∏Å‡πÉ‡∏ô‡∏Å‡∏≤‡∏£ NIV ‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏ó‡∏µ‡πà acute respiratory failure ‡πÑ‡∏î‡πâ‡πÅ‡∏Å‡πà #recall1 \n\t\t- **hypercarbic COPD exacerbation**\n\t\t- acute cardiogenic pulmonary edema\n\t\t- **‡∏≠‡∏≤‡∏à‡πÉ‡∏ä‡πâ post-extubation respiratory failure** ‡∏î‡πâ‡∏ß‡∏¢‡∏ñ‡πâ‡∏≤‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ high-risk\n\t- Modes: CPAP, BiPAP\n- Sedation Adequacy:\n\t- Agitated -\u003e ‡∏≠‡∏≤‡∏à‡∏ï‡πâ‡∏≠‡∏á‡πÉ‡∏ä‡πâ fentanyl iv con\n\t- Delirium -\u003e ‡∏≠‡∏≤‡∏à‡∏ï‡πâ‡∏≠‡∏á‡πÉ‡∏ä‡πâ haloperidol / quetiapine\n\t- RASS Score\n\t\t- ![[Pasted image 20230130223010.png|600]]\n- Invasive Mechanical Ventilation\n\t- Assist / Control\n\t\t- ‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡πÑ‡∏°‡πà‡∏ï‡πâ‡∏≠‡∏á‡∏ó‡∏≥‡πÑ‡∏£‡πÄ‡∏•‡∏¢ ‡∏Å‡πá‡∏´‡∏≤‡∏¢‡πÉ‡∏à‡πÑ‡∏î‡πâ‡πÇ‡∏î‡∏¢‡∏à‡∏∞‡∏°‡∏µ‡∏ó‡∏±‡πâ‡∏á PCV (pressure controlled ventilation) ‡πÅ‡∏•‡∏∞ VCV (volume controlled ventilation) ‡∏ó‡∏±‡πâ‡∏á‡∏™‡∏≠‡∏á‡∏≠‡∏±‡∏ô‡∏Ñ‡∏∑‡∏≠ Continuous mandatory ventilation (CMV)\n\t- Support\n\t\t- ‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏ï‡πâ‡∏≠‡∏á‡πÄ‡∏£‡∏¥‡πà‡∏°‡∏´‡∏≤‡∏¢‡πÉ‡∏à ‡∏´‡∏¢‡∏∏‡∏î‡∏´‡∏≤‡∏¢‡πÉ‡∏à‡πÄ‡∏≠‡∏á\n\n## Medications\n- Anesthetics PK\n\t- Context-sensitive half-lives ‡∏´‡∏°‡∏≤‡∏¢‡∏ñ‡∏∂‡∏á ‡∏¢‡∏≤‡∏¢‡∏¥‡πà‡∏á‡πÉ‡∏ä‡πâ‡∏ô‡∏≤‡∏ô (infusion duration ‡πÄ‡∏¢‡∏≠‡∏∞) ‡∏¢‡∏≤‡∏Å‡πá‡∏à‡∏∞‡∏¢‡∏¥‡πà‡∏á half-life ‡∏ô‡∏≤‡∏ô\n- Airway Medications\n\t- Sedatives: opioids | BZPs | propofol | etomidate | ketamine | barbiturates\n\t- NMBAs: succinylcholine | rocuronium | cisatracurium\n- RSI medication\n\t- IV Anesthetics\n\t\t- Propofol\n\t\t\t- 0.5 - 1.5 mg/kg\n\t\t- Etomidate\n\t\t\t- 0.3 - 0.5 mg/kg\n\t\t- Ketamine\n\t\t\t- 1 - 2 mg/kg\n\t- NMBAs\n\t\t- for RSI\n\t\t\t- Succinylcholine\n\t\t\t\t- 1 mg/kg/ IV\n\t\t\t\t- ‡πÄ‡∏û‡∏¥‡πà‡∏° potassium ‡∏î‡∏±‡∏á‡∏ô‡∏±‡πâ‡∏ô‡∏£‡∏∞‡∏ß‡∏±‡∏á arrythymia ‡πÉ‡∏ô‡∏Ñ‡∏ô‡∏ó‡∏µ‡πà K ‡∏™‡∏π‡∏á‡∏´‡∏£‡∏∑‡∏≠ CKD\n\t\t\t- Rocuronium\n\t\t\t\t- 1 - 1.2 mg/kg\n\t\t\t\t- ‡∏ú‡πà‡∏≤‡∏ô‡∏ï‡∏±‡∏ö ‡πÄ‡∏•‡∏µ‡πà‡∏¢‡∏á‡πÉ‡∏ô liver failure\n\t\t- for moderate to severe ARDs\n\t\t\t- Cisatracurium (NIMBEX)\n\t\t\t\t- ‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πâ RSI ‡πÄ‡∏û‡∏£‡∏≤‡∏∞ slow onset\n- Continuous IV Sedations\n\t- ![[Pasted image 20230202223902.png|675]]\n\t- **Fentanyl**\n\t\t- typical dose 50-100 mcg IV bolus\n\t\t\t- 25-100 mcg/h IV infusion\n\t\t- ‡πÄ‡∏û‡∏¥‡πà‡∏°‡∏•‡∏î‡∏¢‡∏≤‡∏ó‡∏µ‡∏•‡∏∞ 25 \n\t- Morphine\n\t- **Midazolam**\n\t\t- ‡∏£‡∏∞‡∏ß‡∏±‡∏á amnesia ‡πÅ‡∏•‡∏∞ respiratory depression\n\t- Propofol\n\t\t- 0.5 - 1.5 mg/kg IV bolus\n\t\t- 1 - 5 mg/kg/h IV infusion\n\t\t- **‡∏£‡∏∞‡∏ß‡∏±‡∏á amnesia ‡πÅ‡∏•‡∏∞ respiratory depression**\n\t\t- **high dose \u0026 prolonged infusion -\u003e PRIS**\n\t\t- **‡πÄ‡∏Å‡∏¥‡∏î brady / hypotension ‡πÑ‡∏î‡πâ‡πÄ‡∏¢‡∏≠‡∏∞**\n\t- Dexmedetomidine\n\t\t- ‡πÄ‡∏Å‡∏¥‡∏î brady / hypotension ‡πÑ‡∏î‡πâ‡πÄ‡∏¢‡∏≠‡∏∞\n\n## Weaning off\n- ‡∏≠‡∏≤‡∏à‡∏•‡∏≠‡∏á‡∏ó‡∏≥ spontaneous breathing trial (SBT)\n\t- ‡πÉ‡∏ä‡πâ T-piece ‡πÑ‡∏°‡πà‡∏ï‡πà‡∏≠‡πÄ‡∏Ç‡πâ‡∏≤‡πÄ‡∏Ñ‡∏£‡∏∑‡πà‡∏≠‡∏á ‡∏´‡∏£‡∏∑‡∏≠ low-level pressure support ventilation\n\t- ‡πÄ‡∏õ‡πá‡∏ô‡∏Å‡∏≤‡∏£‡∏à‡∏≥‡∏•‡∏≠‡∏á post-extubating conditions\n- ‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏ñ‡∏≠‡∏î‡∏ó‡πà‡∏≠‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ ‡∏´‡∏≤‡∏¢‡πÉ‡∏à‡πÄ‡∏≠‡∏á‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏ï‡πâ‡∏≠‡∏á‡∏û‡∏∂‡πà‡∏á‡∏û‡∏≤‡πÄ‡∏Ñ‡∏£‡∏∑‡πà‡∏≠‡∏á = ventilator dependence\n- cuff leak test ‡πÄ‡∏õ‡πá‡∏ô‡∏Å‡∏≤‡∏£‡∏ó‡∏î‡∏™‡∏≠‡∏ö‡∏î‡∏π‡∏ß‡πà‡∏≤‡∏à‡∏∞‡πÄ‡∏Å‡∏¥‡∏î post-extubating stridor (PES) ‡πÑ‡∏´‡∏° ‡πÄ‡∏õ‡πá‡∏ô‡∏Å‡∏≤‡∏£‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô‡∏ß‡πà‡∏≤‡∏´‡∏•‡∏≠‡∏î‡∏•‡∏°‡∏à‡∏∞‡∏ö‡∏ß‡∏°‡πÑ‡∏´‡∏° ‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å‡∏´‡∏•‡∏≠‡∏î‡∏•‡∏°‡∏ö‡∏ß‡∏° (cuff leak negative) ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏≠‡∏≤‡∏à‡∏à‡∏∞‡∏ï‡πâ‡∏≠‡∏á‡πÉ‡∏™‡πà‡πÄ‡∏Ç‡πâ‡∏≤‡πÑ‡∏õ‡πÉ‡∏´‡∏°‡πà ‡∏ñ‡πâ‡∏≤‡∏ï‡πâ‡∏≠‡∏á‡πÉ‡∏™‡πà‡πÄ‡∏Ç‡πâ‡∏≤‡πÑ‡∏õ‡πÉ‡∏´‡∏°‡πà‡πÄ‡∏£‡∏≤‡∏≠‡∏≤‡∏à‡∏ï‡πâ‡∏≠‡∏á‡πÉ‡∏™‡πà‡∏ó‡πà‡∏≠‡∏ä‡πà‡∏ß‡∏¢‡∏´‡∏≤‡∏¢‡πÉ‡∏à‡πÄ‡∏ö‡∏≠‡∏£‡πå‡πÄ‡∏•‡πá‡∏Å‡∏°‡∏≤‡∏Å‡∏Ç‡∏∂‡πâ‡∏ô‡πÄ‡∏û‡∏∑‡πà‡∏≠‡πÉ‡∏´‡πâ‡∏°‡∏±‡∏ô‡πÉ‡∏™‡πà‡πÄ‡∏Ç‡πâ‡∏≤‡πÑ‡∏õ‡πÑ‡∏î‡πâ ‡∏õ‡∏±‡∏ç‡∏´‡∏≤‡∏Ñ‡∏∑‡∏≠ O2 ‡∏à‡∏∞‡πÄ‡∏Ç‡πâ‡∏≤‡πÑ‡∏õ‡πÑ‡∏î‡πâ‡∏ô‡πâ‡∏≠‡∏¢‡∏•‡∏á\n\t- ‡∏ï‡∏≠‡∏ô‡πÉ‡∏™‡πà‡∏ó‡πà‡∏≠‡πÅ‡∏•‡πâ‡∏ß‡πÉ‡∏™‡πà pressure ‡πÄ‡∏Ç‡πâ‡∏≤ cuff ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏•‡∏°‡πÄ‡∏Ç‡πâ‡∏≤‡πÅ‡∏Ñ‡πà‡∏ú‡πà‡∏≤‡∏ô‡∏ó‡πà‡∏≠‡∏ä‡πà‡∏ß‡∏¢‡∏´‡∏≤‡∏¢‡πÉ‡∏à\n\t- ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤‡πÄ‡∏≠‡∏≤‡∏ö‡∏°‡∏≠‡∏≠‡∏Å ‡∏•‡∏°‡∏Å‡πá‡∏à‡∏∞‡∏ú‡πà‡∏≤‡∏ô‡πÄ‡∏Ç‡πâ‡∏≤‡∏≠‡∏≠‡∏Å‡πÑ‡∏î‡πâ‡πÑ‡∏î‡πâ‡∏´‡∏•‡∏≤‡∏¢‡∏ó‡∏≤‡∏á ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡πÄ‡∏ß‡∏•‡∏≤‡∏ü‡∏±‡∏á‡∏´‡∏•‡∏≠‡∏î‡∏•‡∏°‡∏¢‡∏±‡∏á‡πÑ‡∏î‡πâ‡∏¢‡∏¥‡∏ô‡πÄ‡∏™‡∏µ‡∏¢‡∏á‡∏≠‡∏¢‡∏π‡πà ‡πÅ‡∏õ‡∏•‡∏ß‡πà‡∏≤ cuff leak test positive ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏°‡∏±‡∏ô‡πÑ‡∏°‡πà‡∏ö‡∏ß‡∏°\n\t\t- ![[Pasted image 20230131183309.png|275]]\n\t- ‡∏ñ‡πâ‡∏≤‡∏´‡∏•‡∏≠‡∏î‡∏•‡∏°‡∏ö‡∏ß‡∏° ‡∏°‡∏±‡∏ô‡∏à‡∏∞‡∏ü‡∏±‡∏á‡πÅ‡∏•‡πâ‡∏ß‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏¢‡∏¥‡∏ô‡πÄ‡∏™‡∏µ‡∏¢‡∏á ‡∏´‡∏°‡∏≤‡∏¢‡∏ñ‡∏∂‡∏á cuff leak test negative\n- cuff leak ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏ö‡πà‡∏á‡∏ö‡∏≠‡∏Å‡∏ß‡πà‡∏≤‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏à‡∏∞‡∏ñ‡∏≠‡∏î‡∏ó‡πà‡∏≠‡πÑ‡∏î‡πâ‡∏´‡∏£‡∏∑‡∏≠‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ ‡πÅ‡∏ï‡πà‡∏ö‡πà‡∏á‡∏ö‡∏≠‡∏Å‡∏Ñ‡∏ß‡∏≤‡∏°‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á‡πÑ‡∏î‡πâ‡∏´‡∏•‡∏±‡∏á‡∏à‡∏≤‡∏Å‡∏ñ‡∏≠‡∏î‡∏ó‡πà‡∏≠ ‡πÄ‡∏£‡∏≤‡∏à‡∏∞‡πÑ‡∏î‡πâ‡πÄ‡∏ï‡∏£‡∏µ‡∏¢‡∏°‡∏Å‡∏≤‡∏£ manage ‡πÑ‡∏î‡πâ‡∏ñ‡∏π‡∏Å‡∏ß‡πà‡∏≤‡∏à‡∏∞‡∏ó‡∏≥‡∏¢‡∏±‡∏á‡πÑ‡∏á‡πÉ‡∏´‡πâ‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏ñ‡∏≠‡∏î‡∏ó‡πà‡∏≠‡πÑ‡∏î‡πâ ‡∏Å‡∏≤‡∏£‡∏à‡∏±‡∏î‡∏Å‡∏≤‡∏£‡πÑ‡∏î‡πâ‡πÅ‡∏Å‡πà #recall1 \n\t- ‡∏Å‡πà‡∏≠‡∏ô‡∏ñ‡∏≠‡∏î 24 ‡∏ä‡∏°‡πÉ‡∏ä‡πâ **dexamethasone** IV\n\t- ‡∏´‡∏•‡∏±‡∏á‡∏ñ‡∏≠‡∏î ‡∏≠‡∏≤‡∏à‡πÉ‡∏ä‡πâ **adrenaline nebulization** q4h ‡∏ñ‡πâ‡∏≤‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏à‡∏£‡∏¥‡∏á ‡πÜ ‡∏Ñ‡πà‡∏≠‡∏¢‡πÉ‡∏™‡πà‡πÉ‡∏´‡∏°‡πà\n\n## Stress-related mucosal damage\n- ‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏ó‡∏µ‡πà‡πÉ‡∏™‡πà mechanical ventilation, coagulopathy ‡∏à‡∏∞‡∏°‡∏µ‡∏Ñ‡∏ß‡∏≤‡∏°‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á\n- ‡∏ô‡∏¥‡∏¢‡∏°‡πÉ‡∏´‡πâ PPI prophylaxis (omeprazole IV 40mg od ‡∏´‡∏£‡∏∑‡∏≠ oral 20 od / bid ‡∏ñ‡πâ‡∏≤‡∏´‡∏ô‡∏±‡∏Å) ‡πÅ‡∏Ñ‡πà‡πÉ‡∏ô‡πÄ‡∏Ñ‡∏™‡∏ó‡∏µ‡πà risk \u003e 4% ‡πÑ‡∏î‡πâ‡πÅ‡∏Å‡πà\n\t\t- concerning coagulopathy\n\t\t- chronic liver disease\n\t\t- mechanical ventilation **without enteral nutrition** (‡∏´‡∏£‡∏∑‡∏≠‡∏≠‡∏≤‡∏à‡πÉ‡∏ä‡πâ NG feed)\n\t\t\t- ‡∏Å‡∏≤‡∏£‡πÉ‡∏´‡πâ NG feed ‡πÄ‡∏û‡∏∑‡πà‡∏≠‡πÄ‡∏û‡∏¥‡πà‡∏° integrity ‡∏•‡∏î Gi infection\n\t\t- ‡∏´‡∏£‡∏∑‡∏≠ 2 ‡∏Ç‡πâ‡∏≠‡πÉ‡∏ô‡∏ï‡πà‡∏≠‡πÑ‡∏õ‡∏ô‡∏µ‡πâ\n\t\t\t- mechanical ventilation with enteral nutrition\n\t\t\t- AKI\n\t\t\t- sepsis shock","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/SLE":{"title":"SLE","content":"## Definition \u0026 Risk Factors\n- ‡πÄ‡∏õ‡πá‡∏ô‡πÇ‡∏£‡∏Ñ autoimmune ‡∏ó‡∏±‡πâ‡∏á CMI, HMI\n- ‡πÄ‡∏õ‡πá‡∏ô‡πÉ‡∏ô‡∏ú‡∏π‡πâ‡∏´‡∏ç‡∏¥‡∏á \u003e ‡∏ú‡∏π‡πâ‡∏ä‡∏≤‡∏¢\n- ‡∏Æ‡∏≠‡∏£‡πå‡πÇ‡∏°‡∏ô ‡πÄ‡∏ä‡πà‡∏ô estrogen\n- ‡πÄ‡∏õ‡πá‡∏ô‡πÉ‡∏ô‡∏ß‡∏±‡∏¢‡πÄ‡∏à‡∏£‡∏¥‡∏ç‡∏û‡∏±‡∏ô‡∏ò‡∏∏‡πå‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤\n- ‡∏û‡∏±‡∏ô‡∏ò‡∏∏‡∏Å‡∏£‡∏£‡∏°‡∏°‡∏µ‡∏™‡πà‡∏ß‡∏ô‡πÄ‡∏Å‡∏µ‡πà‡∏¢‡∏ß‡∏Ç‡πâ‡∏≠‡∏á\n- ‡∏™‡∏¥‡πà‡∏á‡πÅ‡∏ß‡∏î‡∏•‡πâ‡∏≠‡∏° ‡∏™‡∏≤‡∏£‡∏ó‡∏µ‡πà‡πÑ‡∏î‡πâ‡∏£‡∏±‡∏ö‡∏Å‡πá‡∏°‡∏µ‡∏™‡πà‡∏ß‡∏ô‡πÄ‡∏Å‡∏µ‡πà‡∏¢‡∏ß‡∏Ç‡πâ‡∏≠‡∏á\n\t- ‡∏Å‡∏≤‡∏£‡πÑ‡∏î‡πâ‡∏£‡∏±‡∏ö‡πÑ‡∏õ‡∏ô‡∏≤‡∏ô ‡πÜ ‡πÄ‡∏´‡∏°‡∏∑‡∏≠‡∏ô self-tolerance ‡∏Ç‡∏≠‡∏á innate immunity ‡∏•‡∏î‡∏•‡∏á ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡πÄ‡∏Å‡∏¥‡∏î auto-antibodies production\n- ‡∏Å‡∏≤‡∏£‡∏ï‡∏¥‡∏î‡πÄ‡∏ä‡∏∑‡πâ‡∏≠ EBV\n- UV\n\n## Pathophysiology and Clinical Features\n- ‡∏°‡∏µ‡∏Å‡∏≤‡∏£‡∏™‡∏£‡πâ‡∏≤‡∏á‡∏†‡∏π‡∏°‡∏¥‡∏Ñ‡∏∏‡πâ‡∏°‡∏Å‡∏±‡∏ô‡∏ï‡πà‡∏≠ nucleus ‡∏Ç‡∏≠‡∏á‡πÄ‡∏ã‡∏•‡∏•‡πå (autoantibody) ‡πÄ‡∏ä‡πà‡∏ô **anti-dsDNA** ‡πÅ‡∏•‡∏∞ **anti-Sm**\n- immune complex ‡∏ó‡∏µ‡πà‡πÄ‡∏Å‡∏¥‡∏î‡πÑ‡∏õ‡∏ï‡∏Å‡∏ï‡∏∞‡∏Å‡∏≠‡∏ô‡∏ï‡∏≤‡∏°‡∏≠‡∏ß‡∏±‡∏¢‡∏ß‡∏∞‡∏ï‡πà‡∏≤‡∏á ‡πÜ ‡πÄ‡∏Å‡∏¥‡∏î‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏ï‡∏≤‡∏°‡∏≠‡∏ß‡∏±‡∏¢‡∏ß‡∏∞‡∏ô‡∏±‡πâ‡∏ô ‡πÜ\n- ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏û‡∏ö‡πÑ‡∏î‡πâ‡∏°‡∏≤‡∏Å‡∏ó‡∏µ‡πà‡∏™‡∏∏‡∏î‡∏à‡∏∞‡πÄ‡∏õ‡πá‡∏ô‡∏ó‡∏≤‡∏á‡∏Ç‡πâ‡∏≠‡πÅ‡∏•‡∏∞‡∏ú‡∏¥‡∏ß‡∏´‡∏ô‡∏±‡∏á (90%) ‡∏ã‡∏∂‡πà‡∏á‡∏´‡∏≤‡∏Å‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏°‡∏µ‡πÅ‡∏Ñ‡πà 2 ‡∏£‡∏∞‡∏ö‡∏ö‡∏ô‡∏µ‡πâ prognosis ‡∏°‡∏±‡∏Å‡∏à‡∏∞‡∏î‡∏µ ‡πÉ‡∏ô‡∏ó‡∏≤‡∏á‡∏ï‡∏£‡∏á‡∏Å‡∏±‡∏ô‡∏Ç‡πâ‡∏≤‡∏° ‡∏´‡∏≤‡∏Å‡∏°‡∏µ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏£‡∏∞‡∏ö‡∏ö‡∏≠‡∏∑‡πà‡∏ô ‡πÜ ‡πÄ‡∏ä‡πà‡∏ô CNS ‡∏´‡∏£‡∏∑‡∏≠ renal ‡∏°‡∏±‡∏Å‡∏à‡∏∞ prognosis ‡∏´‡πà‡∏ß‡∏¢‡πÅ‡∏ï‡∏Å\n\n### Skin\n- ‡∏à‡∏∞‡∏°‡∏µ‡∏ú‡∏∑‡πà‡∏ô‡∏ó‡∏µ‡πà‡πÄ‡∏â‡∏û‡∏≤‡∏∞‡πÄ‡∏à‡∏≤‡∏∞‡∏à‡∏á‡∏Å‡∏±‡∏ö‡πÇ‡∏£‡∏Ñ\n- acute LE\n\t- malar rash or butterfly rash : ‡πÄ‡∏õ‡πâ‡∏ô‡∏ú‡∏∑‡πà‡∏ô‡∏ó‡∏µ‡πà‡πÑ‡∏°‡πà‡πÄ‡∏Å‡∏¥‡∏î‡πÉ‡∏ô‡∏ö‡∏£‡∏¥‡πÄ‡∏ß‡∏ì nasolabial folds\n\t- bullous LE ‡πÄ‡∏õ‡πá‡∏ô‡∏ú‡∏∑‡πà‡∏ô‡∏ï‡∏∏‡πà‡∏°‡∏ô‡πâ‡∏≥\n- subacute LE\n\t- psoriatic like, ‡∏ß‡∏á ‡πÜ ‡∏Ç‡∏≠‡∏ö‡πÅ‡∏î‡∏á ‡∏Å‡∏•‡∏≤‡∏á‡∏Ç‡∏≤‡∏ß\n- chronic LE\n\t- discoid rash\n\t\t- ‡πÄ‡∏õ‡πá‡∏ô‡πÄ‡∏´‡∏°‡∏∑‡∏≠‡∏ô‡∏™‡πÄ‡∏Å‡πá‡∏î‡πÄ‡∏á‡∏¥‡∏ô‡πÄ‡∏•‡πá‡∏Å ‡πÜ\n\t\t- ‡∏°‡∏µ‡∏™‡πÄ‡∏Å‡πá‡∏î\n\t\t- ‡∏û‡∏ö hair scaring ‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏ï‡πà‡∏≠‡∏°‡πÑ‡∏Ç‡∏°‡∏±‡∏ô‡πÅ‡∏•‡∏∞‡∏£‡∏π‡∏Ç‡∏∏‡∏°‡∏Ç‡∏ô‡∏ñ‡∏π‡∏Å‡∏ó‡∏≥‡∏ó‡∏•‡∏≤‡∏¢‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡πÄ‡∏°‡πá‡∏î‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡∏Ç‡∏≤‡∏ß\n\n### Joint\n- arthritis ‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤ 2 ‡∏Ç‡πâ‡∏≠ ‡∏Ñ‡∏•‡πâ‡∏≤‡∏¢ RA\n- +- ‡∏õ‡∏ß‡∏î ‡∏Å‡∏≤‡∏£‡∏î‡∏≥‡πÄ‡∏ô‡∏¥‡∏ô‡πÇ‡∏£‡∏Ñ‡πÑ‡∏°‡πà‡πÄ‡∏£‡∏∑‡πâ‡∏≠‡∏£‡∏±‡∏á\n- **‡∏ú‡∏• film ‡∏à‡∏∞‡πÑ‡∏°‡πà‡πÄ‡∏à‡∏≠ erosion!! ‡∏ï‡πà‡∏≤‡∏á‡∏à‡∏≤‡∏Å [[notes/OA]] ‡πÅ‡∏•‡∏∞ [[notes/RA]]**\n\n### Renal\n- Lupus nephritis ‡∏û‡∏ö‡πÉ‡∏ô‡πÄ‡∏≠‡πÄ‡∏ä‡∏µ‡∏¢‡πÄ‡∏¢‡∏≠‡∏∞‡∏™‡∏∏‡∏î\n- ‡∏°‡∏±‡∏Å‡πÄ‡∏Å‡∏¥‡∏î‡πÉ‡∏ô 3-5 ‡∏õ‡∏µ‡πÅ‡∏£‡∏Å‡∏Ç‡∏≠‡∏á‡πÇ‡∏£‡∏Ñ\n- ‡∏°‡∏±‡∏Å‡∏û‡∏ö‡πÇ‡∏õ‡∏£‡∏ï‡∏µ‡∏ô‡∏£‡∏±‡πà‡∏ß ‡πÅ‡∏°‡πâ‡∏Ñ‡∏∏‡∏° BP ‡πÑ‡∏î‡πâ‡πÅ‡∏•‡πâ‡∏ß‡∏Å‡πá‡∏ï‡∏≤‡∏°\n- ‡∏Å‡∏≤‡∏£‡∏ó‡∏≥‡∏á‡∏≤‡∏ô‡πÑ‡∏ï‡∏•‡∏î‡πÄ‡∏£‡πá‡∏ß‡∏Å‡∏ß‡πà‡∏≤ AKI\n- ‡∏Ñ‡∏ß‡∏£‡∏ó‡∏≥ biopsy ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏°‡∏µ‡∏Å‡∏≤‡∏£ classify ‡∏ï‡∏≤‡∏° histology\n\t- Class III , Class IV ‡∏Ñ‡πà‡∏≠‡∏ô‡∏Ç‡πâ‡∏≤‡∏á active\n\t- Class V cell ‡∏ï‡∏≤‡∏¢\n\t- Class VI ‡πÑ‡∏°‡πà‡πÄ‡∏´‡∏•‡∏∑‡∏≠‡πÑ‡∏£‡πÅ‡∏•‡πâ‡∏ß\n- ‡∏£‡∏±‡∏Å‡∏©‡∏≤‡∏ï‡∏≤‡∏° **KDIGO2021**\n- ‡πÄ‡∏Å‡∏¥‡∏î‡∏à‡∏≤‡∏Å immune complex ‡πÑ‡∏õ deposit ‡πÅ‡∏ï‡πà organ ‡∏≠‡∏∑‡πà‡∏ô‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡πÅ‡∏õ‡∏•‡∏ß‡πà‡∏≤‡∏à‡∏∞‡∏ï‡πâ‡∏≠‡∏á‡∏°‡∏≤‡∏à‡∏≤‡∏Å immune complex!\n\n### Hematologic\n- ‡∏≠‡∏≤‡∏à‡πÄ‡∏Å‡∏¥‡∏î autolytic hemolysis ‡∏ú‡∏¥‡∏î‡∏õ‡∏Å‡∏ï‡∏¥‡∏ó‡∏±‡πâ‡∏á wbc, rbc ‡πÅ‡∏•‡∏∞ platelet (leukopenia, lymphopenia, thrombocytopenia)\n- ‡∏ñ‡πâ‡∏≤ autoimmune hemolytic anema ‡∏à‡∏∞‡∏ï‡πâ‡∏≠‡∏á‡∏û‡∏ö‡∏ú‡∏• coomb's test positive \n\t- coomb test ‡πÄ‡∏õ‡πá‡∏ô‡∏Å‡∏≤‡∏£‡∏ó‡∏î‡∏™‡∏≠‡∏ö‡∏ß‡πà‡∏≤‡∏°‡∏µ anti-rbc antibody ‡∏≠‡∏¢‡∏π‡πà‡∏´‡∏£‡∏∑‡∏≠‡πÑ‡∏°‡πà / ‡πÄ‡∏õ‡πá‡∏ô‡∏Å‡∏≤‡∏£‡∏ó‡∏î‡∏™‡∏≠‡∏ö‡∏ß‡πà‡∏≤‡∏°‡∏µ antibody ‡πÄ‡∏Å‡∏≤‡∏∞‡∏≠‡∏¢‡∏π‡πà‡∏ö‡∏ô rbc ‡∏´‡∏£‡∏∑‡∏≠‡πÑ‡∏°‡πà\n- ‡∏£‡∏∞‡∏ß‡∏±‡∏á‡∏™‡∏±‡∏ö‡∏™‡∏ô‡∏Å‡∏≤‡∏£‡∏ã‡∏µ‡∏î‡∏à‡∏≤‡∏Å‡∏¢‡∏≤‡∏Å‡∏î‡∏†‡∏π‡∏°‡∏¥\n- SLE ‡∏°‡∏µ‡∏õ‡∏±‡∏ç‡∏´‡∏≤‡∏ó‡∏≤‡∏á‡∏î‡πâ‡∏≤‡∏ô metabolic ‡∏î‡∏±‡∏á‡∏ô‡∏±‡πâ‡∏ô‡πÄ‡∏õ‡πá‡∏ô major risk ‡∏Ç‡∏≠‡∏á‡πÇ‡∏£‡∏Ñ‡∏ó‡∏≤‡∏á CVD\n\n## Classification (Diagnosis)\n- ‡πÑ‡∏°‡πà‡∏°‡∏µ‡πÄ‡∏Å‡∏ì‡∏ë‡πå‡∏ß‡∏¥‡∏ô‡∏¥‡∏à‡∏â‡∏±‡∏¢ ‡πÄ)‡πâ‡∏ô‡πÅ‡∏Ñ‡πà‡πÄ‡∏Å‡∏ì‡∏ë‡πå‡πÉ‡∏ô‡∏Å‡∏≤‡∏£ classification\n\t- ACR\n\t- 2012 SLICC\n\t- **2019 EULAR/ACR** ‡πÉ‡∏´‡∏°‡πà‡∏™‡∏∏‡∏î ‡∏Ç‡πâ‡∏≠‡πÄ‡∏™‡∏µ‡∏¢‡∏Ñ‡∏∑‡∏≠‡∏ó‡∏î‡∏™‡∏≠‡∏ö‡πÅ‡∏Ñ‡πà‡πÉ‡∏ô US\u0026EU ‡πÅ‡∏•‡∏∞‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏ó‡∏î‡∏™‡∏≠‡∏ö‡πÉ‡∏ô‡πÄ‡∏î‡πá‡∏Å\n- EULAR/ACR entry criteria\n\t- ANA positive at \u003e= 1:80 titer\n\t\t- pos -\u003e additive criteria ‡πÇ‡∏î‡∏¢‡∏ï‡πâ‡∏≠‡∏á \u003e= 10 ‡∏Ñ‡∏∞‡πÅ‡∏ô‡∏ô ‡πÅ‡∏•‡∏∞‡∏à‡∏∞‡∏ï‡πâ‡∏≠‡∏á‡∏°‡∏µ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏ó‡∏≤‡∏á‡∏ù‡∏±‡πà‡∏á clinic ‡∏≠‡∏¢‡πà‡∏≤‡∏á‡∏ô‡πâ‡∏≠‡∏¢ 1 ‡∏Ç‡πâ‡∏≠ ‡∏Å‡πá‡∏à‡∏∞‡∏ñ‡∏∑‡∏≠‡∏ß‡πà‡∏≤‡πÄ‡∏õ‡πá‡∏ô classified SLE\n\t\t- neg -\u003e ‡πÑ‡∏°‡πà‡∏ï‡πâ‡∏≠‡∏á‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô‡∏ï‡πà‡∏≠\n\t\t- note: ‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å‡∏Ñ‡∏∞‡πÅ‡∏ô‡∏ô‡πÑ‡∏°‡πà‡∏ñ‡∏∂‡∏á 10 ‡πÅ‡∏ï‡πà‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡πÄ‡∏Ç‡πâ‡∏≤‡πÑ‡∏î‡πâ ‡∏´‡∏£‡∏∑‡∏≠ ANA neg ‡πÅ‡∏ï‡πà entry criterion ‡∏≠‡∏∑‡πà‡∏ô‡πÄ‡∏Ç‡πâ‡∏≤ ‡∏Å‡πá‡∏à‡∏∞‡∏ñ‡∏∑‡∏≠‡∏ß‡πà‡∏≤‡πÄ‡∏õ‡πá‡∏ô clinical SLE\n\n### Monitoring\n- SLEDIA-2K\n\t- Remission = 0\n\t- Low Activity = 1-4\n\n## General SLE Management\n\n### Non-pharmacological management\n- [[#Skin]] -\u003e ‡∏Ñ‡∏£‡∏µ‡∏°‡∏Å‡∏±‡∏ô‡πÅ‡∏î‡∏î\n- [[#Joint]] -\u003e ‡∏ó‡∏≥ rehab \n- ‡∏ô‡∏≠‡∏ô‡∏û‡∏±‡∏Å‡∏ú‡πà‡∏≠‡∏ô‡πÉ‡∏´‡πâ‡πÄ‡∏û‡∏µ‡∏¢‡∏á‡∏û‡∏≠ ‡∏£‡∏∞‡∏ß‡∏±‡∏á‡πÄ‡∏£‡∏¥‡∏°‡∏ö‡∏∏‡∏Å‡∏à‡πâ‡∏≤\n- **‡∏Å‡∏≤‡∏£‡∏ß‡∏≤‡∏á‡πÅ‡∏ú‡∏ô‡∏ï‡∏±‡πâ‡∏á‡∏Ñ‡∏£‡∏£‡∏†‡πå‡∏™‡∏≥‡∏Ñ‡∏±‡∏ç‡∏°‡∏≤‡∏Å‡∏Å‡∏Å‡∏Å‡∏Å‡∏Å‡∏Å‡∏Å‡∏Å‡∏Å‡∏Å‡∏Å**\n\n\n### Pharmacological management\n![[Pasted image 20230308154020.png|500]]\n![[Pasted image 20230308154054.png]]\n![[Pasted image 20230308154100.png]]\n\n## Lupus Nephritis Management\n- ACEi, ARB to reduce proteinuria\n- ‡∏Ñ‡∏∏‡∏° BP ‡πÑ‡∏°‡πà‡πÉ‡∏´‡πâ‡πÄ‡∏Å‡∏¥‡∏ô 130/80 mmHg\n- ‡∏°‡∏±‡∏Å‡∏à‡∏∞‡∏£‡∏±‡∏Å‡∏©‡∏≤ Class III ‡πÅ‡∏•‡∏∞ Class IV\n\t- ![[Pasted image 20230308154228.png|475]]\n\t- ![[Pasted image 20230308154238.png|500]]\n\t- Euro-lupus regimen : IV CY 500 every 2 weeks for six dose\n\t\t- response well in white and asian patient\n\t- NIH Regimen : IV CY 500-1000 mg/m2 BSA once a month for six dose\n\t\t- response well in african, american, hispanic\n\t- ‡∏´‡∏•‡∏±‡∏á Maintenance ‡πÉ‡∏´‡πâ tape prednisolone ‡∏•‡∏á‡∏°‡∏≤‡πÉ‡∏´‡πâ‡πÑ‡∏î‡πâ\n- Class V\n\t- ‡∏ñ‡πâ‡∏≤‡∏™‡∏π‡∏ç‡πÄ‡∏™‡∏µ‡∏¢‡πÑ‡∏ï‡πÑ‡∏õ‡∏ö‡∏≤‡∏á‡∏™‡πà‡∏ß‡∏ô‡πÅ‡∏•‡πâ‡∏ß ‡πÉ‡∏´‡πâ‡∏ä‡∏±‡πà‡∏á risk and benefit ‡πÉ‡∏´‡πâ‡∏î‡∏µ‡∏ß‡πà‡∏≤‡∏Ñ‡∏ß‡∏£‡πÄ‡∏£‡∏¥‡πà‡∏° immunsupressive ‡∏°‡∏±‡πâ‡∏¢\n\t- ‡πÄ‡∏ô‡πâ‡∏ô‡∏Å‡∏≤‡∏£‡∏Ñ‡∏∏‡∏° level of proteinuria and complication ‡∏ó‡∏µ‡πà‡∏≠‡∏≤‡∏à‡∏ï‡∏≤‡∏°‡∏°‡∏≤\n\n## Pharmacotherapy ‡πÅ‡∏ö‡∏ö‡πÄ‡∏ô‡πâ‡∏ô ‡πÜ\n- ![[CC1 - MCQ#^519a53]]\n- ‡∏Å‡∏≤‡∏£‡πÉ‡∏´‡πâ Corticosteroid ‡πÉ‡∏ô SLE ‡∏°‡∏µ‡∏´‡∏•‡∏≤‡∏¢‡πÅ‡∏ö‡∏ö\n\t- Pulse GC : \u003e= 250 mg PDNeq/day ‡πÉ‡∏ä‡πâ‡∏™‡∏≥‡∏´‡∏£‡∏±‡∏ö‡πÄ‡∏Ñ‡∏™ life threatening ‡πÉ‡∏´‡πâ‡∏£‡∏∞‡∏ß‡∏±‡∏á fluid overload, neuro symptoms, uncontrolled bp, cardiac arhythmia ‡∏°‡∏±‡∏Å‡πÉ‡∏ä‡πâ‡πÑ‡∏°‡πà‡πÄ‡∏Å‡∏¥‡∏î 2-3 ‡∏ß‡∏±‡∏ô\n\t- Moderate Dose : \u003e7.5-30 PDNeq/day IV or po ‡∏°‡∏±‡∏Å‡πÉ‡∏ä‡πâ‡πÄ‡∏ß‡∏•‡∏≤ flare\n\t- Low Dose GCs: \u003c= 7.5 PDNeq/day po\n\t- Alternate-day : ‡πÉ‡∏ä‡πâ tape seteroid ‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤\n- ‡∏≠‡∏¢‡πà‡∏≤‡∏•‡∏∑‡∏° ADR steroid\n\t- osteonecrosis ‡∏≠‡∏±‡∏ô‡∏ï‡∏£‡∏≤‡∏¢!\n\t- osteoporosis when long-term use -\u003e fracture\n\t- adrenal insuff -\u003e tired\n\t- psychosis\n- Contraindication ‡πÉ‡∏ô‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ Pulse\n\t- Infection\n\t- Pregnancy and Lactation\n\t- Current peptic ulcer disease\n\t- Glaucoma\n\t- Badly controlled HTN or DM\n- Immunosupressive agents\n\t- ‡∏à‡∏∞‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡πÄ‡∏Ñ‡∏™‡∏ó‡∏µ‡πà serious, severe\n\t- HCQ or CQ ‡πÉ‡∏ä‡πâ‡∏•‡∏î constitutional symptoms ‡∏ô‡∏¥‡∏¢‡∏°‡πÉ‡∏ä‡πâ‡∏£‡πà‡∏ß‡∏°‡∏Å‡∏±‡∏ö‡∏¢‡∏≤‡∏≠‡∏∑‡πà‡∏ô\n\n\n## ‡∏Å‡∏≤‡∏£‡∏£‡∏±‡∏Å‡∏©‡∏≤‡∏≠‡∏∑‡πà‡∏ô ‡πÜ\n- Plasmaexchange (Plsamapheresis) ‡∏£‡∏∞‡∏´‡∏ß‡πà‡∏≤‡∏á‡∏ó‡∏≥‡∏à‡∏∞‡πÉ‡∏™‡πà albumin ‡πÑ‡∏õ‡∏î‡πâ‡∏ß‡∏¢, ‡∏£‡∏∞‡∏ß‡∏±‡∏á hypocalcemia\n- IVIG ‡∏ä‡∏∞‡∏•‡∏≠‡∏Å‡∏≤‡∏£‡∏ó‡∏≥‡∏•‡∏≤‡∏¢‡∏Ç‡∏≠‡∏á antibody coated autologous red blood cell ‡πÅ‡∏•‡∏∞ ‡∏•‡∏î‡∏Å‡∏≤‡∏£‡∏™‡∏£‡πâ‡∏≤‡∏á cytokine \u0026 anti-idiotypic antibody ‡∏à‡∏∞‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡πÄ‡∏Ñ‡∏™‡∏ó‡∏µ‡πà severe life-threatening ‡∏ó‡∏µ‡πà‡πÉ‡∏ä‡πâ steroid or immunosupressive ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ\n\t- ‡πÄ‡∏õ‡πá‡∏ô‡πÅ‡∏Ñ‡πà cas-report\n- Vitamin D esp ‡∏Ñ‡∏ô‡∏ú‡∏¥‡∏ß‡∏î‡∏≥ ‡πÅ‡∏•‡∏∞ vit d def ‡πÄ‡∏Å‡∏µ‡πà‡∏¢‡∏ß‡∏Ç‡πâ‡∏≠‡∏á‡∏Å‡∏±‡∏ö‡∏Å‡∏≤‡∏£‡∏°‡∏µ cytokine/allergy ‡∏ó‡∏µ‡πà high\n\t- ‡∏Ñ‡∏ß‡∏£‡πÄ‡∏à‡∏≤‡∏∞ baseline 25(OH) vit D ‡πÄ‡∏õ‡πá‡∏ô baseline ‡πÇ‡∏î‡∏¢‡∏Ñ‡∏ß‡∏£ \u003e 30 ng/mL\n\t- ‡∏≠‡∏≤‡∏à‡πÉ‡∏´‡πâ‡∏£‡∏±‡∏ö‡∏õ‡∏£‡∏∞‡∏ó‡∏≤‡∏ô vit D 30-50 ug (1000-2000 IU) ‡πÇ‡∏î‡∏¢‡πÄ‡∏â‡∏û‡∏≤‡∏∞‡πÉ‡∏ô‡∏Ñ‡∏ô‡∏ó‡∏µ‡πà‡∏Å‡∏¥‡∏ô steroid\n\t- ‡πÉ‡∏ô‡πÑ‡∏ó‡∏¢‡∏°‡∏±‡∏Å‡πÉ‡∏ä‡πâ D2 ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏ñ‡∏π‡∏Å\n\t- D2 ‡∏ï‡πâ‡∏≠‡∏á‡∏ú‡πà‡∏≤‡∏ô‡∏ï‡∏±‡∏ö (‡πÄ‡∏ï‡∏¥‡∏°25-OH)\n\t- D3 ‡∏ï‡πâ‡∏≠‡∏á‡∏ú‡πà‡∏≤‡∏ô‡πÑ‡∏ï (‡πÄ‡∏ï‡∏¥‡∏° 1-OH)\n\t- ‡∏õ‡∏Å‡∏ï‡∏¥‡∏à‡∏∞ ‡∏ï‡∏±‡∏ö ‡πÄ‡∏ï‡∏¥‡∏° 25-OH -\u003e ‡πÑ‡∏ï ‡πÄ‡∏ï‡∏¥‡∏° 1 OH\n \n## Antiphospholipid syndrome (APS)\n- ‡∏à‡∏∞‡∏°‡∏≠‡∏á‡πÄ‡∏õ‡πá‡∏ô‡πÇ‡∏£‡∏Ñ‡∏´‡∏£‡∏∑‡∏≠ complication ‡∏Å‡πá‡πÑ‡∏î‡πâ\n- ‡∏°‡∏±‡∏Å‡∏à‡∏∞‡πÉ‡∏ä‡πâ LDA ‡∏´‡∏£‡∏∑‡∏≠ anticoagulants ‡πÄ‡∏õ‡πá‡∏ô‡∏´‡∏•‡∏±‡∏Å\n- ‡∏≠‡∏≤‡∏à‡πÉ‡∏ä‡πâ HCQ or statin (‡πÅ‡∏ï‡πà‡∏õ‡∏Å‡∏ï‡∏¥‡∏Ñ‡∏ô‡∏ó‡∏µ‡πà SLE ‡∏à‡∏∞‡πÑ‡∏î‡πâ‡∏£‡∏±‡∏ö HCQ ‡∏≠‡∏¢‡∏π‡πà‡πÅ‡∏•‡πâ‡∏ß)\n#### ‡πÉ‡∏ô‡∏Ñ‡∏ô‡∏ó‡∏±‡πà‡∏ß‡πÑ‡∏õ\n- ‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ SLE ‡πÑ‡∏°‡πà‡∏à‡∏≥‡πÄ‡∏õ‡πá‡∏ô‡∏ï‡πâ‡∏≠‡∏á‡∏ï‡∏£‡∏ß‡∏à aPL (antiphospholipidantibodies) ‡∏ó‡∏∏‡∏Å‡∏£‡∏≤‡∏¢\n- asymptomatic aPL carriers -\u003e ‡πÉ‡∏´‡πâ‡πÉ‡∏ä‡πâ prophylaxis LDA 75-100 mg\n- ‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ SLE ‡∏ñ‡πâ‡∏≤ high risk of aPL profile ‡πÉ‡∏´‡πâ prophylaxis ‡∏î‡πâ‡∏ß‡∏¢ LDA\n- ‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ SLE ‡∏ñ‡πâ‡∏≤ low risk of aPL profile **‡∏≠‡∏≤‡∏à**‡πÉ‡∏´‡πâ prophylaxis ‡∏î‡πâ‡∏ß‡∏¢ LDA\n#### ‡πÉ‡∏ô‡∏ú‡∏π‡πâ‡∏´‡∏ç‡∏¥‡∏á‡∏ó‡∏µ‡πà APS ‡πÅ‡∏•‡∏∞‡∏ó‡πâ‡∏≠‡∏á\n- ‡∏ñ‡πâ‡∏≤ high-risk aPL ‡πÉ‡∏´‡πâ‡πÉ‡∏ä‡πâ LDA ‡∏£‡∏∞‡∏´‡∏ß‡πà‡∏≤‡∏á‡∏ó‡πâ‡∏≠‡∏á\n- ‡∏ñ‡πâ‡∏≤‡πÄ‡∏Ñ‡∏¢‡∏°‡∏µ‡∏õ‡∏£‡∏∞‡∏ß‡∏±‡∏ï‡∏¥ APS\n\t- ‡πÅ‡∏ó‡πâ‡∏á GA \u003c 10 wk -\u003e ‡πÅ‡∏ô‡∏∞‡∏ô‡∏≥ LDA and heparin ‡∏£‡∏∞‡∏´‡∏ß‡πà‡∏≤‡∏á‡∏ó‡πâ‡∏≠‡∏á\n\t- ‡∏Ñ‡∏•‡∏≠‡∏î‡∏Å‡πà‡∏≠‡∏ô‡∏Å‡∏≥‡∏´‡∏ô‡∏î (\u003c 34 wks) -\u003e ‡πÅ‡∏ô‡∏∞‡∏ô‡∏≥‡πÉ‡∏´‡πâ LDA and heparin ‡∏£‡∏∞‡∏´‡∏ß‡πà‡∏≤‡∏á‡∏ó‡πâ‡∏≠‡∏á ‡πÅ‡∏ï‡πà‡πÉ‡∏´‡πâ‡∏î‡∏π risk ‡∏≠‡∏∑‡πà‡∏ô‡∏£‡πà‡∏ß‡∏°‡∏î‡πâ‡∏ß‡∏¢\n\t- ‡∏´‡∏•‡∏±‡∏á‡∏Ñ‡∏•‡∏≠‡∏î ‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å‡πÉ‡∏ä‡πâ heparin ‡∏õ‡πâ‡∏≠‡∏á‡∏Å‡∏±‡∏ô‡∏°‡∏≤‡∏Å‡πà‡∏≠‡∏ô ‡πÉ‡∏´‡πâ‡πÉ‡∏ä‡πâ‡∏ï‡πà‡∏≠‡πÑ‡∏õ‡∏≠‡∏¢‡πà‡∏≤‡∏á‡∏ô‡πâ‡∏≠‡∏¢ 6 ‡∏™‡∏±‡∏õ‡∏î‡∏≤‡∏´‡πå‡∏´‡∏•‡∏±‡∏á‡∏Ñ‡∏•‡∏≠‡∏î\n- Dose\n\t- heparin 5000 u sc bid\n\t- LMWH 1 mg/kg/day\n## Pregnancy and Contraception\n- cyclophosphamide 18-23 cumulative gram dose ‡∏≠‡∏≤‡∏à‡∏ó‡∏≥‡πÉ‡∏´‡πâ ovarian insufficiency\n- ‡∏Ñ‡∏∏‡∏°‡∏Å‡∏≥‡πÄ‡∏ô‡∏¥‡∏î‡∏î‡πâ‡∏ß‡∏¢‡∏¢‡∏≤‡∏Æ‡∏≠‡∏£‡πå‡πÇ‡∏°‡∏ô‡∏ó‡∏µ‡πà‡∏°‡∏µ estrogen ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ ‡πÉ‡∏´‡πâ‡πÉ‡∏ä‡πâ POP ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤‡∏ï‡∏£‡∏ß‡∏à‡πÅ‡∏•‡πâ‡∏ß‡πÑ‡∏°‡πà‡∏û‡∏ö antiphospholipid antibodies ‡∏Å‡πá‡∏≠‡∏≤‡∏à‡πÉ‡∏ä‡πâ‡πÑ‡∏î‡πâ ‡πÅ‡∏ï‡πà‡πÉ‡∏ä‡πâ‡πÇ‡∏î‡∏™‡∏ô‡πâ‡∏≠‡∏¢\n- ‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å antiphospholipid antibodies positive ‡∏´‡πâ‡∏≤‡∏°‡πÉ‡∏ä‡πâ estrogen ‡πÄ‡∏û‡∏£‡∏≤‡∏∞ thrombosis risk ‡∏à‡∏∞‡πÄ‡∏û‡∏¥‡πà‡∏°‡πÑ‡∏î‡πâ ‡πÅ‡∏•‡∏∞ SLE ‡∏à‡∏∞‡∏Å‡∏≥‡πÄ‡∏£‡∏¥‡∏ö‡πÑ‡∏î‡πâ\n\t- ‡πÉ‡∏ä‡πâ pop, copper iud (adr ‡πÄ‡∏¢‡∏≠‡∏∞‡∏Å‡∏ß‡πà‡∏≤) ‡∏´‡∏£‡∏∑‡∏≠ progestin iud ‡πÅ‡∏ó‡∏ô\n- ‡∏Å‡∏≤‡∏£‡∏ó‡πâ‡∏≠‡∏á‡∏à‡∏∞‡πÄ‡∏Å‡∏¥‡∏î‡∏ú‡∏•‡πÄ‡∏™‡∏µ‡∏¢‡∏≠‡∏∞‡πÑ‡∏£‡∏ö‡πâ‡∏≤‡∏á‡πÉ‡∏ô‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ SLE\n\t- pre-eclampsia\n\t\t- ‡∏•‡∏î‡πÑ‡∏î‡πâ‡∏î‡πâ‡∏ß‡∏¢‡∏Å‡∏≤‡∏£‡πÉ‡∏´‡πâ LDA 16 wks ‡∏Å‡πà‡∏≠‡∏ô‡∏ó‡πâ‡∏≠‡∏á ‡∏´‡∏£‡∏∑‡∏≠ HCQ ‡∏ï‡∏•‡∏≠‡∏î‡πÄ‡∏ß‡∏•‡∏≤‡∏ó‡πâ‡∏≠‡∏á\n\t- congenital heart block\n\t\t- ‡∏ñ‡πâ‡∏≤‡πÅ‡∏°‡πà‡∏°‡∏µ anti-RO/SSA or anti-LA/SSB ‡∏•‡∏π‡∏Å‡∏à‡∏∞‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á‡πÄ‡∏Å‡∏¥‡∏î‡∏°‡∏≤‡∏î‡πâ‡∏ß‡∏¢‡πÄ‡∏£‡∏∑‡πà‡∏≠‡∏á‡∏´‡∏±‡∏ß‡πÉ‡∏à ‡∏™‡∏≤‡∏°‡∏≤‡∏£‡∏ñ‡∏•‡∏î‡πÑ‡∏î‡πâ‡∏î‡πâ‡∏ß‡∏¢‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ HCQ\n\t- miscarriages\n- ‡∏Ñ‡∏ß‡∏£‡∏ó‡πâ‡∏≠‡∏á‡∏°‡∏±‡πâ‡∏¢\n\t- ‡πÇ‡∏£‡∏Ñ‡∏ô‡∏¥‡πà‡∏á ‡πÑ‡∏°‡πà‡∏°‡∏µ autoabs -\u003e low risk\n\t- ‡πÇ‡∏£‡∏Ñ‡∏ô‡∏¥‡πà‡∏á ‡∏°‡∏µ autoabs -\u003e intermediate risk ‡πÉ‡∏´‡πâ‡∏£‡∏∞‡∏ß‡∏±‡∏á\n\t- ‡πÇ‡∏£‡∏Ñ‡πÑ‡∏°‡πà‡∏ô‡∏¥‡πà‡∏á ‡∏°‡∏µ autoabs ‡πÅ‡∏•‡∏∞ irreversible damage -\u003e ‡πÑ‡∏°‡πà‡∏Ñ‡∏ß‡∏£‡∏ó‡πâ‡∏≠‡∏á\n\t- **‡∏´‡∏≤‡∏Å‡∏û‡∏∂‡πà‡∏á flare ‡πÉ‡∏ô‡∏ä‡πà‡∏ß‡∏á 6 ‡πÄ‡∏î‡∏∑‡∏≠‡∏ô‡∏ó‡∏µ‡πà‡∏ú‡πà‡∏≤‡∏ô‡∏°‡∏≤ ‡∏´‡∏£‡∏∑‡∏≠‡∏°‡∏µ active lupus nephritis ‡∏´‡∏£‡∏∑‡∏≠ stsroke ‡πÑ‡∏°‡πà‡πÅ‡∏ô‡πà‡∏ô‡∏≥‡πÉ‡∏´‡πâ‡∏ó‡πâ‡∏≠‡∏á** ‡∏î‡∏µ‡∏™‡∏∏‡∏î‡∏Ñ‡∏∑‡∏≠ inactive for 6 months ‡∏Å‡πà‡∏≠‡∏ô‡∏ó‡πâ‡∏≠‡∏á\n- ‡∏ñ‡πâ‡∏≤‡∏à‡∏∞‡∏ó‡πâ‡∏≠‡∏á ‡πÉ‡∏´‡πâ‡πÉ‡∏ä‡πâ HCQ ‡∏ï‡πà‡∏≠‡πÑ‡∏õ‡πÄ‡∏£‡∏∑‡πà‡∏≠‡∏¢ ‡πÜ ‡∏ï‡∏•‡∏≠‡∏î‡∏Å‡∏≤‡∏£‡∏ó‡πâ‡∏≠‡∏á\n- Teratogenic drugs\n\t- MTX, thalidomide 1-3 month before\n\t- MMF 6 wks before\n\t- cyclophosphamide 3 mo before\n\t- leflunomide 2 yrs before (‡∏™‡∏≤‡∏°‡∏≤‡∏£‡∏ñ‡πÄ‡∏£‡πà‡∏á‡πÑ‡∏î‡πâ‡∏î‡πâ‡∏ß‡∏¢‡∏Å‡∏≤‡∏£‡πÉ‡∏´‡πâ cholestyramine)\n- ‡∏´‡∏≤‡∏Å‡∏ó‡πâ‡∏≠‡∏á‡πÅ‡∏•‡πâ‡∏ß‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏Å‡∏≥‡πÄ‡∏£‡∏¥‡∏ö\n\t- AZA ‡πÑ‡∏°‡πà‡πÄ‡∏Å‡∏¥‡∏ô 2 mkday ‡∏≠‡∏≤‡∏à‡πÉ‡∏ä‡πâ‡πÑ‡∏î‡πâ\n\t- cyclosporine, tacrolimus best alternative choices\n\t- VitD, calcium, folic ‡∏Ñ‡∏ß‡∏£‡πÉ‡∏´‡πâ‡∏≠‡∏¢‡∏π‡πà‡πÅ‡∏•‡πâ‡∏ß\n\t- ‡∏ñ‡πâ‡∏≤‡∏à‡∏∞‡πÉ‡∏ä‡πâ steroid ‡∏Ñ‡∏ß‡∏£‡πÉ‡∏ä‡πâ‡∏ï‡πà‡∏≥‡∏ó‡∏µ‡πà‡∏™‡∏∏‡∏î‡∏ó‡∏µ‡πà‡∏ï‡πà‡∏≥‡πÑ‡∏î‡πâ (7.5 or less)\n\t- ‡∏ï‡∏≠‡∏ô‡∏à‡∏∞‡∏Ñ‡∏•‡∏≠‡∏î ‡∏≠‡∏≤‡∏à‡∏ï‡πâ‡∏≠‡∏á‡∏´‡∏ô‡∏±‡∏Å steroid ‡∏•‡∏î‡∏Å‡∏≤‡∏£‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡πÑ‡∏°‡πà‡πÉ‡∏´‡πâ‡πÄ‡∏¢‡∏≠‡∏∞‡πÄ‡∏Å‡∏¥‡∏ô\n\t- ‡∏≠‡∏≤‡∏à‡∏°‡∏µ‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ fluorinated corticosteroid ‡πÄ‡∏ä‡πà‡∏ô dexamethasone, betamethasone ‡∏´‡∏≤‡∏Å‡∏ï‡πâ‡∏≠‡∏á‡∏Å‡∏≤‡∏£‡πÉ‡∏´‡πâ‡∏•‡∏π‡∏Å‡πÑ‡∏î‡πâ‡∏£‡∏±‡∏ö‡∏¢‡∏≤‡∏î‡πâ‡∏ß‡∏¢ ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏°‡∏±‡∏ô‡∏ú‡πà‡∏≤‡∏ô placenta\n- biologics no ‡∏Ç‡πâ‡∏≠‡∏°‡∏π‡∏•!\n\t- certolizumab ‡∏î‡∏π safe ‡∏™‡∏∏‡∏î‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡πÑ‡∏°‡πà‡∏°‡∏µ Fc chain\n\t- Rituximab ‡πÑ‡∏°‡πà‡∏Ñ‡∏ß‡∏£‡πÉ‡∏´‡πâ\n- Cyclophosphamide damage male sperm ‡πÑ‡∏î‡πâ ‡∏î‡∏±‡∏á‡∏ô‡∏±‡πâ‡∏ô‡∏Ñ‡∏ß‡∏£‡∏´‡∏¢‡∏∏‡∏î‡∏≠‡∏¢‡πà‡∏≤‡∏á‡∏ô‡πâ‡∏≠‡∏¢ 12 wks\n## Drug Induced Lupus\n- proposed mech\n\t- haptenization\n\t- macrophage uptake apoptotic or necrotic cells leading to accumulation of self-antigen\n\t- stimualation of NETs form cell death that let self-antigen stimulate autoreactive T or B cell\n\t- dysregulation of T cell\n- no standard criteria\n- ‡∏≠‡∏≤‡∏à‡πÄ‡∏à‡∏≠ anti-histone ‡∏´‡∏£‡∏∑‡∏≠ anti-ssDNA\n- ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏°‡∏±‡∏Å‡πÑ‡∏°‡πà‡∏£‡∏∏‡∏ô‡πÅ‡∏£‡∏á\n- positive lupus band test\n- sweet syndrome \n- High risk drugs\n\t- Procainamide\n\t\t- **‡πÄ‡∏î‡πà‡∏ô‡∏õ‡∏±‡∏ç‡∏´‡∏≤‡∏õ‡∏≠‡∏î** ‡πÅ‡∏•‡∏∞‡∏õ‡∏ß‡∏î‡πÑ‡∏Ç‡πâ\n\t\t- ‡∏°‡∏±‡∏Å‡∏ó‡∏≥‡πÉ‡∏´‡πâ ANA positive\n\t- Hydralazine\n\t\t- **‡πÄ‡∏î‡πà‡∏ô‡∏õ‡∏±‡∏ç‡∏´‡∏≤‡πÑ‡∏ï** ‡πÅ‡∏•‡∏∞‡∏õ‡∏ß‡∏î‡πÑ‡∏Ç‡πâ\n\t\t- esp dose over 200 mg/day or cumulative ‡πÄ‡∏Å‡∏¥‡∏ô 100 g\n\t\t- ‡πÄ‡∏à‡∏≠ ANA pos ‡∏ô‡πâ‡∏≠‡∏¢\n- Moderate risk\n\t- minocycline\n\t- isoniazid\n\t- methyldopa\n\t- cbz\n\t- chlorpromazine\n- drug induced subacute cutaneous\n\t- ‡πÄ‡∏Å‡∏µ‡πà‡∏¢‡∏ß‡∏Ç‡πâ‡∏≠‡∏á‡∏Å‡∏±‡∏ö terbinafine ‡πÅ‡∏•‡∏∞ TNF-alpha ‡∏°‡∏≤‡∏Å‡∏ó‡∏µ‡πà‡∏™‡∏∏‡∏î\n\t- ‡∏≠‡∏≤‡∏à‡∏û‡∏ö positive ANA, anti-ro, anti-la ‡πÑ‡∏î‡πâ\n\t- ‡∏≠‡∏≤‡∏à‡πÄ‡∏Å‡∏¥‡∏î‡πÉ‡∏ô‡∏ä‡πà‡∏ß‡∏á 1 ‡∏õ‡∏µ‡∏´‡∏•‡∏±‡∏á‡πÄ‡∏£‡∏¥‡πà‡∏°‡∏¢‡∏≤\n\t- ‡∏°‡∏±‡∏Å‡πÄ‡∏Å‡∏¥‡∏î‡∏Å‡∏±‡∏ö‡∏Ñ‡∏ô‡πÅ‡∏Å‡πà\n- chronic cutaenous lupus\n\t- ‡∏û‡∏ö‡πÄ‡∏à‡∏≠‡πÉ‡∏ô 5-FU\n- management\n\t- ‡∏´‡∏¢‡∏∏‡∏î‡∏¢‡∏≤ ‡πÅ‡∏•‡∏∞‡∏à‡∏∞‡∏î‡∏µ‡∏Ç‡∏∂‡πâ‡∏ô‡πÉ‡∏ô 1 wks ‡πÅ‡∏•‡∏∞‡∏≠‡∏≤‡∏à‡πÉ‡∏ä‡πâ‡πÄ‡∏ß‡∏•‡∏≤ recover ‡∏ô‡∏≤‡∏ô‡∏ñ‡∏∂‡∏á 1 ‡∏õ‡∏µ\n\t- low-dose pred ‡∏ñ‡πâ‡∏≤‡∏à‡∏≥‡πÄ‡∏õ‡πá‡∏ô\n\t- nsaids ‡∏ñ‡πâ‡∏≤‡∏õ‡∏ß‡∏î‡∏°‡∏≤‡∏Å ‡πÜ\n\t- ‡∏´‡∏≤‡∏Å‡∏°‡∏µ‡∏õ‡∏±‡∏ç‡∏´‡∏≤‡πÑ‡∏ï‡πÅ‡∏ö‡∏ö biopsy proven ‡πÅ‡∏•‡πâ‡∏ß‡∏Å‡πá‡∏≠‡∏≤‡∏à‡∏ï‡πâ‡∏≠‡∏á aggressive immunosupression","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/Steroid":{"title":"Steroid","content":"\n- steroid ‡∏à‡∏∞‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πâ‡πÄ‡∏î‡∏µ‡πà‡∏¢‡∏ß ‡πÜ ‡∏à‡∏∞‡∏ï‡πâ‡∏≠‡∏á‡πÉ‡∏ä‡πâ‡∏Ñ‡∏π‡πà‡∏Å‡∏±‡∏ö‡∏≠‡∏∞‡πÑ‡∏£‡∏™‡∏±‡∏Å‡∏≠‡∏¢‡πà‡∏≤‡∏á ‡∏ó‡∏µ‡πà‡πÄ‡∏õ‡πâ‡∏ô‡∏¢‡∏≤‡∏£‡∏±‡∏Å‡∏©‡∏≤‡∏Ç‡∏≠‡∏á‡πÇ‡∏£‡∏Ñ‡∏ô‡∏±‡πâ‡∏ô ‡πÜ\n- steroid ‡πÉ‡∏ä‡πâ‡πÑ‡∏°‡πà‡πÄ‡∏Å‡∏¥‡∏ô 1 wks ‡πÑ‡∏°‡πà‡∏ï‡πâ‡∏≠‡∏á tape ‡πÑ‡∏°‡πà‡∏ï‡πâ‡∏≠‡∏á‡∏Å‡∏•‡∏±‡∏ß adrenal insuff\n- ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤‡πÉ‡∏ä‡πâ‡∏û‡∏ß‡∏Å dexa ‡∏ó‡∏µ‡πà duration ‡∏ô‡∏≤‡∏ô‡∏≠‡∏≤‡∏à‡∏°‡∏µ‡πÇ‡∏≠‡∏Å‡∏≤‡∏™‡πÄ‡∏Å‡∏¥‡∏î adrenal insuff ‡∏™‡∏π‡∏á‡∏Å‡∏ß‡πà‡∏≤\n- steroid ‡∏™‡∏≥‡∏´‡∏£‡∏±‡∏ö autoimmune ‡∏à‡∏∞‡πÉ‡∏ä‡πâ high dose ‡∏õ‡∏£‡∏∞‡∏°‡∏≤‡∏ì 1-2 mg/kg/day ‡∏ñ‡πâ‡∏≤‡∏õ‡∏£‡∏±‡∏ö‡πÑ‡∏°‡πà‡πÄ‡∏´‡∏°‡∏≤‡∏∞‡∏à‡∏∞‡∏ï‡∏¥‡∏î‡∏¢‡∏≤\n- steroid ‡∏•‡∏î 50% ‡∏ó‡∏∏‡∏Å 1-2 weeks ‡∏î‡∏∏‡∏Å‡∏≤‡∏£‡∏Ñ‡∏∏‡∏°‡πÇ‡∏£‡∏Ñ\n- ‡πÇ‡∏£‡∏Ñ autoimmune ‡∏°‡∏±‡∏Å‡∏à‡∏∞‡∏•‡∏î steroid ‡∏Å‡πà‡∏≠‡∏ô ‡πÉ‡∏´‡πâ‡∏ô‡πâ‡∏≠‡∏¢‡∏ó‡∏µ‡πà‡∏™‡∏∏‡∏î ‡∏´‡∏£‡∏∑‡∏≠‡∏´‡∏¢‡∏∏‡∏î‡πÑ‡∏î‡πâ‡∏è‡πá‡∏à‡∏∞‡∏î‡∏µ\n- ‡∏ó‡∏ö‡∏ó‡∏ß‡∏ô ADR steroids","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/Synovial-Analysis":{"title":"Synovial Analysis","content":"## Definitions\n- mixture of protein-rich ultrafiltrate of plasma and hyaluronan synthesized by synoviocytes\n- functions: to aid in nutrition and mechanical function\n- ‡∏Å‡∏≤‡∏£‡πÄ‡∏à‡∏≤‡∏∞‡∏ô‡πâ‡∏≥‡πÉ‡∏ô‡∏Ç‡πâ‡∏≠‡πÄ‡∏£‡∏µ‡∏¢‡∏Å‡∏ß‡πà‡∏≤ arthrocentesis ‡∏õ‡∏Å‡∏ï‡∏¥‡∏´‡∏°‡∏≠‡∏à‡∏∞‡∏ï‡πâ‡∏≠‡∏á‡∏î‡∏π‡∏ï‡∏≥‡πÅ‡∏´‡∏ô‡πà‡∏á‡πÄ‡∏à‡∏≤‡∏∞‡πÄ‡∏≠‡∏á / ‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ U/S sound ‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πà standard\n\n## Normal SF (Class I)\n- **‡∏°‡∏±‡∏Å‡πÄ‡∏à‡∏≠‡πÉ‡∏ô OA, trauma (‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏°‡∏±‡∏ô‡∏°‡∏±‡∏Å‡∏à‡∏∞‡πÑ‡∏°‡πà inflammation)**\n- ‡∏à‡∏∞‡∏ï‡πâ‡∏≠‡∏á‡πÉ‡∏™‡πà clear (transparaent; ‡∏≠‡πà‡∏≤‡∏ô‡∏ï‡∏±‡∏ß‡∏´‡∏ô‡∏±‡∏á‡∏™‡∏∑‡∏≠‡πÑ‡∏î‡πâ)\n- ‡∏™‡∏µ‡πÉ‡∏™‡∏´‡∏£‡∏∑‡∏≠‡πÄ‡∏´‡∏•‡∏∑‡∏≠‡∏á\n- ‡∏õ‡∏£‡∏¥‡∏°‡∏≤‡∏ì \u003c 3.5 ml\n- WBC \u003c 2000\n- Differential PMN \u003c 25%\n- viscosity ‡∏™‡∏π‡∏á (4-6 cm )\n\n## Example of Abnormal SF\n- Inflammatory (Class 2) ^09e8b5\n\t- ‡∏™‡∏µ‡πÄ‡∏´‡∏•‡∏∑‡∏≠‡∏á\n\t- WBC 2000-100,000\n\t- **transculent/opaque**\n\t- Differential PMN \u003e 50%\n- Septic (Class 3) *-\u003e ‡∏°‡∏±‡∏Å‡∏´‡∏°‡∏≤‡∏¢‡∏ñ‡∏∂‡∏á septic arthritis (‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏ñ‡πâ‡∏≤ culture positive ‡∏°‡∏±‡∏ô‡∏Å‡πá‡∏à‡∏∞‡∏Ñ‡πà‡∏≠‡∏ô‡∏Ç‡πâ‡∏≤‡∏á‡∏ä‡∏±‡∏î‡πÅ‡∏•‡πâ‡∏ß*)\n\t- ‡∏™‡∏µ‡πÄ‡∏´‡∏•‡∏∑‡∏≠‡∏á\n\t- ‡∏°‡∏±‡∏Å‡∏à‡∏∞ **opaque**\n\t- **WBC \u003e 100,000**\n\t- culture positive\n\t- Differential PMN \u003e 90%\n- Hemorrhagic (Class 4)\n\t- **Opaque**\n\t- ‡∏™‡∏µ‡πÅ‡∏î‡∏á\n\n## Impression\n- ‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏°‡∏±‡∏ô‡∏Ç‡∏∏‡πà‡∏ô ‡∏≠‡∏≤‡∏à‡πÄ‡∏Å‡∏¥‡∏î‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏°‡∏±‡∏ô‡∏°‡∏µ‡∏ú‡∏•‡∏∂‡∏Å calcium pyrophosphate dehydrate (pseudogout) ‡∏´‡∏£‡∏∑‡∏≠ monosodium urate (gout) ‡∏´‡∏£‡∏∑‡∏≠ hydroxyapatite (‡∏Å‡∏£‡∏∞‡∏î‡∏π‡∏Å‡∏™‡∏•‡∏≤‡∏¢‡∏à‡∏≤‡∏Å‡πÇ‡∏£‡∏Ñ autoimmune ‡πÄ‡∏ä‡πà‡∏ô severe RA)\n\t- ‡∏Å‡∏≤‡∏£‡∏™‡πà‡∏≠‡∏á crystal ‡∏õ‡∏Å‡∏ï‡∏¥‡∏à‡∏∞‡πÉ‡∏ä‡πâ polarized light microscope ‡πÄ‡∏õ‡πá‡∏ô standard ‡πÅ‡∏ï‡πà IRL ‡πÉ‡∏ä‡πâ ordinary light microscope\n- Xanthochromia ‡∏≠‡∏≤‡∏à‡∏°‡∏≤‡∏à‡∏≤‡∏Å‡πÄ‡∏à‡∏≤‡∏∞‡πÑ‡∏°‡πà‡∏î‡∏µ ‡∏´‡∏£‡∏∑‡∏≠‡∏°‡∏µ‡∏≠‡∏∞‡πÑ‡∏£‡∏ö‡∏≤‡∏á‡∏≠‡∏¢‡πà‡∏≤‡∏á‡∏ó‡∏≥‡πÉ‡∏´‡πâ heme from RBC leak ‡πÄ‡∏Ç‡πâ‡∏≤‡πÑ‡∏õ‡πÉ‡∏ô‡∏Ç‡πâ‡∏≠\n- ‡∏õ‡∏Å‡∏ï‡∏¥‡πÅ‡∏•‡πâ‡∏ß‡πÉ‡∏ô‡∏Ç‡πâ‡∏≠‡∏°‡∏±‡∏Å‡∏à‡∏∞‡πÄ‡∏Å‡∏∑‡∏≠‡∏ö acellular\n\n### Mono-arthritis\n- ‡∏î‡∏π‡∏õ‡∏£‡∏∞‡∏ß‡∏±‡∏ï‡∏¥‡∏Å‡πà‡∏≠‡∏ô ‡∏ñ‡πâ‡∏≤‡πÄ‡∏õ‡πá‡∏ô septic arthritis ‡∏Å‡πá‡∏à‡∏ö ‡∏ñ‡πâ‡∏≤‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πà‡πÉ‡∏´‡πâ‡∏î‡∏π‡∏Å‡πà‡∏≠‡∏ô‡∏ß‡πà‡∏≤‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á‡∏°‡∏±‡πâ‡∏¢ ‡∏ñ‡πâ‡∏≤‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á‡∏Å‡πá‡∏≠‡∏≤‡∏à‡πÄ‡∏à‡∏≤‡∏∞‡∏≠‡∏µ‡∏Å‡∏£‡∏≠‡∏ö ‡∏ñ‡πâ‡∏≤‡πÑ‡∏°‡πà‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á‡∏Å‡πá‡πÑ‡∏õ‡∏î‡∏π RF/ Anti CCP ‡πÄ‡∏•‡∏¢‡∏Å‡πá‡πÑ‡∏î‡πâ\n- ‡∏ï‡∏£‡∏∞‡∏Å‡∏π‡∏• [[#^09e8b5|Inflammatory (Class 2)]] ‡∏°‡∏±‡∏Å‡∏à‡∏∞‡∏°‡∏≤‡∏à‡∏≤‡∏Å crystal arthritis (gout/pseudogout) ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ inflam ‡πÉ‡∏´‡πâ‡∏î‡∏π‡∏Å‡πà‡∏≠‡∏ô‡∏ß‡πà‡∏≤ trauma / OA ‡∏°‡∏±‡πâ‡∏¢\n\n### Oligo or Poly-arthritis\n- Psoriatic arthritis\n\t- ‡∏ú‡∏•‡∏ü‡∏¥‡∏•‡πå‡∏°‡∏à‡∏∞‡∏¢‡∏±‡∏á‡πÄ‡∏´‡πá‡∏ô‡∏Ñ‡∏ß‡∏≤‡∏°‡∏ú‡∏¥‡∏î‡∏õ‡∏Å‡∏ï‡∏¥‡∏ô‡∏∞ ‡∏ï‡πà‡∏≤‡∏á‡∏à‡∏≤‡∏Å [[notes/SLE]] ‡∏ó‡∏µ‡πà‡πÑ‡∏°‡πà‡πÄ‡∏´‡πâ‡∏ô‡∏´‡πà‡∏≤‡πÑ‡∏£‡πÄ‡∏•‡∏¢\n- HIV infection\n- Behcet's syndrome\n- RA\n- sjogren syndrome\n- crystal arthritic\n- osteoarthritis","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/UGIB":{"title":"UGIB","content":"\nUpper GI ‡∏ï‡∏±‡∏î‡∏ó‡∏µ‡πà ligament of treitz ‡∏Ç‡∏∂‡πâ‡∏ô‡πÑ‡∏õ ‡∏ã‡∏∂‡πà‡∏á‡∏Å‡πá‡∏Ñ‡∏∑‡∏≠‡∏´‡∏•‡∏≠‡∏î‡∏≠‡∏≤‡∏´‡∏≤‡∏£‡∏à‡∏ô‡∏ñ‡∏∂‡∏á duodenum\n\n**Variceal bleeding is UGIB caused by esophageal or gastric varices.**\n- ‡πÉ‡∏ô‡∏™‡πÑ‡∏•‡∏î‡πå‡∏≠‡∏à. ‡∏°‡∏µ‡∏≠‡∏¢‡πà‡∏≤‡∏á‡πÄ‡∏î‡∏µ‡∏¢‡∏ß‡∏Ñ‡∏∑‡∏≠ Gastroesophageal varices\n\n**Non-variceal bleeding is caused by any etiology of UGIB other than varices**.\n- Situation\n\t- ‡πÄ‡∏à‡∏≠‡∏ô‡πâ‡∏≠‡∏¢‡∏•‡∏á‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏ß‡∏¥‡∏ó‡∏¢‡∏≤‡∏Å‡∏≤‡∏£‡∏î‡∏µ‡∏Ç‡∏∂‡πâ‡∏ô ‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ PPI ‡πÅ‡∏•‡∏∞‡∏£‡∏±‡∏Å‡∏©‡∏≤ *H. pylori* ‡πÑ‡∏î‡πâ‡∏î‡∏µ‡∏Ç‡∏∂‡πâ‡∏ô\n\t- Erosive esophagitis, PUD ‡∏û‡∏ö‡∏ô‡πâ‡∏≠‡∏¢‡∏•‡∏á ‡πÄ‡∏Å‡∏¥‡∏î‡∏à‡∏≤‡∏Å *H. pylori* ‡∏ô‡πâ‡∏≠‡∏¢‡∏•‡∏á ‡πÅ‡∏ï‡πà‡∏à‡∏∞‡πÄ‡∏Å‡∏¥‡∏î‡∏à‡∏≤‡∏Å NSAIDs ‡∏°‡∏≤‡∏Å‡∏Ç‡∏∂‡πâ‡∏ô\n\t- Dieulafoy lesions, Angiodysplasia ‡∏û‡∏ö‡∏°‡∏≤‡∏Å‡∏Ç‡∏∂‡πâ‡∏ô\n\t- ‡∏°‡∏±‡∏Å‡πÄ‡∏™‡∏µ‡∏¢‡∏ä‡∏µ‡∏ß‡∏¥‡∏ï‡πÄ‡∏û‡∏£‡∏≤‡∏∞ complication ‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤ bleeding (mortality 1-11%)\n- pH Factors\n\t- Coagulation\n\t\t- 6.8 ‡∏Å‡∏≤‡∏£‡πÅ‡∏Ç‡πá‡∏á‡∏ï‡∏±‡∏ß‡∏•‡∏î‡∏•‡∏á\n\t\t- 6.4 ‡∏à‡∏±‡∏ö‡∏Å‡∏•‡∏∏‡πà‡∏°‡∏•‡∏î‡∏•‡∏á 50%\n\t\t- **5.9 inhibit ‡∏Å‡∏≤‡∏£‡πÅ‡∏Ç‡πá‡∏á‡∏ï‡∏±‡∏ß** ‡πÄ‡∏Å‡∏•‡πá‡∏î‡πÄ‡∏•‡∏∑‡∏≠‡∏≠‡∏î‡∏ó‡∏µ‡πà‡∏à‡∏±‡∏ö‡πÄ‡∏Å‡∏¥‡∏î‡∏Å‡∏≤‡∏£‡πÅ‡∏¢‡∏Å‡∏ï‡∏±‡∏ß\n\t- Gastric Enzymes\n\t\t- ![[Pasted image 20230214124138.png|325]]\n\t\t- \u003c 4 pepsinogen ‡∏à‡∏∞‡πÄ‡∏õ‡∏•‡∏µ‡πà‡∏¢‡∏ô‡πÄ‡∏õ‡πá‡∏ô pepsin ‡πÑ‡∏î‡πâ\n\t\t- **\u003e 6 ‡∏à‡∏∞‡∏¢‡∏±‡∏ö‡∏¢‡∏±‡πâ‡∏á pepsin**\n\t- Goal ‡∏à‡∏∂‡∏á **pH \u003e6**\n- Pathophysiology\n\t- Mucosal Defects - local pH ‡∏à‡∏≤‡∏Å nsaid, LDA ‡∏´‡∏£‡∏∑‡∏≠ H.pylori ‡∏™‡∏£‡πâ‡∏≤‡∏á muricase **‡∏´‡∏£‡∏∑‡∏≠ cox ‡∏ñ‡∏π‡∏Å‡∏¢‡∏±‡∏ö‡∏¢‡∏±‡πâ‡∏á**\n\t\t- **‡∏£‡∏∞‡∏ß‡∏±‡∏á! COX1 damage mucosal ‡∏à‡∏≤‡∏Å‡∏ú‡∏•‡∏Å‡∏≤‡∏£‡∏¢‡∏±‡∏ö‡∏¢‡∏±‡πâ‡∏á‡∏Å‡∏≤‡∏£‡∏™‡∏£‡πâ‡∏≤‡∏á mucus ‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πà‡∏•‡∏î‡∏Å‡∏≤‡∏£‡πÅ‡∏Ç‡πá‡∏á‡∏ï‡∏±‡∏ß** // Systemically, NSAIDs contribute to mucosal damage by inhibiting the prostaglandin secretion associated with cyclooxygenase 1 (COX1; also known as PTGS1) and COX2. The reduction in prostaglandin levels disrupts the mucosal barrier as prostaglandins stimulate mucous and bicarbonate secretion by epithelial cells, inhibit acid secretion and promote cell proliferation and mucosal blood flow. [ref](https://www.nature.com/articles/nrdp201820)\n\t- Vascular defects ‡πÄ‡∏ä‡πà‡∏ô‡∏°‡∏µ‡πÇ‡∏£‡∏Ñ‡∏õ‡∏£‡∏∞‡∏à‡∏≥‡∏ï‡∏±‡∏ß\n\t- Coagulation Defects ‡πÄ‡∏ä‡πà‡∏ô pH ‡∏ï‡πà‡∏≥ \n- Diseases / Medical Conditions\n\t- PUD\n\t- Esophagitis\n\t- Vascular lesion (Dieulafoy lesions)\n\t\t- ‡∏Ñ‡∏ß‡∏≤‡∏°‡∏ú‡∏¥‡∏î‡∏õ‡∏Å‡∏ï‡∏¥‡∏ó‡∏≤‡∏á artery, ‡∏´‡∏•‡∏≠‡∏î‡πÄ‡∏•‡∏∑‡∏≠‡∏î GI ‡∏ó‡∏µ‡πà‡πÉ‡∏´‡∏ç‡πà ‡∏°‡∏±‡∏Å‡πÄ‡∏õ‡πá‡∏ô‡∏´‡∏•‡∏≠‡∏î‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡∏ö‡∏£‡∏¥‡πÄ‡∏ß‡∏ì submucosal erodes and bleed\n\t- Vascular ectasia (angiodysplasia)\n\t\t- ‡∏´‡∏•‡∏≠‡∏î‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡πÄ‡∏•‡πá‡∏Å ‡πÜ ‡∏°‡∏µ‡∏ú‡∏ô‡∏±‡∏á‡∏ó‡∏µ‡πà‡∏ö‡∏≤‡∏á‡∏Å‡∏ß‡πà‡∏≤‡∏Ñ‡∏ô‡∏≠‡∏∑‡πà‡∏ô ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏â‡∏µ‡∏Å‡∏Ç‡∏≤‡∏î ‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡∏≠‡∏≠‡∏Å ‡∏ã‡∏∂‡∏°‡∏≠‡∏≠‡∏Å‡∏°‡∏≤‡πÑ‡∏î‡πâ‡∏á‡πà‡∏≤‡∏¢ ‡πÅ‡∏ï‡πà‡∏à‡∏∞ bleed ‡πÑ‡∏°‡πà‡πÅ‡∏£‡∏á‡πÄ‡∏ó‡πà‡∏≤ Dieulafoy\n\t- Malloy-Weiss tears\n\t- Neoplastic lesion\n- ‡∏Å‡∏≤‡∏£‡∏õ‡πâ‡∏≠‡∏á‡∏Å‡∏±‡∏ô\n\t- **Risk of NVUGIB**\n\t\t- ![[Pasted image 20230214124431.png]]\n\t- ‡∏≠‡∏¢‡πà‡∏≤‡∏•‡∏∑‡∏°‡∏ß‡πà‡∏≤ SSRI ‡∏´‡∏£‡∏∑‡∏≠ corticosteroid ‡∏™‡∏≤‡∏°‡∏≤‡∏£‡∏ñ induce ‡πÑ‡∏î‡πâ ‡∏õ‡πâ‡∏≠‡∏á‡∏Å‡∏±‡∏ô‡πÇ‡∏î‡∏¢‡∏Å‡∏≤‡∏£‡πÉ‡∏´‡πâ PPI\n- ‡∏Å‡∏≤‡∏£‡∏£‡∏±‡∏Å‡∏©‡∏≤\n\t- 0 Emergency Triage\n\t\t- ‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô‡∏ó‡∏±‡πà‡∏ß‡πÑ‡∏õ‡∏ï‡∏≤‡∏°‡∏ó‡∏µ‡πà‡∏ó‡∏≥‡πÉ‡∏ô ER ‡πÅ‡∏ï‡πà‡πÄ‡∏ô‡πâ‡∏ô\n\t\t- HPI: hematemesis? (R/O lung cause ‡∏î‡πâ‡∏ß‡∏¢ ‡∏ñ‡πâ‡∏≤‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡∏≠‡∏≠‡∏Å 500-1000 cc ‡∏°‡∏±‡∏Å‡∏à‡∏∞ vomit), melena (‡∏û‡∏ö‡∏ö‡πà‡∏≠‡∏¢‡∏Å‡∏ß‡πà‡∏≤ ‡∏î‡∏≥‡∏¢‡∏≤‡∏á ‡πÜ ‡∏°‡∏µ‡∏Å‡∏•‡∏¥‡πà‡∏ô‡πÄ‡∏â‡∏û‡∏≤‡∏∞‡∏ï‡∏±‡∏ß), ‡∏à‡∏∞‡πÑ‡∏°‡πà‡∏û‡∏ö hematochezia ‡∏¢‡∏Å‡πÄ‡∏ß‡πâ‡∏ô massive bleeding\n\t\t- LAB: Hb/Hct, INR, BUN/Scr (‡∏°‡∏±‡∏Å 30:1), LFTs (‡∏à‡∏∞‡πÑ‡∏î‡πâ check ‡∏ß‡πà‡∏≤ variceal or non variceal), cirrhosis? (‡∏ö‡πà‡∏á‡∏ö‡∏≠‡∏Å‡∏ß‡πà‡∏≤‡πÄ‡∏Å‡∏¥‡∏î varcies // Varices are¬†**dilated veins in the distal esophagus or proximal stomach caused by elevated pressure in the portal venous system, typically from cirrhosis** [ref](https://www.msdmanuals.com/professional/gastrointestinal-disorders/gastrointestinal-bleeding/varices#:~:text=Varices%20are%20dilated%20veins%20in,endoscopic%20banding%20and%20IV%20octreotide..) )\n\t- 1 Stabilization protocols (pre-endoscope)\n\t\t- Orotracheal intubation only in case of large volume hematemesis (to avoid aspiration pneumonia from blood vomiting)\n\t\t- NG Tube\n\t\t\t- ‡∏ó‡∏≥‡πÅ‡∏ó‡∏ô endoscope ‡πÉ‡∏ô‡∏ö‡∏≤‡∏á‡πÄ‡∏Ñ‡∏™ ‡πÄ‡∏û‡∏∑‡πà‡∏≠‡πÉ‡∏ä‡πâ‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô‡∏Å‡∏≤‡∏£‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡∏≠‡∏≠‡∏Å ‡∏´‡∏£‡∏∑‡∏≠‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡∏≠‡∏≠‡∏Å‡∏ã‡πâ‡∏≥\n\t\t\t- ‡πÉ‡∏ä‡πâ‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô‡πÄ‡∏ö‡∏∑‡πâ‡∏≠‡∏á‡∏ï‡πâ‡∏ô ‡πÄ‡∏ä‡πà‡∏ô ‡∏î‡∏π‡∏î‡∏ô‡πâ‡∏≥‡∏≠‡∏≠‡∏Å‡∏°‡∏≤ ‡∏ñ‡πâ‡∏≤‡πÑ‡∏°‡πà‡∏°‡∏µ‡πÄ‡∏•‡∏∑‡∏≠‡∏î ‡πÅ‡∏™‡∏î‡∏á‡∏ß‡πà‡∏≤‡∏≠‡∏≤‡∏à‡∏°‡∏≤‡∏à‡∏≤‡∏Å‡∏õ‡∏≠‡∏î\n\t\t\t- ‡πÄ‡∏û‡∏∑‡πà‡∏≠ gastric lavage ‡∏Å‡πà‡∏≠‡∏ô endoscope ‡πÇ‡∏î‡∏¢‡πÉ‡∏´‡πâ‡∏ú‡∏•‡πÑ‡∏°‡πà‡∏ï‡πà‡∏≤‡∏á‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡πÉ‡∏´‡πâ prokinetics\n\t\t\t- **Guideline ‡∏à‡∏∞‡πÅ‡∏ô‡∏∞‡∏ô‡∏≥ erythromycin 250 mg IV 20-90 ‡∏ô‡∏≤‡∏ó‡∏µ ‡∏Å‡πà‡∏≠‡∏ô endoscopy!**\n\t\t- 2 large peripheral IV access\n\t\t- ‡∏™‡∏≤‡∏£‡∏ô‡πâ‡∏≥ and blood product\n\t\t\t- PRC ‡∏Å‡∏£‡∏ì‡∏µ Hb \u003c 7 ‡∏´‡∏£‡∏∑‡∏≠ \u003c8\n\t\t\t- Platelet ‡∏Å‡∏£‡∏ì‡∏µ Pt \u003c 50,000\n\t\t\t- FFP ‡∏ï‡∏≤‡∏°‡∏ï‡πà‡∏≤ INR (‡πÉ‡∏ä‡πâ reverse INR)\n\t- 2 Assess risk of bleeding / re-bleeding\n\t\t- Guideline ‡πÑ‡∏ó‡∏¢‡πÅ‡∏ô‡∏∞‡∏ô‡∏≥ **Glasgow-Blatchford** ‡πÅ‡∏ï‡πà‡∏à‡∏∞‡πÉ‡∏ä‡πâ‡∏Ñ‡πà‡∏≤ lab ‡πÄ‡∏¢‡∏≠‡∏∞\n\t\t- ‡∏≠‡∏µ‡∏Å‡∏≠‡∏±‡∏ô‡∏Ñ‡∏∑‡∏≠ **Rockall** ‡πÑ‡∏Å‡∏î‡πå‡πÑ‡∏•‡∏ô‡πå‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡πÅ‡∏ô‡∏∞‡∏ô‡∏≥ ‡πÅ‡∏ï‡πà‡∏≠‡∏±‡∏ô‡∏ô‡∏µ‡πâ‡πÑ‡∏°‡πà‡∏ï‡πâ‡∏≠‡∏á‡πÉ‡∏ä‡πâ‡∏ú‡∏• lab ‡∏≠‡∏≤‡∏à‡πÉ‡∏ä‡πâ‡∏ï‡∏≠‡∏ô admission ‡πÇ‡∏î‡∏¢‡∏à‡∏∞‡∏°‡∏µ‡∏™‡∏≠‡∏á‡πÅ‡∏ö‡∏ö‡πÉ‡∏´‡πâ‡πÉ‡∏ä‡πâ‡∏Ñ‡∏∑‡∏≠ pre-endoscopy (admission rockall score) ‡πÅ‡∏•‡∏∞ post-endoscopy (full rockall score) ‡πÅ‡∏ï‡πà‡πÅ‡∏ö‡∏ö post ‡∏à‡∏∞‡πÉ‡∏ä‡πâ‡∏Ç‡πâ‡∏≠‡∏°‡∏π‡∏•‡∏´‡∏•‡∏±‡∏á‡∏Å‡∏≤‡∏£‡∏™‡πà‡∏≠‡∏á‡∏Å‡∏•‡πâ‡∏≠‡∏á‡∏î‡πâ‡∏ß‡∏¢\n\t- 3 initial before endoscopy\n\t\t- ‡∏´‡∏≤‡∏Å‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô‡∏Å‡πà‡∏≠‡∏ô‡∏´‡∏ô‡πâ‡∏≤‡πÑ‡∏î‡πâ non-low-risk ‡πÉ‡∏´‡πâ‡πÉ‡∏ä‡πâ IV bolus PPI ‡∏ï‡πà‡∏≠‡∏î‡πâ‡∏ß‡∏¢ continuous infusion\n\t\t\t- dose: omeprazole, esomeprazole, pantoprazole ‡πÉ‡∏ä‡πâ 80 mg loading dose then 8 mg/hr maintenance\n\t\t\t- ‡∏¢‡∏Å‡πÄ‡∏ß‡πâ‡∏ô lansoprazole ‡πÉ‡∏ä‡πâ 60 mg LD ‡πÅ‡∏•‡∏∞ 6 mg/hr maintenance\n\t\t- ‡∏´‡∏≤‡∏Å low risk ‡∏≠‡∏≤‡∏à‡πÅ‡∏Ñ‡πà IV bolus ‡πÅ‡∏•‡∏∞ oral PPI bid (maybe high dose) ‡πÅ‡∏•‡∏∞‡∏≠‡∏≤‡∏à‡πÑ‡∏°‡πà‡∏ï‡πâ‡∏≠‡∏á‡∏™‡πà‡∏≠‡∏á‡∏Å‡∏•‡πâ‡∏≠‡∏á observe and discharge\n\t- 4 endoscopy\n\t\t- erythromycin 250 mg IV 20-90 ‡∏ô‡∏≤‡∏ó‡∏µ‡∏Å‡πà‡∏≠‡∏ô endoscopy (ACG 2021)\n\t\t- guideline ‡πÅ‡∏ô‡∏∞‡∏ô‡∏≥‡πÉ‡∏´‡πâ‡πÉ‡∏ä‡πâ‡∏™‡∏≠‡∏á‡∏ß‡∏¥‡∏ò‡∏µ‡∏£‡πà‡∏ß‡∏°‡∏Å‡∏±‡∏ô‡πÉ‡∏ô‡∏Å‡∏≤‡∏£‡∏£‡∏±‡∏Å‡∏©‡∏≤ NVUGIB ‡∏î‡πâ‡∏ß‡∏¢ endoscopy\n\t\t- acute bleeding (type I)\n\t\t\t- Spurting (a), Oozing (b) ‡∏ï‡πâ‡∏≠‡∏á‡∏£‡∏±‡∏Å‡∏©‡∏≤ endoscopic / ‡∏≠‡∏≤‡∏à‡∏ï‡πâ‡∏≠‡∏á surgery\n\t\t- sign of recent bleeding (type II)\n\t\t\t- non-bleeding (a) ‡∏ï‡πâ‡∏≠‡∏á‡∏£‡∏±‡∏Å‡∏©‡∏≤ endoscopic / ‡∏≠‡∏≤‡∏à‡∏ï‡πâ‡∏≠‡∏á surgery\n\t\t\t- adherent clot (b)  ‡∏ï‡πâ‡∏≠‡∏á‡∏£‡∏±‡∏Å‡∏©‡∏≤ endoscopic ‡πÑ‡∏°‡πà‡∏à‡∏≥‡πÄ‡∏õ‡πá‡∏ô surgery\n\t\t\t- flat pigmented spot (c) ‡∏≠‡∏±‡∏ô‡∏ô‡∏µ‡πâ‡∏≠‡∏≤‡∏à‡πÑ‡∏°‡πà‡∏Ç‡∏≥‡πÄ‡∏õ‡πá‡∏ô‡∏ï‡πâ‡∏≠‡∏á‡∏ú‡πà‡∏≤ ‡∏´‡∏£‡∏∑‡∏≠ endoscopic ‡πÅ‡∏•‡∏∞‡πÇ‡∏≠‡∏Å‡∏≤‡∏™ bleed ‡∏ô‡πâ‡∏≠‡∏¢\n\t\t- no sign of bleeding ‡πÅ‡∏ï‡πà‡∏°‡∏µ lesion (type III)\n\t\t- ‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏à‡∏≥‡πÄ‡∏õ‡πá‡∏ô‡∏ï‡πâ‡∏≠‡∏á‡∏£‡∏±‡∏Å‡∏©‡∏≤ endoscopic ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏à‡∏∞ persistent bleeding or re-bleeding ‡πÑ‡∏î‡πâ‡∏ñ‡πâ‡∏≤‡πÑ‡∏°‡πà‡∏ó‡∏≥‡∏≠‡∏∞‡πÑ‡∏£‡πÄ‡∏•‡∏¢! ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤‡∏≠‡∏±‡∏ô‡πÅ‡∏£‡∏Å ‡πÜ ‡πÄ‡∏ä‡πà‡∏ô 1a 1b 2a ‡∏à‡∏∞‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á rebleeding ‡∏≠‡∏µ‡∏Å‡πÅ‡∏°‡πâ endoscopic ‡πÅ‡∏•‡πâ‡∏ß\n\t- 5 post endoscopic PPI\n\t\t- ‡∏•‡∏î‡πÇ‡∏≠‡∏Å‡∏≤‡∏™‡πÄ‡∏Å‡∏¥‡∏î rebleeding, ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏´‡∏≤‡∏¢‡πÄ‡∏£‡πá‡∏ß\n\t\t- ‡πÄ‡∏õ‡πâ‡∏≤‡∏´‡∏°‡∏≤‡∏¢ pH \u003e 6 ‡πÇ‡∏î‡∏¢‡πÉ‡∏´‡πâ PPI bid ‡∏ú‡∏•‡πÑ‡∏°‡πà‡πÅ‡∏ï‡∏Å‡∏ï‡πà‡∏≤‡∏á‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡πÉ‡∏´‡πâ IV ‡πÄ‡∏û‡∏µ‡∏¢‡∏á‡πÅ‡∏ï‡πà IV ‡∏à‡∏∞‡πÄ‡∏£‡πá‡∏ß‡∏Å‡∏ß‡πà‡∏≤ oral ‡∏õ‡∏£‡∏∞‡∏°‡∏≤‡∏ì 1 ‡∏ä‡∏°\n\t\t- ‡∏à‡∏∞‡πÉ‡∏´‡πâ IV PPI 72 hr then oral PPI 2 wks\n\t\t- ‡∏≠‡∏¢‡πà‡∏≤‡∏•‡∏∑‡∏° H. pylori ‡∏ñ‡πâ‡∏≤‡∏™‡∏á‡∏™‡∏±‡∏¢ ‡πÅ‡∏•‡∏∞‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ‡∏¢‡∏≤‡∏î‡πâ‡∏ß‡∏¢\n\t\t- ‡∏õ‡∏£‡∏±‡∏ö‡πÄ‡∏õ‡∏•‡∏µ‡πà‡∏¢‡∏ô‡∏¢‡∏≤‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ\n\t\t\t- antiplatelets\n\t\t\t\t- ‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å Ia Ib IIa or IIb (‡∏ï‡πâ‡∏≠‡∏á endoscopic)\n\t\t\t\t\t- primary\n\t\t\t\t\t\t- ‡∏´‡∏¢‡∏∏‡∏î‡∏¢‡∏≤ ‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô indication / ‡∏Ñ‡∏ß‡∏≤‡∏°‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á‡∏≠‡∏µ‡∏Å‡∏Ñ‡∏£‡∏±‡πâ‡∏á\n\t\t\t\t\t- secondary\n\t\t\t\t\t\t- aspirin\n\t\t\t\t\t\t\t- resume in 3-5 days\n\t\t\t\t\t\t- DAPT\n\t\t\t\t\t\t\t- continue ‡πÅ‡∏Ñ‡πà LDA ‡πÅ‡∏ï‡πà DAPT ‡πÉ‡∏´‡πâ consult ‡∏Å‡πà‡∏≠‡∏ô\n\t\t\t\t\t\t- ‡∏ó‡∏±‡πâ‡∏á‡∏Ñ‡∏π‡πà‡πÉ‡∏´‡πâ‡∏î‡∏π‡∏≠‡∏µ‡∏Å‡∏£‡∏≠‡∏ö‡∏Å‡πá‡πÑ‡∏î‡πâ ‡πÄ‡∏ú‡∏∑‡πà‡∏≠ rebleed / ‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏°‡∏µ PPI ‡∏≠‡∏¢‡∏π‡πà‡πÅ‡∏•‡πâ‡∏ß‡∏î‡πâ‡∏ß‡∏¢\n\t\t\t\t- ‡∏´‡∏≤‡∏Å IIc or III\n\t\t\t\t\t- primary\n\t\t\t\t\t\t- ‡∏´‡∏¢‡∏∏‡∏î‡∏¢‡∏≤\n\t\t\t\t\t- secondary\n\t\t\t\t\t\t- ‡πÉ‡∏ä‡πâ‡πÑ‡∏î‡πâ‡∏õ‡∏Å‡∏ï‡∏¥\n\t\t\t- Vit K antagonist\n\t\t\t\t- ‡πÉ‡∏´‡πâ‡∏´‡∏¢‡∏∏‡∏î‡∏¢‡∏≤‡∏ó‡∏±‡∏ô‡∏ó‡∏µ‡∏´‡∏•‡∏±‡∏á‡πÄ‡∏Å‡∏¥‡∏î‡πÄ‡∏´‡∏ï‡∏∏ NVUGIB ‡πÅ‡∏•‡πâ‡∏ß‡∏ï‡∏¥‡∏î‡∏ï‡∏≤‡∏° INR\n\t\t\t\t\t- \u003c 2.5\n\t\t\t\t\t\t- endoscope ‡πÑ‡∏î‡πâ‡∏õ‡∏Å‡∏ï‡∏¥\n\t\t\t\t\t- \u003e 2.5\n\t\t\t\t\t\t- reverse ‡∏Å‡πà‡∏≠‡∏ô‡∏î‡πâ‡∏ß‡∏¢‡∏Å‡∏≤‡∏£‡πÉ‡∏´‡πâ FFP ‡∏´‡∏£‡∏∑‡∏≠ vit K IV 5-10 mg over 30 mins\n\t\t\t- DOACs\n\t\t\t\t- ‡∏ñ‡πâ‡∏≤ mild ‡πÉ‡∏´‡πâ PPI ‡∏™‡∏±‡∏Å‡∏û‡∏±‡∏Å‡πÅ‡∏•‡πâ‡∏ß resume ‡πÑ‡∏î‡πâ\n\t\t\t\t- ‡∏ñ‡πâ‡∏≤ moderate to severe ‡πÉ‡∏´‡πâ‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô overdose?\n\t\t\t\t\t- ‡∏ñ‡πâ‡∏≤ dabigatrain ‡πÅ‡∏ô‡∏∞‡∏ô‡∏≥ haemodialysis or IV idarucizumab\n\t\t\t\t\t- anti-factor Xa ‡πÉ‡∏´‡πâ four-factor PCC\n\t\t\t\t- life-threatening\n\t\t\t\t\t- dabigatarn ‡πÉ‡∏´‡πâ IV idacurizumab\n\t\t\t\t\t- anti-factor Xa ‡πÉ‡∏´‡πâ four-factor PCC","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/Viral-Hepatitis":{"title":"Viral Hepatitis","content":"\n- Upper GI Bleed ‡πÄ‡∏Å‡∏µ‡πà‡∏¢‡∏ß‡∏Ç‡πâ‡∏≠‡∏á‡∏Å‡∏±‡∏ö Hepatitis ‡πÄ‡∏ô‡∏∑‡πà‡∏≠‡∏á‡∏à‡∏≤‡∏Å‡∏™‡∏°‡∏≠‡∏á‡∏°‡∏µ‡∏Ñ‡∏ß‡∏≤‡∏°‡∏™‡∏≥‡∏Ñ‡∏±‡∏ç‡∏Å‡∏ß‡πà‡∏≤‡∏ï‡∏±‡∏ö ‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡∏à‡∏∂‡∏á‡∏≠‡∏≤‡∏à‡πÑ‡∏õ‡πÄ‡∏•‡∏µ‡πâ‡∏¢‡∏á‡∏ó‡∏µ‡πà‡∏ï‡∏±‡∏ö‡∏ô‡πâ‡∏≠‡∏¢‡∏•‡∏á‡πÄ‡∏û‡∏∑‡πà‡∏≠‡∏£‡∏±‡∏Å‡∏©‡∏≤‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡∏ó‡∏µ‡πà‡∏¢‡∏±‡∏á‡πÄ‡∏´‡∏•‡∏∑‡∏≠ ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡πÄ‡∏Å‡∏¥‡∏î Ischemia ‡∏ó‡∏µ‡πà‡∏ï‡∏±‡∏ö‡πÑ‡∏î‡πâ\n- ‡∏ô‡∏≠‡∏Å‡∏à‡∏≤‡∏Å Blood circulation ‡∏•‡∏î‡∏•‡∏á ‡∏Å‡πá‡∏≠‡∏≤‡∏à‡∏°‡∏≤‡∏à‡∏≤‡∏Å‡∏™‡∏≤‡∏£‡∏û‡∏¥‡∏©‡πÄ‡∏ä‡πà‡∏ô alpha-toxin ‡∏´‡∏£‡∏∑‡∏≠ autoimmune disease ‡∏ï‡πà‡∏≤‡∏á ‡πÜ ‡∏´‡∏£‡∏∑‡∏≠‡∏Å‡∏≤‡∏£‡∏ï‡∏¥‡∏î‡πÄ‡∏ä‡∏∑‡πâ‡∏≠‡∏ï‡πà‡∏≤‡∏á ‡πÜ\n- Acute (\u003c 6 months)\n\t- Viral hepatitis A,E\n\t- ‡∏°‡∏±‡∏Å‡∏°‡∏≤‡∏î‡πâ‡∏ß‡∏¢‡∏≠‡∏≤‡∏Å‡∏≤‡∏£ Abdominal Pain\n\t- ‡∏£‡πà‡∏≤‡∏á‡∏Å‡∏≤‡∏¢‡∏Ç‡∏±‡∏ö bilirubin ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ ‡∏à‡∏∂‡∏á‡πÑ‡∏°‡πà‡∏≠‡∏≠‡∏Å‡∏ó‡∏≤‡∏á‡∏≠‡∏∏‡∏à‡∏≤‡∏£‡∏∞‡πÄ‡∏•‡∏¢ ‡πÅ‡∏•‡∏∞‡πÑ‡∏õ‡∏≠‡∏≠‡∏Å‡∏ó‡∏≤‡∏á‡∏õ‡∏±‡∏™‡∏™‡∏≤‡∏ß‡∏∞‡πÅ‡∏ó‡∏ô -\u003e dark urine, jaundice\n\t- hepatomegaly\n- Chronic (\u003e 6 months)\n\t- Viral hepatitis B,C,D\n\t- Non-alcoholic fatty liver disease (NAFLD) ‡∏´‡∏£‡∏∑‡∏≠ ‡πÑ‡∏Ç‡∏°‡∏±‡∏ô‡∏û‡∏≠‡∏Å‡∏ï‡∏±‡∏ö\n\t- hepatomegaly\n\t- ‡∏™‡∏£‡πâ‡∏≤‡∏á albumin ‡πÑ‡∏î‡πâ‡∏ô‡πâ‡∏≠‡∏¢ ‡∏£‡πà‡∏≤‡∏á‡∏Å‡∏≤‡∏¢‡∏à‡∏∂‡∏á‡∏î‡∏∂‡∏á‡∏ô‡πâ‡∏≥‡πÑ‡∏î‡πâ‡∏ô‡πâ‡∏≠‡∏¢ ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡πÄ‡∏Å‡∏¥‡∏î peripheral oedema, ascites, cirrhosis\n\t\t- cirrhosis ‡∏°‡∏≤‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡πÄ‡∏ã‡∏•‡∏•‡πå‡∏ï‡∏±‡∏ö‡∏ñ‡∏π‡∏Å‡πÅ‡∏ó‡∏ô‡∏ó‡∏µ‡πà‡∏î‡πâ‡∏ß‡∏¢ fibrous\n\n| A               | B                                     | C                            | D                        | E               |\n| --------------- | ------------------------------------- | ---------------------------- | ------------------------ | --------------- |\n| acute only      | 5-10% chronic                         | 80% chronic -\u003e easily cancer | 5% chronic               | acute only      |\n| RNA naked -\u003e ‡∏ó‡∏ô fecal/oral ‡πÑ‡∏î‡πâ | sex/parenteral                        | sex/parenteral               | sex/parenteral           | RNA naked -\u003e ‡∏ó‡∏ô fecal/oral ‡πÑ‡∏î‡πâ|\n|                 | **‡πÄ‡∏õ‡πá‡∏ô‡∏ï‡∏±‡∏ß‡πÄ‡∏î‡∏µ‡∏¢‡∏ß‡∏ó‡∏µ‡πà‡πÄ‡∏õ‡πá‡∏ô DNA enveloped** | RNA enveloped                | enveloped but incomplete ‡∏ï‡πâ‡∏≠‡∏á‡∏Å‡∏≤‡∏£ HbsAg |                 |\n|                 |serology ‡∏û‡∏ö HbsAg, HbsAb, HBeAb HBeAg|                              |                          |                 |\n- ‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å‡∏ï‡∏¥‡∏î D -\u003e ‡∏ï‡∏¥‡∏î B ‡∏î‡πâ‡∏ß‡∏¢‡πÅ‡∏ô‡πà ‡πÜ\n- ‡∏ñ‡πâ‡∏≤‡∏ï‡∏¥‡∏î B -\u003e ‡∏ï‡πâ‡∏≠‡∏á‡πÄ‡∏ä‡πá‡∏Ñ‡∏ß‡πà‡∏≤‡∏ï‡∏¥‡∏î D ‡∏´‡∏°\n- ‡∏û‡∏ß‡∏Å naked ‡πÉ‡∏´‡πâ‡πÉ‡∏ä‡πâ sodium hypochlorite ‡πÄ‡∏õ‡πá‡∏ô disinfectant ‡πÄ‡∏ô‡∏∑‡πà‡∏≠‡∏á‡∏à‡∏≤‡∏Å‡∏°‡∏±‡∏ô‡πÄ‡∏õ‡πá‡∏ô naked / ‡πÑ‡∏°‡πà‡πÅ‡∏ô‡∏∞‡∏ô‡∏≥ surfactant ‡∏´‡∏£‡∏∑‡∏≠ alcohol ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏≠‡∏≤‡∏à‡πÑ‡∏°‡πà‡∏™‡∏≤‡∏°‡∏≤‡∏£‡∏ñ‡∏Ü‡πà‡∏≤‡πÑ‡∏î‡πâ\n\n- Phase\n\t- 1 - Viral replication phase ‡πÑ‡∏°‡πà‡∏°‡∏µ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£ ‡πÅ‡∏•‡∏õ‡∏≠‡∏≤‡∏à‡πÄ‡∏£‡∏¥‡πà‡∏°‡πÄ‡∏õ‡∏•‡∏µ‡πà‡∏¢‡∏ô ‡∏û‡∏ö viral serology\n\t- 2 - Prodromal phase ‡∏°‡∏µ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏ô‡∏≥ ‡∏≠‡∏≤‡∏à N/V ‡∏õ‡∏ß‡∏î‡πÄ‡∏°‡∏∑‡πà‡∏≠‡∏¢ ‡∏°‡∏µ acute viral syndrome ‡∏ñ‡πâ‡∏≤‡πÄ‡∏õ‡πá‡∏ô Hep A ‡∏≠‡∏≤‡∏à‡∏à‡∏∞‡πÄ‡∏£‡πá‡∏ß‡∏°‡∏≤‡∏Å ‡πÜ \n\t- 3 - Icteric phase ‡∏î‡∏µ‡∏ã‡πà‡∏≤‡∏ô ‡∏õ‡∏±‡∏™‡∏™‡∏≤‡∏ß‡∏∞‡∏™‡∏µ‡πÄ‡∏Ç‡πâ‡∏° ‡πÄ‡∏à‡πá‡∏ö RUQ ‡∏ï‡∏±‡∏ö‡πÇ‡∏ï\n\t- 4 - Convalescent phase ‡∏Ç‡∏±‡πâ‡∏ô‡∏ô‡∏µ‡πâ‡πÅ‡∏õ‡∏•‡∏ß‡πà‡∏≤‡∏´‡∏≤‡∏¢‡∏Ç‡∏≤‡∏î / LAB \u0026 S\u0026S ‡∏õ‡∏Å‡∏ï‡∏¥\n\n### Hepatitis A\n- fecal - oral ‡πÑ‡∏î‡πâ\n- incubation 2-6 wks\n- ‡∏°‡∏±‡∏Å‡∏°‡∏µ‡πÄ‡∏î‡πá‡∏Å‡πÄ‡∏õ‡πâ‡∏ô reservoirs\n- ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡πÑ‡∏°‡πà‡∏£‡∏∏‡∏ô‡πÅ‡∏£‡∏á ‡∏°‡∏±‡∏Å‡∏´‡∏≤‡∏¢‡πÑ‡∏î‡πâ‡πÄ‡∏≠‡∏á\n- ‡πÉ‡∏ä‡πâ IgHAV ‡πÉ‡∏ô‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏ó‡∏µ‡πà‡πÑ‡∏°‡πà‡∏°‡∏µ‡∏†‡∏π‡∏°‡∏¥‡πÄ‡∏´‡∏•‡∏∑‡∏≠‡πÄ‡∏•‡∏¢\n- ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏ï‡∏±‡∏ö‡πÇ‡∏ï‡∏°‡∏±‡∏Å‡∏à‡∏∞‡∏ô‡∏≥‡∏°‡∏≤‡∏Å‡πà‡∏≠‡∏ô\n- ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏ô‡∏≥ ‡∏´‡∏£‡∏∑‡∏≠‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏ï‡πà‡∏≤‡∏á ‡πÜ ‡∏°‡∏±‡∏Å‡∏à‡∏∞‡∏°‡∏≤‡∏ï‡∏≠‡∏ô‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏£‡∏∏‡∏ô‡πÅ‡∏£‡∏á‡πÅ‡∏•‡πâ‡∏ß (2-8 wks) ‡πÇ‡∏î‡∏¢ ALT ‡πÅ‡∏•‡∏∞ IgM ‡∏≠‡∏≤‡∏à‡∏à‡∏∞‡∏Ç‡∏∂‡πâ‡∏ô‡∏ô‡∏≥‡∏°‡∏≤‡∏Å‡πà‡∏≠‡∏ô ‡πÅ‡∏•‡πâ‡∏ß IgG ‡∏à‡∏∞‡∏ï‡∏≤‡∏°‡∏°‡∏≤‡∏ó‡∏µ‡∏´‡∏•‡∏±‡∏á‡∏õ‡∏£‡∏∞‡∏°‡∏≤‡∏ì 2-3 wks \n\t- ‡∏õ‡∏•. IgM ‡πÅ‡∏Ñ‡πà‡∏ö‡πà‡∏á‡∏ö‡∏≠‡∏Å‡∏ß‡πà‡∏≤‡∏ï‡∏¥‡∏î‡πÄ‡∏ä‡∏∑‡πâ‡∏≠\n- ‡∏Å‡∏≤‡∏£‡∏õ‡πâ‡∏≠‡∏á‡∏Å‡∏±‡∏ô\n\t- ‡πÅ‡∏¢‡∏Å‡∏Ç‡∏≠‡∏á‡πÉ‡∏ä‡πâ 1-2 ‡πÄ‡∏î‡∏∑‡∏≠‡∏ô\n\t- ‡∏Å‡∏¥‡∏ô‡∏£‡πâ‡∏≠‡∏ô 85 'C 1 ‡∏ô‡∏≤‡∏ó‡∏µ\n\t- sodiuim hypochlorite\n\t- ‡∏ß‡∏±‡∏Ñ‡∏ã‡∏µ‡∏ô (1 mo) ‡∏Å‡πà‡∏≠‡∏ô‡πÄ‡∏Ç‡πâ‡∏≤‡∏û‡∏∑‡πâ‡∏ô‡∏ó‡∏µ‡πà‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á ‡∏´‡∏£‡∏∑‡∏≠ periodical Ig (‡∏ó‡∏∏‡∏Å 4-6 wks ‡∏ï‡∏≠‡∏ô‡∏≠‡∏¢‡∏π‡πà‡∏û‡∏∑‡πâ‡∏ô‡∏ó‡∏µ‡πà‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á)\n\t- post-exposure Ig (‡∏†‡∏≤‡∏¢‡∏´‡∏•‡∏±‡∏á 48 ‡∏ä‡∏° ‡∏´‡∏•‡∏±‡∏á‡∏™‡∏±‡∏°‡∏ú‡∏±‡∏™ ‡πÑ‡∏°‡πà‡πÄ‡∏Å‡∏¥‡∏ô 1 ‡∏™‡∏±‡∏õ‡∏î‡∏≤‡∏´‡πå)\n- Vaccine\n\t- HAVRIX, VAQTA ‡∏â‡∏µ‡∏î‡∏™‡∏•‡∏±‡∏ö‡∏Å‡∏±‡∏ô‡πÑ‡∏î‡πâ ‡πÇ‡∏î‡∏¢‡∏â‡∏±‡∏î 0, 6-12 mo ‡∏´‡∏£‡∏∑‡∏≠ 6-18 (VAQTA)\n\t- TWINRIX ‡∏°‡∏µ‡∏ó‡∏±‡πâ‡∏á A,B\n\t- thai epi: \n\t\t- ‡πÉ‡∏´‡πâ inactivated viral vaccine 2 ‡∏Ñ‡∏£‡∏±‡πâ‡∏á ‡∏´‡πà‡∏≤‡∏á‡∏Å‡∏±‡∏ô 6-12 ‡πÄ‡∏î‡∏∑‡∏≠‡∏ô\n\t\t- ‡∏´‡∏≤‡∏Å live ‡πÉ‡∏´‡πâ‡∏â‡∏µ‡∏î‡∏Ñ‡∏£‡∏±‡πâ‡∏á‡πÄ‡∏î‡∏µ‡∏¢‡∏ß‡∏ï‡∏≠‡∏ô age 18 mo +\n\n### Hepatitis B\n- sex/parenteral\n\t- ‡∏ï‡∏¥‡∏î‡∏ó‡∏≤‡∏á sex ‡πÑ‡∏î‡πâ ‡∏î‡∏±‡∏á‡∏ô‡∏±‡πâ‡∏ô‡∏û‡∏ö‡πÄ‡∏¢‡∏≠‡∏∞‡πÉ‡∏ô‡∏õ‡∏£‡∏∞‡πÄ‡∏ó‡∏®‡∏ó‡∏µ‡πà‡∏°‡∏µ‡∏Ñ‡∏ß‡∏≤‡∏°‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á STD ‡πÄ‡∏¢‡∏≠‡∏∞\n\t- hepB ‡∏ï‡∏¥‡∏î‡∏á‡πà‡∏≤‡∏¢‡∏Å‡∏ß‡πà‡∏≤ AIDs ‡∏õ‡∏£‡∏∞‡∏°‡∏≤‡∏ì 100 ‡πÄ‡∏ó‡πà‡∏≤\n- incubatio 1-6 months\n- ‡∏ï‡∏¥‡∏î‡∏ó‡∏≤‡∏á perinatal ‡πÑ‡∏î‡πâ‡∏î‡πâ‡∏ß‡∏¢ ‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å‡πÅ‡∏°‡πà HBsAg positive ‡∏´‡∏•‡∏±‡∏á‡∏Ñ‡∏•‡∏≠‡∏î ‡πÉ‡∏´‡πâ‡∏â‡∏µ‡∏î‡∏ß‡∏±‡∏Ñ‡∏ã‡∏µ‡∏ô‡πÅ‡∏•‡∏∞ Ig ‡πÉ‡∏´‡πâ‡∏•‡∏π‡∏Å\n- ![[Pasted image 20230306162101.png|625]]\n- Serology\n\t- HBsAgs ‡πÑ‡∏î‡πâ‡∏£‡∏±‡∏ö‡πÄ‡∏ä‡∏∑‡πâ‡∏≠ ‡πÅ‡∏ï‡πà‡πÑ‡∏°‡πà‡∏£‡∏π‡πâ‡∏ß‡πà‡∏≤‡∏≠‡∏¢‡∏π‡πà‡∏£‡∏∞‡∏¢‡∏∞‡πÑ‡∏´‡∏ô (‡∏ú‡∏•‡∏ö‡∏ß‡∏Å \u003e 6 months) ‡πÇ‡∏î‡∏¢‡∏≠‡∏≤‡∏à‡πÄ‡∏õ‡πá‡∏ô ‡∏£‡∏∞‡∏¢‡∏∞‡∏ï‡∏¥‡∏î‡∏ï‡πà‡∏≠ ‡∏´‡∏£‡∏∑‡∏≠‡πÄ‡∏õ‡πá‡∏ô‡∏û‡∏≤‡∏´‡∏∞‡∏Å‡πá‡πÑ‡∏î‡πâ\n\t- HBeAgs ‡πÑ‡∏î‡πâ‡∏£‡∏±‡∏ö‡πÄ‡∏ä‡∏∑‡πâ‡∏≠ ‡∏≠‡∏¢‡∏π‡πà‡∏ä‡πà‡∏ß‡∏á high infectivity\n\t\t- HBeAg ‡∏à‡∏∞‡∏≠‡∏≠‡∏Å‡∏°‡∏≤‡πÅ‡∏Ñ‡πà‡∏ï‡∏≠‡∏ô replicate ‡πÄ‡∏ä‡∏∑‡πâ‡∏≠‡πÅ‡∏•‡πâ‡∏ß\n\t- **HbsAbs ‡∏ö‡πà‡∏á‡∏ö‡∏≠‡∏Å‡∏ß‡πà‡∏≤‡∏°‡∏µ‡∏†‡∏π‡∏°‡∏¥ ‡∏•‡∏∞‡∏ï‡πâ‡∏≠‡∏á‡∏°‡∏µ‡πÉ‡∏ô‡∏Ñ‡∏ô‡∏ó‡∏µ‡πà‡∏´‡∏≤‡∏¢‡∏Ç‡∏≤‡∏î** ‡∏´‡∏°‡∏≤‡∏¢‡∏ñ‡∏∂‡∏á ‡∏à‡∏∞‡∏ï‡πâ‡∏≠‡∏á‡πÄ‡∏Å‡∏¥‡∏î seroconversion ‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å‡πÑ‡∏°‡πà‡πÄ‡∏Å‡∏¥‡∏î‡πÅ‡∏™‡∏î‡∏á‡∏ß‡πà‡∏≤‡πÄ‡∏õ‡πá‡∏ô carrier\n\t- HbeAbs ‡∏ö‡πà‡∏á‡∏ö‡∏≠‡∏Å‡∏ß‡πà‡∏≤‡πÄ‡∏Ñ‡∏¢‡πÑ‡∏î‡πâ‡∏£‡∏±‡∏ö‡πÄ‡∏ä‡∏∑‡πâ‡∏≠‡∏ó‡∏µ‡πà replicate ‡πÑ‡∏î‡πâ ‡πÅ‡∏ï‡πà‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏ö‡∏≠‡∏Å‡∏ß‡πà‡∏≤‡∏´‡∏≤‡∏¢‡πÅ‡∏•‡πâ‡∏ß‡∏´‡∏£‡∏∑‡∏≠‡πÄ‡∏õ‡πá‡∏ô‡∏û‡∏≤‡∏´‡∏∞\n\t- HbcAbs ‡πÅ‡∏Ñ‡πà‡∏ö‡πà‡∏á‡∏ö‡∏≠‡∏Å‡∏ß‡πà‡∏≤‡πÄ‡∏Ñ‡∏¢‡∏ï‡∏¥‡∏î‡πÄ‡∏ä‡∏∑‡πâ‡∏≠‡πÄ‡∏´‡∏°‡∏∑‡∏≠‡∏ô HbeAbs\n- ![[Pasted image 20230306162224.png|625]]\n\t- ‡πÄ‡∏ô‡πâ‡∏ô‡∏ß‡πà‡∏≤ HBsAb ‡∏à‡∏∞‡πÄ‡∏à‡∏≠‡∏ï‡∏≠‡∏ô‡∏ó‡∏µ‡πà‡∏°‡∏±‡∏ô‡∏´‡∏≤‡∏¢‡πÅ‡∏•‡πâ‡∏ß‡πÄ‡∏ó‡πà‡∏≤‡∏ô‡∏±‡πâ‡∏ô ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤‡πÑ‡∏°‡πà‡πÄ‡∏Å‡∏¥‡∏î ‡πÅ‡∏•‡πâ‡∏ß‡πÇ‡∏ú‡∏•‡πà‡∏°‡∏≤‡πÅ‡∏ï‡πà HBeAbs ‡πÅ‡∏™‡∏î‡∏á‡∏ß‡πà‡∏≤‡∏≠‡∏≤‡∏à‡πÄ‡∏õ‡πá‡∏ô carrier\n- ‡∏à‡∏∞‡πÄ‡∏Å‡∏¥‡∏î‡πÄ‡∏õ‡πá‡∏ô HCC ‡πÑ‡∏´‡∏°‡∏Å‡πá‡∏î‡∏π‡∏õ‡∏±‡∏à‡∏à‡∏±‡∏¢‡∏≠‡∏∑‡πà‡∏ô ‡πÜ ‡∏£‡πà‡∏ß‡∏°‡πÄ‡∏≠‡∏≤ ‡πÄ‡∏ä‡πà‡∏ô HBV ‡∏™‡∏π‡∏á‡πÄ‡∏õ‡πâ‡∏ô‡∏£‡∏∞‡∏¢‡∏∞‡πÄ‡∏ß‡∏•‡∏≤‡∏ô‡∏≤‡∏ô ‡∏´‡∏£‡∏∑‡∏≠ HBsAg ‡∏™‡∏π‡∏á‡∏ô‡∏≤‡∏ô ‡∏´‡∏£‡∏∑‡∏≠ genetics ‡∏´‡∏£‡∏∑‡∏≠‡∏ú‡∏π‡πâ‡∏õ‡πà‡∏ß‡∏¢‡∏°‡∏µ‡∏õ‡∏±‡∏à‡∏à‡∏±‡∏¢‡∏≠‡∏∑‡πà‡∏ô‡∏£‡πà‡∏ß‡∏°‡∏î‡πâ‡∏ß‡∏¢‡∏≠‡∏¢‡∏π‡πà‡∏•‡πÅ‡πâ‡∏ß\n- ‡∏Ç‡πâ‡∏≠‡∏ö‡πà‡∏á‡∏ä‡∏µ‡πâ‡πÉ‡∏ô‡∏Å‡∏≤‡∏£‡∏£‡∏±‡∏Å‡∏©‡∏≤ ‡πÑ‡∏°‡πà‡∏ß‡πà‡∏≤‡∏à‡∏∞ HBeAg + ‡∏´‡∏£‡∏∑‡∏≠ HBeAg - ‡∏Å‡πá‡∏ï‡∏≤‡∏°\n\t- HBsAg + ‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤ 6 ‡πÄ‡∏î‡∏∑‡∏≠‡∏ô\n\t- HBV DNA \u003e 2000 IU / ml\n\t- ALT \u003e 2 ‡πÄ‡∏ó‡πà‡∏≤, 2 ‡∏£‡∏≠‡∏ö ‡πÅ‡∏•‡∏∞‡πÄ‡∏õ‡πá‡∏ô‡∏ô‡∏≤‡∏ô 3 ‡πÄ‡∏î‡∏∑‡∏≠‡∏ô\n\t\t- ‡∏´‡∏≤‡∏Å‡∏ô‡πâ‡∏≠‡∏¢‡∏Å‡∏ß‡πà‡∏≤ ‡∏ï‡πâ‡∏≠‡∏á‡∏°‡∏µ necroinflammation ‡∏à‡∏∂‡∏á‡∏£‡∏±‡∏Å‡∏©‡∏≤\n\t- ALT ‡∏õ‡∏Å‡∏ï‡∏¥ ‡∏´‡∏£‡∏∑‡∏≠‡∏°‡∏µ‡∏Ç‡πâ‡∏≠‡∏ö‡πà‡∏á‡∏ä‡∏µ‡πâ‡∏ß‡πà‡∏≤‡∏à‡∏∞‡πÄ‡∏Å‡∏¥‡∏î‡∏û‡∏±‡∏á‡∏ú‡∏∑‡∏î, ‡∏´‡∏£‡∏∑‡∏≠‡∏ï‡∏±‡∏ö‡πÅ‡∏Ç‡πá‡∏á, ‡∏´‡∏£‡∏∑‡∏≠‡∏°‡∏∞‡πÄ‡∏£‡πá‡∏á‡∏ï‡∏±‡∏ö, ‡∏´‡∏£‡∏∑‡∏≠‡∏≠‡∏≤‡∏¢‡∏∏ \u003e 40 ‡∏õ‡∏µ, ‡∏´‡∏£‡∏∑‡∏≠‡πÄ‡∏û‡∏®‡∏ä‡∏≤‡∏¢\n- ‡∏Å‡∏≤‡∏£‡∏£‡∏±‡∏Å‡∏©‡∏≤\n\t- Biologics\n\t\t- **‡∏≠‡∏≤‡∏à induce ‡πÉ‡∏´‡πâ‡πÄ‡∏Å‡∏¥‡∏î‡∏ï‡∏±‡∏ö‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö (‡∏î‡∏±‡∏á‡∏ô‡∏±‡πâ‡∏ô‡∏ï‡∏≤‡∏° ALT ‡∏ñ‡∏µ‡πà‡πÉ‡∏ô‡∏ä‡πà‡∏ß‡∏á‡πÅ‡∏£‡∏Å)** ‡∏à‡∏∞‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πâ‡∏´‡∏≤‡∏Å‡∏°‡∏µ cirrosis ‡∏≠‡∏¢‡∏π‡πà‡πÅ‡∏•‡πâ‡∏ß ‡∏û‡∏ß‡∏Å‡∏ô‡∏µ‡πâ‡πÑ‡∏°‡πâ‡πà‡∏°‡∏µ‡∏î‡∏∑‡πâ‡∏≠‡∏¢‡∏≤ ‡πÅ‡∏•‡∏∞ paper ‡∏ö‡∏≠‡∏Å‡∏ß‡πà‡∏≤‡πÄ‡∏´‡∏°‡∏≤‡∏∞‡∏Å‡∏±‡∏ö‡∏Ñ‡∏ô‡∏ó‡∏µ‡πà‡∏†‡∏π‡∏°‡∏¥‡∏Ç‡∏¢‡∏±‡∏ô (LFT \u003e 2 ULT ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏ô‡πà‡∏≤‡∏à‡∏∞‡∏ö‡πà‡∏á‡∏ö‡∏≠‡∏Å‡∏ß‡πà‡∏≤‡∏†‡∏π‡∏°‡∏¥‡∏Ç‡∏¢‡∏±‡∏ô)\n\t\t- S/E ‡∏Ñ‡∏∑‡∏≠ flu-like symptoms\n\t\t- ‡∏¢‡∏≤‡∏ó‡∏µ‡πà‡∏°‡∏µ\n\t\t\t- IFN-a 2a 3times/wks 6 mo\n\t\t\t- Pegylated Interferon-a 2a once a wks 12 mo\n\t\t\t- Pegylated interferon-a 2 once a wks 12 mo\n\t\t- ‡πÉ‡∏ä‡πâ‡πÄ‡∏õ‡πá‡∏ô alpha ‡πÄ‡∏ô‡∏∑‡πà‡∏≠‡∏á‡∏à‡∏≤‡∏Å‡∏°‡∏µ‡∏§‡∏ó‡∏ò‡∏¥‡πå‡∏ï‡πâ‡∏≤‡∏ô‡πÑ‡∏ß‡∏£‡∏±‡∏™‡∏™‡∏∏‡∏á‡∏™‡∏∏‡∏î ‡∏™‡∏π‡∏á‡∏Å‡∏ß‡πà‡∏≤ b ‡πÅ‡∏•‡∏∞ gamma\n\t- Anti-viral drugs\n\t\t- **‡∏ñ‡πâ‡∏≤‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á‡πÄ‡∏£‡∏∑‡πà‡∏≠‡∏á nephro ‡∏à‡∏∞‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πâ‡∏û‡∏ß‡∏Å TDF** ‡∏à‡∏∞‡πÉ‡∏ä‡πâ‡∏û‡∏ß‡∏Å -vudine ‡πÅ‡∏ó‡∏ô ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á‡∏ô‡πâ‡∏≠‡∏¢‡∏™‡∏∏‡∏î\n\t\t- Lamivudine ‡∏°‡∏µ‡πÉ‡∏ô‡πÑ‡∏ó‡∏¢ ‡πÉ‡∏ä‡πâ‡πÄ‡∏¢‡∏≠‡∏∞‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏°‡∏µ generic ‡πÅ‡∏ï‡πà‡∏î‡∏∑‡πâ‡∏≠‡πÄ‡∏£‡πá‡∏ß (6 months) **‡∏≠‡∏¢‡πà‡∏≤‡∏•‡∏∑‡∏°‡∏î‡∏π AIDs ‡∏ñ‡πâ‡∏≤‡∏à‡∏∞‡πÑ‡∏°‡πà‡∏£‡∏±‡∏Å‡∏©‡∏≤ AIDs ‡∏à‡∏∞‡πÉ‡∏ä‡πâ 3TC/TDF ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ**\n\t\t- Telbivudine ‡∏≠‡∏≤‡∏à‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡∏Ñ‡∏ô‡∏ó‡∏µ‡πà‡∏ô‡πà‡∏≤‡∏à‡∏∞‡∏î‡∏∑‡πâ‡∏≠‡∏¢‡∏≤ Lamivudine ‡πÅ‡∏•‡πâ‡∏ß\n\t\t- Guideline ‡πÅ‡∏ô‡∏∞‡∏ô‡∏≥ Entecavir / TDF\n\t\t- ‡∏Ñ‡∏ô‡∏ó‡πâ‡∏≠‡∏á‡πÉ‡∏´‡πâ‡πÉ‡∏ä‡πâ TDF\n\t- **‡∏¢‡∏≤ ABC ‡∏õ‡∏£‡∏±‡∏ö‡∏ï‡∏≤‡∏°‡∏ï‡∏±‡∏ö ‡∏ô‡∏≠‡∏Å‡∏ô‡∏±‡πâ‡∏ô‡∏ï‡πâ‡∏≠‡∏á‡∏õ‡∏£‡∏±‡∏ö‡∏ï‡∏≤‡∏°‡πÑ‡∏ï‡∏´‡∏°‡∏î‡πÄ‡∏•‡∏¢ [[HIV Infection#^49c9cf|‡πÉ‡∏ô‡∏Å‡∏•‡∏∏‡πà‡∏° NRTIs]] **\n- Hep B co-infection **‡∏à‡∏≤‡∏Å‡∏™‡∏£‡∏∏‡∏õ‡∏™‡∏≠‡∏ö‡πÉ‡∏ö‡∏õ‡∏£‡∏∞‡∏Å‡∏≠‡∏ö** ![[HIV Infection#Hep B co-infection]]\n- ‡∏´‡∏≤‡∏Å‡πÉ‡∏ä‡πâ IFN ‡∏ï‡∏¥‡∏î‡∏ï‡∏≤‡∏° ALT ‡∏ñ‡∏µ‡πà‡πÉ‡∏ô‡∏ä‡πà‡∏ß‡∏á‡πÅ‡∏£‡∏Å ‡∏à‡∏ô‡∏Ç‡∏¢‡∏±‡∏ö‡πÄ‡∏õ‡πá‡∏ô‡∏ó‡∏∏‡∏Å 4-6 wks ‡πÑ‡∏î‡πâ\n- ‡∏ï‡∏¥‡∏î‡∏ï‡∏≤‡∏°‡∏Ñ‡πà‡∏≤ viral ‡∏ó‡∏±‡πâ‡∏ß‡∏´‡∏°‡∏î‡∏ó‡∏∏‡∏Å 6 ‡πÄ‡∏î‡∏∑‡∏≠‡∏ô\n- ‡∏≠‡∏¢‡πà‡∏≤‡∏•‡∏∑‡∏°‡∏ï‡∏¥‡∏î‡∏ï‡∏≤‡∏° ALT ‡∏ó‡∏∏‡∏Å 3 ‡πÄ‡∏î‡∏∑‡∏≠‡∏ô‡∏´‡∏≤‡∏Å‡πÉ‡∏ä‡πâ oral antiviral\n- ‡∏≠‡∏¢‡πà‡∏≤‡∏•‡∏∑‡∏°‡∏ï‡∏¥‡∏î‡∏ï‡∏≤‡∏°‡πÑ‡∏ï‡∏´‡∏≤‡∏Å‡πÉ‡∏ä‡πâ TDF\n- ‡∏´‡∏¢‡∏∏‡∏î‡∏¢‡∏≤: \n\t- ‡∏´‡∏¢‡∏∏‡∏î‡πÑ‡∏î‡πâ‡πÄ‡∏°‡∏∑‡πà‡∏≠ HBeAg ‡πÄ‡∏õ‡πá‡∏ô‡∏•‡∏ö HBeAb ‡πÄ‡∏õ‡πá‡∏ô‡∏ö‡∏ß‡∏Å ‡∏£‡πà‡∏ß‡∏°‡∏Å‡∏±‡∏ö‡πÑ‡∏°‡πà‡∏û‡∏ö HBV DNA ‡πÉ‡∏ô‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡πÄ)‡πâ‡∏ô‡∏≠‡∏¢‡πà‡∏≤‡∏á‡∏á‡∏ô‡πâ‡∏≠‡∏¢ 1 ‡∏õ‡∏µ\n\t- ‡∏´‡∏≤‡∏Å HBeAg ‡∏•‡∏ö‡∏≠‡∏¢‡∏π‡πà‡πÅ‡∏•‡πâ‡∏ß ‡πÉ‡∏´‡πâ‡∏£‡∏±‡∏ö‡∏õ‡∏£‡∏∞‡∏ó‡∏≤‡∏ô‡∏¢‡∏≤‡∏à‡∏ô‡∏Å‡∏ß‡πà‡∏≤ HBsAg ‡∏•‡∏ö ‡πÅ‡∏•‡∏∞ HBsAb ‡∏ö‡∏ß‡∏Å\n- ‡∏î‡∏∑‡πâ‡∏≠‡∏¢‡∏≤\n\t- ‡∏´‡∏≤‡∏Å‡∏î‡∏∑‡πâ‡∏≠ tenofovir ‡∏Å‡πá‡πÄ‡∏ß‡∏µ‡∏¢‡∏ô‡πÑ‡∏õ‡πÉ‡∏ä‡πâ‡∏û‡∏ß‡∏Å -vudine ‡∏´‡∏≤‡∏Å‡∏î‡∏∑‡πâ‡∏≠ -vudine ‡∏Å‡πá‡πÄ‡∏ß‡∏µ‡∏¢‡∏ô‡∏°‡∏≤‡πÉ‡∏ä‡πâ tenofovir ‡∏´‡∏£‡∏∑‡∏≠‡∏à‡∏∞‡∏à‡∏ö ‡πÜ ‡∏î‡πâ‡∏ß‡∏¢‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ pegylated interferon\n- ‡∏Å‡∏≤‡∏£‡∏õ‡πâ‡∏≠‡∏á‡∏Å‡∏±‡∏ô\n\t- HepB vaccination 0 1 2 4 6\n\n### Hepatitis C\n- ‡πÑ‡∏°‡πà‡∏Ñ‡πà‡∏≠‡∏¢‡∏°‡∏µ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡πÅ‡∏™‡∏î‡∏á ‡πÑ‡∏°‡πà‡∏Ñ‡πà‡∏≠‡∏¢‡∏Å‡∏£‡∏∞‡∏ï‡∏∏‡πâ‡∏ô‡∏†‡∏π‡∏°‡∏¥‡∏à‡∏∂‡∏á‡∏°‡∏±‡∏Å‡πÄ‡∏õ‡πá‡∏ô chronic\n- ‡∏°‡∏µ 6 genotypes ‡∏ß‡∏±‡∏Ñ‡∏ã‡∏µ‡∏ô‡∏à‡∏∂‡∏á‡∏™‡∏≥‡∏Ñ‡∏±‡∏ç‡∏ó‡∏µ‡πà‡∏à‡∏∞‡∏ï‡πâ‡∏≠‡∏á‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏Ñ‡∏£‡∏≠‡∏ö‡∏Ñ‡∏•‡∏∏‡∏°‡∏ñ‡∏∂‡∏á‡∏ó‡∏∏‡∏Å genotype\n- ‡∏Ñ‡∏±‡∏î‡∏Å‡∏£‡∏≠‡∏á‡πÇ‡∏î‡∏¢‡∏Å‡∏≤‡∏£‡∏ï‡∏£‡∏ß‡∏à anti-HCV\n- ‡∏´‡∏≤‡∏Å anti-HCV+ ‡πÉ‡∏´‡πâ‡∏ï‡∏£‡∏ß‡∏à HCV RNA ‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å‡∏ö‡∏ß‡∏Å = ‡πÄ‡∏õ‡πá‡∏ô‡πÑ‡∏ß‡∏£‡∏±‡∏™‡∏ï‡∏±‡∏ö‡∏≠‡∏±‡∏Å‡πÄ‡∏ã‡∏ö‡∏ã‡∏µ ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å‡∏•‡∏ö ‡πÉ‡∏´‡πâ‡∏ï‡∏£‡∏ß‡∏à‡∏ã‡πâ‡∏≥‡πÉ‡∏ô‡∏≠‡∏µ‡∏Å 3-6 ‡πÄ‡∏î‡∏∑‡∏≠‡∏ô ‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å‡∏•‡∏ö‡πÅ‡∏™‡∏î‡∏á‡∏ß‡πà‡∏≤‡∏´‡∏≤‡∏¢‡πÅ‡∏•‡πâ‡∏ß ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤‡∏ö‡∏ß‡∏Å‡πÅ‡∏™‡∏î‡∏á‡∏ß‡πà‡∏≤‡πÄ‡∏õ‡πá‡∏ô‡∏ï‡∏±‡∏ö‡∏≠‡∏±‡∏Å‡πÄ‡∏ã‡∏ö‡∏ã‡∏µ\n\t- ‡∏ï‡πâ‡∏≠‡∏á‡∏£‡∏±‡∏Å‡∏©‡∏≤‡∏ó‡∏∏‡∏Å‡∏Ñ‡∏ô ‡∏¢‡∏Å‡πÄ‡∏ß‡πâ‡∏ô life expectancy ‡∏ï‡πà‡∏≥\n- ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å anti-HCV - ‡∏≠‡∏≤‡∏à‡πÅ‡∏õ‡∏•‡∏ß‡πà‡∏≤ ‡πÑ‡∏°‡πà‡πÄ‡∏Ñ‡∏¢‡∏™‡∏±‡∏°‡∏ú‡∏±‡∏™‡πÇ‡∏£‡∏Ñ‡∏°‡∏≤‡∏Å‡πà‡∏≠‡∏ô ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤ suspect ‡∏à‡∏∞‡πÑ‡∏õ‡∏ï‡∏£‡∏ß‡∏à HCV RNA ‡∏Å‡πá‡πÑ‡∏î‡πâ\n- ‡∏Å‡∏≤‡∏£‡∏£‡∏±‡∏Å‡∏©‡∏≤\n\t- ‡∏™‡∏°‡∏±‡∏¢‡∏Å‡πà‡∏≠‡∏ô‡πÉ‡∏ä‡πâ Ribavirin (**‡πÅ‡∏ï‡πà S/E ‡πÄ‡∏¢‡∏≠‡∏∞‡∏ä‡∏¥‡∏ö‡∏´‡∏≤‡∏¢!! ‡∏à‡∏∂‡∏á‡∏°‡∏µ DAA ‡∏Ç‡∏∂‡πâ‡∏ô‡∏°‡∏≤**) ‡∏´‡∏£‡∏∑‡∏≠ Pegylated interferon-alpha 2a/2b ‡πÅ‡∏ï‡πà‡∏´‡∏•‡∏±‡∏á ‡πÜ ‡∏°‡∏µ direct antiviral agents (DAA) ‡∏ï‡∏±‡πâ‡∏á‡πÅ‡∏ï‡πà 2561 ‡πÄ‡∏õ‡πá‡∏ô‡∏ï‡πâ‡∏ô‡∏°‡∏≤\n\t- Direct Antiviral agents (DAA) ‡πÑ‡∏î‡πâ‡πÅ‡∏Å‡πà\n\t\t- Nonstrucutral protein (NS) 5b polymerase inhibitors ‡πÄ‡∏ä‡πà‡∏ô Sofosbuvir (nucleostide) inhibitors ‡∏ï‡∏±‡∏ß‡∏ô‡∏µ‡πâ‡∏°‡∏µ‡πÉ‡∏ä‡πâ‡∏ú‡∏™‡∏°‡∏¢‡∏≤‡∏ï‡∏±‡∏ß‡∏≠‡∏∑‡πà‡∏ô‡πÄ‡∏¢‡∏≠‡∏∞ ‡πÄ‡∏ô‡∏∑‡πà‡∏≠‡∏á‡∏à‡∏≤‡∏Å‡∏î‡∏∑‡πâ‡∏≠‡∏ô‡πâ‡∏≠‡∏¢ ‡∏ú‡∏•‡∏Ç‡πâ‡∏≤‡∏á‡πÄ‡∏Ñ‡∏µ‡∏¢‡∏á‡∏ô‡πâ‡∏≠‡∏¢\n\t\t- NS3-4A protease inhibitor\n\t\t\t- ‡πÄ‡∏ä‡πà‡∏ô Simeprevir, MK-5172\n\t\t- NS5A inhibitors\n\t\t\t- ‡πÄ‡∏ä‡πà‡∏ô Daclatasir, ledipasvir\n\t- **‡∏Å‡∏≤‡∏£‡∏£‡∏±‡∏Å‡∏©‡∏≤‡πÅ‡∏ï‡∏Å‡∏ï‡πà‡∏≤‡∏á‡∏Å‡∏±‡∏ô‡πÅ‡∏•‡πâ‡∏ß‡πÅ‡∏ï‡πà genotype** ‡∏à‡∏≥‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏´‡∏£‡∏≠‡∏Å‡∏≠‡∏µ‡πÄ‡∏ß‡∏£ ‡πÑ‡∏°‡πà‡∏ô‡πà‡∏≤‡∏≠‡∏≠‡∏Å‡∏™‡∏≠‡∏ö‡∏°‡∏±‡πâ‡∏á‡∏ô‡∏∞\n\t- ‡∏¢‡∏≤‡∏™‡πà‡∏ß‡∏ô‡πÉ‡∏´‡∏ç‡πà‡∏õ‡∏£‡∏±‡∏ö‡∏ï‡∏≤‡∏°‡∏ï‡∏±‡∏ö ‡πÅ‡∏•‡∏∞ protein binding ‡πÄ‡∏¢‡∏≠‡∏∞ **(‡∏à‡∏∂‡∏á‡∏ô‡∏¥‡∏¢‡∏°‡πÉ‡∏´‡πâ‡∏£‡∏±‡∏ö‡∏õ‡∏£‡∏∞‡∏ó‡∏≤‡∏ô‡∏ï‡∏≠‡∏ô‡∏ó‡πâ‡∏≠‡∏á‡∏ß‡πà‡∏≤‡∏á ‡πÄ‡∏ä‡πà‡∏ô ‡∏Å‡πà‡∏≠‡∏ô‡∏≠‡∏≤‡∏´‡∏≤‡∏£)**\n- ‡πÄ‡∏°‡∏∑‡πà‡∏≠‡∏Å‡πà‡∏≠‡∏ô‡∏à‡∏∞‡∏°‡∏µ‡∏Å‡∏≤‡∏£‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô response ‡∏´‡∏•‡∏±‡∏á‡πÑ‡∏î‡πâ‡πÉ‡∏ä‡πâ‡∏¢‡∏≤ ‡πÅ‡∏ï‡πà‡∏õ‡∏±‡∏à‡∏à‡∏∏‡∏ö‡∏±‡∏ô‡∏¢‡∏≤‡∏Ñ‡πà‡∏≠‡∏ô‡∏Ç‡πâ‡∏≤‡∏á‡∏°‡∏µ‡∏õ‡∏£‡∏∞‡∏™‡∏¥‡∏ó‡∏ò‡∏¥‡∏†‡∏≤‡∏û‡∏™‡∏π‡∏á‡∏°‡∏≤‡∏Å ‡πÜ ‡∏à‡∏∂‡∏á‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô‡πÅ‡∏•‡πâ‡∏ß\n\t- ‡∏´‡∏•‡∏±‡∏Å ‡πÜ ‡∏Ñ‡∏∑‡∏≠‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡πÑ‡∏°‡πà‡∏û‡∏ö HCV-RNA ‡∏´‡∏•‡∏±‡∏á‡∏à‡∏ö‡∏Å‡∏≤‡∏£‡∏£‡∏±‡∏Å‡∏©‡∏≤ 12 ‡∏™‡∏±‡∏õ‡∏î‡∏≤‡∏´‡πå\n\n### Hepatitis E ‡πÄ‡∏à‡∏≠‡∏ô‡πâ‡∏≠‡∏¢‡∏°‡∏≤‡∏Å ‡πÜ ‡πÉ‡∏ô‡πÑ‡∏ó‡∏¢","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/callouts":{"title":"Callouts","content":"\n## Callout support\n\nQuartz supports the same Admonition-callout syntax as Obsidian.\n\nThis includes\n- 12 Distinct callout types (each with several aliases)\n- Collapsable callouts\n\nSee [documentation on supported types and syntax here](https://help.obsidian.md/How+to/Use+callouts#Types).\n\n## Showcase\n\n\u003e [!EXAMPLE] Examples\n\u003e\n\u003e Aliases: example\n\n\u003e [!note] Notes\n\u003e\n\u003e Aliases: note\n\n\u003e [!abstract] Summaries \n\u003e\n\u003e Aliases: abstract, summary, tldr\n\n\u003e [!info] Info \n\u003e\n\u003e Aliases: info, todo\n\n\u003e [!tip] Hint \n\u003e\n\u003e Aliases: tip, hint, important\n\n\u003e [!success] Success \n\u003e\n\u003e Aliases: success, check, done\n\n\u003e [!question] Question \n\u003e\n\u003e Aliases: question, help, faq\n\n\u003e [!warning] Warning \n\u003e\n\u003e Aliases: warning, caution, attention\n\n\u003e [!failure] Failure \n\u003e\n\u003e Aliases: failure, fail, missing\n\n\u003e [!danger] Error\n\u003e\n\u003e Aliases: danger, error\n\n\u003e [!bug] Bug\n\u003e\n\u003e Aliases: bug\n\n\u003e [!quote] Quote\n\u003e\n\u003e Aliases: quote, cite\n","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/config":{"title":"Configuration","content":"\n## Configuration\nQuartz is designed to be extremely configurable. You can find the bulk of the configuration scattered throughout the repository depending on how in-depth you'd like to get.\n\nThe majority of configuration can be found under `data/config.yaml`. An annotated example configuration is shown below.\n\n```yaml {title=\"data/config.yaml\"}\n# The name to display in the footer\nname: Jacky Zhao\n\n# whether to globally show the table of contents on each page\n# this can be turned off on a per-page basis by adding this to the\n# front-matter of that note\nenableToc: true\n\n# whether to by-default open or close the table of contents on each page\nopenToc: false\n\n# whether to display on-hover link preview cards\nenableLinkPreview: true\n\n# whether to render titles for code blocks\nenableCodeBlockTitle: true \n\n# whether to render copy buttons for code blocks\nenableCodeBlockCopy: true \n\n# whether to render callouts\nenableCallouts: true\n\n# whether to try to process Latex\nenableLatex: true\n\n# whether to enable single-page-app style rendering\n# this prevents flashes of unstyled content and improves\n# smoothness of Quartz. More info in issue #109 on GitHub\nenableSPA: true\n\n# whether to render a footer\nenableFooter: true\n\n# whether backlinks of pages should show the context in which\n# they were mentioned\nenableContextualBacklinks: true\n\n# whether to show a section of recent notes on the home page\nenableRecentNotes: false\n\n# whether to display an 'edit' button next to the last edited field\n# that links to github\nenableGitHubEdit: true\nGitHubLink: https://github.com/jackyzha0/quartz/tree/hugo/content\n\n# whether to render mermaid diagrams\nenableMermaid: true\n\n# whether to use Operand to power semantic search\n# IMPORTANT: replace this API key with your own if you plan on using\n# Operand search!\nsearch:\n  enableSemanticSearch: false\n  operandApiKey: \"REPLACE-WITH-YOUR-OPERAND-API-KEY\"\n  operandIndexId: \"REPLACE-WITH-YOUR-OPERAND-INDEX-ID\"\n\n# page description used for SEO\ndescription:\n  Host your second brain and digital garden for free. Quartz features extremely fast full-text search,\n  Wikilink support, backlinks, local graph, tags, and link previews.\n\n# title of the home page (also for SEO)\npage_title:\n  \"ü™¥ Quartz 3.3\"\n\n# links to show in the footer\nlinks:\n  - link_name: Twitter\n    link: https://twitter.com/_jzhao\n  - link_name: Github\n    link: https://github.com/jackyzha0\n```\n\n### Code Block Titles\nTo add code block titles with Quartz:\n\n1. Ensure that code block titles are enabled in Quartz's configuration:\n\n    ```yaml {title=\"data/config.yaml\", linenos=false}\n    enableCodeBlockTitle: true\n    ```\n\n2. Add the `title` attribute to the desired [code block\n   fence](https://gohugo.io/content-management/syntax-highlighting/#highlighting-in-code-fences):\n\n      ```markdown {linenos=false}\n       ```yaml {title=\"data/config.yaml\"}\n       enableCodeBlockTitle: true  # example from step 1\n       ```\n      ```\n\n**Note** that if `{title=\u003cmy-title\u003e}` is included, and code block titles are not\nenabled, no errors will occur, and the title attribute will be ignored.\n\n### HTML Favicons\nIf you would like to customize the favicons of your Quartz-based website, you \ncan add them to the `data/config.yaml` file. The **default** without any set \n`favicon` key is:\n\n```html {title=\"layouts/partials/head.html\", linenostart=15}\n\u003clink rel=\"shortcut icon\" href=\"icon.png\" type=\"image/png\"\u003e\n```\n\nThe default can be overridden by defining a value to the `favicon` key in your \n`data/config.yaml` file. For example, here is a `List[Dictionary]` example format, which is\nequivalent to the default:\n\n```yaml {title=\"data/config.yaml\", linenos=false}\nfavicon:\n  - { rel: \"shortcut icon\", href: \"icon.png\", type: \"image/png\" }\n#  - { ... } # Repeat for each additional favicon you want to add\n```\n\nIn this format, the keys are identical to their HTML representations.\n\nIf you plan to add multiple favicons generated by a website (see list below), it\nmay be easier to define it as HTML. Here is an example which appends the \n**Apple touch icon** to Quartz's default favicon:\n\n```yaml {title=\"data/config.yaml\", linenos=false}\nfavicon: |\n  \u003clink rel=\"shortcut icon\" href=\"icon.png\" type=\"image/png\"\u003e\n  \u003clink rel=\"apple-touch-icon\" sizes=\"180x180\" href=\"/apple-touch-icon.png\"\u003e\n```\n\nThis second favicon will now be used as a web page icon when someone adds your \nwebpage to the home screen of their Apple device. If you are interested in more \ninformation about the current and past standards of favicons, you can read \n[this article](https://www.emergeinteractive.com/insights/detail/the-essentials-of-favicons/).\n\n**Note** that all generated favicon paths, defined by the `href` \nattribute, are relative to the `static/` directory.\n\n### Graph View\nTo customize the Interactive Graph view, you can poke around `data/graphConfig.yaml`.\n\n```yaml {title=\"data/graphConfig.yaml\"}\n# if true, a Global Graph will be shown on home page with full width, no backlink.\n# A different set of Local Graphs will be shown on sub pages.\n# if false, Local Graph will be default on every page as usual\nenableGlobalGraph: false\n\n### Local Graph ###\nlocalGraph:\n    # whether automatically generate a legend\n    enableLegend: false\n    \n    # whether to allow dragging nodes in the graph\n    enableDrag: true\n    \n    # whether to allow zooming and panning the graph\n    enableZoom: true\n    \n    # how many neighbours of the current node to show (-1 is all nodes)\n    depth: 1\n    \n    # initial zoom factor of the graph\n    scale: 1.2\n    \n    # how strongly nodes should repel each other\n    repelForce: 2\n\n    # how strongly should nodes be attracted to the center of gravity\n    centerForce: 1\n\n    # what the default link length should be\n    linkDistance: 1\n    \n    # how big the node labels should be\n    fontSize: 0.6\n    \n    # scale at which to start fading the labes on nodes\n    opacityScale: 3\n\n### Global Graph ###\nglobalGraph:\n\t# same settings as above\n\n### For all graphs ###\n# colour specific nodes path off of their path\npaths:\n  - /moc: \"#4388cc\"\n```\n\n\n## Styling\nWant to go even more in-depth? You can add custom CSS styling and change existing colours through editing `assets/styles/custom.scss`. If you'd like to target specific parts of the site, you can add ids and classes to the HTML partials in `/layouts/partials`. \n\n### Partials\nPartials are what dictate what gets rendered to the page. Want to change how pages are styled and structured? You can edit the appropriate layout in `/layouts`.\n\nFor example, the structure of the home page can be edited through `/layouts/index.html`. To customize the footer, you can edit `/layouts/partials/footer.html`\n\nMore info about partials on [Hugo's website.](https://gohugo.io/templates/partials/)\n\nStill having problems? Checkout our [FAQ and Troubleshooting guide](notes/troubleshooting.md).\n\n## Language Support\n[CJK + Latex Support (ÊµãËØï)](notes/CJK%20+%20Latex%20Support%20(ÊµãËØï).md) comes out of the box with Quartz.\n\nWant to support languages that read from right-to-left (like Arabic)? Hugo (and by proxy, Quartz) supports this natively.\n\nFollow the steps [Hugo provides here](https://gohugo.io/content-management/multilingual/#configure-languages) and modify your `config.toml`\n\nFor example:\n\n```toml\ndefaultContentLanguage = 'ar'\n[languages]\n  [languages.ar]\n    languagedirection = 'rtl'\n    title = 'ŸÖÿØŸàŸÜÿ™Ÿä'\n    weight = 1\n```\n","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/custom-Domain":{"title":"Custom Domain","content":"\n### Registrar\nThis step is only applicable if you are using a **custom domain**! If you are using a `\u003cYOUR-USERNAME\u003e.github.io` domain, you can skip this step.\n\nFor this last bit to take effect, you also need to create a CNAME record with the DNS provider you register your domain with (i.e. NameCheap, Google Domains).\n\nGitHub has some [documentation on this](https://docs.github.com/en/pages/configuring-a-custom-domain-for-your-github-pages-site/managing-a-custom-domain-for-your-github-pages-site), but the tldr; is to\n\n1. Go to your forked repository (`github.com/\u003cYOUR-GITHUB-USERNAME\u003e/quartz`) settings page and go to the Pages tab. Under \"Custom domain\", type your custom domain, then click **Save**.\n2. Go to your DNS Provider and create a CNAME record that points from your domain to `\u003cYOUR-GITHUB-USERNAME.github.io.` (yes, with the trailing period).\n\n\t![Example Configuration for Quartz](/notes/images/google-domains.png)*Example Configuration for Quartz*\n3. Wait 30 minutes to an hour for the network changes to kick in.\n4. Done!","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/docker":{"title":"Hosting with Docker","content":"\nIf you want to host Quartz on a machine without using a webpage hosting service, it may be easier to [install Docker Compose](https://docs.docker.com/compose/install/) and follow the instructions below than to [install Quartz's dependencies manually](notes/preview%20changes.md).\n## Hosting Quartz Locally\nYou can serve Quartz locally at `http://localhost:1313` with the following script, replacing `/path/to/quartz` with the \nactual path to your Quartz folder.\n\ndocker-compose.yml\n```\nservices:\n  quartz-hugo:\n    image: ghcr.io/jackyzha0/quartz:hugo\n    container_name: quartz-hugo\n    volumes:\n      - /path/to/quartz:/quartz\n    ports:\n      - 1313:1313\n\n    # optional\n    environment:\n      - HUGO_BIND=0.0.0.0\n      - HUGO_BASEURL=http://localhost\n      - HUGO_PORT=1313\n      - HUGO_APPENDPORT=true\n      - HUGO_LIVERELOADPORT=-1\n```\n\nThen run with: `docker-compose up -d` in the same directory as your `docker-compose.yml` file.\n\nWhile the container is running, you can update the `quartz` fork with: `docker exec -it quartz-hugo make update`.\n\n## Exposing Your Container to the Internet\n\n### To Your Public IP Address with Port Forwarding (insecure)\n\nAssuming you are already familiar with [port forwarding](https://en.wikipedia.org/wiki/Port_forwarding) and [setting it up with your router model](https://portforward.com):\n\n1. You should set the environment variable `HUGO_BASEURL=http://your-public-ip` and then start your container.\n2. Set up port forwarding on your router from port `p` to `your-local-ip:1313`.\n3. You should now be able to access Quartz from outside your local network at `http://your-public-ip:p`.\n\nHowever, your HTTP connection will be unencrypted and **this method is not secure**.\n\n### To a Domain using Cloudflare Proxy\n\n1. Port forward 443 (HTTPS) from your machine.\n2. Buy a custom domain (say, `your-domain.com`) from [Cloudflare](https://www.cloudflare.com/products/registrar/). Point a DNS A record from `your-domain.com` to your public IP address and enable the proxy.\n3. Set the environment variables `HUGO_BASEURL=https://your-domain.com`, `HUGO_PORT=443`, and `HUGO_APPENDPORT=false`. Change `1313:1313` to `443:443` for the `ports` in `docker-compose.yml`.\n4. Spin up your Quartz container and enjoy it at `https://your-domain.com`!\n\n### To a Domain using a Reverse Proxy\n\nIf you want to serve more than just Quartz to the internet on this machine (or don't want to use the Cloudflare registrar and proxy), you should follow the steps in the section above (as appropriate) and also set up a reverse proxy, like [Traefik](https://doc.traefik.io/traefik). Be sure to configure your TLS certificates too!\n","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/editing":{"title":"Editing Content in Quartz","content":"\n## Editing \nQuartz runs on top of [Hugo](https://gohugo.io/) so all notes are written in [Markdown](https://www.markdownguide.org/getting-started/).\n\n### Folder Structure\nHere's a rough overview of what's what.\n\n**All content in your garden can found in the `/content` folder.** To make edits, you can open any of the files and make changes directly and save it. You can organize content into any folder you'd like.\n\n**To edit the main home page, open `/content/_index.md`.**\n\n### Front Matter\nHugo is picky when it comes to metadata for files. Make sure that your title is double-quoted and that you have a title defined at the top of your file like so, otherwise the generated page will not have a title!\n\nYou can also add tags here as well.\n\n```yaml\n---\ntitle: \"Example Title\"\ntags:\n- example-tag\n---\n\nRest of your content here...\n```\n\n### Obsidian\nI recommend using [Obsidian](http://obsidian.md/) as a way to edit and grow your digital garden. It comes with a really nice editor and graphical interface to preview all of your local files.\n\nThis step is **highly recommended**.\n\n\u003e üîó Step 3: [How to setup your Obsidian Vault to work with Quartz](notes/obsidian.md)\n\n## Previewing Changes\nThis step is purely optional and mostly for those who want to see the published version of their digital garden locally before opening it up to the internet. This is *highly recommended* but not required.\n\n\u003e üëÄ Step 4: [Preview Quartz Changes](notes/preview%20changes.md)\n\nFor those who like to live life more on the edge, viewing the garden through Obsidian gets you pretty close to the real thing.\n\n## Publishing Changes\nNow that you know the basics of managing your digital garden using Quartz, you can publish it to the internet!\n\n\u003e üåç Step 5: [Hosting Quartz online!](notes/hosting.md)\n\nHaving problems? Checkout our [FAQ and Troubleshooting guide](notes/troubleshooting.md).\n","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/hosting":{"title":"Deploying Quartz to the Web","content":"\n## Hosting on GitHub Pages\nQuartz is designed to be effortless to deploy. If you forked and cloned Quartz directly from the repository, everything should already be good to go! Follow the steps below.\n\n### Enable GitHub Actions Permissions\nBy default, GitHub disables workflows from modifying your files (for good reason!). However, Quartz needs this to write the actual site files back to GitHub.\n\nHead to `Settings \u003e Action \u003e General \u003e Workflow Permissions` and choose `Read and Write Permissions`\n\n![[notes/images/github-actions.png]]\n*Enable GitHub Actions*\n\n### Enable GitHub Pages\n\nHead to the 'Settings' tab of your forked repository and go to the 'Pages' tab.\n\n1. (IMPORTANT) Set the source to deploy from `master` (and not `hugo`) using `/ (root)`\n2. Set a custom domain here if you have one!\n\n![Enable GitHub Pages](/notes/images/github-pages.png)*Enable GitHub Pages*\n\n### Pushing Changes\nTo see your changes on the internet, we need to push it them to GitHub. Quartz is a `git` repository so updating it is the same workflow as you would follow as if it were just a regular software project.\n\n```shell\n# Navigate to Quartz folder\ncd \u003cpath-to-quartz\u003e\n\n# Commit all changes\ngit add .\ngit commit -m \"message describing changes\"\n\n# Push to GitHub to update site\ngit push origin hugo\n```\n\nNote: we specifically push to the `hugo` branch here. Our GitHub action automatically runs everytime a push to is detected to that branch and then updates the `master` branch for redeployment.\n\n### Setting up the Site\nNow let's get this site up and running. Never hosted a site before? No problem. Have a fancy custom domain you already own or want to subdomain your Quartz? That's easy too.\n\nHere, we take advantage of GitHub's free page hosting to deploy our site. Change `baseURL` in `/config.toml`. \n\nMake sure that your `baseURL` has a trailing `/`!\n\n[Reference `config.toml` here](https://github.com/jackyzha0/quartz/blob/hugo/config.toml)\n\n```toml\nbaseURL = \"https://\u003cYOUR-DOMAIN\u003e/\"\n```\n\nIf you are using this under a subdomain (e.g. `\u003cYOUR-GITHUB-USERNAME\u003e.github.io/quartz`), include the trailing `/`. **You need to do this especially if you are using GitHub!**\n\n```toml\nbaseURL = \"https://\u003cYOUR-GITHUB-USERNAME\u003e.github.io/quartz/\"\n```\n\nChange `cname` in `/.github/workflows/deploy.yaml`. Again, if you don't have a custom domain to use, you can use `\u003cYOUR-USERNAME\u003e.github.io`.\n\nPlease note that the `cname` field should *not* have any path `e.g. end with /quartz` or have a trailing `/`.\n\n[Reference `deploy.yaml` here](https://github.com/jackyzha0/quartz/blob/hugo/.github/workflows/deploy.yaml)\n\n```yaml {title=\".github/workflows/deploy.yaml\"}\n- name: Deploy  \n  uses: peaceiris/actions-gh-pages@v3  \n  with:  \n\tgithub_token: ${{ secrets.GITHUB_TOKEN }} # this can stay as is, GitHub fills this in for us!\n\tpublish_dir: ./public  \n\tpublish_branch: master\n\tcname: \u003cYOUR-DOMAIN\u003e\n```\n\nHave a custom domain? [Learn how to set it up with Quartz ](notes/custom%20Domain.md).\n\n### Ignoring Files\nOnly want to publish a subset of all of your notes? Don't worry, Quartz makes this a simple two-step process.\n\n‚ùå [Excluding pages from being published](notes/ignore%20notes.md)\n\n## Docker Support\nIf you don't want to use a hosting service, you can host using [Docker](notes/docker.md) instead!\nI would *not use this method* unless you know what you are doing.\n\n---\n\nNow that your Quartz is live, let's figure out how to make Quartz really *yours*!\n\n\u003e Step 6: üé® [Customizing Quartz](notes/config.md)\n\nHaving problems? Checkout our [FAQ and Troubleshooting guide](notes/troubleshooting.md).\n","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/ignore-notes":{"title":"Ignoring Notes","content":"\n### Quartz Ignore\nEdit `ignoreFiles` in `config.toml` to include paths you'd like to exclude from being rendered.\n\n```toml\n...\nignoreFiles = [  \n    \"/content/templates/*\",  \n    \"/content/private/*\", \n    \"\u003cyour path here\u003e\"\n]\n```\n\n`ignoreFiles` supports the use of Regular Expressions (RegEx) so you can ignore patterns as well (e.g. ignoring all `.png`s by doing `\\\\.png$`).\nTo ignore a specific file, you can also add the tag `draft: true` to the frontmatter of a note.\n\n```markdown\n---\ntitle: Some Private Note\ndraft: true\n---\n...\n```\n\nMore details in [Hugo's documentation](https://gohugo.io/getting-started/configuration/#ignore-content-and-data-files-when-rendering).\n\n### Global Ignore\nHowever, just adding to the `ignoreFiles` will only prevent the page from being access through Quartz. If you want to prevent the file from being pushed to GitHub (for example if you have a public repository), you need to also add the path to the `.gitignore` file at the root of the repository.","lastmodified":"2023-03-08T16:23:53.031543707Z","tags":null},"/notes/obsidian":{"title":"Obsidian Vault Integration","content":"\n## Setup\nObsidian is the preferred way to use Quartz. You can either create a new Obsidian Vault or link one that your already have.\n\n### New Vault\nIf you don't have an existing Vault, [download Obsidian](https://obsidian.md/) and create a new Vault in the `/content` folder that you created and cloned during the [setup](notes/setup.md) step.\n\n### Linking an existing Vault\nThe easiest way to use an existing Vault is to copy all of your files (directory and hierarchies intact) into the `/content` folder.\n\n## Settings\nGreat, now that you have your Obsidian linked to your Quartz, let's fix some settings so that they play well.\n\nOpen Settings \u003e Files \u0026 Links and look for these two items:\n\n1. Set the **New link format** to **Absolute Path in vault**. If you have a completely flat vault (no folders), this step isn't necessary.\n2. Turn **on** the **Automatically update internal links** setting.\n\n\n![[notes/images/obsidian-settings.png]]*Obsidian Settings*\n\n## Templates\nInserting front matter everytime you want to create a new Note gets annoying really quickly. Luckily, Obsidian supports templates which makes inserting new content really easily.\n\n\u003e [!WARNING]\n\u003e \n\u003e **If you decide to overwrite the `/content` folder completely, don't remove the `/content/templates` folder!**\n\nHead over to Options \u003e Core Plugins and enable the Templates plugin. Then go to Options \u003e Hotkeys and set a hotkey for 'Insert Template' (I recommend `[cmd]+T`). That way, when you create a new note, you can just press the hotkey for a new template and be ready to go!\n\n\u003e üëÄ Step 4: [Preview Quartz Changes](notes/preview%20changes.md)\n","lastmodified":"2023-03-08T16:23:53.035544017Z","tags":null},"/notes/philosophy":{"title":"Quartz Philosophy","content":"\n\u003e ‚Äú[One] who works with the door open gets all kinds of interruptions, but [they] also occasionally gets clues as to what the world is and what might be important.‚Äù ‚Äî Richard Hamming\n\n## Why Quartz?\nHosting a public digital garden isn't easy. There are an overwhelming number of tutorials, resources, and guides for tools like [Notion](https://www.notion.so/), [Roam](https://roamresearch.com/), and [Obsidian](https://obsidian.md/), yet none of them have super easy to use *free* tools to publish that garden to the world.\n\nI've personally found that\n1. It's nice to access notes from anywhere\n2. Having a public digital garden invites open conversations\n3. It makes keeping personal notes and knowledge *playful and fun*\n\nI was really inspired by [Bianca](https://garden.bianca.digital/) and [Joel](https://joelhooks.com/digital-garden)'s digital gardens and wanted to try making my own.\n\n**The goal of Quartz is to make hosting your own public digital garden free and simple.** You don't even need your own website. Quartz does all of that for you and gives your own little corner of the internet.\n","lastmodified":"2023-03-08T16:23:53.035544017Z","tags":null},"/notes/preview-changes":{"title":"Preview Changes","content":"\nIf you'd like to preview what your Quartz site looks like before deploying it to the internet, the following\ninstructions guide you through installing the proper dependencies to run it locally.\n\n\n## Install `hugo-obsidian`\nThis step will generate the list of backlinks for Hugo to parse. Ensure you have [Go](https://golang.org/doc/install) (\u003e= 1.16) installed.\n\n```bash\n# Install and link `hugo-obsidian` locally\ngo install github.com/jackyzha0/hugo-obsidian@latest\n```\n\nIf you are running into an error saying that `command not found: hugo-obsidian`, make sure you set your `GOPATH` correctly (see [[notes/troubleshooting#`command not found: hugo-obsidian`|the troubleshooting page]])! This will allow your terminal to correctly recognize hugo-obsidian as an executable.\n\n##  Installing Hugo\nHugo is the static site generator that powers Quartz. [Install Hugo with \"extended\" Sass/SCSS version](https://gohugo.io/getting-started/installing/) first. Then,\n\n```bash\n# Navigate to your local Quartz folder\ncd \u003clocation-of-your-local-quartz\u003e\n\n# Start local server\nmake serve\n\n# View your site in a browser at http://localhost:1313/\n```\n\n\u003e [!INFO] Docker Support\n\u003e\n\u003e If you have the Docker CLI installed already, you can avoid installing `hugo-obsidian` and `hugo`. Instead, open your terminal, navigate to your folder with Quartz and run `make docker`\n\nAfterwards, start the Hugo server as shown above and your local backlinks and interactive graph should be populated! Now, let's get it hosted online.\n\n\u003e üåç Step 5: [Hosting Quartz online!](notes/hosting.md)\n","lastmodified":"2023-03-08T16:23:53.035544017Z","tags":null},"/notes/search":{"title":"Search","content":"\nQuartz supports two modes of searching through content.\n\n## Full-text\nFull-text search is the default in Quartz. It produces results that *exactly* match the search query. This is easier to setup but usually produces lower quality matches.\n\n```yaml {title=\"data/config.yaml\"}\n# the default option\nenableSemanticSearch: false\n```\n\n## Natural Language\nNatural language search is powered by [Operand](https://beta.operand.ai/). It understands language like a person does and finds results that best match user intent. In this sense, it is closer to how Google Search works.\n\nNatural language search tends to produce higher quality results than full-text search.\n\nHere's how to set it up.\n\n1. Login or Register for a new Operand account. Click the verification link sent to your email, and you'll be redirected to the dashboard. (Note) You do not need to enter a credit card to create an account, or get started with the Operand API. The first $10 of usage each month is free. To learn more, see pricing. If you go over your free quota, we'll (politely) reach out and ask you to configure billing.\n2. Create your first index. On the dashboard, under \"Indexes\", enter the name and description of your index, and click \"Create Index\". Note down the ID of the index (obtained by clicking on the index name in the list of indexes), as you'll need it in the next step. IDs are unique to each index, and look something like `uqv1duxxbdxu`.\n3. Click into the index you've created. Under \"Index Something\", select \"SITEMAP\" from the dropdown and click \"Add Source\".\n4. For the \"Sitemap.xml URL\", put your deployed site's base URL followed by `sitemap.xml`. For example, for `quartz.jzhao.xyz`, put `https://quartz.jzhao.xyz/sitemap.xml`. Leave the URL Regex empty. \n5. Get your API key. On the dashboard, under \"API Keys\", you can manage your API keys. If you don't already have an API key, click \"Create API Key\". You'll need this for the next step.\n6. Open `data/config.yaml`. Set `enableSemanticSearch` to `true`, `operandApiKey` to your copied key, and `operandIndexId` to the ID of the index we created from earlier..\n\n```yaml {title=\"data/config.yaml\"}\n# the default option\nsearch:\n  enableSemanticSearch: true\n  operandApiKey: \"jp9k5hudse2a828z98kxd6z3payi8u90rnjf\"\n  operandIndexId: \"s0kf3bd6tldw\"\n```\n7. Push your changes to the site and wait for it to deploy.\n8. Check the Operand dashboard and wait for your site to index. Enjoy natural language search powered by Operand!\n","lastmodified":"2023-03-08T16:23:53.035544017Z","tags":null},"/notes/setup":{"title":"Setup","content":"\n## Making your own Quartz\nSetting up Quartz requires a basic understanding of `git`. If you are unfamiliar, [this resource](https://resources.nwplus.io/2-beginner/how-to-git-github.html) is a great place to start!\n\n### Forking\n\u003e A fork is a copy of a repository. Forking a repository allows you to freely experiment with changes without affecting the original project.\n\nNavigate to the GitHub repository for the Quartz project:\n\nüìÅ [Quartz Repository](https://github.com/jackyzha0/quartz)\n\nThen, Fork the repository into your own GitHub account. **Make sure that when you fork, you _uncheck_ the 'Copy the `hugo` branch only' option**.\n\nIf you don't have an account, you can make on for free [here](https://github.com/join). More details about forking a repo can be found on [GitHub's documentation](https://docs.github.com/en/get-started/quickstart/fork-a-repo).\n\n![[notes/images/fork.png]]\n\n### Cloning\nAfter you've made a fork of the repository, you need to download the files locally onto your machine. Ensure you have `git`, then type the following command in your terminal replacing `YOUR-USERNAME` with your GitHub username.\n\n```shell\ngit clone https://github.com/YOUR-USERNAME/quartz\n```\n\n## Editing\nGreat! Now you have everything you need to start editing and growing your digital garden. If you're ready to start writing content already, check out the recommended flow for editing notes in Quartz.\n\n\u003e ‚úèÔ∏è Step 2: [Editing Notes in Quartz](notes/editing.md)\n\nHaving problems? Checkout our [FAQ and Troubleshooting guide](notes/troubleshooting.md).\n","lastmodified":"2023-03-08T16:23:53.035544017Z","tags":null},"/notes/showcase":{"title":"Showcase","content":"\nWant to see what Quartz can do? Here are some cool community gardens :)\n\n- [Quartz Documentation (this site!)](https://quartz.jzhao.xyz/)\n- [Jacky Zhao's Garden](https://jzhao.xyz/)\n- [Scaling Synthesis - A hypertext research notebook](https://scalingsynthesis.com/)\n- [AWAGMI Intern Notes](https://notes.awagmi.xyz/)\n- [Shihyu's PKM](https://shihyuho.github.io/pkm/)\n- [SlRvb's Site](https://slrvb.github.io/Site/)\n- [Course notes for Information Technology Advanced Theory](https://a2itnotes.github.io/quartz/)\n- [Brandon Boswell's Garden](https://brandonkboswell.com)\n- [Siyang's Courtyard](https://siyangsun.github.io/courtyard/)\n- [Data Dictionary üß†](https://glossary.airbyte.com/)\n- [sspaeti.com's Second Brain](https://brain.sspaeti.com/)\n- [oldwinter„ÅÆÊï∞Â≠óËä±Âõ≠](https://garden.oldwinter.top/)\n- [SethMB Work](https://sethmb.xyz/)\n- [Abhijeet's Math Wiki](https://abhmul.github.io/quartz/Math-Wiki/)\n\nIf you want to see your own on here, submit a [Pull Request adding yourself to this file](https://github.com/jackyzha0/quartz/blob/hugo/content/notes/showcase.md)!\n","lastmodified":"2023-03-08T16:23:53.035544017Z","tags":null},"/notes/troubleshooting":{"title":"Troubleshooting and FAQ","content":"\nStill having trouble? Here are a list of common questions and problems people encounter when installing Quartz.\n\nWhile you're here, join our [Discord](https://discord.gg/cRFFHYye7t) :)\n\n### Does Quartz have Latex support?\nYes! See [CJK + Latex Support (ÊµãËØï)](notes/CJK%20+%20Latex%20Support%20(ÊµãËØï).md) for a brief demo.\n\n### Can I use \\\u003cObsidian Plugin\\\u003e in Quartz?\nUnless it produces direct Markdown output in the file, no. There currently is no way to bundle plugin code with Quartz.\n\nThe easiest way would be to add your own HTML partial that supports the functionality you are looking for.\n\n### My GitHub pages is just showing the README and not Quartz\nMake sure you set the source to deploy from `master` (and not `hugo`) using `/ (root)`! See more in the [hosting](/notes/hosting) guide\n\n### Some of my pages have 'January 1, 0001' as the last modified date\nThis is a problem caused by `git` treating files as case-insensitive by default and some of your posts probably have capitalized file names. You can turn this off in your Quartz by running this command.\n\n```shell\n# in the root of your Quartz (same folder as config.toml)\ngit config core.ignorecase true\n\n# or globally (not recommended)\ngit config --global core.ignorecase true\n```\n\n### Can I publish only a subset of my pages?\nYes! Quartz makes selective publishing really easy. Heres a guide on [excluding pages from being published](notes/ignore%20notes.md).\n\n### Can I host this myself and not on GitHub Pages?\nYes! All built files can be found under `/public` in the `master` branch. More details under [hosting](notes/hosting.md).\n\n### `command not found: hugo-obsidian`\nMake sure you set your `GOPATH` correctly! This will allow your terminal to correctly recognize `hugo-obsidian` as an executable.\n\n```shell\n# Add the following 2 lines to your ~/.bash_profile (~/.zshrc if you are on Mac)\nexport GOPATH=/Users/$USER/go\nexport PATH=$GOPATH/bin:$PATH\n\n# In your current terminal, to reload the session\nsource ~/.bash_profile # again, (~/.zshrc if you are on Mac)\n```\n\n### How come my notes aren't being rendered?\nYou probably forgot to include front matter in your Markdown files. You can either setup [Obsidian](notes/obsidian.md) to do this for you or you need to manually define it. More details in [the 'how to edit' guide](notes/editing.md).\n\n### My custom domain isn't working!\nWalk through the steps in [the hosting guide](notes/hosting.md) again. Make sure you wait 30 min to 1 hour for changes to take effect.\n\n### How do I setup analytics?\nQuartz by default uses [Plausible](https://plausible.io/) for analytics. \n\nIf you would prefer to use Google Analytics, you can follow this [guide in the Hugo documentation](https://gohugo.io/templates/internal/#google-analytics). \n\nAlternatively, you can also import your Google Analytics data into Plausible by [following this guide](https://plausible.io/docs/google-analytics-import).\n\n\n### How do I change the content on the home page?\nTo edit the main home page, open `/content/_index.md`.\n\n### How do I change the colours?\nYou can change the theme by editing `assets/custom.scss`. More details on customization and themeing can be found in the [customization guide](notes/config.md).\n\n### How do I add images?\nYou can put images anywhere in the `/content` folder.\n\n```markdown\nExample image (source is in content/notes/images/example.png)\n![Example Image](/content/notes/images/example.png)\n```\n\n### My Interactive Graph and Backlinks aren't up to date\nBy default, the `linkIndex.json` (which Quartz needs to generate the Interactive Graph and Backlinks) are not regenerated locally. To set that up, see the guide on [local editing](notes/editing.md)\n\n### Can I use React/Vue/some other framework?\nNot out of the box. You could probably make it work by editing `/layouts/_default/single.html` but that's not what Quartz is designed to work with. 99% of things you are trying to do with those frameworks you can accomplish perfectly fine using just vanilla HTML/CSS/JS.\n\n## Still Stuck?\nQuartz isn't perfect! If you're still having troubles, file an issue in the GitHub repo with as much information as you can reasonably provide. Alternatively, you can message me on [Twitter](https://twitter.com/_jzhao) and I'll try to get back to you as soon as I can.\n\nüêõ [Submit an Issue](https://github.com/jackyzha0/quartz/issues)\n","lastmodified":"2023-03-08T16:23:53.035544017Z","tags":null},"/notes/updating":{"title":"Updating","content":"\nHaven't updated Quartz in a while and want all the cool new optimizations? On Unix/Mac systems you can run the following command for a one-line update! This command will show you a log summary of all commits since you last updated, press `q` to acknowledge this. Then, it will show you each change in turn and press `y` to accept the patch or `n` to reject it. Usually you should press `y` for most of these unless it conflicts with existing changes you've made! \n\n```shell\nmake update\n```\n\nOr, if you don't want the interactive parts and just want to force update your local garden (this assumed that you are okay with some of your personalizations been overriden!)\n\n```shell\nmake update-force\n```\n\nOr, manually checkout the changes yourself.\n\n\u003e [!warning] Warning!\n\u003e\n\u003e If you customized the files in `data/`, or anything inside `layouts/`, your customization may be overwritten!\n\u003e Make sure you have a copy of these changes if you don't want to lose them.\n\n\n```shell\n# add Quartz as a remote host\ngit remote add upstream git@github.com:jackyzha0/quartz.git\n\n# index and fetch changes\ngit fetch upstream\ngit checkout -p upstream/hugo -- layouts .github Makefile assets/js assets/styles/base.scss assets/styles/darkmode.scss config.toml data \n```\n","lastmodified":"2023-03-08T16:23:53.035544017Z","tags":null}}